ISSN

2435-0877

目 次【Review Article】
１．Immunopharmacological management of COVID-19 : Possible potency of anti-allergic agents
Hiroichi Nagai and1Miki Kawada【原著】
１．Relationship between maximum calf circumference and body composition in patients with type 2
diabetes: A cross-sectional study

14

Keisuke Suzuki，Toshio Ozawa，Tomohiko Kamo，Takayasu Koike，
Masato Hosokawa，Takayoshi Saito，Satoshi Otake
２．快・不快画像を用いた感情的状況のシミュレーションによる前頭前野賦活について

20

大星有美
３．慢性脳卒中者 発病から10年間の介護保険・要介護度の推移と分析 −慢性脳卒中者の総合的追跡調査
研究

要介護度の程度をみる評価法の提案−

30

澤俊二、園田 茂、山川百合子、伊佐地隆、大仲功一、安岡利一、金田喜清、

壹岐英、酒野直樹、松田智之、宇佐美知子、藤井雅也、酒向俊治、前島伸一郎、
才藤栄一、土屋隆、磯博康、大田仁史【研究報告】
１．小学校低学年サッカー選手の基礎技能に影響する因子及び基礎技能間の関連（第一報）−身体能力、学年別の比較−

42
田中智之、高橋洋、曾我奈央、贄田裕太、山本咲

２．半側空間無視患者の歩行開始時における非麻痺側下肢筋活動と転倒予防対策
髙橋啓太、高橋54

洋

３．転倒予防に関係する股関節屈曲筋力に影響する足関節底屈角度について白椛郁美、高橋65

洋【実践報告】
１．新型コロナウイルス感染症モニタリング検査（PCR検査）の取り組み

72

栃本千鶴、稲葉政德、榊原麻子、岩瀬通江、小池孝康、河田美紀、室敬之

２．新型コロナウイルス感染症禍における地域交流活動から見えてきた課題
栃本千鶴、畑吉節未、森77

裕志、宇佐美知子、秀山正和、

水谷真理子、田神信弘、松波実智誉
３．コロナ禍における通所介護施設（デイサービス）利用者の日常生活活動と活力の関連性について
小澤敏夫、鈴木啓介、金田成九、井戸
岐阜保健大学投稿規程
編集後記

雅

83

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Review Articleࠚ

Immunopharmacological management of COVID-19: Possible potency of anti-allergic agents
Hiroichi Nagai and Miki Kawada
Gifu University of Health Sciences
Abstract
The novel severe respiratory syndrome coronavirus-2 㸦SARS-CoV-2㸧 causes deadly coronavirus induced
disease-19 㸦COVID-19㸧 . Despite many trials having been done to prevent infection, strengthening immunity by
inoculation of vaccine is the only way to survive the disease. From immunopharmacological point of view, we havesearched for the possible remedy for COVID-19 in a vast repository of information reported in Pub-Med.
1㸧7KH-DSDQHVHJRYHUQPHQWKDVDOUHDG\DSSURYHG¿YHGUXJVUHPGHVLYLUGH[DPHWKDVRQHEDULYLWLQLEURQDSUHYHDQG
VRWURYLPDEIRUWKHWUHDWPHQWRI&29,'$PRQJWKHPGH[DPHWKDVRQHDQGEDULFLWLQLEVKRZHGDSRWHQWDQWLDOOHUJLF
action in human. It suggests the involvement of similar processes in both COVID-19 and allergic diseases.
2㸧 There is much literature to indicate the role of mast cells in the process of COVID-19. The main suspected
processes are the onset of cytokine storm and the post-infected illness.
3㸧 Some researchers indicated possible application of anti-allergic agents as a remedy for COVID-19. A novelanti-allergic drug, tranilast which was developed in our laboratory is one of candidates for therapeutics. Tranilast
showed anti-allergic action through mast cell stabilizing activity and interference of NLRP3 inflammasome. These
pharmacological actions might contribute to the suppression of cytokine storm and post infection symptoms because
PDVWFHOOVDQGLQÀDPPDVRPHSOD\DQLPSRUWDQWUROHIRUWKHRQVHWRIWKHDERYHWZRV\PSWRPV/XWHROLQDQRYHODQWLDOOHUJLFÀDYRQRLGLVDOVRQRPLQDWHGDVDUHPHG\RI&29,'EHFDXVHLWVSHFL¿FDOO\LQKLELWVthe binding of SARS-CoV-2 and host receptors, and the release of allergic chemical mediators from mast cells.
Moreover, some investigators have demonstrated that anti-histamines including azelastine and other histamine
antagonists 㸦H1 and H2㸧 showed a potency as a remedy for COVID-19.The accumulating data suggest the potential
role of anti-allergic agents as therapy for COVID-19.
Keywords : Anti-allergic drug, Allergy, COVID-19, SARS-CoV-2, tranilast, luteolinᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

treatment 㸦Ashworth 2021, Liu 2020, Kaur 2020a,b㸧.

Introduction
The novel severe respiratory syndrome coronavirus-2

7KHUHIRUH VLQFH YDFFLQDWLRQ DORQH LV LQVX൶FLHQW WR㸦SARS-CoV-2㸧 emerged in Wuhan, China in December

complete the COVID-19, the discovery of new drugs for2019. It causes deadly Coronavirus induced disease-19

the treatment of COVID-19 is eagerly desired 㸦Moore,㸦COVID-19㸧 that has rapidly spread across the world.

2021, Salgo, 2021㸧

After infection, signs of COVID-19 are heterologous,

For the above reason, we aimed to study the possible

patients range from being asymptomatic to death. There

remedy for COVID-19 in a vast repository of information

KDYH QRZ EHHQ RYHU  FRQ¿UPHG FDVHV DQGreported in Pub-Med from immunopharmacologicalGHDWKV㸦In World Health Organization region,

perspective. During research, we found that some anti-

4 July 2021㸧.

allergic agents are nominated as a remedy for COVID-19.

Typical sever symptoms are upper respiratory disorders,

Most anti-allergic agents have been previously studied insevere viral pneumonia requiring hospitalization, acute

RXU ODERUDWRU\:H FRQGXFWHG RQOLQH UHVHDUFK WR H[SORUH

respiratory distress syndrome 㸦ARDS㸧 with cytokine

studying the possible potency of such anti-allergic agentsstorm or death. It appears that all ages of population are

for the treatment of COVID-19.

susceptible to SARS-CoV-2 infection, and the median age

A systemic literature research was performed in theof infection is around 50 years old and decreasing now

PubMed database, which was terminated at the end of June

㸦Green, 2020㸧. Although individuals who are older

2021. There are 30 hits in Pub-Med when used

adults with lowered immunity have a relatively higher risk

͆immunopharmacology and COVID-19͇ as keywordsof infection by this disease, most young people and children

and 82 hits for ͆anti-allergic drugs and COVID-19͇.

have only mild pneumonia or are asymptomatic.

$GGLWLRQDO UHOHYDQW DUWLFOHV ZHUH LGHQWL¿HG IURP WKHDespite many trials that have been done to prevent

bibliographies, and from our own archives. Methods and¿QGLQJVRIWKHVWXGLHVZHUHFULWLFDOO\UHYLHZHG

infection at the moment, strengthening immunity by
vaccination is the best way to survive the disease. The

Targeting point of approved therapeutics

vaccines have been shown to reduce the incidence of
COVID-19 symptoms and serious illness, and to prevent

It is well known that the SARS-CoV-2 transmission iscorona virus transmission. Harrison et al., 㸦2020㸧

made by respiratory secretions in the form of droplets orreported that viral transmission from these individuals toaerosol when a person comes in close contact with theothers in their household was 40-50% lower thaninfected person.

WUDQVPLVVLRQLQKRXVHKROGVLQZKLFKWKH¿UVWSHUVRQWRWHVWWhen the SARS-CoV-2 virus enters the body, a series of
HYHQWV RFFXUV 7KH SURFHVV LV FODVVL¿HG LQWR  VWHSV

positive had not been vaccinated.
Whereas numerous studies indicated the decrease inincluding the cell attachment 㸦1㸧, cell entry 㸦2㸧, viral

severity of the disease by vaccination, its coverage isuncoating 㸦3㸧, nucleotide replication 㸦4㸧, viralincomplete and some individuals have poor response to theassembly 㸦5㸧, release of cell entry 㸦6㸧 and appearance

Figure 1 The process of SARS-Cov-2 induced-infection in target cellsᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

of systemic symptoms 㸦㸧 as shown in Fig. 1.

assembly of the various components into particular

7KH ¿UVW VWHS LV LQLWLDWHG E\ VSHFL¿F ELQGLQJ RI WKHstructures, capsids and ultimately infectious virus particles

coronavirus spike protein to the cellular entry receptors,

㸦step 5 in Fig.1㸧. Then, infected cells break open andZKLFKKDYHEHHQLGHQWL¿HGIRUVHYHUDOFRURQDYLUXVHVDQG

release the virus 㸦step 6 in Fig1㸧. Many viruses encode

include human aminopeptidase N, angiotensin peptidase

proteins that stimulate apoptosis, which can result in release

4-converting enzyme 2 㸦ACE2㸧 and dipeptidyl peptidaseof virus particles.

4 㸦step1 in Fig.1㸧.

$VLQGLFDWHGLQ¿JXUHWKHSURFHVVRILQIHFWLRQE\51$

After attachment, virus particles enter into the interior ofvirus is common. Therefore, the treatment of COVID-19 is

the cells 㸦step2 in Fig 1㸧. The release of the viral nucleic¿UVWO\VHDUFKHGRQDOUHDG\HVWDEOLVKHGNQRZOHGJHDERXWWKH

acid from the capsid is the results of a still unsolved process,treatment of RNA virus-induced diseases includingwhich is referred as uncoating 㸦step3 in Fig1㸧. AfterLQÀXHQ]D DFTXLUHG LPPXQH GH¿FLHQF\ V\QGURPH DQGuncoating, the genome of RNA viruses remains as a

Ebola hemorrhage fever.

ULERQXFOHLFDFLGSURWHLQFRPSOH[LQWKHF\WRSODVPZKHUH

The USA Food and Drug Administration 㸦FDA㸧 has

WKHQH[WVWHSVRIWKHLQIHFWLRQF\FOHRFFXU9LUDOUHSOLFDWLRQ

approved some drugs as a remedy for COVID-19 and

LVWKHYHU\FRPSOH[SURFHVVHVRIELRORJLFDOYLUDOIRUPDWLRQauthorized others for emergency. In addition, many more

It results in the production of multiple copies of the virus

therapeutics are being tested in clinical trials to evaluate

in the infected cells. Although, virus processes the genetic

WKHLUH൶FDF\RQ&29,'

information for most of the factors required for their own

After collecting the information from the world including

JHQHH[SUHVVLRQDQGJHQRPHUHSOLFDWLRQVSHFL¿FFHOOXODU

86$)'$WKH-DSDQHVHJRYHUQPHQWWHVWHGWKHH൶FDF\RISURWHLQVDUHRIWHQHVVHQWLDOIRUYLUXVJHQHH[SUHVVLRQ$IWHU

some applicant drugs on COVID-19.

replication, the viral structural protein and genome are)LQDOO\WKH-DSDQHVHJRYHUQPHQWDSSURYHG¿YHGUXJV

present in multiple copies in the cell 㸦step 4 in Fig1㸧.

UHPGHVLYLU GH[DPHWKDVRQH EDULYLWLQLE URQDSUHYH DQGThe process of viral morphogenesis described the ordinary

sotrovimab to use as treatments for COVID-19 as listed inTable 1 The approved drugs for the treatment of COVID-19 in Japan

Drugs

mechanism

Remdesivir

RNA polymerase inhibitor

Dexamethasone

Anti -inflammatory drugs

Baricitinib

JAK inhibitor

Ronapreve

A combination of two monoclonal antibodies
against SARS-CoV-2 (casirivimab andimdevimab)

Sotrovimab

Monoclonal antibody against spike protein of
SARS-CoV-2
and had evidence of lower respiratory tract infection 㸦De

Table 1.
7KH¿UVWDSSURYHGGUXJZDVUHPGHVLYLUZKLFKLV51$

Wit, 2020, Jorgensen, 2020a, Singh, 2020㸧. The Japanesepolymerase inhibitor usually used for the treatment of Ebola

Ministry of Health, Labor and Welfare 㸦MHLW㸧

hemorrhage fever.

approved the usage of remdesivir in May, 2020. Remdesivir

Remdesivir has been studied in several clinical trials foracts on step 4 in Fig. 1.

the treatment of COVID-19. Much data indicates that

'H[DPHWKDVRQHLVDFRUWLFRVWHURLGWKDWLVXVHGIRUWKH

remdesivir was superior to placebo in shortening the time

WUHDWPHQWRIZLGHUDQJHLQÀDPPDWRU\DQGLPPXQRORJLFDO

to recovery in adults who were hospitalized with COVID-19

GLVHDVHV 'H[DPHWKDVRQH UHGXFHG WKH GHDWK UDWH LQᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

hospitalized patients with severe COVID-19 㸦Berlin,

evaluated. Sotrovimab is not authorized for patients who

2020, Rizk, 2020㸧

DUH KRVSLWDOL]HG RU UHTXLUH R[\JHQ WKHUDS\ GXH WR

0+/:KDVDSSURYHGWKHXVHRIGH[DPHWKDVRQHIRUWKH

COVID-19 because of the lack of evidence on clinicaltreatment of coronavirus infected patients, following the

H൵HFWLYHQHVV $OWKRXJK OLPLWHG VFLHQWL¿F LQIRUPDWLRQ LV

DSSURYDORIUHPGHVLYLURQ0D\'H[DPHWKDVRQHDFWV

available, it is reasonable to believe that sotrovimab may

RQK\SHULQÀDPPDWLRQDVLQGLFDWHGVWHSLQ)LJ

EH H൵HFWLYH IRU WKH WUHDWPHQW RI PLOGWR PRGHUDWH

The additional therapeutic options for COVID-19

COVID-19.

pneumonia in patients with an ordinal score are necessary

MHLW approved sotrovimab for the treatment of

to reduce the likelihood of further progression to inversive

COVID-19 on September, 2021. Sotrovimab acts on step

procedures and death. A double-blind, randomized,

1 and 2 in Fig. 1.

placebo-controlled trial for evaluating balicitinib, an)URPWKHDERYH¿QGLQJVWZRDSSURYHGGUXJVIRUXVHLQ

inhibitor of Janus kinase 㸦JAK1㸧 and JAK2, indicated

WKH &29,' WKHUDS\ GH[DPHWKDVRQH DQG EDULFLWLQLE

EHQH¿FLDOH൵HFWVIRU&29,'WUHDWPHQW㸦Favalli, 2020,

LQGLFDWHG H൶FDF\ RQ DOOHUJLF GLVHDVHV ,W VXJJHVWV WKHJorgensen, 2020b, Cantini, 2020㸧 . Balicitinib may act on

H[LVWHQFH RI VLPLODU SURFHVVHV LQ ERWK &29,' DQGVWHSLQ)LJ0+/:DSSURYHGWKHXVHRIEDOLFLWLQLEIRU

allergic diseases.

the treatment of COVID-19 pneumonia on April 2021.
Involvement of mast cells in COVID-19

Balicinitib is usually employed for the treatment of adultpatients with moderately to severely active rheumatoid

The typical symptom of COVID-19 is hyper-

arthritis who have tried at least one or other medicine calledLQÀDPPDWRU\ SQHXPRQLD ZKLFK LV SUREDEO\ FDXVHG E\

a tumor necrosis factor 㸦TNF㸧 antagonist that did not

immunological mechanism. The precise pathophysiologicalwork well enough or could not be tolerated. Regarding themechanism is still unclear, but the participation of mast

H൵HFWRIEDULFLWLQLERQDOOHUJLFGLVHDVHV1DSROLWDQRHWDOcells has been suggested by many recent studies.

㸦2020㸧 have reported the improvement of the signs andTan et al., 㸦2021㸧 have reported widespread

symptoms of moderate to severe atopic dermatitis by thedegranulation of mast cells during acute and unresolved

oral administration of the agent. This means that baricitinib

DLUZD\ LQÀDPPDWLRQ LQ 6$56&R9 LQIHFWHG PLFH DQGVKRZVDQDQWLDOOHUJLFDFWLRQEHVLGHVDQWLLQÀDPPDWRU\DQG

non-human primates.
,QKXPDQWKHDFWLYDWLRQRIPDVWFHOOVLVFRQ¿UPHGE\WKH

anti-COVID-19 actions.
Ronapreve is a combination of two monoclonal㸦casirivimab

transcriptional changes in the mast cells from the infected

these

SDWLHQWV UHTXLULQJ R[\JHQ VXSSOHPHQWDWLRQ 㸦Garvin,

antibodies are believed to bind to the critical receptor

2020, Anderson, 2021, Aminu, 2021㸧. And the closebinding domain of SARS-CoV-2 spike protein. Ronapreve

UHODWLRQVKLSEHWZHHQWKHVHUXPOHYHORIPDVWFHOOVSHFL¿F

has been shown to improve survival in high-risk, non-protease, chymase and disease severity is reported andhospitalized COVID-19 patients by reducing the risk ofthereby strongly suggests the participation of mast cells in

hospitalization and death. In addition, its ability to retain

the processes of COVID-19 㸦Diver, 2021㸧.

antibodies

and

imdevimab㸧,

activity against emerging variants, including Delta variant,

Mast cells are granulocytes with granules containing a

has been demonstrated in pre-clinical studies 㸦Kaplon,

number of potent chemical mediators such as histamine,

2021, Phan, 2021㸧. MHLW approved ronapreve for the

serotonin, tryptase and chymase which have an ability to

WUHDWPHQWRI&29,'RQ-XO\5RQDSUHYHD൵HFWV

FDXVHVHYHUHLQÀDPPDWLRQ$QGPDVWFHOOVDUHSUHVHQWLQ

on step 1 and 2 in Fig. 1.

airway epithelium, contributing tissue homeostasis and

6RWURYLPDELVDPRQRFORQDODQWLERG\WKDWLVVSHFL¿FDOO\barrier defense 㸦innate immunity㸧. This stage isdirected against the spike protein of SARS-CoV-2 andVXSSRVHGWREHWKH¿UVWVWHSIRUSDUWLFLSDWLRQRIPDVWFHOOV

designed to block the virus attachment and entry into humanduring the progression of COVID-19.

cells. The USA FDA has issued an emergency use of this

7KH¿UVWUROHRIPDVWFHOOVLVVXJJHVWHGLQWKHRQVHWRI

monoclonal antibody for the treatment of COVID-19. The

cytokine storm, and the second role may be post-infected

VDIHW\ DQG H൵HFWLYHQHVV RI VRWURYLPDE FRQWLQXHV WR EH

illness 㸦Hafezi, 2021, Theoharides, 2021㸧ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

Regarding the cause of cytokine storm, the role of mast

smell and taste dysfunctions, cough, headache and cardiac

cells in elimination of the virus by an innate immune

disorders 㸦Demeco, 2020, 2021, Huang 2021, Sankar,mechanism2020㸧.

issuspected.

Following

SARS-CoV-2

LQIHFWLRQPDVWFHOOVSURGXFHSURLQÀDPPDWRU\F\WRNLQHV

Some of clinical signs of PIS are similar to the symptoms

such as interleukin-1ࠉ㸦IL-1㸧 and IL-6 to remove thecaused by mast cell activating syndrome 㸦MCAS㸧

virus. The elevation of these cytokines in the serum from

㸦<RQJ'L[LW㸧. MCAS is recently recognized

severe COVID-19 patients has been shown by Conti et al.,nonneoplastic mast cell disease driving chronic multisystem

㸦2020a,b㸧. Then IL-1 and IL-6 induce a broad spectrumLQÀDPPDWLRQ DQG DOOHUJ\ 㸦)ULHUL  $NLQ 㸧.

of biological activities including the introduction of innate

Various symptoms involving the skin, respiratory,

and acquired immunity and reinforcement of bothcardiovascular and neurologic systems are recognized after

macrophages and mast cells activation. The activation of

H[SORVLYHPDVWFHOODFWLYDWLRQUHVXOWHGLQDODUJHDPRXQWRI

mast cells triggers the release of several kinds of chemical

mediator release.

PHGLDWRUV DQG GH QRYR V\QWKHVLV RI SURLQÀDPPDWRU\

As is well known, mast cells and their activation

cytokines repeatedly. This is cytokine storm and septic

contribute to airway health through innate and acquired

shock, and it causes severe metabolic cellular abnormalities

immune responses to respiratory pathogens. In addition,

which can lead to death 㸦Karakike, 2019㸧. Mast cells

mast cells are involved in the diseases processes

may play a role in cytokine storm through the above

FKDUDFWHUL]HG E\ LQÀDPPDWLRQ DQG UHPRGHOLQJ RI WLVVXH

pathway.

structure. In these cases, mast cells are often inappropriately

In addition, the participation of mast cells in the virus

and chronically activated. There is some evidence on theattachment and entry to the target cells in airways is

DFWLYDWLRQ RI PDVW FHOOV LQ DVWKPD SXOPRQDU\ ¿EURVLVsuspected 㸦Kritas. 2020㸧. Since mast cells have thechronic obstructive pulmonary disease, acute distressrenin-angiotensin system which plays an important role insyndrome and lung cancer.

the initiation of SARS-CoV-2 infection, the angiotensin

7KHH[SORVLYHDFWLYDWLRQRIPDVWFHOOVFDXVHVPDVWFHOO

converting enzyme 2 is the essential component for binding

activation syndrome 㸦MCAS㸧 and then may lead tothe virus to host cells. And, mast cells have serine proteases¿EURWLFFKDQJHVUHPRGHOLQJDQGSUROLIHUDWLYHFKDQJHVLQ

including transmembrane protease serine 2 㸦TMPRSS2

target tissues. It strongly suggests the involvement of mast㸧, which acts for priming of corona spike protein. This

cells in PIS.

evidence is proposed to be the possible participation of mast

On the other hand, the associated risk factors to PIS maycells in the initiation of infection. However, at present, more

LQFOXGH VH[ PRUH WKDQ HDUO\ V\PSWRPV DQG VSHFL¿F

evidence is needed to determine the role of mast cells inbiomarkers 㸦e. g. CRP and lymphocyte counts increase㸧

these steps. This is further motivation to research the role

have not yet been determined in the cases of MCAS. Moreof mast cells in the infection processes.

investigation needs to be done to identify the participation

While various studies have been conducted on the roleof MCAS in PIS.

of mast cells in virus infection, some studies recently

In conclusion, some studies indicated the contribution ofsuggest the role of mast cells in the post infected syndrome

mast cells in the pathogenesis of COVID-19 including

㸦PIS㸧 in COVID-19 㸦Afrin, 2020, Malone 2021㸧.

cytokine storm and PIS through the release of pro-

The PIS means a high proportion of patients struggle withLQÀDPPDWRU\PHGLDWRUVDVLQGLFDWHGLQ¿JXUH

persistent symptoms after recovery. The most common

Therefore, it is possible to consider prophylactic

reported symptoms are fatigue, brain fog and respiratory

treatment with mediator antagonists or mast cell stabilizers

trouble lasting for months after infection. Other persistentfor patients diagnosed as having COVID-19 with mild

symptoms are mental impairments, chest and joint pains,

symptoms.

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

Figure 2 The participation of mast cells in pathogenesis of COVID-19

COVID-19 and anti-allergic agents

Tranilast

As described above, mast cells may play a critical role

Tranilast㸦N-㸦3̓,4̓GLPHWKR[\FLQQDPR\O㸧-

LQ&29'WKHDJHQWVD൵HFWLQJPDVWFHOOV㸦anti-allergic

anthranilic acid㸧ZDV¿UVWO\IRXQGLQRXUODERUDWRU\DVDQ

agents㸧 KHOS WR DPHOLRUDWH WKH K\SHULQÀDPPDWLRQ DQGanti-allergic agent and developed as a drug for treatment ofother symptoms, PIS in COVID-19.

allergic diseases by Kissei Pharmaceutical Company.

For a long time in our laboratory, we have investigatedTranilast is originally derived from nantenoside contained

WKHDQWLDOOHUJLFH൵HFWRIVHYHUDONLQGVRIDJHQWVLQFOXGLQJ

in Nangina Doetica.

mast cell stabilizers and mediator blockers. Our results

A summary of our results on anti-allergic actions is

LQGLFDWHG WKH H൶FDF\ RI PDVW FHOO VWDELOL]HUV LQFOXGLQJ

indicated in Table 2 㸦.RGD   1DJDL  tranilast, luteolin, quercetine and chromoglycate, and anti-DEF㸧

mediator agents such as anti-histamines, anti-leukotrienes

Tranilast showed clear anti-allergic actions in human and

DQGDQWLF\WRNLQHRQWKHH[SHULPHQWDODOOHUJLFPRGHOV:H

H[SHULPHQWDODQLPDOVERWKLQYLWURDQGLQYLYR7KHPDLQFRQGXFWHGRQOLQHUHVHDUFKWRH[SORUHWKHSRVVLELOLW\RIWKHVH

pharmacological action is based on the inhibition oftreatments ͂eligibility as COVID-19 remedied.

immunological mediator release from mast cells. In
DGGLWLRQWKHH൶FDF\DSSHDUVWREHE\RUDODGPLQLVWUDWLRQTable 2 Anti-allergic action of tranilast in our laboratory

1 Inhibition of anaphylactic histamine release from anddegranulation of rat peritoneal mast
cells.
2 Inhibition of histamine release from isolated rat peritoneal mast cells caused by calcium
ionophore A 23187, phospholipase A2 and dextran.
3 Inhibition of histamine and leukotriene release from sensitized hum an, guinea pig andmonkey lung tissues in vitro.
4 Inhibition of exo vivo allergic histamine release from atopic patient leukocyte.
5 Inhibition of passive cutaneous anaphylaxis in rats, mice and guinea pigs by oral
administration.
6 Inhibition of Praus hnits-Kustner reaction in human.
7 Inhibition of experimental asthma in rats and guinea pigs by oral administration.

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

Following our research, many studies have been done in

PLJUDWLRQ LQWR LQÀDPPDWRU\ VLWHV FDXVHG E\ LQWHUOHXNLQ

several countries and our data concerning anti-allergic

㸦IL㸧-5 and IL-33. In addition, it has shown the inhibitory

DFWLYLW\ZDVFRQ¿UPHGDFWLRQRQVRPHNH\LQÀDPPDWLRQDVVRFLDWHGWUDQVFULSWLRQDO

7KHQWUDQLODVWVKRZHGH൶FDF\IRUWKHWUHDWPHQWRINHORLGIDFWRUVVXFKDV1)N%DQGLPSHGLQJ1/53LQÀDPPDVRPH

DQGK\SHUWURSKLFVFDUGXHWRLWVXQLTXHDQWLLQÀDPPDWRU\㸦Huang, 2018㸧.

actions in a clinical settimg 㸦Huang, 2018 , Arno, 2014

Subsequently, the results showed that it could be also㸧.

H൵HFWLYHLQWKHPDQDJHPHQWRIDZLGHUDQJHRIFRQGLWLRQV

Ebihara et al., 㸦㸧 and Hiraide et al., 㸦2008㸧

VXFK DV ¿EURVLV SUROLIHUDWLYH GLVRUGHUV FDQFHU

KDYH VKRZQ LQKLELWRU\ DFWLYLW\ RQ WKH LQÀDPPDWRU\ FHOO

cardiovascular problems, autoimmune disorders, ocular

Figure 3 Summary of pharmacological actions of tranilast

diseases, diabetes and renal diseases 㸦Darakhshan, 2005,

storm㸧 and PIS in COVID-19. We also recommend theStrilchuk, 2019, Arno, 2014, Rogosnitzky, 2012, Petrilli,

H[SHULPHQWDO XVH RI WUDQLODVW IRU WKH WUHDWPHQW RI 3,6 LQ

2008, Osman, 2021㸧. Moreover, several trials have shown

COVID-19.

WKDWLWKDVYHU\ORZDGYHUVHH൵HFWVDQGLWLVJHQHUDOO\ZHOO
tolerated by patients 㸦Fig 3㸧.

Luteolin

Therefore, Ali Saeedi-Boroujeni et al., 㸦2021㸧 have

Flavone, luteolin is an important natural polyphenol

described the possibility of tranilast for the treatment of

which shows a potent mast cell stabilizing activity resulted&29,'EHFDXVHPDVWFHOOVDQG1/53LQÀDPPDVRPH

in the inhibition of allergic chemical mediator release from

SOD\DQLPSRUWDQWUROHLQK\SHULQÀDPPDWLRQ㸦cytokine

mast cells. We have already reported anti-allergic action of

7DEOH$QWLDOOHUJLFH൵HFWRIOXWHROLQLQRXUODERUDWRU\

1. Inhibition of the release of histamine, leukotrienes, prostaglandin D2

and granulocyte

macrophage-colony stimulating factor from cultured human mast cells and murine
mast cells.
2 Inhibition of the IgE mediated release of histamine, tumor necrosis factors andinterleukin-6 from bone marrow derived murine mast cells.
3. Inhi bition of IgE mediated biphasic cutaneous reaction in mice
4. Inhibition of p 72 sky protein kinase activity in mast cells
5. Inhibition of extracellular signal -regulated kinases and c-JunNH2-terminal kinase.
6. Inhibition of immunological activation of protein kinase c translocation and activation
7. Inhibition of IgE mediated Ca++ influx into mast cellsᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

luteolin as shown in Table 3 㸦Kimata. 2000a,b, Shichijo,

WR PHDVXUH WKH H൵HFW RQ LQIHFWLRQ RI9HUR ( FHOOV ZLWK2003㸧. In addition to our data, many investigators have

SARS-CoV-2 isolate USA-UF-1/2020. Yang et al., 㸦2021

FRQ¿UPHG DQWLDOOHUJLF DFWLYLW\ RI OXWHROLQ 㸦Seelinger,㸧 have also reported similar results on the antiviral activity.ULWDV-DQJ㸧.

of azelastine and inhibitory activity of virus entry to the

3UHYLRXVO\ WKH GLUHFW H൵HFW RI OXWHROLQ RQ 6$56&RY

FHOOV7KH\H[DPLQHGWKHH൵HFWRIFOLQLFDOO\DSSURYHG

infection was studied. In 2004, Yi et al., 㸦2004㸧 reported

drugs on the antiviral activity against SASR-CoV-2 by

WKDWOXWHROLQVSHFL¿FDOO\ELQGVWRWKHVXUIDFHVSLNHSURWHLQ

similar method to Reznikov et al 㸦2021㸧 and virus entryof SARS-Cov and inhibits entry of virus into host cells.

inhibiting activity by using high throughput screening$QWL6$56&RY DFWLYLW\ ZDV H[DPLQHG E\ XVLQJ D ZLOGDVVD\7KH\IRXQGDFWLYHGUXJVDVVSHFL¿F6$56&R9

type SARS-Cov infection system. Recently, Theoharides

pseudo-virus entry inhibitors. Among 15 positive drugs,

et al., 㸦2020㸧KDVFRQ¿UPHGWKHH൶FDF\RIOXWHROLQRQ

three anti-histamines, clemastine, trimeprazine andthe binding to SARS-CoV-2 spike protein by using a two-azelastine were included.

VWHS VFUHHQLQJ PHWKRG FRQVLVWLQJ RI IURQWDO D൶QLW\In addition, Jeon et al., 㸦2020㸧 have investigated thechromatography-mass spectrometry coupled with a viralanti-viral activity of 3,000 FDA -approved drugs, andLQIHFWLRQDVVD\EDVHGRQKXPDQLPPXQRGH¿FLHQF\YLUXV

reported 30 positive drugs. They recommended 13 drugs

luc/SARS pseud typed virus. In addition, Xia et al., 㸦2020

including azelastine, mequitazine and ciclesonide for㸧 have also indicated the luteolin inhibits Akt1 which is

HYDOXDWLRQRIFOLQLFDOH൶FDF\7KHVHGUXJVKDYHXVHGIRU

LQYROYLQJ LQ OXQJ LQMXU\ OXQJ ¿EURJHQHVLV DQG YLUXVWKHWUHDWPHQWRIDOOHUJLFGLVHDVHVDQGVKRZQH൶FDF\DQG

infection.

safety.

Recent studies by some researchers including Shadrack,

7KH LQ YLWUR H൶FDF\ RI D]HODVWLQH LQ WKH LQIHFWLRQ RI

2021, Alzaabi, 2021, Shawan, 2021, Chen, 2020, Russo,

SARS-CoV-2 was also reported by Ge et al., 㸦2021㸧.

2020, Junior, 2021, have also indicated the inhibitory action

Moreover, the possible potency of other anti-allergic agent

RIVRPHÀDYRQRLGVLQFOXGLQJOXWHROLQRQYLUXVHQWU\LQWR

including montelukast, sodium cromoglycate and anti-IgE

the host cells.

antibody

have

also

been

reported

㸦Liu,

2020,

7KLV HYLGHQFH VXJJHVWV WKDW ÀDYRQRLGV SDUWLFXODUO\Bhattacharyya, 2020, Farmani, 2021,Theoharide, 2020㸧.

OXWHROLQFDQH[KLELWSURPLVLQJPXOWLWDUJHWDFWLYLW\DJDLQVW

These studies suggest that anti-allergic agents particularly

SARS-Cov-2, which promote their use in the current and

D]HODVWLQH FDQ H[KLELW SURPLVLQJ PXOWLWDUJHW DFWLYLW\future outbreaks.

against COVID-19, which promote their use in the current
and future outbreak.

Azelastine
Conclusion

Some bioinformatics/drug repurposing studies indicatedthat, among several medicines, H1 and H2 receptor

1㸧$PRQJ ¿YH GUXJV DSSURYHG IRU WKH WUHDWPHQW RI

antagonists interact with key enzymes 㸦ACE 2㸧 or spike

COVID-19 in Japan 㸦UHPGHVLYLU GH[DPHWKDVRQH

protein in in vitro study 㸦Ennis 2021, Yang 2021, Gupta

barivitinib, ronapreve and sotrovimab㸧GH[DPHWKDVRQH

2021, Ge, 2021a,b, Ghosh, 2020, Mather, 2020, Cheung,

DQGEDULFLWLQLEVKRZHGSRWHQWFOLQLFDOH൵HFWLYHQHVVDJDLQVW

2021㸧㸧

allergic diseases beside COVID-19. It suggests the
H[LVWHQFH RI VLPLODU SURFHVVHV LQ ERWK &29,' DQG

Reznikov et al., 㸦2021㸧 reported that they haveinvestigated by searching electronic health records of usage

allergic diseases.

in population of more than 219,000 subjects tested for2㸧 There is much literature to indicate the role of mast

SARS-CoV-2. Usage of anti-histamine 㸦diphenhydramine,cells during the processes of COVID-19. Main suspected

K\GUR[\]LQHDQGD]HODVWLQH㸧 was associated with reduced

processes are the onset of cytokine storm and the post-

incidence of SARS-CoV-2 positivity in subjects greater

infected illness.

than age 61. And they also found diphenhydramine,

3㸧 Some anti-allergic agents are reported as possible

K\GUR[\]LQH DQG D]HODVWLQH WR H[KLELW GLUHFW DQWLYLUDO

remedies for COVID-19. Novel anti-allergic drugs,

activity against SARS-CoV-2 in vitro by testing the ability

tranilast, luteolin and anti-histamine 㸦diphenhydramine,ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

K\GUR[\]LQHDQGD]HODVWLQH㸧 are nominated as a remedy

vaccination rates, Proc Natl Acad Soc, 118㸦32㸧,for the treatment of COVID-19.

e2108225118s

These accumulating data suggest the possible potential

Berlin DA, Gulick RM, Martinez FJ, 㸦2020㸧, Severerole of anti-allergic agents for the therapy to COVID-19.

COVID-19, N Engl J Med, 383㸦25㸧, 2451-2460
Bhattacharyya D, 㸦2020㸧 Reposition of montelukast

Conflict of interest statement

either alone or combination with levocetizine against

7KHDXWKRUVKDYHQRFRQÀLFWRILQWHUHVWUHODWHGWRUHVHDUFKSARS-CoV-2, Med Hypotheses, 144, 110046
Cantini F, Niccoli L, Matarresr D, et al., 㸦2020㸧,presented in this manuscript.

Baricitinib therapy in COVID 19 : A pilot study on safety
Acknowledgement

and clinical impact, Infect, 81㸦2㸧, 318-356

ࠉWe appreciate Dr Hiroyuki Tanaka and Dr Naoki

Chen YR, Lan R, Shen R, et al., 㸦2020㸧, Computational

Inagaki 㸦GifuࠉPharmaceutical University㸧 , Ms. Elana

screening of antagonists against the SARS-CoV-2

Pistorio and Nagoya Industrial Science Research Institute㸦COVID-19㸧 coronavirus by molecular docking, Int

for cooperation of this manuscript.

Antimicrobio Agents, 56㸦2㸧, 196912
Cheung KS, Hung IFN, Leung WK, 㸦2021㸧, Association

References

between famotidine use and COVID-19 severity in Hong

Afrin LB, Weinstock LB, Molderings GJ, 㸦2020㸧,Kong: A territory wide study, Gastroenterology, 160㸦5&29,' K\SHULQÀDPPDWLRQ DQG SRVW&29,'㸧, 1898-1899&RQWL 3 &DUD൵D$ 7HWH * HW DO 㸦2020a㸧 Mast cell

illness may be rooted in mast cell activation syndrome,,QW-,QIHFW'LV

activated by SARS-CoV-2 release histamine which

Akin C, 㸦㸧, Mast cell activation syndromes, J

increase IL-1 levels causing cytokine storm andLQÀDPPDWRU\ UHDFWLRQ LQ &29,' - %LRO 5HJXO

Allergy Clin Immunol, 140㸦2㸧, 349-355
Ali Saeedi-Boroujeni, Muhammad-Reza Mashmoudian-Homeost Agents, 34㸦5㸧, 1629-1632

Sani, Roohangiz Nashibi, et al.,, 㸦2021㸧, Tranilast: a&RQWL 3 &DUD൵D $ *DOOHQJD &( HW DO 㸦2020b㸧

SRWHQW DQWLLQÀDPPDWRU\ DQG 1/53 LQÀDPPDVRPH

Coronavirus-19 㸦SARS-CoV-2㸧 induces acute severe

inhibitors drug for COVID-19, Immunopharmacol

OXQJ LQÀDPPDWLRQ YLD ,/ FDXVLQJ F\WRNLQH VWRUP LQ

,PPXQRWR[LFRO㸦3㸧

COVID-19: a promising strategy, J Biol Regul Homeost

Alzaabi MN, Hamdy R, Ashmawy NS, et al., 㸦2021㸧

Agents, 34㸦6㸧

againstDarakhshan S, Pour AB, 㸦2015㸧, Tranilast: a review of

Aminu AJ, Petkova M, Atkinson AJ, et al., 㸦2021㸧,de Wit E, Feldmann, F, Cronin J, et al., 㸦2020㸧,)XUWKHU LQVLJKWV LQWR WKH PROHFXODU FRPSOH[LW\ RI WKHProphylactic and therapeutic remdesivir 㸦*6㸧

human sinus node-The role of novel transcription factors

treatment in the rhesus macaque model of MERS-CoV

DQG PLFUR 51$V %LRSK\V 0RO %LRO  6

LQIHFWLRQ3URF1DWO$FDG6RF㸦12㸧

Flavonoidsarepromising

safe

therapy

COVID-19. Phytochem Rev, 22, 1-22

its therapeutic applications, Pharmacol Res, 91, 15-28

㸦21㸧 00038-9

Demeco A, Marotta N, Barletta M, et al., 㸦2020㸧,Anderson G, Carbone A, Mazzoccoli G, 㸦2021㸧,Rehabilitation of patients post-COVID-19 infection: aliterature

Tryptophan metabolites and aryl hydrocarbon receptor

review,

Int

Med

Res,

48㸦8㸧,

300060520948382

in sever acute respiratory syndrome, Coronavirus-2

Demeco S, Khalfaoui L, Emson C, et al., 㸦2021㸧(൵HFW㸦SARS-Cov-2㸧 pathophysiology, Int J Mol Sci, 22㸦4RI WH]HSHOXPDE RQ DLUZD\ LQÀDPPDWRU\ FHOOV㸧Arno AI, Gauglitz GG, Barret JP, et al., 㸦2014㸧, Up-to-

remodeling, and hyper-responsiveness in patients withdate approach to manage keloids and hyper trophic scars,

moderate to severe uncontrolled asthma 㸦CASCADE㸧

Burns, 40㸦㸧, 1255-1266: a double-blind, randomized placebo-controlled, phase

Ashworth M, Thunstrom V, Chelly TL, et al., 㸦2021㸧,2 trial, Lancet Resir Med, S2213-2600 㸦21㸧 00226-5(PSKDVL]HSHUVRQDOKHDOWKEHQH¿WWRERRVW&29,''L[LW 10 &KXUFKLOO$ 1VDLU$ HW DO 㸦2021㸧, Post-ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

DFXWH&29,'V\QGURPHDQGFDUGLRYDVFXODUV\VWHPWhat is known? J Am Heart Plus, 5, 100025s

Immunol, 41㸦12㸧, 1100-1115
Hiraide S, Yanagawa Y, Izuka K, 㸦2018㸧 Tranilast

Ebihara S, Kurachi H, Watanabe Y, 㸦㸧, A simple

inhibits interleukin-33 production by macrophages, Eur

preparation method for mouse eosinophils and theirUHVSRQVHVWRDQWLDOOHUJLFGUXJV,QÀDPP5HV㸦3㸧,J pharmacol, 818, 235-240
Huang C, Huang L, Wang Y, et al. 㸦2021㸧, 6-month

consequences of COVID-19 in patients discharged from

Ennis M, Tiligada K, 㸦2021㸧, Histamine receptors and

KRVSLWDODFRKRUWVWXG\/DQFHW㸦㸧, 220-

&29,',QÀDPP5HV㸦1㸧

232

Farmani AR. Mahadavinezhad F, Moslei Z, et al., 㸦2021

Huang Y, Jiang H, Chen Y, et al., 㸦2018㸧, Tranilast

㸧, Anti-IgE monoclonal antibodies as potential

GLUHFWO\ WDUJHWV 1/53 WR WUHDW LQÀDPPDVRPHGHULYHG

treatmentdisease, EMBO Mol Med, 10㸦4㸧, e8689

in

COVID-19,

Immunopharmacol,PPXQRWR[\FRO㸦3㸧, 259-264

Jang TY, Jung AY, Kyung TS, et al., 㸦㸧, Anti-allergic

Favalli EG, Biggioggero M, Maioli G, et al., 㸦2020㸧,H൵HFWRIOXWHROLQLQPLFHZLWKDOOHUJLFDVWKPDDQGUKLQLWLV

Baricitinib for COVID-19: a suitable treatment? InfectDis, 20㸦9㸧,1012-1013

Cent Eur I Immunol, 42㸦1㸧, 24-29
Jeon S, Meehyun K, Lee J, et al., 㸦2020㸧,GHQWL¿FDWLRQ

Frieri M, 㸦2018㸧, Mast cell activation syndrome, Clinof antiviral drug candidates against SARS-CoV-2 from

Rev Allergy Immunol, 54㸦3㸧, 353-365

FDA-approved drugs, Antimicrobial Agents andGarvin MR, Alvarez C, Miller JL, et al., 㸦2020㸧, A&KHPRWKHUDS\

mechanistic model and therapeutic interventions for

Jorgensen SCJ, Kobriaei R, Dresser LD, 㸦2020a㸧,

COVID-19 involving a RAS-mediated bradykinin storm,

Remdesivir: Review of pharmacology, pre-clinical data,(OLIHH

DQG HPHUJLQJ FOLQLFDO H[SHULHQFH LQ &29,'

Ge S, Lu J, Hou Y, et al., 㸦2021a㸧, Azelastine inhibits

Pharmacotherapy, 40㸦㸧

viruses of SARS-CoV-2 spike pseudo-virus by binding

Jorgensen SCJ, Tse CLY, Burry L, et al., 㸦2020b㸧,

to SARS-CoV-2 entry receptor ACE2, Virology, 560,

%DULFLWLQLE  $ UHYLHZ RI SKDUPDFRORJ\ VDIHW\ DQG110-115

HPHUJLQJ

Ge S, Wang X, Hou Y., 㸦2021b㸧, Repositioning of

FOLQLFDO

H[SHULHQFH

LQ

&29,'

Pharmacotherapy, 40㸦8㸧, 843-856

H㸦1㸧 UHFHSWRU DQWDJRQLVW 'R[HSLQ

Junior AG, Tolouei SEL, Dos Reis Livero FA, et al., 㸦2021

YLURSH[LV RI 6$56&R9 VSLNH SVHXGRYLUXV E\㸧. Natural agents modulating ACE-2: A review

EORFNLQJ$&((XU-3KDUPDFRO

compounds

histaminewithpotential

againstSARS-CoV-2

Ghosh R, Chatterjee S, Dubey S, et al., 㸦2020㸧,LQIHFWLRQV&XUU3KDUP'HV㸦13㸧, 1588-1596

Famotidine against SARS-CoV-2: a hope or hype? Mayo

Kaur G, Lungarella G, Rahman I, 㸦2020a㸧, SARS&R9&29,'VXVFHSWLELOLW\DQGOXQJLQÀDPPDWRU\Clin Proc, 95㸦8㸧
Green DN, Jackson M, Hillyard DR, et al., 㸦2020㸧,VWRUPE\VPRNLQJDQGYDSLQJ-,QÀDPP㸦London㸧,

Decreasing median age of COVID-19 cases in the UnitedState-changing epidemiology or changing surveillance ?

Kaur SP, Gupta V, 㸦2020b㸧, COVID-19 vaccine: A

PLoS One, 15㸦10㸧H
Gupta PSS, Biswal S, Singha D, et al., 㸦2021㸧 Binding

comprehensive status report, Virus Res, 288, 198114
Kaplon H, Reichert JM, 㸦2021㸧, Antibody to watch ininsight of clinically oriented drug famotidine with the
LGHQWL¿HG SRWHQWLDO WDUJHW RI 6$56&R9 - %LRPRO

2021, MAbs, 13㸦1㸧H
Karakike E, Giamarellos-Bourboukis EJ, 㸦2019㸧,Struct Dyn, 39㸦14㸧

Macrophage activation-like syndrome: A distinct entry

Hafezi B, Chan L, Knapp JP, 㸦2021㸧, Cytokine storm

leading to early death in sepsis, Front Immunol, 10, 55

syndrome in SARS-CoV-2 infections: Functional role ofKimata M, Inagaki N, Nagai H, 㸦2000a㸧 (൵HFWV RI
OXWHROLQ DQG RWKHU ÀDYRQRLGV RQ ,J(PHGLDWHG DOOHUJLF

mast cells, Cells, 19㸦㸧
Harrison AG, Lin T, Wang P, et al.,㸦2018㸧, Mechanismof SARS-CoV-2 transmission and pathogenesis, Trends

reactions, Planta Med., 66㸦1㸧, 25-29
Kimata M, Shichijo M, Miura T, et al., 㸦2000b㸧(൵HFWVᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

of luteolin, quercetin and baicalein on IgE mediatedFDUER[\OLFDFLGRQLPPHGLDWHDOOHUJLFUHDFWLRQV$UFK

mediator release from human cultured mast cells. Clin

,QW3KDUPDFRG\Q7KHU

([S$OOHUJ\㸦4㸧, 501-508

Nagai H, Yamada H, Yakuo I, et al.,㸦D㸧(൵HFWRI

Koda A, Nagai H, Watanabe S, et al., 㸦㸧, Inhibition

FLQQDUL]LQH RQ ,J( DQWLERG\PHGLDWHG H[SHULPHQWDO

of hypersensitivity reactions by a new drug, N㸦3̓,4̓-

allergic reactions in guinea pigs, Allergy, 42㸦2㸧, 135-

GLPHWKR[\FLQQDPR\ODQWKUDQLOLFDFLG㸦N-5̓㸧, JACI,㸦5㸧140
Nagai H, Yakuo I, Togawa M, et al., 㸦E㸧(൵HFWRI

Koda A, Nagai H, Mori H, et al., 㸦1986㸧(൵HFWRIWKH

2.<DQHZWKURPER[DQH$V\QWKHWDVHLQKLELWRU

QHZ DQWLDOOHUJLF GUXJ R[\+ 3\ULGR>E@

RQH[SHULPHQWDODVWKPDLQJXLQHDSLJV3URVWDJODQGLQVTXLQD]ROLQHFDUER[\OLF DFLG RQ LPPHGLDWH DOOHUJLF

Leukot Med, 39㸦2-3㸧, 111-121

reactions, Arzeneimittel- forshung, 36㸦11㸧, 1609-

Nagai H, Yakuo I, Yamada H, et al., 㸦1986㸧(൵HFWRI

1618

cinnarizine on IgE antibody mediated allergic reaction in

Kritas SK, Saggini A, Vaevara G, et al., 㸦2013㸧, Luteolin

mice and rats, J Pharmacobiodyn, 9㸦11㸧

LQKLELWVPDVWFHOOPHGLDWHGDOOHUJLFLQÀDPPDWLRQ-%LRO

Nagai H, Yamada H, Matsuura N, et al., 㸦F㸧,5HJO+RPHRVW$JHQWV㸦4㸧, 955-959

Pharmacological studies on the release of slow reacting.ULWDV6.5RQFRQL*&DUD൵D$HWDO㸦2020㸧, Mast

substances during anti-IgE antibody mediated passive

FHOO FRQWULEXWH WR FRURQDYLUXVLQGXFHG LQÀDPPDWLRQ

SHULWRQHDODQDSK\OD[LVLQUDWV-3KDUPDFRG\Q㸦1㸧,QHZDQWLLQÀDPPDWRU\VWUDWHJ\-%LRO5HJXO+RPRVW

49-54

9-14

Napolitano M, Fabbrocini G, Cinelli E, et al., 㸦2020㸧,Liu S, Zhi Y, Ying S, 㸦2020㸧, COVID-19 and asthma:

3UR¿OH RI EDULFLWLQLE DQG LWV WUHDWPHQW RI PRGHUDWH WR

5HÀHFWLRQGXULQJSDQGHPLF&OLQ5HY$OOHUJ\,PPXQROVHYHUHDWRSLFGHUPDWLWLVDVKRWUHYLHZRQWKHHPHUJLQJ

59㸦1㸧

clinical evidence, J Asthma Allergy, 13, 89-94

Malone RW, Tisdall P, Fremont-Smith P, et al., 㸦2021㸧,Osman S, Raza A, AL-Zaidan L, et al., 㸦2021㸧, Anti-

COVID-19: Famotidine, histamine, mast cells andFDQFHU H൵HFW RI WUDQLODVW $Q XSGDWH %LRPHG

mechanisms, Front Pharmacol., 12, 633680

Pharmacother, 141, 1118444

Mather JF, Seip RL, McKay RG, 㸦2020㸧, Impact ofPetrilli J, Wadsworth S, Cooper K, et al., 㸦2008㸧,famotidine use on clinical outcome of hospitalized

Tranilast: a pharmaceutical candidate for reduction ofpatients with COVID-19, Am J Gastroenterol, 115㸦10adhesions using a novel approach, Semin Reprot Med,㸧

26㸦4㸧 341-348

Moore S, Hill EM, Tildesley MJ, et al., 㸦2021㸧,Reznikov LR, Norris MH, Bahisht R, et al., 㸦2021㸧,Vaccination and non-pharmaceutical intervention for,GHQWL¿FDWLRQRIDQWLYLUDODQWLKLVWDPLQHIRU&29,'

COVID-19: a mathematical modelling study, Lancet

UHSXUSRVLQJ%LRFKHP%LRSK\V5HV&RPPXQ

Infect Dis, 21 㸦6㸧



Nagai H, Nishiyori T, Daikoku M, et al., 㸦1983㸧,Phan AT, Gukasyan J, Arabian S, et al., 㸦2021㸧, Emergent

Immunopharmacological studies of sodium copper

inpatient administration of casirivimab and imdemimab

chlorphyllin 㸦SCC㸧, Jpn J Pharmacol, 33㸦4㸧, 819-

antibody cocktail for the treatment of COVID-19

828

pneumonia, Cures, 13㸦5㸧, e15280- 52801

Nagai H, Suda H, Kitagaki K, et al., 㸦1991a㸧(൵HFWRI

Rizk JG, Kalntar-Zadeh K, Mehra MR et al., 㸦2020㸧,

tranilast on endothelin-induced broncho- constriction in

Pharmaco-Immunomodulatory therapy in COVID-19,

guinea pigs, J Pharmacobiodyn, 14㸦6㸧, 309-314

Drugs, 80㸦13㸧

Nagai H, Sakurai T, Inagaki N, et al., 㸦1995㸧, An

Rogosnitzky M, Danks , Kardash E, 㸦2012㸧, Therapeutic

immunopharmacological study of biphasic skin reaction

potential of tranilast, anti-allergic drug, in proliferativein mice, Bio Pharm Bull, 18㸦2㸧, 239-245

disorders, Anticancer res, 32㸦㸧

Nagai H, Tsuji F, Goto S, et al., 㸦1991b㸧(൵HFWRIQHZ

Russo M, Moccia S, Spagnuolo C, et al., 㸦2020㸧, Role

DQWLDOOHUJLFGUXJR[R+S\ULGR>E@TXLQD]ROLQ

RIÀDYRQRLGVDJDLQVWFRURQDYLUXVLQIHFWLRQ&KHP%LROᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

Interact, 328, 109211

SARS-CoV-2 entry inhibitors among already approved

Salgo MP, 㸦2021㸧, COVID-19: Zinc and angiotensin-

drugs, Acta Pharmacol Sin, 42㸦8㸧

2㸦ACE2㸧 GH¿FLHQFLHV DV

Yang L, Liu S, Liu J, et al., 㸦2020㸧, COVID-19 :determinants of risk and severity of disease: A narrative

immunopathogenesis and immune- therapeutics, Signal

review, Infect Dis Ther, 10㸦3㸧, 1215-1225

Transduct Target Ther, 5㸦1㸧, 128

converting

enzymeSankar J, Dhochak N, Kabra SK, 㸦2020㸧, COVID-19 in

Yi L, Li Z, Yuan K, et al., 㸦2004㸧, Small moleculeschildren: Clinical approach and management, Indian J

blocking the entry of severe respiratory syndrome

3HGLDWU㸦6㸧, 433-442

FRURQDYLUXV LQWR KRVW FHOOV -9LURO 㸦20㸧, 11334-

Seelinger G, Merfort I, Scempp CM, 㸦2008㸧, AntiR[LGDQWDQWLLQÀDPPDWRU\DQGDQWLDOOHUJLFDFWLYLWLHVRI

11339
Yong, SJ, 㸦2021㸧, Long COVID-19 or post COVID-19

OXWHROLQ3ODQUWD0HG㸦14㸧

syndrome: putative pathophysiology, risk factors andtreatment, Infect Dis 㸦Lond㸧, 53㸦10㸧

Shadrack DM, Deogratias G, Kirui LA, 㸦2021㸧,
Luteolin: blocker of SARS-CoV-2 cell entry based on
UHOD[HG FRPSOH[ VFKHPH PROHFXODU G\QDPLFVVLPXODWLRQ DQG PHWDG\QDPLFV 0RO 0RGHO㸦8㸧,
221
Shawan MMAK, Halder SK, Hasan MA, 㸦2021㸧,
Luteolin and abyssinone II as potential inhibitors of
SARS-VoV-2 : an in sillico molecular modeling approachin battling the COVID-19 outbreak, Bull Nat Res Cnt, 45
㸦1㸧
Singh AK, Singh A, Singh R, et al., 㸦2020㸧, A criticalreview of pharmacology, pre-clinical and clinical studies,
Diabetes Metab Syndr, 14㸦4㸧, 641-648
Shichijo M, Yamamoto N, Tsujisita H, 㸦2003㸧, Inhibitionof sky activity and degranulation of human mast cells byÀDYRQRLGV%LR3KDUP%XOO㸦12㸧, 1685-1690
Strilchuk L, Fogacci F, Cirero AF, 㸦2019㸧, Safety andtolerability of available urate-lowering drugs: a critical
UHYLHZ([SHUW2SLQ'UXJ6DI㸦4㸧Tan J, Anderson DE, Rathore APS, et al., 㸦2021㸧,Signatures of mast cells activation are associated with
VHYHUH&39,'PHG5[LY
Theoharides TC, Cholevas C, Polyzoids K, et al., 㸦2021
㸧/RQJ&29,'DVVRFLDWHGEUDLQIRJDQGFKPRIRJ/XWHROLQWRWKHUHVFXH%LRIDFWRUV㸦2㸧, 232-241
Theoharides TC, Conti P, 㸦2020㸧, COVID-19 and
PXOWLV\VWHPLQÀDPPDWRU\V\QGURPHRULVLWPDVWFHOO
activation syndrome? J Biol Regul Homeost Agents, 34㸦5㸧, 1633-1636
Xia QD, Xun Y, Lu JL, et al., 㸦2020㸧, Network
pharmacology and molecular docking analyses on
Lianhsu Qingwen capsule indicate Akt1 is a target to treat
and preventCOVID-19, Cell Prolif, 53㸦12㸧, e12949
Yang L, Pei RJ, Li H, et al., 㸦2021㸧,GHQWL¿FDWLRQRIᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙⥲ㄝࠚ&29,' ࡢච␿⸆⌮Ꮫⓗ࣐ࢿ࣮ࢪ࣓ࣥࢺ
ᢠ࢔ࣞࣝࢠ࣮⸆ࡢຠ⬟ࡢྍ⬟ᛶỌ஭༤ᘤ *1ࠉἙ⏣⨾⣖ *1*1 ᒱ㜧ಖ೺኱Ꮫ

せ᪨᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫ㸦SARS-CoV-2㸧࡟ࡼࡿឤᰁ⑕㸦COVID-19㸧ࡣୡ⏺࡟ࣃࣥࢹ࣑ࢵࢡࢆ㉳ࡇࡋࡓࠋCOVID-19 㜵Ṇ࡟㛵ࡋ࡚ࠊ⌧᫬Ⅼ࡛ࡣ࣡ࢡࢳࣥ᥋✀࡟ࡼࡿච␿ࡢᙉ໬௨እࠊ㐺ษ࡞᪉ἲࡀ࡞࠸ࠋࡑࡇ࡛᪂つ἞⒪⸆ࢆච␿⸆⌮Ꮫⓗ
ほⅬ࠿ࡽ pub-med ࢆ⏝࠸᳨࡚⣴ࡋࡓࠋձࠉ⌧᫬Ⅼ࡛ COVID-19 ࡢ἞⒪࡟౑⏝ྍ⬟࡞⸆≀ࡢ࠺ࡕࠊࢹ࢟ࢧ࣓ࢱࢰࣥࠊࣂࣜࢩࢳࢽࣈࡣᢠ࢔ࣞࣝࢠ࣮స⏝ࢆ♧ࡍࠋࡇࡢࡇ࡜ࡣࠊCOVID-19 ࡢ⑓ែᙧᡂ࡟࢔ࣞࣝࢠ࣮㢮ఝࡢᶵᗎࡢᏑᅾࢆ♧၀ࡍࡿࠋղࠉCOVID-19 ࡢࢧ࢖ࢺ࢝࢖࣭ࣥࢫࢺ࣮࣒࡜ឤᰁᚋࡢᚋ㑇⑕Ⓨ⑕࡟⫧‶⣽⬊ࡢ㛵୚ࢆ♧၀ࡍࡿᡂ⦼ࡀᩘከࡃ࠶ࡿࠋ
ճࠉᡃࠎࡀ㛤Ⓨࡋࡓᢠ࢔ࣞࣝࢠ࣮⸆࣭ࢺࣛࢽࣛࢫࢺࡣ COVID-19 ࡢⓎ⑕࡟㛵୚ࡍࡿ⫧‶⣽⬊ࡢάᛶ໬࡜ NLRP3 ࢖ࣥࣇ࣐ࣛࢰ࣮࣒ࢆᢚ࠼ࡿࡇ࡜࡛ COVID-19 ἞⒪⸆࡜ࡋ࡚ࡢྍ⬟ᛶࡀ♧ࡉࢀࡓࠋࡲࡓࠊࣇࣛ࣎ࣀ࢖ࢻᛶࡢᢠ࢔ࣞࣝࢠ࣮
⸆ࣝࢸ࢜ࣜࣥ࡜ᢠࣄࢫࢱ࣑ࣥ⸆ࡶ COVID-19 ἞⒪⸆ࡢྍ⬟ᛶࡀ♧ࡉࢀ࡚࠸ࡿࠋ
௨ୖࠊᢠ࢔ࣞࣝࢠ࣮⸆࡟ࡣࠊCOVID-19 ἞⒪⸆࡜ࡋ࡚ࡢྍ⬟ᛶࡀ࠶ࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋࠉ

࣮࣮࢟࣡ࢻ㸸ᢠ࢔ࣞࣝࢠ࣮⸆ࠊ࢔ࣞࣝࢠ࣮ࠊCOVID-19, SARS-CoV-2ࠊࢺࣛࢽࣛࢫࢺࠊࣝࢸ࢜ࣜࣥ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Original Articleࠚ

5HODWLRQVKLSEHWZHHQPD[LPXPFDOIFLUFXPIHUHQFHDQGERG\FRPSRVLWLRQLQ
patients with type 2 diabetes: A cross-sectional study
Keisuke Suzuki*1 Toshio Ozawa*1 Tomohiko Kamo*2 Takayasu Koike*1
Masato Hosokawa*3 Takayoshi Saito*3 Satoshi Otake*3*1 Department of Physical Therapy, Gifu University of Health Sciences*2 Department of Physical Therapy, Japan University of Health Sciences*3 Department of Physical Therapy, International University of Health and Welfare
Abstract
7KH SXUSRVH RI WKLV VWXG\ ZDV WR LQYHVWLJDWH WKH UHODWLRQVKLS EHWZHHQ PD[LPXP FDOI FLUFXPIHUHQFH 㸦MCC㸧 andskeletal muscle mass in patients with type 2 diabetes. We included 134 patients with type 2 diabetes 㸦85 males and 49
females㸧. We used a tape measure to measure MCC and a bioelectrical impedance analyzer 㸦BIA㸧 to measure skeletal
PXVFOHPDVVDQGERG\IDWSHUFHQWDJH6NHOHWDOPXVFOHLQGH[㸦SMI㸧 was calculated by dividing the sum of muscle massof the upper and lower limbs by the squared value of height. The results showed that MCC in patients with type 2 diabetes
ZDVFRUUHODWHGZLWKGL൵HUHQWDQWKURSRPHWULFSDUDPHWHUV7KHPDOHJURXSVKRZHGDVWURQJUHODWLRQVKLSEHWZHHQ0&&DQG
SMI, whereas the female group showed a strong relationship between MCC and body fat percentage. Therefore, MCC in
SDWLHQWVZLWKW\SHGLDEHWHVLVVWURQJO\UHODWHGWR60,KRZHYHUWKHUHODWLRQVKLSLVD൵HFWHGE\WKHSDWLHQW VVH[.H\ZRUGVW\SHGLDEHWHVVNHOHWDOPXVFOHPDVV60,ERG\IDWSHUFHQWDJHVH[ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

2. Methods

1. Introduction$Q HVWLPDWHG  PLOOLRQ SHRSOH JOREDOO\ DUH D൵HFWHG

2.1 Study subjects

with type 2 diabetes mellitus 㸦T2DM㸧 as reported by the

We included 134 patients with T2DM 㸦85 males and 49

International Diabetes Federation 㸦Diabetes Atlas 2019

females㸧 who participated in a two̺week educational

㸧. In Japan, according to the National Health and Nutrition

hospitalization

Survey released by the Ministry of Health, Labor, andcomplications, sick day treatment, lifestyle guidance,

Welfare in 2020, there are 11.96 million people who are

GLHWDU\ JXLGDQFH PHGLFDWLRQ JXLGDQFH DQG H[HUFLVH

strongly suspected of having diabetes and another 10.55

JXLGDQFHE\H[SHUWV㸧. The subjects were informed about

million people who cannot be ruled out as having diabetes

WKHVWXG\ERWKRUDOO\DQGRQSDSHUWKRVHZKRDJUHHGWR

㸦Ministry of Health, Labor and Welfare 2020㸧.

participate provided written informed consent. The study

Prolonged disease of T2DM increases the prevalence of

was conducted after obtaining ethical approval from theneuropathies, nephropathies, and cardiovascular events andEthics Committee, International University of Health andentails a higher mortality. A recent concern is that T2DM

Welfare, Tokyo, Japan 㸦Reg no - 16-Io-158㸧.

program㸦preventionofdiabetic

can cause muscle weakness in the lower limbs 㸦Nomura
2019㸧, leading to an increased incidence of falls and a

2.2 Anthropometric measurements

reduction in the ability to perform activities of daily living

7KHVXEMHFW VKHLJKWZHLJKWDQG0&&ZHUHPHDVXUHG

and the overall quality of life. This muscular weakness induring the daytime in the rehabilitation room in a standing

7'0LVEHOLHYHGWREHEHFDXVHRIQHXURSDWK\KRZHYHUSRVLWLRQZLWKERWKDUPVH[WHQGHGDORQJWKHERG\DQGOHJV

it is reportedly accompanied by a loss of muscle mass

slightly open. The rehabilitation room is a room where㸦Nomura 2018, Lee 2018㸧. Furthermore, T2DM is also

inpatients and outpatients receive physical therapy.

a contributing factor in the development of sarcopenia.

Bodyweight and standing height were measured to theisnearest 0.1 kg and 0.1 cm using an electronic weighing scale

recommended for the diagnosis of sarcopenia 㸦Chen 2020

DQGDKHLJKWVFDOHUHVSHFWLYHO\%RG\PDVVLQGH[㸦BMI㸧㸧 through techniques such as dual̺energy X̺ray

ZDVGH¿QHGDVWKHZHLJKW㸦in kg㸧 divided by the squareabsorptiometry 㸦DXA㸧 and bioelectrical impedanceof height 㸦in m㸧 㸦kg/m2㸧. Three trained physicalanalysis. However, the clinical application of these methods

therapists measured calf circumference at 0.1 cm intervals

LV GDPDJHG E\ UHDVRQV VXFK DV WKH QHHG IRU H[SHQVLYH

using a measuring tape while being cautious about not

equipment and the limited number of locations wherecompressing the subcutaneous tissue when placing the

PHDVXUHPHQWV FDQ EH PDGH 7KHUHIRUH PD[LPXP FDOI

measuring tape around the calf. The MCC was measured

circumference 㸦MCC㸧 is often used as an alternative

where the circumference was the largest in the standing

method to measure skeletal muscle mass in clinical practice.

SRVLWLRQWZRPHDVXUHPHQWVRQHDFKVLGHZHUHWDNHQDQG

The

measurementofskeletalmusclemass

MCC can be measured with a single measuring tape andtheir average was calculated.

GRHVQRWUHTXLUHH[SHQVLYHHTXLSPHQW,WLVDOVRUHSRUWHGO\UHODWHGWRWKHVNHOHWDOPXVFOHPDVVLQGH[㸦SMI㸧 of the

2.3 Muscle mass and body fat percentage measurements

H[WUHPLWLHVDQGLWVXVHIXOQHVVKDVEHHQZLGHO\GHVFULEHGWe used the bioelectrical impedance analyzer 㸦BIA㸧

in the literature 㸦Kawakami 2020㸧. However, most of㸦Inner Scan, BC̺7DQLWD&RUS7RN\R-DSDQ㸧 tothese reports are for community̺dwelling elderly people,

measure the bioimpedance according to the manufacturer̓s

and it is unclear whether they can be employed in patients

protocol. BIA is used to estimate the body composition

with T2DM. Therefore, the purpose of this study was to

DFFRUGLQJWRWKHGL൵HUHQFHLQWKHFRQGXFWLYLW\RIYDULRXV

investigate the relationship between MCC and skeletal

tissues based on the variation in their biologicalmuscle mass in patients with T2DM. We hypothesized thatcharacteristics. With the participant wearing light clothing

WKHUHZLOOEHDVLJQL¿FDQWUHODWLRQVKLSEHWZHHQ0&&DQG

and standing barefoot, the Inner Scan automatically

SMI in patients with T2DM.

estimates weight, percentage body fat, and lean soft tissueof the upper and lower limbs. SMI, measured as
appendicular muscle mass 㸦AMM㸧/height2㸧 㸦in kg/ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

m2㸧 㸦Visser 2005㸧, was calculated as the sum of the

7DEOH&RUUHODWLRQEHWZHHQ0&&DQGGL൵HUHQWYDULDEOHV

two upper limbs and two lower limbs.
2.4 Data Analysis
Statistical analysis was performed using IBM SPSS for
Windows version 23.0 㸦IBM Corp., Armonk, NY, USA㸧.
Descriptive statistics 㸦means and standard deviations㸧were computed for quantitative variables. Correlation
analysis was performed for the entire diabetic population,and the male and female subgroups separately. Pearson
FRUUHODWLRQFRH൶FLHQWZDVFDOFXODWHGEHWZHHQ0&&DQG
age, height, weight, BMI, SMI, body fat percent, andPD[LPXP DQNOH SODQWDUGRUVLÀH[LRQ VWUHQJWK 3HDUVRQFRUUHODWLRQFRH൶FLHQWLVDUHOLDEOHDQGYDOLGPHDVXUHIRU
correlation analysis 㸦Kawakami 2020 and Yasutake 2018
㸧7KHDOSKDOHYHORIVLJQL¿FDQFHZDVVHWDW
3. Results
The general characteristics of all participants arepresented in Table1.

Table 3 illustrates the relationship between MCC andeach parameter for male patients with T2DM. Similar to
the entire study sample, we obtained a statistically
VLJQL¿FDQWSRVLWLYHUHODWLRQVKLSEHWZHHQ0&&DQG60,㸦r= 0.84, p < 0.05㸧 )XUWKHU D VLJQL¿FDQW UHODWLRQVKLS
between MCC and all parameters was also seen in thissubgroup.
7DEOH&RUUHODWLRQEHWZHHQ0&&DQGGL൵HUHQWYDULDEOHVࠉࠉࠉࠉ in the male group

Table 1: Characteristics of study participants with type 2 ࠉࠉࠉࠉ diabetes mellitus/DVWO\ ZH REWDLQHG D VWDWLVWLFDOO\ VLJQL¿FDQW SRVLWLYHThe results presented in Table 2 illustrate the relationshipcorrelation between MCC and SMI 㸦r = 0.52, p < 0.05㸧

between MCC and each parameter for the study participants.

for the females as well 㸦Table 4㸧. We also observed a:HREVHUYHGDSRVLWLYHDQGVLJQL¿FDQWUHODWLRQVKLSEHWZHHQ
MCC and SMI 㸦r = 0.66, p < 0.05㸧. There was a

VWDWLVWLFDOO\VLJQL¿FDQWUHODWLRQVKLSEHWZHHQ0&&DQGDOO
parameters other than height.

VWDWLVWLFDOO\ VLJQL¿FDQW UHODWLRQVKLS EHWZHHQ 0&& DQGother parameters as well.

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

7DEOH&RUUHODWLRQEHWZHHQ0&&DQGGL൵HUHQWYDULDEOHVࠉ㸦Kawakami 2020㸧. Similar results were described inࠉࠉࠉ in the female groupanother study on MCC and SMI in healthy adults, with r =0.80 for the male group and r = 0.69 for the female group
㸦Kawakami 2015㸧. MCC was also highly correlatedwith muscle mass both for segmental 㸦r = 0.95㸧 and total
㸦r = 0.90㸧 values among Caucasian male cadavers,
ZKHUHDV DPRQJ WKH IHPDOHV WKH FRUUHODWLRQ FRH൶FLHQWV
were not as high at both segmental 㸦U 㸧 and total
㸦U 㸧 levels. Rolland et al. reported that MCC was
positively correlated with DXA measured the active shape
PRGHODPRQJHOGHUO\)UHQFKZRPHQDJHG\HDUV㸦r= 0.63㸧, which was similar to our results for the female

4. Discussion

group. As women have higher fat proportions in their legs

Our results show that the MCC of patients with T2DM

than men, the relationship between calf circumference and㸦ERWKDVDZKROHDQGIRULQGLYLGXDOVH[VXEJURXSV㸧 hasmuscle mass in women might not be as strongly correlated

DVLJQL¿FDQWUHODWLRQVKLSZLWKDJHZHLJKW%0,60,ERG\as in men. Furthermore, leg edema may also act as an

IDWSHUFHQWDJHDQGPD[LPXPDQNOHSODQWDU̺GRUVLÀH[LRQ

important factor that decreases the predictive power of calf

strength. There was a strong positive correlation between

circumference for skeletal muscle mass.

MCC and SMI in males 㸦r = 0.84㸧 and a moderately

In our study, the body fat percentage of the male group

positive correlation 㸦r = 0.53㸧 in females. In contrast,

was 22.2 s 8.1%, while that of the female group was higher

there was a strong positive correlation 㸦U 㸧 between

㸦35.0 s 8.9%㸧. In addition, the correlation between

MCC and body fat percentage in females and a moderate

MCC and body fat percentage was moderate for males 㸦rrelationship 㸦r = 0.53㸧 in the male group.

= 0.53㸧 and strong for females 㸦U 㸧. It has been

Our results regarding the relationship between MCC andreported that diabetics have more ectopic fat and fat

VNHOHWDO PXVFOH PDVV DUH LQ DJUHHPHQW ZLWK WKH H[LVWLQJ

accumulation in the leg muscles than healthy individuals

literature. Kawakami et al. investigated the relationship㸦Almurdhi MM 2016㸧 7KH FRUUHODWLRQ FRH൶FLHQWV

between MCC and SMI in the upright position using BIA

between MCC and SMI in the female group in the present

DQG';$LQKHDOWK\DGXOWVDQGUHSRUWHGDVLJQL¿FDQWVWXG\ZHUHORZHUWKDQWKHFRUUHODWLRQFRH൶FLHQWVIRUWKH

relationship 㸦U  Ѹ0.81㸧 㸦Kawakami 2020㸧. In

general population. In other words, there is a risk that thehuman cadaver studies as well, MCC was highly correlated

accuracy of predicting SMI with MCC will be reduced forwith total muscle mass among male cadavers 㸦r = 0.84㸧

women with diabetes. This indicates that MCC inpatients㸦Martin 1990㸧<DVXGD HW DO DOVR IRXQG D VLJQL¿FDQWZLWK 7'0 PD\ KDYH GL൵HUHQW LPSOLFDWLRQV ZKLFK DUHrelationship between MCC and SMI 㸦r = 0.81㸧 in 249

D൵HFWHGE\WKHSDWLHQW̓VVH[healthy Japanese women 㸦Yasuda 2020㸧. Additionally,

There are several limitations to our study. First, thea study on ambulatory older adults 㸦mean age = 83 years㸧

participants belonged to a single care facility and were not

UHSRUWHGDFRUUHODWLRQFRH൶FLHQWIURPWREHWZHHQ

randomly selected from the population. Therefore, the

MCC and skeletal muscle mass 㸦Bohannon 2016㸧. We

sample may not be representative of the vast population ofobtained a positive correlation of r = 0.66 between MCC

patients with T2DM. Furthermore, the number of older andand SMI in patients with T2DM, which is comparable toyounger participants in our study was small. Further studies

the previously reported value for ambulatory elderly,

including participants of a wider age range are needed.

though the accuracy may be inferior to that in healthy adults.

6HFRQGZHGLGQRWFRQVLGHUWKHH൵HFWRIHGHPDRQ0&&Regarding the correlation between MCC and SMI acrossbecause we could not standardize the time of MCC

GL൵HUHQWVH[.DZDNDPLHWDOUHSRUWHGWKDWWKHFRUUHODWLRQ

measurement in our study. Studies should consider using a

FRH൶FLHQWZDVKLJKHUIRUWKHPDOHJURXSWKDQIRUWKHIHPDOH

standardized time of day for MCC measurement. Finally,group 㸦U   IRU PDOHV U   IRU IHPDOHV㸧this study included only patients with diabetes and notᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

healthy subjects as a control group. Comparing patientsbalance control in older adults with diabetes. Gait

ZLWKGLDEHWHVDQGKHDOWK\VXEMHFWVPD\KHOSWREHWWHUGH¿QH

3RVWXUH

the characteristics of diabetes.

Martin, A.D., Spenst, L.F., Drinkwater, D.T., et al. 㸦1990
㸧. Anthropometric estimation of muscle mass in men.
0HG6FL6SRUWV([HUF±

5. Conclusions
MCC in T2DM patients was found to be positively

Ministry of Health, Labor and Welfare. 㸦2019㸧. Nationalcorrelated to body size, SMI, and body fat percentage.

Health and Nutrition Survey in 2019 㸦2021-9-29㸧.

Further, MCC was also strongly correlated with SMI in

Retrieved frommales and with body fat percentage in females. Therefore,

https://www.mhlw.go.jp/stf/newpage_14156.html.

FDXWLRQ VKRXOG EH H[HUFLVHG LQ LQWHUSUHWLQJ WKH ERG\Nindl, B.C., Scoville, C.R., Sheehan, K.M., et al. 㸦2002

composition related to MCC in T2DM patients as it may

㸧*HQGHUGL൵HUHQFHVLQUHJLRQDOERG\FRPSRVLWLRQDQG

vary with the patient̓VVH[VRPDWRWURSKLF LQÀXHQFHV RI ,*), DQG OHSWLQ - $SSO
3K\VLRO±

6. Conflict of interest

Nomura, T., Kawae, T., Kataoka, H., et al. 㸦2018㸧.

7KHDXWKRUVGHFODUHQRFRQÀLFWRILQWHUHVW$VVHVVPHQW RI ORZHU H[WUHPLW\ PXVFOH PDVV PXVFOH
VWUHQJWK DQG H[HUFLVH WKHUDS\ LQ HOGHUO\ SDWLHQWV ZLWK

7. References

diabetes mellitus. Environ Health Prev Med, 23㸦1㸧,Almurdhi, M.M., Reeves, N.D., Bowling, F.L., et al.

20.

㸦2016㸧. Reduced Lower-Limb Muscle Strength and

Nomura, T., Ishiguro, T., Ohira, M., et al. 㸦2019㸧.

Volume in Patients With Type 2 Diabetes in Relation to,VRPHWULFNQHHH[WHQVLRQIRUFHLQ-DSDQHVHW\SHGLDEHWLF

Neuropathy, Intramuscular Fat, and Vitamin D Levels.

patients without apparent diabetic polyneuropathy: Data

Diabetes Care, 39㸦3㸧

from the Multicenter Survey of the Isometric Lower%RKDQQRQ5:&KX-6WH൷0㸦2016㸧. Association([WUHPLW\6WUHQJWKLQ7\SH'LDEHWHVVWXG\6$*(2SHQ

RIROGHUZRPHQ VOLPEFLUFXPIHUHQFHVDQGPXVFOHPDVV
as estimated with bioelectrical impedance. J Phys Ther

0HG
Rolland, Y., Lauwers-Cances, V., Cournot, M., et al. 㸦2003
㸧. Sarcopenia, calf circumference, and physical function

Sci, 28㸦3㸧, 1016-1019.
Chen, L.K., Woo, J., Assantachai, P., et al. 㸦2020㸧. Asianof elderly women: a cross-sectional study. J Am Geriatr
Soc, 51, 1120 - 1124.

Working Group for Sarcopenia: 2019 Consensus Update
on Sarcopenia Diagnosis and Treatment. J Am Med Dir

Visser, M., Goodpaster, B.H., Kritchevsky, S.B., et al.
㸦2005㸧. Muscle mass, muscle strength, and muscle fat

Assoc, 21㸦3㸧

LQ¿OWUDWLRQDVSUHGLFWRUVRILQFLGHQWPRELOLW\OLPLWDWLRQVIDF Diabetes Atlas 9th edition 2019. 㸦2021-9-29㸧.

in well-functioning older persons. J Gerontol A Biol Sci

Retrieved fromMed Sci, 60㸦3㸧, 324 - 333.

https://www.diabetesatlas.org/en/.
Jonathan, T., Aldo, S., Pieter, CJ., et al. 㸦2013㸧.

Yasuda, T. 㸦2020㸧6LPSOL¿HGPRUSKRORJLFDOHYDOXDWLRQ

Reliability of standard circumferences in domain-related

RIVNHOHWDOPXVFOHPDVVDQGPD[LPXPPXVFOHVWUHQJWKFRQVWLWXWLRQDODSSOLFDWLRQV$P-+XP%LRO±

in healthy young women: Comparison between thigh and

Kawakami, R., Murakami, H., Sanada, K., et al. 㸦2015㸧.

calf. Womens Health 㸦Lond㸧

Calf circumference as a surrogate marker of muscle mass

Yasutake, K., Koga, S., Hokko, Y., et al. 㸦2018㸧.

for diagnosing sarcopenia in Japanese men and women.

Relevance of the Mini Nutritional Assessment in cirrhotic

Geriatr Gerontol Int, 15㸦8㸧

OLYHUGLVHDVHSDWLHQWV$VLD3DF-&OLQ1XWU㸦2㸧, 300

Kawakami, R., Miyachi, M., Sawada, SS., et al. 㸦2020㸧.

- 305.

&XWR൵V IRU FDOI FLUFXPIHUHQFH DV D VFUHHQLQJ WRRO IRUORZ PXVFOH PDVV :$6('$ 6 +HDOWK 6WXG\ *HULDWU
Gerontol Int, 20㸦10㸧, 943-950.
Lee, P.Y., Tsai, Y.J., Liao, Y.T., et al. 㸦2018㸧. Reactiveᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021࠙ཎⴭࠚ ᆺ⢾ᒀ⑓ᝈ⪅ࡢୗ⭣᭱኱࿘ᅖᚄ࡜㌟య⤌ᡂ࡜ࡢ㛵ಀ㕥ᮌၨ௓ *1 ᑠ⃝ᩄኵ *1 ຍⱱᬛᙪ *2 ᑠụᏕᗣ *1⣽ᕝ┿Ⓩ *3 㰻⸨Ꮥ⩏ *3 ኱Ṋ⪷ *3*1 ᒱ㜧ಖ೺኱Ꮫࠉࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊ࠉ⌮Ꮫ⒪ἲᏛ⛉*2 ᪥ᮏಖ೺་⒪኱Ꮫࠉಖ೺་⒪Ꮫ㒊ࠉ⌮Ꮫ⒪ἲᏛ⛉*3 ᅜ㝿་⒪⚟♴኱Ꮫࠉᑠ⏣ཎಖ೺་⒪Ꮫ㒊ࠉ⌮Ꮫ⒪ἲᏛ⛉せ᪨
2 ᆺ⢾ᒀ⑓ᝈ⪅㸦T2DM㸧ࡢ➽ຊపୗࡣ ADL ࢆపୗࡉࡏࠊ೺ᗣᑑ࿨ࡢపୗࢆ᮶ࡍࠋ➽ຊపୗࡣ➽㔞ࡢῶᑡࡀཎᅉ
ࡢ 1 ࡘ࡛࠶ࡾ⡆౽࡟➽㔞ࡢᢕᥱࡀ࡛ࡁࡿ ᐃᣦᶆࡀᚲせ࡛࠶ࡿࠋࡑࡇ࡛ᮏ◊✲ࡣ T2DM ࡢୗ⭣᭱኱࿘ᅖᚄ㸦MCC㸧
࡜య⤌ᡂ࡜ࡢ㛵ಀࢆ᫂ࡽ࠿࡟ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋᑐ㇟ࡣ 2 ᆺ⢾ᒀ⑓ᝈ⪅ 134 ྡ㸦⏨ᛶ 85 ேࠊዪᛶ 49 ே㸧࡜ࡋࡓࠋᐃᣦᶆࡣ MCCࠊ㌟㛗ࠊయ㔜ࠊERG\PDVVLQGH[ࠊ㦵᱁➽ᣦᩘ㸦SMI㸧ࠊయ⬡⫫⋡ࠊ㊊㛵⠇ᗏ⫼ᒅ᭱኱➽ຊ࡜ࡋࡓࠋ
MCC ࡜ྛᣦᶆ࡜ࡢ㛵ಀ࡟ࡘ࠸࡚ Pearson ࡢ┦㛵ศᯒࢆ⾜ࡗࡓࠋ⤖ᯝࡣ 2 ᆺ⢾ᒀ⑓ᝈ⪅ࡢ MCC ࡜ྛᣦᶆ࡜࡟᭷ព
࡞┦㛵㛵ಀࢆ♧ࡋࡓࠋࡲࡓ⏨ᛶ⩌ࡣ MCC ࡜ SMI ࡟ᙉ࠸㛵ಀࢆ♧ࡋࡓࡀࠊ୍᪉ዪᛶ⩌ࡣ MCC ࡜ SMI ࡟୰➼ᗘࡢ㛵ಀࢆ♧ࡋࠊMCC ࡜య⬡⫫⋡࡟ᙉ࠸㛵ಀࢆㄆࡵࡓࠋT2DM ࡢ MCC ࡣ SMI ࡜㛵ಀࡍࡿࡀࠊᛶู࡟ࡼࡗ࡚཯ᫎࡍࡿ
ᣦᶆࡀ␗࡞ࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋ
࣮࣮࢟࣡ࢻ㸸2 ᆺ⢾ᒀ⑓ࠊ㦵᱁➽㔞ࠊ㦵᱁➽ᣦᩘࠊయ⬡⫫⋡ࠊᛶูᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021࠙ཎⴭࠚᛌ࣭୙ᛌ⏬ീࢆ⏝࠸ࡓឤ᝟ⓗ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡿ
๓㢌๓㔝㈿ά࡟ࡘ࠸࡚
኱ᫍ᭷⨾ *1*1 ᒱ㜧ಖ೺኱Ꮫࠉࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊ࠉసᴗ⒪ἲᏛ⛉せ᪨ឤ᝟ㄪᩚᶵ⬟ࡢࡶ࡜࡜࡞ࡿឤ᝟ⓗ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬ࡢ⬻཯ᛂ࡟ࡘ࠸࡚ឤ᝟౯㸦ᛌ࣭୙ᛌ㸧㛫࡟┦㐪ࡀ࠶ࡿ࠿࡝࠺࠿ࢆ᳨ウࡋࠊㄆ▱ᶵ⬟᳨ᰝᡂ⦼࡜ࡢ㛵㐃ᛶࡢ᭷↓ཬࡧㄢ㢟᫬ࡢ๓㢌๓㔝ࡢᙺ๭ࢆ᫂ࡽ࠿࡟ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋᛌ࣭୙ᛌ⏬ീࢆ⏝࠸ࡓឤ᝟ⓗ≧ἣࢩ࣑࣮ࣗࣞࢩࣙࣥㄢ㢟ࢆసᡂࡋࠊ೺ᖖⱝᖺ⪅ࢆᑐ㇟࡜ࡋ⬻⾑ὶ཯ᛂࢆ㏆㉥እศගἲ⿦⨨࡟ࡼࡗ࡚ ᐃࡋࡓࠋ௒ᅇࡢ⤖ᯝ࡛ࡣឤ᝟౯㛫࡟⬻㈿άࡢ᭷ពᕪࡣㄆࡵࡽࢀ࡞࠿ࡗࡓࠋㄆ▱ᶵ⬟ᡂ⦼࡜ࡢ㛵㐃ᛶ࡛ࡣࠊࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬ࡢ⬻㈿άࡢ኱ࡁࡉ࡜グ᠈ࡸὀពᶵ⬟ࡢⰋዲࡉ࡟࠾࠸࡚᭷ព࡞┦㛵ࡀㄆࡵࡽࢀࠊ
ឤ᝟ⓗ≧ἣࢆࢩ࣑࣮ࣗࣞࢩࣙࣥࡍࡿ㝿ࡢ⬻㈿ά࡜ࡇࢀࡽࡢㄆ▱ᶵ⬟ࡀ㛵㐃ࡋ࡚࠸ࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ
࣮࣮࢟࣡ࢻ㸸ឤ᝟ࠊࢩ࣑࣮ࣗࣞࢩࣙࣥࠊ⬻㈿άࠊ๓㢌๓㔝ࠊ㏆㉥እศගἲᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

ࣥ㸦episodic simulation㸧ࠊᮍ᮶ᛮ⪃㸦future thinking㸧ࠊ㸬ᗎㄽ⚾ࡓࡕࡣ᪥ᖖ⏕άࢆ㏦ࡿ㝿࡟ࠊࡇࢀ࠿ࡽ⏕ࡌࡿ≧ἣࡢ

mentalizing㸦perspective taking㸧࡜ ࡞ ࡾ㸦Buckner &ண ࡸ᝿ീࠊࡍ࡞ࢃࡕࠊ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥࢆ⾜ࡗ&DUUROO㸧ࠊ࠸ࡎࢀࡶ DMN ࡜ࡾࢃࡅ MPFC ࡢാࡁ࡚࠸ࡿࠋࡇࢀ࠿ࡽ㉳ࡇࡿ≧ἣࡢண ࡟ࡣࡑࡢ≧ἣࡢࢩࡀ኱ࡁ࠸ࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿࠋ

࣑࣮ࣗࣞࢩࣙࣥࡀᚲ↛ⓗ࡟క࠸ࠊࢩ࣑࣮ࣗࣞࢩࣙࣥࡣ༴

➹⪅ࡽࡣࡇࢀࡲ࡛ࠊᶵ⬟ⓗ MRI ࡟ࡼࡗ࡚⮬ศ࡟㛵ࡍ㝤ᅇ㑊ࡸ࠶ࡽࡺࡿ஦๓‽ഛ࡟ࡣḞ࠿ࡏ࡞࠸ࡶࡢ࡛࠶ࡿࠋ

ࡿឤ᝟ⓗ࡞≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡗ࡚ MPFC ࡢࡲࡓࠊ⚾ࡓࡕࡣࡑࡢ㝿࡟⏕ࡌࡿឤ᝟࡟ࡘ࠸࡚ࡶࠊࡲࡔ

άືࡀ㧗ࡲࡿࡇ࡜ࢆሗ࿌ࡋࡓࠋࡲࡓࠊ๓㢌๓㔝ࡢ๓᪉ᐇ㝿࡟ࡣ㉳ࡁ࡚࠸࡞࠸࡟ࡶ㛵ࢃࡽࡎࠊ௒㉳ࡁ࡚࠸ࡿࡇ࡜

࡟఩⨨ࡍࡿ๓㢌ᴟ࡟࠾࠸࡚ࡶྠᵝ࡞άືࡀࡳࡽࢀࡿࡇ

ࡢࡼ࠺࡟ࢩ࣑࣮ࣗࣞࢩࣙࣥࡍࡿࡇ࡜ࡀࡋࡤࡋࡤ࠶ࡿࠋឤ

࡜ࢆ⡆౽࡟⬻⾑ὶ཯ᛂࡀᢳฟྍ⬟࡞㏆㉥እศගἲ⿦⨨᝟ࡢㄪᩚࡢ㠃࠿ࡽࡍࡿ࡜ࠊ஦๓࡟ᑗ᮶ⓗ࡟⏕ࡌࡿࡔࢁ࠺

㸦near infrared spectroscopyࠊ௨ୗ NIRS㸧࡟ࡼࡿィ ࡢฟ᮶஦࡟ᑐࡋ࡚⮬㌟ࡀ࡝ࡢࡼ࠺࡞ឤ᝟ࢆᢪࡃ࠿࠶ࡽ࠿ࡌ

⤖ᯝ࠿ࡽሗ࿌ࡋ࡚ࡁࡓࠋ≧ἣࢩ࣑࣮ࣗࣞࢩࣙࣥࡢ⚄⤒ᇶࡵண ࡋ࡚࠸ࢀࡤࠊࡑࡢឤ᝟࡬ࡢᑐฎ᪉ἲࡶ⪃࠼ࡿࡇ┙࡟ࡘ࠸࡚ࡣࠊඛ⾜◊✲࡛ࡣ⮬ᕫ࡟㛵㐃ࡋࡓࡶࡢ࡜ࡋ࡚

࡜ࡀྍ⬟࡛࠶ࡿࠋឤ᝟ࢥࣥࢺ࣮ࣟࣝࡢ᪉ἲࡢ୍ࡘ࡟ࠊ

ࡣ MPFC ࢆࡣࡌࡵ࡜ࡍࡿ DMN ࡢᙺ๭ࡀ኱ࡁ࠸࡜࠸࠺ࡇ

ࢿ࢞ࢸ࢕ࣈ࡞ឤ᝟ࡸᛮ⪃ࠊ≧ἣ࡟ᑐࡋู࡚ࡢゎ㔘ࢆࡍࡿ࡜୍࡛⮴ࡋ࡚࠸ࡿࠋ

ࡇ࡜࡟ࡼࡗ࡚ࢿ࢞ࢸ࢕ࣈ࡞ឤ᝟ࢆῶᑡࡉࡏࡿ᪉ἲ࡛࠶ࡿ

ࡋ࠿ࡋ࡞ࡀࡽࠊឤ᝟ⓗ࡞≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡘ

ㄆ ▱ ⓗ ෌ ホ ౯㸦cognitive reappraisal㸧ࡀ ࠶ ࡿ㸦Buhle࠸࡚ࠊឤ᝟౯ࡢᙳ㡪ࠊࡍ࡞ࢃࡕࠊ࣏ࢪࢸ࢕ࣈࡲࡓࡣᛌ

2014㸧ࠋࡇࡢㄆ▱ⓗ෌ホ౯࡟ࡼࡗ࡚⚾ࡓࡕࡣࢿ࢞ࢸ࢕ࣈ

࡞ឤ᝟࠿ࢿ࢞ࢸ࢕ࣈࡲࡓࡣ୙ᛌ࡞ឤ᝟ࡢ㛫࡟┦㐪ࡀ࠶ឤ᝟ࢆᢚไࠊࡲࡓࡣࠊ࣏ࢪࢸ࢕ࣈឤ᝟ࢆ㧗ᥭࡉࡏ࡚࠸

ࡿ࠿࠸࡞࠿࡟ࡘ࠸࡚ࡣ᫂ࡽ࠿࡟࡞ࡗ࡚࠸࡞࠸ࠋⴭ⪅ࡽࡀࡿࡀࠊ࠸ࡎࢀ࡟࠾࠸࡚ࡶ๓ᥦ࡜ࡋ࡚ࡑࡢ≧ἣࡸ᝟ᬒࢆ⮬⾜ࡗࡓඛ⾜◊✲࡟࠾࠸࡚ࠊ⮬㌟ࡢ negative ࡞≧ἣࡢ᝿ศ⮬㌟࡟ᘬࡁᐤࡏ࡚᝿ീࡍࡿࡇ࡜ࡀᚲせ࡛࠶ࡿࠋീ࡛๓㢌ᴟࢆ୰ᚰ࡜ࡋࡓ๓㢌๓㔝ࡢάືࡀ㢧ⴭ࡛ࡣ௚⪅ࡢᚰࡢ≧ែࢆ᥎ࡋ㔞ࡿࡇ࡜ࡣ mentalizing ࡲࡓࡣ࠶ࡗࡓࡀࠊࢿ࢞ࢸ࢕ࣈ㸦unhappy㸧࡜࣏ࢪࢸ࢕ࣈ㸦happy㸧௚⪅どⅬ㸦perspective taking㸧࡜࿧ࡤࢀ࡚࠾ࡾࠊ௚⪅࡬ឤ᝟౯㛫࡟᭷ព࡞┦㐪ࡀㄆࡵࡽࢀ࡞࠿ࡗࡓࠋ௒ᅇࠊឤ

ࡢඹឤࡢᇶ┙࡜࡞ࡗ࡚࠸ࡿࠋࡇࡢ௚⪅ࡢᚰ᝟ࢆ᥎ࡋ㔞᝟ⓗ࡞≧ἣࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬ࡢ⬻཯ᛂ࡜ㄆ▱ᶵ⬟ᡂࡿ㝿࡟ࡶࠊ๓ᥦ࡟௚⪅ࡢ≧ἣࢆ᝿ീࡋࡓࡾࢩ࣑࣮ࣗࣞ

⦼࡜ࡢ㛵㐃ᛶࢆㄪ࡭ࠊࡑࡢほⅬ࠿ࡽᛌ࣭୙ᛌ࡜࠸࠺ឤ

ࢩࣙࣥࡋࡓࡾࡍࡿࡇ࡜ࡀᚲ㡲࡛࠶ࡿࠋ≧ἣࡢࢩ࣑࣮ࣗࣞ

᝟౯㛫ࡢ⬻཯ᛂࡢ┦㐪࡟ࡘ࠸᳨࡚ウࡋࡓࠋࢩࣙࣥࡣࠊᮍ᮶ᛮ⪃㸦future thinking㸧࡜ࡶ࿧ࡤࢀ࡚࠾ࡾࠊ

ࡇࢀࡲ࡛ࡢ➹⪅ࡽࡢ◊✲࡛஦๓࡟ㄢ㢟‽ഛࢆࡋ࡚࠸

ࡲࡔ㉳ࡇࡗ࡚࠸࡞࠸ᮍ᮶ࡢ≧ἣ࡟ᛮ࠸ࢆ㥅ࡏࡿ≧ែࢆࡿ᫬ᮇࡢ๓㢌๓㔝ࡢ⾑ὶୖ᪼ࡢ኱ࡁࡉࡀㄢ㢟ᡂ⦼ࡢⰋᣦࡍࠋዲࡉ࡜㛵㐃ࡋ࡚࠸ࡿࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋࡓ㸦Oboshi 2014㸧ࠋࡇࡢࡼ࠺࡞ほⅬ࠿ࡽࠊ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥࡣ⮬㌟

ࡇࡢ᫬ᮇ࡟ᚲࡎࡋࡶ඲ဨࡀḟ࡟᮶ࡿ࡜ண ࡍࡿㄢ㢟ࡢࢩࡢ㐣ཤࡢグ᠈ࢆᇶ࡟ࡋ࡚ᵓ⠏ࡉࢀࡿ࡜⪃࠼ࡽࢀ࡚࠸ࡿ

࣑࣮ࣗࣞࢩࣙࣥࢆ⾜ࡗ࡚࠸ࡓ࠿࡝࠺࠿ࡣ᩿ゝ࡛ࡁ࡞࠸ࡶ

㸦6FKDFWHU㸧ࠋಶேⓗ࡞ฟ᮶஦ࡢグ᠈ࡸࡑࢀࢆᇶ

ࡢࡢࠊᐇ㦂ᚋࡢ⫈ࡁྲྀࡾ࠿ࡽࠊண ࡟㉳ᅉࡍࡿ⬻㈿ά

࡜ࡋ࡚ᵓ⠏ࡉࢀࡿಶேⓗ࡞≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ

ࡀㄆ▱ᶵ⬟࡜㛵㐃ࡋ࡚࠸ࡿ࡜᥎

㸦episodic simulation ࢚ࣆࢯ࣮ࢻࢩ࣑࣮ࣗࣞࢩࣙࣥ㸧ࡣ࢚ᮏ◊✲࡛ࡣࠊ⿕㦂⪅ࡢㄆ▱ᶵ⬟ࡢⰋዲࡉ࡜᝿ീ᫬ࡢ⬻ࣆࢯ࣮ࢻグ᠈࡜ඹ㏻ࡢ⚄⤒ᇶ┙ࢆᣢࡘࡇ࡜ࡀ⬻ᶵ⬟࢖㈿άࡢ኱ࡁࡉ࡟㛵㐃ᛶࡀ࠶ࡿ࡜௬ᐃࡋࡓࠋ

ࡉࢀࡓࠋࡑࡢࡓࡵࠊ

࣓࣮ࢪࣥࢢ࡟ࡼࡗ࡚᫂ࡽ࠿ ࡟࡞ࡗ࡚࠾ࡾ㸦Andrews-≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ࡜ㄆ▱ᶵ⬟࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸+DQQD$GGLV㸧ࠊࡇࢀࡽ࡟ඹ㏻ࡋࡓ⚄⤒ᇶ┙࡚ࡣࠊprospective memory ࡜ࡢ㛵㐃ᛶ㸦Spreng 2018㸧ࠊ࡜ࡋ࡚ෆഃ๓㢌๓㔝ࠊᚋᖏ≧⓶㉁ࠊᴂ๓㒊ࠊୗ㢌㡬ᑠ

FRJQLWLYHÀH[LELOLW\ ࡜ࡢ㛵ಀ㸦5REHUWV㸧ࡀሗ࿌ࡉࢀ

ⴥ࡞࡝ࡢ㡿ᇦ࠿ࡽ࡞ࡿࢹࣇ࢛ࣝࢺ࣮ࣔࢻࢿࢵࢺ࣮࣡ࢡ

࡚࠸ࡿࡀࠊ➹⪅ࡀ▱ࡿ㝈ࡾᩘᑡ࡞࠸ࠋᛌ࣭୙ᛌ࡜࠸࠺ឤ

㸦default mode networkࠊ௨ୗࠊDMN㸧㡿ᇦࡀ▱ࡽࢀ࡚᝟౯࡟ࡼࡗ࡚ᕪࡀ࠶ࡿࡢ࠿࡟ࡘ࠸࡚ࡶ᫂ࡽ࠿࡟࡞ࡗ࡚࠸

࠸ࡿ㸦1RUWKR൵6SUHQJ㸧ࠋ୰࡛ࡶ⮬ᕫ㛵㐃ᛶ࡞࠸ࠋࡑࡢࡓࡵࠊᮏ◊✲࡛ࡣࠊᛌ࣭୙ᛌ࡜࠸࠺ 2 ࡘࡢࡸ⮬ᕫཧ↷ⓗ࡞ሙ㠃࡛ࡣࠊDMN ࡢ࠺ࡕෆഃ๓㢌๓㔝ឤ᝟ⓗ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡿ⬻⾑ὶୖ᪼ࡀྛ

㸦PHGLDOSUHIURQWDOFRUWH[ࠊ௨ୗ MPFC㸧ࡢάືࡀሗ࿌

✀ㄆ▱ᶵ⬟ᡂ⦼ࡢ࠸ࡎࢀ࡜㛵㐃ࡍࡿ࠿࡟ࡘ࠸࡚᪂ࡓ࡟

ࡉࢀ࡚࠸ࡿ㸦%XFNQHU㸧ࠋࡍ࡞ࢃࡕࠊ⮬ศ㸦Self㸧ࢆసᡂࡋࡓឤ᝟ⓗ࡞≧ἣࢆ᝿ീࡍࡿㄢ㢟ࢆ⏝࠸࡚ㄪ࡭ࡓࠋ

㐣ཤ࣭ᮍ᮶࣭௚⪅࡟ᢞᑕࡍࡿࡇ࡜ࡀࠊࡑࢀࡒࢀ࢚ࣆࢯ࣮
ࢻグ᠈㸦episodic memory㸧ࠊ࢚ࣆࢯ࣮ࢻࢩ࣑࣮ࣗࣞࢩࣙ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021㸬┠ⓗ

3.3㸬⬻㈿άㄢ㢟ᮏ◊✲ࡢ┠ⓗࡣࠊឤ᝟ⓗ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬㈿ ά ㄢ 㢟 ࡣ ,QWHUQDWLRQDO$൵HFWLYH3LFWXUH6\VWHPVࡢ๓㢌๓㔝ࡢ⬻⾑ὶ཯ᛂࢆㄪ࡭ࠊឤ᝟౯㛫࡟┦㐪ࡀ࠶⏬ീ㸦Lang 2008㸧ࡢᛌཬࡧ୙ᛌ⏬ീࢆ⏝࠸࡚సᡂࡋࡓࠋ

ࡿ࠿࡝࠺࠿ࢆ᳨ウࡋࠊㄆ▱ᶵ⬟᳨ᰝᡂ⦼࡜ࡢ㛵㐃ᛶࡢᛌ⏬ീᖹᆒࡣឤ᝟౯ࡀ  s 0.30ࠊぬ㓰ᗘࡀ  s᭷↓ࠊཬࡧࠊㄢ㢟᫬ࡢ๓㢌๓㔝ࡢᙺ๭ࢆ᫂ࡽ࠿࡟ࡍࡿ

0.83 ࡛࠶ࡾࠊ୙ᛌ⏬ീᖹᆒࡣࠊឤ᝟౯ࡀ  s 0.80ࠊ

ࡇ࡜࡛࠶ࡿࠋぬ㓰ᗘࡀ 5.98 s 0.53 ࡛࠶ࡾ୧⩌㛫ࡢぬ㓰ᗘ࡟᭷ពᕪ
ࡣ࡞࠸ࠋ

㸬᪉ἲ

ㄢ㢟࡟ࡣࠊ࿊♧ࡉࢀࡓᛌࡲࡓࡣ୙ᛌ࡞⏬ീࡢ≧ἣࢆࡑࡢឤ᝟ࡶྵࡵ࡚࡛ࡁࡿࡔࡅ㩭᫂࡟᝿ീࡍࡿ᮲௳㸦᝿ീ

3.1㸬⿕㦂⪅೺ᖖⱝᖺ⪅ 34 ྡ㸦ᖹᆒᖺ㱋 22.4s1.6 ṓࠋ⏨ᛶ 16 ྡ࣭᮲௳㸧࡜ࠊᐈほⓗ࡟⏬ീࢆほᐹࡍࡿ᮲௳㸦ほᐹ᮲௳㸧ࡀ

ዪᛶ 18 ྡ㸧ࡀཧຍࡋࡓࠋ฼ࡁᡭࡣ Edinburgh Handednessྵࡲࢀ࡚࠸ࡿࠋ᝿ീ᮲௳࡛ࡣࠊ⿕㦂⪅࡟࿊♧ࡉࢀࡿ⏬

Inventory ࡟ࡼࡗ࡚඲ဨྑ࡜ุᐃࡉࢀࡓ㸦2OG¿HOG㸧ࠋീ࡟ࡘ࠸࡚ࠕࡑࡢሙ࡟࠸ࡿࠊࡲࡓࡣࠊࡑࡢ≧ἣࡀ┠ࡢ๓ᮏ◊✲ࡣࠊ὾ᯇ་⛉኱Ꮫ೔⌮ጤဨ఍ࡢᢎㄆࢆᚓ࡚ᐇ᪋

࡟࠶ࡿ࡜ᛮࡗ࡚ࡃࡔࡉ࠸ࠖ࡜ᣦ♧ࡋࡓࠋ⿕㦂⪅ࡣྛヨ⾜ࡋࡓ㸦ᢎㄆ᪥㸸2016 ᖺ 12 ᭶ 5 ᪥ࠊᢎㄆ␒ྕ㸸16-056㸧ࠋᚋ࡟ࠕ㠀ᖖ࡟୙ᛌࠖ࠿ࡽࠕ㠀ᖖ࡟ᛌࠖࡲ࡛ 9 ẁ㝵࡛฼ࡁ

1 ྡࡣ ᐃ᫬ࡢᢏ⾡ⓗ࢚࣮ࣛࡢࡓࡵࠊ1 ྡࡣ࠺ࡘⓗഴྥᡭ ࡟ ࡚ ࣎ ࢱ ࣥ㸦TR14-D, Current Designs Inc.,ࡢᣦᶆ࡛࠶ࡿ BDI- ϩ್ࡀ  Ⅼ࡛࠶ࡾ࠺ࡘⓗഴྥࡀᙉ࠸

Philadelphia, PA, USA㸧ࢆᢲࡋ࡚⮬㌟ࡢẼศࢆホ౯ࡋࡓ࡜ุ᩿ࡉࢀࡓࡓࡵゎᯒ࠿ࡽ㝖እࡋࡓࠋ⤖ᯝ࡜ࡋ࡚ 32 ྡ㸦ᅗ 2㸧ࠋどぬ่⃭ㄢ㢟సᡂ࡟ࡣ Presentation software㸦ᖹᆒᖺ㱋 22.5 s 1.6 ṓࠋ⏨ᛶ 15 ྡ࣭ዪᛶ  ྡ㸧࡛㸦Neurobehavioral System Inc., Albany, CA, USA㸧ࢆ౑⏝ゎᯒࢆᐇ᪋ࡋࡓࠋ඲㐣⛬࡟࠾࠸࡚ࠕ࣊ࣝࢩࣥ࢟ᐉゝࠖࢆࡋࠊㄢ㢟ࡣࣔࢽࢱ࣮ࢫࢡ࣮ࣜࣥ࡟ᫎࡋฟࡉࢀࡓࠋ

㑂Ᏺࡋ࡚ᐇ᪋ࡋࡓࠋ⿕㦂⪅࡟ࡣ◊✲Ⓩ㘓ࡢ๓࡟◊✲ࡢ⿕㦂⪅ࡣࠊ᝿ീ࣭ほᐹ᮲௳ࢆࣛࣥࢲ࣒࡟ 2 ࡘࡎࡘྵ┠ⓗࡸ᪉ἲ➼࡟ࡘ࠸࡚༑ศ࡞ㄝ᫂ࢆ⾜࠸඲⿕㦂⪅࠿ࡽ

ࡴ 1 ヨ⾜㸦⣙ 4 ศ㸧ࢆࠊᛌ᮲௳ 2 ᅇࠊ୙ᛌ᮲௳ 2 ᅇࡢᩥ᭩࡟ࡼࡿྠពࢆᚓࡓࠋ

ィ 4 ヨ⾜ࢆࣛࣥࢲ࣒࡟⾜ࡗࡓࠋྛヨ⾜㛫࡟ࡣ⣙ 3̺5 ศ⛬ᗘఇ᠁ࢆධࢀ࡚ᐇ᪋ࡋࡓࠋ ᐃᐇ᪋๓࡟ูࡢ⏬ീࢆ

3.2㸬NIRS ⿦⨨⬻⾑ὶ౑⏝ࡋࡓ⦎⩦ࢆ⾜࠸ࠊㄢ㢟᪉ἲ࡟ࡘ࠸࡚༑ศ࡟⌮ゎࠊᐃ࡟ࡣࠊOEG-SpO2
㸦Spectratech ♫ࠊ඲ 16࠿ࡘ᝿ീ࣭ほᐹࡀྍ⬟࡛࠶ࡗࡓࡇ࡜ࢆ☜ㄆࡋࡓ࠺࠼࡛ᮏ

ࢳࣕࣥࢿࣝ㸧ࢆ⏝࠸ࡓࠋNIRS ⿦ ⨨ Ἴ 㛗 ࡣQPࠊ

ᐃࢆ⾜ࡗࡓࠋ㢌㒊ࡢືࡁࡢᢚไࡢࡓࡵ࡟⬻⾑ὶ ᐃ

840nm ࡢ 2 Ἴ㛗ࢆ⏝࠸࡚࠾ࡾࠊࢧࣥࣉࣜࣥࢢ࣮ࣞࢺࡣ

୰ࡣ㢡ࢆ㢡ྎ࡟஌ࡏ࡚ࡶࡽ࠸ࠊ㢌㒊ࠊ๓㢠㒊ࡢືࡁࢆ

12.2Hz ࡛࠶ࡿࠋᅜ㝿⬻Ἴ 10-20 ἲࡢ Fpz ࢆࣉ࣮ࣟࣈୗ

ࡣࡌࡵ࡛ࡁࡿ㝈ࡾయືࢆᢚไࡍࡿࡼ࠺ᣦ♧ࡋࡓࠋ➃୰ኸ࡟ྜࢃࡏ࡚๓㢠㒊࡟⿦╔ࡋࡓࠋࣉ࣮ࣟࣈ㓄⨨ࢆ
ᅗ 1 ࡟♧ࡍࠋᅗ 㸬1,56 ගᴟ఩⨨ཬࡧࢳࣕࣥࢿࣝ఩⨨ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

ᅗ 㸬⬻㈿άㄢ㢟ィⓗ࡟ゎᯒࡋࡓࠋࡉࡽ࡟ࠊࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡿ⬻㈿3.4㸬ㄆ▱ᶵ⬟᳨ᰝㄆ▱ᶵ⬟᳨ᰝ࡜ࡋ࡚ࠊㄽ⌮ⓗグ᠈㸦࢙࢘ࢡࢫ࣮ࣛグ᠈άࡢኚ໬್࡜ࡋ࡚୧ヨ⾜㛫ࡢᕪศࡢ R[\+E㸦᝿ീ᫬ᖹ᳨ᰝࠊ┤ᚋ࣭㐜ᘏ෌⏕㸧ࠊᩘᏐࡢ㡰ၐ࣭㏫ၐࠊDigit

ᆒǼ >R[\+E@ ್㸫ほᐹ᫬ᖹᆒǼ >R[\+E@ ್㸧ࢆࢳࣕࣥ

symbol substitution testࠊ ᩥ Ꮠ ὶ ᬸ ᛶ ㄢ 㢟㸦Letterࢿࣝࡈ࡜࡟⟬ฟࡋࡓࠋࡇࡢ್࡟࡟ࡘ࠸࡚ᛌ࣭୙ᛌ࡛ᕪࡀ

Fluency Testࠊ௨ୗ LFTࠊ3 ㄒ㢌㡢㸸࠶࣭࠿࣭ࡋ㸧ࠊព࠶ࡿ࠿ paired t-test ࡟ࡼࡗ࡚ゎᯒࡋࡓࠋ࿡ὶᬸᛶㄢ㢟㸦Category Fluency Testࠊ௨ୗ CFTࠊ3 ࢝⤫ィⓗゎᯒ࡟ࡣ SPSS
㸦version25ࠊ᪥ᮏ IBM ♫㸧ࢆ⏝ࢸࢦ࣮ࣜ㸸ື≀࣭⫋ᴗ࣭ࢫ࣏࣮ࢶ㸧ࠊTrail Making Test࠸ࠊ᭷ពỈ‽ࢆ p < 0.05 ࡜ࡋࡓࠋ-A/B
㸦௨ୗࠊTMT -A/B㸧ࢆ⬻⾑ὶ ᐃ࡜ྠ᪥࡟ᐇ᪋ࡋࡓࠋ
3.5.3㸬⬻⾑ὶኚ໬࡜ㄆ▱ᶵ⬟ᡂ⦼࡜ࡢ┦㛵ࢩ࣑࣮ࣗࣞࢩࣙࣥ⮬య࡟ࡼࡿ R[\+E ኚ໬್㸦᝿ീ᫬

3.5㸬ゎᯒ᪉ἲ
3.5.1㸬⾜ືᏛⓗᣦᶆẼศホ౯ᚓⅬ࡟ࡘ࠸࡚ᛌ࣭୙ᛌࡈ࡜࡟ paired t-test ࡟ࡼࡾ᮲௳㸦᝿ീ࣭ほᐹ㸧㛫ẚ㍑ࢆ⾜ࡗࡓࠋᖹᆒǼ >R[\+E@ ್㸫ほᐹ᫬ᖹᆒǼ >R[\+E@ ್㸧࡜ㄆ▱ᶵ⬟᳨ᰝᚓⅬཬࡧ཯ᛂ᫬㛫࡜ࡢ┦㛵࡟ࡘ࠸࡚ゎᯒࡋࡓࠋṇつᛶ᳨ᐃᚋ࡟ࣆ࢔ࢯࣥ┦㛵ಀᩘࠊࡲࡓࡣࢫࣆ࢔࣐ࣥ
┦㛵ಀᩘࢆ⏝࠸࡚ゎᯒࡋࡓࠋ┦㛵ಀᩘ࡟ࡘ࠸࡚ࡣ 0.4

3.5.2㸬⬻⾑ὶኚ໬௨ୖࢆ┦㛵᭷ࡾࠊ0.3 ௨ୖࢆᙅ࠸┦㛵᭷ࡾ࡜ࡋࡓࠋ

Brain Vision Analyzer2㸦Brain Products GmbH,
Gilching, Germany㸧 ࡜ MATLAB㸦MathWorks, Inc.,㸬⤖ᯝ

Natick, MA, USA㸧ࢆ⏝࠸࡚ゎᯒࡋࡓࠋ⬻⾑ὶୖ᪼ࡢᣦ

4.1㸬⾜ືᏛⓗᣦᶆᶆ࡜ࡋ࡚㓟⣲໬࣊ࣔࢢࣟࣅࣥ⃰ᗘኚ໬㸦Ǽ >R[\+E@㸧ࢆㄆ▱ᶵ⬟᳨ᰝ⤖ᯝࢆ⾲ 1 ࡟♧ࡍࠋㄽ⌮ⓗグ᠈㸦࢙࢘⏝࠸ࡓ㸦Hoshi 2001㸧ࠋゎᯒ࡟ඛ❧ࡕࠊయື➼࡟ࡼࡿࣀࢡࢫ࣮ࣛグ᠈᳨ᰝ㸧┤ᚋ෌⏕ཬࡧ㐜ᘏ෌⏕ࡢᚓⅬࡣࠊ࢖ࢬࡀ࡞࠸ࡇ࡜ࢆ☜ㄆࡋࡓࠋ࣮࣋ࢫࣛ࢖ࣥࢆㄢ㢟㛤ጞ๓่⃭ᩥ A ࡜่⃭ᩥ B ࡢྜィⅬ࡛࠶ࡿࠋẼศᚓⅬࡣࠊࡢ 5 ⛊㛫࡜ࡋࠊㄢ㢟㛤ጞᚋ  ⛊㛫ࡢǼ >R[\+E@ ࢆࢳࣕᛌ≧ἣ࡛ࡣほᐹ᫬࡜ẚ࡭᝿ീ᫬࡟᭷ព࡟㧗ࡃ㸦df = 32,ࣥࢿࣝࡈ࡜ࠊ᮲௳ࡈ࡜࡟ຍ⟬ᖹᆒ໬ࡋࡓࠋ඲⿕㦂⪅t = 6.155, p < 0.0001㸧ࠊ୙ᛌ≧ἣ࡛ࡣ᭷ព࡟ప࠿ࡗࡓ㸦df

㸦n=32㸧ࡢྛ᮲௳࡟࠾ࡅࡿᖹᆒǼ >R[\+E@ ࢆ⟬ฟࡋ⤫W S㸧㸦ᅗ 3㸧ࠋ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

⾲ 㸬ㄆ▱ᶵ⬟᳨ᰝ⤖ᯝ㡯┠

ᚓⅬࡲࡓࡣᡤせ᫬㛫㸦⛊㸧

ㄽ⌮ⓗグ᠈㸦࢙࢘ࢡࢫ࣮ࣛグ᠈᳨ᰝ㸧┤ᚋ෌⏕ ᚓⅬs

ㄽ⌮ⓗグ᠈㸦࢙࢘ࢡࢫ࣮ࣛグ᠈᳨ᰝ㸧㐜ᘏ෌⏕ ᚓⅬs

ᩘᏐࡢ㡰ၐ ṇ⟅ᩘs

ᩘᏐࡢ㏫ၐ ṇ⟅ᩘsᩥᏐὶᬸᛶㄢ㢟㸦/)7㸪ㄒ㢌㡢ࠕ࠶ࠖ㸧ṇ⟅ᩘ

s

ᩥᏐὶᬸᛶㄢ㢟㸦/)7㸪ㄒ㢌㡢ࠕ࠿ࠖ㸧ṇ⟅ᩘ

s

ᩥᏐὶᬸᛶㄢ㢟㸦/)7㸪ㄒ㢌㡢ࠕࡋࠖ㸧ṇ⟅ᩘ

s

ᩥᏐὶᬸᛶㄢ㢟 ㄒ ྜィṇ⟅ᩘྜィs

ព࿡ὶᬸᛶㄢ㢟㸦࢝ࢸࢦ࣮ࣜࠕື≀ࠖ㸧ṇ⟅ᩘ

s

ព࿡ὶᬸᛶㄢ㢟㸦࢝ࢸࢦ࣮ࣜࠕ⫋ᴗࠖ㸧ṇ⟅ᩘ

s

ព࿡ὶᬸᛶㄢ㢟㸦࢝ࢸࢦ࣮ࣜࠕࢫ࣏࣮ࢶࠖ
㸧ṇ⟅ᩘ

s

ព࿡ὶᬸᛶㄢ㢟 ࢝ ࢸࢦ࣮ࣜṇ⟅ᩘྜィs

7UDLO0DNLQJ7HVW̻$㸦⛊㸧s

7UDLO0DNLQJ7HVW̻%㸦⛊㸧s
ᖹᆒ್sᶆ‽೫ᕪ

4.2㸬⬻⾑ὶࢹ࣮ࢱ୙ᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥࡣᛌ≧ἣ࡟ẚ࡭࡚⬻⾑ὶୖ᪼ࢆక࠺ഴྥࡀࡳࡽࢀࡓࠋࡋ࠿ࡋࠊ⤫ィⓗゎᯒ࡛ࡣࠊR[\+E㸦᝿ീ᫬ᖹᆒǼ >R[\+E@ ್㸫ほᐹ᫬ᖹᆒǼ>R[\+E@ ್㸧࡟ࡘ࠸࡚ᛌ࣭୙ᛌ㛫࡛᭷ពᕪࡀ♧ࡉࢀࡓࢳࣕࣥࢿࣝࡣ࡞࠿ࡗࡓ㸦ᅗ 4㸧ࠋᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙ
࡛ࣥୖ᪼ࡋࡓࢳࣕࣥࢿࣝࡣ๓㢌๓㔝ࡢእഃ㒊ࡢࡳ࡛࠶ࡗࡓࠋ
4.3㸬⬻⾑ὶࢹ࣮ࢱ࡜ㄆ▱ᶵ⬟ᡂ⦼࡜ࡢ┦㛵ࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡿᖹᆒǼ >R[\+E@ ್㸦᝿ീ᫬ᖹ*** p < 0.001, paired t testᆒǼ >R[\+E@ ್㸫ほᐹ᫬ᖹᆒǼ >R[\+E@ ್㸧࡜ㄆ▱ᶵ⬟᳨ᰝᚓⅬ㸦TMT-A/B ࡟ࡘ࠸࡚ࡣ཯ᛂ᫬㛫㸧࡜ࡢ㛫࡟Ip, Imagination pleasant㸦᝿ീ ᛌ㸧
Op, Observation pleasant㸦ほᐹ ᛌ㸧Iu, Imagination unpleasant㸦᝿ീ ୙ᛌ㸧
Ou, Observation unpleasant㸦ほᐹ ୙ᛌ㸧ᖹᆒ್ s ᶆ‽೫ᕪᅗ 㸬ẼศᚓⅬ௨ୗࡢ᭷ព࡞┦㛵ࡀㄆࡵࡽࢀࡓ㸦ᅗ 5㸧ࠋ< ᛌ≧ἣ >
ㄽ⌮ⓗグ᠈㸦㐜ᘏ෌⏕㸧㸸ch1
㸦U S 㸧ࠊព࿡ὶᬸᛶㄢ㢟㸦3 ࢝ࢸࢦ࣮ࣜྜィ⏕ᡂㄒᩘ㸧㸸ch16
㸦r= 0.388, p = 0.0343㸧
ᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩ࡛ࣙࣥࡣㄽ⌮ⓗグ᠈㐜ᘏ෌⏕ᚓⅬ࡜ ch1 ࡢǼ >R[\+E@ ್㛫ࠊព࿡ὶᬸᛶㄢ㢟㸦3 ࢝ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021᝿ീ᫬ᖹᆒǼ>R[\+E@್㸫ほᐹ᫬ᖹᆒǼ>R[\+E@್㸦ᖹᆒ s ᶆ‽ㄗᕪ㸧ᅗ 㸬ࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡿ R[\+E ኚ໬್ࡢឤ᝟౯㛫ẚ㍑

A㸬ᛌ࡞≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬࡟࠾࠸࡚᭷ព࡞┦㛵ࡀ♧ࡉࢀࡓࡶࡢ
B㸬୙ᛌ࡞≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬࡟࠾࠸࡚᭷ព࡞┦㛵ࡀ♧ࡉࢀࡓࡶࡢᅗ ࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡿ R[\+E ኚ໬್࡜ㄆ▱ᶵ⬟᳨ᰝᡂ⦼࡜ࡢ㛵㐃ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ࢸࢦ࣮ࣜྜィ⏕ᡂㄒᩘ㸧࡜ ch16 ࡢǼ >R[\+E@ ್㛫࡟ṇࡀࡳࡽࢀࡓࠋᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩ࡛ࣙࣥࡣㄽ⌮ⓗグ┦㛵ࡀ♧ࡉࢀࡓࠋ

᠈㐜ᘏ෌⏕ᚓⅬࡢⰋዲࡉ࡜๓㢌๓㔝እഃ㒊࡟┦ᙜࡍࡿ< ୙ᛌ≧ἣ >ࢳࣕࣥࢿࣝ 1 ࡢ⬻㈿άࡢ኱ࡁࡉ࡜ࡢ㛫࡟㛵㐃ᛶࡀ♧ࡉࢀ

TMT-A㸸ch4㸦 Ȩ = -0.393ࠊp = 0.0351㸧ࠊch6㸦 Ȩ=ࡓࠋእഃ㒊ࡢ๓㢌๓㔝ࡣ๓㢌๓㔝ࡢ୰࡛ࡶ࣮࣡࢟ࣥࢢ
࣓࣮ࣔࣜ➼ࡢㄆ▱ⓗ࡞㠃࡟㛵ࢃࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿ

-0.386ࠊp = 0.0354㸧
୙ᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩ࡛ࣙࣥࡣ TMT-A ࡢ཯ᛂ᫬㛫

㸦Liu 2013㸧ࠋࡲࡓࠊᕥእഃ㒊๓㢌๓㔝࡟┦ᙜࡍࡿࢳࣕ

࡜ ch4࣭ch16 ࡢǼ >R[\+E@ ್㛫࡟㈇ࡢ┦㛵ࡀ♧ࡉࢀࡓࠋࣥࢿࣝ 16 ࡢ⬻㈿άࡢ኱ࡁࡉ࡜ࠊព࿡ὶᬸᛶㄢ㢟 3 ࢝ࢸࢦ࣮ࣜྜィ⏕ᡂㄒᩘࡢከࡉ࡜ࡢ㛫࡟ࡶ᭷ព࡞┦㛵ࡀ♧

㸬⪃ᐹ

ࡉࢀࡓࠋ

ᛌ≧ἣ࡛ࡣ᝿ീ᮲௳ࡢࡳ࡞ࡽࡎほᐹ᫬࡟࠾࠸࡚ࡶ๓

WMS-R ࡢㄽ⌮ⓗグ᠈࡛ࡣࠊ᳨ᰝ⪅ࡀㄞࡳୖࡆࡿ▷㢌๓㔝ࡢ㈿άࡀ♧ࡉࢀࠊほᐹ᫬ࡢ⬻཯ᛂࡀ኱ࡁ࠸ഴྥ

࠸≀ㄒࢆ⿕㦂⪅࡟グ᠈ࡋ࡚ࡶࡽ࠸ࠊㄞࡳ⤊࠼ࡓ┤ᚋ㸦┤ࡀ♧ࡉࢀࡓࠋほᐹ᮲௳࡛ࡣ࡛ࡁࡿ㝈ࡾᐈほⓗ࡟ほᐹࡍᚋ෌⏕㸧࠶ࡿ࠸ࡣ 30 ศᚋ㸦㐜ᘏ෌⏕㸧࡟⿕㦂⪅࡟≀ㄒࡿࡇ࡜ࢆᩍ♧ࡋࡓࡀࠊ⬻཯ᛂ࡜ࡋ࡚ࡣᛌ୙ᛌ⏬ീࢆぢࡓࢆ෌⏕ࡋ࡚ࡶࡽ࠺ㄢ㢟࡛࠶ࡿࠋࡇࡢㄢ㢟࡛ࡣࠊグ᠈ࡢࡓ㝿࡟⬻⾑ὶୖ᪼ࡀ⏕ࡌ࡚࠾ࡾࠊほᐹ᫬࡟ࡣឤ᝟ࢆច㉳ࡵ࡟≀ㄒࡢ᝟ᬒࢆ᝿ീ࠶ࡿ࠸ࡣ㢌࡟ᛮ࠸ᥥࡃࡇ࡜ࡀᚓ

ࡋ࡞࠸ࡇ࡜ࡀồࡵࡽࢀࡓࡀ⬻⾑ὶ཯ᛂ࡜ࡋ࡚ࡣఱࡽ࠿ࡢ

ⅬࡢⰋዲࡉ࡟ࡘ࡞ࡀࡿࠋ௒ᅇࠊᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙ

ឤ᝟ࡀច㉳ࡋࡓ⤖ᯝ࡜⪃࠼ࡽࢀࡓࠋ

ࣥ᫬ࡢ⬻㈿άࡢ኱ࡁࡉࡀ෌⏕ᚓⅬࡢⰋዲࡉ࡜㛵㐃ࡋ࡚࠾ឤ᝟౯ࡢ┦㐪࡟ࡘ࠸࡚ࠊ᭷ពᕪࡣ♧ࡉࢀ࡞࠿ࡗࡓࡶ

ࡾࠊグ᠈࡟࠶ࡓࡾࡑࡢ≀ㄒࡢ≧ἣࢆࢩ࣑࣮ࣗࣞࢩ࡛ࣙࣥ

ࡢࡢᛌ≧ἣ࡜ẚ࡭࡚୙ᛌ≧ἣࡢ᝿ീ࡟࠾ࡅࡿ⬻⾑ὶୖࡁࡿ⬟ຊ࡟㛵ࢃࡿྍ⬟ᛶࡀ࠶ࡿࠋ㛵㐃ᛶࡀ♧ࡉࢀࡓ㒊᪼ࡀ኱ࡁ࠸ഴྥࡀ♧ࡉࢀࡓࠋ఩ࡣ๓㢌๓㔝ࡢእഃ㒊࡛࠶ࡾࠊࡇࡢ㒊఩ࡣㄆ▱ⓗឤ᝟➹⪅ࡽࡀྠㄢ㢟ࢆ⏝࠸࡚ᐇ᪋ࡋࡓ fMRI ࡛ࡢ◊✲࡛ไᚚ࡟㛵ࢃࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿࠋឤ᝟ⓗ≧ἣࡢࢩ࣑ࣗ

ࡶྠᵝ࡟୙ᛌ≧ἣ࡛ࡢࢩ࣑࣮ࣗࣞࢩ࡛ࣙࣥ⬻⾑ὶୖ࣮᪼ࣞࢩࣙࣥ᫬࡟ࡣࠊグ᠈ࡢྲྀࡾฟࡋ㸦retrieval㸧࡜෌ᵓᡂࡀ MPFC 㡿ᇦࡸ๓㢌๓㔝࡟ࡳࡽࢀ࡚࠾ࡾࠊMPFC 㡿ᇦ㸦re-construction㸧ࠊไᚚ㸦regulation㸧ࡢ㠃࡛๓㢌๓㔝ࡣᚰࡢ⌮ㄽࡸඹឤ࡛ࡶ㈿άࡍࡿ㒊఩࡛࠶ࡿࡓࡵࠊ୙ᛌ

ࡢእഃ㒊ࡀ㛵୚ࡋ࡚࠸ࡿࡇ࡜ࡀ♧၀ࡉࢀࡿࠋ

≧ἣ࡛ࡣඹឤⓗ࡞⬻཯ᛂࡀ⏕ࡌ࡚࠸ࡿྍ⬟ᛶࡀ᥎ ࡉ୙ᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟࠾ࡅࡿ⬻㈿άࡣᛌ≧ἣࢀࡓࠋ࡞࠾ࠊ୙ᛌࢆࡣࡌࡵ࡜ࡍࡿ negative ࡞ឤ᝟่⃭࡟ẚ࡭࡚኱ࡁ࠸ഴྥࡀࡳࡽࢀࡓࡀࠊ୙ᛌ≧ἣࢆࢩ࣑ࣗ

࡟ࡼࡿ๓㢌๓㔝ࡢ⬻⾑ὶୖ᪼ࡀඛ⾜◊✲࡛ሗ࿌ࡉࢀ࡚

࣮ࣞࢩࣙࣥࡍࡿ⬟ຊࡣࠊ༴㝤ᅇ㑊࡟࡜ࡗ࡚ࡣ㔜せ࡛࠶࠸ࡿ㸦Minematsu 2018㸧ࠋ⚾ࡓࡕࡀ᪥ᖖ⏕άࢆ㏦ࡿୖ࡛ࡿࠋ୙ᛌ≧ἣࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬ࡢ⬻㈿άࡢ኱ࡁࡉࡣࠊ

ឤ᝟ไᚚࢆࡼࡾᚲせ࡜ࡍࡿࡢࡣࢿ࢞ࢸ࢕ࣈཬࡧ୙ᛌ࡞ឤ

TMT-A ཯ᛂ᫬㛫ࡢ㏿ࡉ࡜᭷ព࡞┦㛵ࡀ♧ࡉࢀࡓࠋ┦㛵᝟࡟ࡘ࠸࡚࡛࠶ࡿࠋࡑࡢࡓࡵࠊ୙ᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙ

ࡀㄆࡵࡽࢀࡓࡢࡣࠊ⭡እഃ㒊ࡢ๓㢌๓㔝࡛࠶ࡗࡓࡀࠊ

ࣥࡢ࡯࠺ࡀࡼࡾ኱ࡁ࡞⬻཯ᛂࢆ⏕ࡌࡉࡏࡿྍ⬟ᛶࡀ㧗ࡇࡢ㒊఩ࡣᡥ᱈యࡢάືࢆᢚไࡍࡿࡇ࡜࡛୙ᛌឤ᝟ࡢ

࠸ࠋ๓㏙ࡢࢹࣇ࢛ࣝࢺ࣮ࣔࢻࢿࢵࢺ࣮࣡ࢡ㸦DMN㸧ࡣࠊㄪᩚࡍࡿ㒊఩࡜ࡋ࡚▱ࡽࢀ࡚࠸ࡿ㸦Hoshi 2011, Tupak೺ ᖖ ⪅ཬࡧ ⢭ ⚄ ⑌ ᝈࢆᣢ ࡘ ᑐ ㇟ ⪅ ࡟ ࠾࠸࡚ෆ ┬2014㸧ࠋTMT-A ࡢ཯ᛂ᫬㛫ࡢ㏿ࡉࡣࠊὀព⬟ຊࢆ⾲ࡍ㸦introspection㸧ࡸ཯ⱄᛮ⪃㸦rumination㸧࡟㛵୚ࡋࠊ๓࡜ࡉࢀࠊ୙ᛌ≧ἣࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬࡟⏕ࡌࡿ୙ᛌឤ᝟

㢌๓㔝ࡀ่⃭ࡢឤ᝟ⓗ࡞෌ホ౯࡟㔜せ࡛࠶ࡿ࡜ࡉࢀࡿ

ࡢᢚไ࡛ࡢ⬻㈿άࡢ኱ࡁࡉ࡜ὀព⬟ຊࡢⰋዲࡉࡀ㛵㐃

㸦Fettes 2018㸧ࠋ ୙ᛌ≧ ἣࡢࢩ࣑࣮ࣗࣞࢩ࡛ࣙࣥࡣࠊ

ᛶࢆ♧ࡋࡓࡇ࡜࠿ࡽࠊ୙ᛌឤ᝟ࢆࡼࡾ᭷ຠ࡟ᢚไ࡛ࡁࡿ

DMN 㡿ᇦࡀ㈿άࡋ࡚࠸ࡿ࡜⪃࠼ࡽࢀࠊ๓㢌๓㔝ࡣࡑࢀࡇ࡜࡟ࡼࡗ࡚ὀពࢆຠ⋡ⓗ࡟᣺ࡾྥࡅࡿࡇ࡜ࢆྍ⬟࡜ࡍࡽࡢάືࢆไᚚࡋ࡚࠸ࡿ࡜᥎ ࡉࢀࡿࠋࡿࡇ࡜ࡀ♧၀ࡉࢀࡿࠋ୙ᛌឤ᝟ࢆᐹ▱ࡋไᚚࡍࡿࡇ࡜࡟

≧ἣࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬ࡢ⬻㈿άࡢ኱ࡁࡉ࡜ㄆ▱ᶵ⬟ᡂ⦼ࡢⰋዲࡉ࡜ࡢ㛫࡟ᛌࠊ୙ᛌ≧ἣ࡜ࡶ࡟㛵㐃ᛶࡀ♧ࡼࡗ࡚እ⏺࡬ࡢὀពࢆࡍࡤࡸࡃྥࡅࡿࡇ࡜ࡣࠊ༴ᶵࡸ༴
㝤ᅇ㑊࡟ᚲせ࡞⬟ຊ࡛࠶ࡿࠋ

ࡉࢀࠊᮏ◊✲࡟࠾࠸࡚ࡶண ࡟㉳ᅉࡍࡿ⬻㈿ά࡜ㄆ▱ᶵ⬟࡜ࡢ㛵㐃ࡀ♧၀ࡉࢀࡓࠋ

௒ᅇࡢ⤖ᯝ࡛ࡣࠊ୙ᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥࡀᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥࡼࡾࡶ⬻㈿άࡀ኱ࡁ࠸ഴྥࡀࡳࡽ

⬻⾑ὶୖ᪼ࡢ኱ࡁࡉ࡟ࡘ࠸࡚ࡣࠊᛌ≧ἣ᫬࡜୙ᛌ≧ࢀࠊὀពᶵ⬟ࡢᡂ⦼ࡢⰋዲࡉ࡜㛵㐃ࡋ࡚࠸ࡓࠋ୙ᛌ≧ἣ᫬࡛ࡢ᭷ព࡞ᕪࡀぢ࠸ࡔࡏ࡞࠿ࡗࡓࡀࠊㄢ㢟᫬ࡢ⬻ἣࢆணᮇࡍࡿࡇ࡜ࡣࣄࢺࡢ᪥ᖖ⏕άࡢ୰࡛༴ᶵ࣭༴㝤ᅇ⾑ὶୖ᪼ࡢ኱ࡁࡉ࡜ㄆ▱ᶵ⬟ᚓⅬ࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸࡚

㑊࡟࡜ࡗ࡚㔜せ࡛࠶ࡿࡓࡵࠊ⬻཯ᛂࡀ኱ࡁࡃࠊ࠿ࡘࡑࡢ

ࡣࠊᛌ࣭୙ᛌࡢ㛫࡛㛵㐃ᛶࢆ♧ࡍㄆ▱ᶵ⬟ᣦᶆ࡟┦㐪⬻㈿άࡣグ᠈ࡸὀព࡞࡝࡜㛵㐃ࡋ࡚࠸ࡿࡇ࡜ࡀࢃ࠿ࡗ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

ࡓࠋ

the past and imagining the future: Common and distinctࡋ࠿ࡋ࡞ࡀࡽࠊᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬ࡢ⬻㈿ά

neural substrates during event construction and
HODERUDWLRQ1HXURSV\FKRORJLD

ࡢ኱ࡁࡉ࡜グ᠈ᶵ⬟ࡢⰋዲࡉࡀ㛵㐃ࡋ࡚࠸ࡓࡇ࡜࠿ࡽࠊ
ᛌ࡞࢚ࣆࢯ࣮ࢻグ᠈ࢆ࣮࣋ࢫ࡜ࡋࡓᛌ≧ἣࢆ᝿㉳ࡋ࡚ࡶ

Andrews-Hanna JR 㸦2012㸧: The brain̓s defaultࡽ࠺ᶵ఍ࡸሙ㠃ࡣㄆ▱ᶵ⬟ࢆ㧗ࡵࡿྍ⬟ᛶࡀ᥎ ࡉࢀ

network and its adaptive role in internal mentation,ࡿࠋᛌ≧ἣࡢ᝿㉳ࡣࠊᅇ᝿ἲⓗ࡞௓ධ࡛ᘬࡁฟࡉࢀࡿ

Neuroscientist, 18㸦3㸧
Buckner RL, Carroll DC 㸦㸧: Self-projection and theࡇ࡜ࡀከࡃࠊ㧗㱋⪅ࡢᚰ⌮㠃ࡢᏳᐃࡸ⏕άࡢ㉁ࡢྥୖ

EUDLQ7UHQGVLQ&RJQLWLYH6FLHQFHV࡟ࡘ࡞ࡀࡿ࢔ࣉ࣮ࣟࢳ࡜ࡋ࡚╔┠ࡉࢀ࡚࠸ࡿࠋ୙ᛌ≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟࠾࠸࡚ࠊឤ᝟ࡢᢚไ࡟㛵㐃ࡋ࡚๓

Buhle JT, Silvers JA, Wager TD, et al. 㸦2014㸧: Cognitive㢌๓㔝ࡢ⬻཯ᛂࡣ㧗ࡲࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓࡀࠊ୙ᛌ

reappraisal of emotion: a meta-analysis of human≧ἣࡢࢩ࣑࣮ࣗࣞࢩࣙࣥࡣᑐ㇟⪅ࡢ࠺ࡘⓗഴྥࢆᙉࡵࠊ

QHXURLPDJLQJ VWXGLHV &HUHE &RUWH[ 㸦11㸧, 2981-

QOL పୗ࡟ࡘ࡞ࡀࡿྍ⬟ᛶࡀ㧗࠸ࠋࢿ࢞ࢸ࢕ࣈ࡞่⃭2990.

ࢆ⏝࠸ࡿሙྜࡣࠊࢩ࣑࣮ࣗࣞࢩࣙࣥ࡜࡜ࡶ࡟ㄆ▱ⓗ෌ホ

Fettes PW, Moayedi M, Dunlop K, et al. 㸦2018㸧:౯ࡀࢭࢵࢺ࡟࡞ࡗ࡚࠸ࡿ௓ධࡀዲࡲࡋࡃࠊᐇ㝿࡟ࢿ࢞ࢸ࢕

Abnormal Functional Connectivity of Frontopolarࣈ่⃭࡬ࡢㄆ▱ⓗ෌ホ౯ࡀࢿ࢞ࢸ࢕ࣈ࡞ឤ᝟ࢆῶᑡࡉ

Subregionsࡏࡿࡇ࡜ࡀሗ࿌ࡉࢀ࡚࠸ࡿ㸦Webb 2012㸧ࠋ

Depressive Disorder, Biol Psychiatry Cogn Neurosci௒ᅇࡢ⤖ᯝ࡛ࡣࠊឤ᝟ⓗ≧ἣࡢ᝿ീ࡜ほᐹ᫬ࡢ⬻⾑inTreatment-Nonresponsive

Major

Neuroimaging, 3㸦4㸧

ὶኚ໬࡟᭷ព࡞ᕪࡀ࡞ࡃࠊ࠿ࡘࠊᛌࠊ୙ᛌ࡜࠸࠺ឤ᝟

Hoshi Y, Huang J, Kohri S, et al. 㸦2011㸧: Recognition౯㛫ࡢ᭷ព࡞ᕪࡣㄆࡵࡽࢀ࡞࠿ࡗࡓࠋࡋ࠿ࡋ࡞ࡀࡽࠊ

RIKXPDQHPRWLRQVIURPFHUHEUDOEORRGÀRZFKDQJHVLQࢩ࣑࣮ࣗࣞࢩࣙࣥ᫬ࡢ⬻㈿ά࡜ㄆ▱ᶵ⬟ᡂ⦼࡜ࡢ㛫࡟the frontal region: a study with event-related near-㛵㐃ᛶࡀ♧ࡉࢀࡓࠋ௒ᚋࡢᒎᮃ࡜ࡋ࡚ࠊឤ᝟ⓗ≧ἣࡢ

infrared spectroscopy, J Neuroimaging, 21㸦2㸧, e94-ࢩ࣑࣮ࣗࣞࢩࣙࣥࢆ㧗㱋ᑐ㇟⪅ࡢㄆ▱ᶵ⬟࡬ࡢ௓ධ࡟

101.
Hoshi Y, Kobayashi N, Tamura M 㸦2001㸧: Interpretationࡘ࡞ࡆ࡚࠸ࡁࡓ࠸࡜⪃࠼ࡿࠋof near-infrared spectroscopy signals: a study with a㸬⤖ㄽ

newly developed perfused rat brain model, J Applᛌ࣭୙ᛌ⏬ീࢆ⏝࠸࡚ឤ᝟ⓗ≧ἣࢆ᝿ീࡲࡓࡣほᐹ

Physiol, 90㸦5㸧

ࡍࡿࡇ࡜࡟ࡼࡿࠊឤ᝟౯࡟ࡼࡿ⬻㈿άࡢ┦㐪࡜≧ἣࢆࢩ

Lang PJ, Bradley MM, Cuthbert BN 㸦2008㸧:࣑࣮ࣗࣞࢩࣙࣥࡍࡿࡇ࡜࡟ࡼࡗ࡚⏕ࡌࡿ⬻㈿ά࡜ㄆ▱ᶵ,QWHUQDWLRQDO D൵HFWLYH SLFWXUH V\VWHP 㸦IAPS㸧:⬟ᡂ⦼࡜ࡢ㛵㐃ࢆ᳨ウࡋࡓࠋᛌ≧ἣ࡜ࡃࡽ࡭࡚୙ᛌ≧$൵HFWLYH UDWLQJV RI SLFWXUHV DQG LQVWUXFWLRQ PDQXDOἣࡢࢩ࣑࣮ࣗࣞࢩ࡛ࣙࣥ⬻⾑ὶୖ᪼ࡀ኱ࡁ࠿ࡗࡓࡀ᭷ព

Technical Report A-8, University of Florida, Gainesville,ᕪࡣㄆࡵࡽࢀࡎࠊ⬻㈿άࡢឤ᝟౯㛫ࡢ㈿άࡢ┦㐪ࡣ᫂

FL.

ࡽ࠿࡟ࡍࡿࡇ࡜ࡀ࡛ࡁ࡞࠿ࡗࡓࠋ⬻㈿ά࡜ㄆ▱ᶵ⬟ᡂ

Liu H, Qin W, Li W, et al. 㸦2013㸧: Connectivity-based⦼࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸࡚ࡣࠊᛌ≧ἣ࡛ࡣグ᠈ㄢ㢟㛫࡟ࠊ

SDUFHOODWLRQ RI WKH KXPDQ IURQWDO SROH ZLWK GL൵XVLRQ୙ᛌ≧ἣ࡛ࡣὀពᶵ⬟ㄢ㢟㛫࡛㛵㐃ᛶࡀ♧ࡉࢀࡓࠋ

tensor imaging, J Neurosci, 33㸦16㸧
Minematsu Y, Ueji K, Yamamoto T 㸦2018㸧: Activity of
IURQWDOSROHFRUWH[UHÀHFWLQJKHGRQLFWRQHRIIRRGDQG㸬฼┈┦཯
ᮏ◊✲ࡢᐇ᪋࡟࠾࠸࡚⏦࿌ࡍ࡭ࡁ฼┈┦཯ࡣ࡞࠸ࠋ

drink: fNIRS study in humans, Sci Rep, 8㸦1㸧
1RUWKR൵ * %HUPSRKO ) 㸦2004㸧: Cortical midline㸬ㅰ㎡

structures and the self, Trends in Cognitive Science, 8,

ᮏ◊✲ࡣࠊJSPS ⛉◊㈝ࠉ-3. ࡢຓᡂࢆཷࡅ
࡚ᐇ᪋ࡋࡓࠋ

Oboshi Y, Kikuchi M, Shimizu Y, et al. 㸦2014㸧: Pre-task
prefrontal activation during cognitive processes in aging:ᘬ⏝ᩥ⊩Addis DR, Wong AT, Schacter DL 㸦㸧: Rememberinga near-infrared spectroscopy study, PLoS One, 9㸦6㸧,H2OG¿HOG 5& 㸦㸧: The assessment and analysis ofᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

handedness: the Edinburgh inventory, Neuropsychologia,
9㸦1㸧
Roberts RP, Wiebels K, Sumner RL, et al. 㸦㸧: An
fMRI investigation of the relationship between future
LPDJLQDWLRQDQGFRJQLWLYHÀH[LELOLW\1HXURSV\FKRORJLD
Schacter DL, Addis DR, Buckner RL 㸦㸧:
Remembering the past to imagine the future: theprospective brain, Nature Reviews Neuroscience, 8㸦9㸧
Spreng RN, Grady CL 㸦2010㸧: Patterns of brain activity
supporting autobiographical memory, prospection, andtheory of mind, and their relationship to the default mode
network, Journal of Cognitive Neuroscience, 22, 11121123.
Spreng RN, Madore KP, Schacter DL 㸦2018㸧: Better
imagined: Neural correlates of the episodic simulation
boost

to

prospective

memoryperformance,

Neuropsychologia, 113, 22-28.
Tupak S V, Dresler T, Guhn A, et al. 㸦2014㸧: Implicit
emotion regulation in the presence of threat: neural and
DXWRQRPLFFRUUHODWHV1HXURLPDJH
Webb TL, Miles E, Sheeran P 㸦2012㸧: Dealing With)HHOLQJ $ 0HWD$QDO\VLV RI WKH (൵HFWLYHQHVV RI
Strategies Derived From the Process Model of Emotion
Regulation, Psychological Bulletin, 138㸦4㸧
ཧ⪃ᩥ⊩Wechsler D㸦㸧/ ᮡୗᏲᘯヂ㸦2001㸧㸸᪥ᮏ∧࢙࢘ࢡࢫ࣮ࣛグ᠈᳨ᰝ㸦WMS-R㸧㸪᪥ᮏᩥ໬♫㸪ᮾி㸬ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Original Articleࠚ

3UHIURQWDOFRUWH[DFWLYDWLRQE\VLPXODWLRQRIHPRWLRQDOVLWXDWLRQVXVLQJ
pleasant and unpleasant images
Yumi Oboshi*1*1 Gifu University of Health Sciences

Abstract
7KHSXUSRVHRIWKLVVWXG\ZDVWRH[DPLQHZKHWKHUWKHUHLVDGLIIHUHQFHEHWZHHQHPRWLRQDOYDOHQFHV 㸦pleasantand unpleasant㸧 in the brain response during simulation of an emotional situation, which is the basis of emotional
regulation, and to clarify whether the brain response has a relationship with cognitive function test results and the role
RIWKHSUHIURQWDOFRUWH[$QHPRWLRQDOVLWXDWLRQVLPXODWLRQWDVNXVLQJSOHDVDQWDQGXQSOHDVDQWLPDJHVZDVFUHDWHGDQGWKHFHUHEUDOEORRGÀRZ
response in healthy young subjects was measured by a near-infrared spectroscopy.
,QWKLVUHVXOWWKHUHZDVQRVLJQL¿FDQWGL൵HUHQFHLQWKHEUDLQDFWLYDWLRQEHWZHHQWKHHPRWLRQDOYDOHQFHV5HJDUGLQJWKH
UHODWLRQVKLSZLWKFRJQLWLYHIXQFWLRQSHUIRUPDQFHDVLJQL¿FDQWFRUUHODWLRQZDVIRXQGEHWZHHQWKHPDJQLWXGHRIEUDLQ
activation during the simulation and good memory and attention function test scores, suggesting that the brain activation
during simulation of emotional situations is related to these cognitive functions.
.H\ZRUGVHPRWLRQVLPXODWLRQEUDLQDFWLYDWLRQSUHIURQWDOFRUWH[1,56ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021࠙ཎⴭࠚ៏ᛶ⬻༞୰⪅Ⓨ⑓࠿ࡽ  ᖺ㛫ࡢ௓ㆤಖ㝤࣭せ௓ㆤᗘࡢ᥎⛣࡜ศᯒ ៏ᛶ⬻༞୰⪅ࡢ⥲ྜⓗ㏣㊧ㄪᰝ◊✲ࠉせ௓ㆤᗘࡢ⛬ᗘࢆࡳࡿホ౯ἲࡢᥦ᱌ ⃝ಇ஧ *1ࠉᅬ⏣ⱱ *2ࠉᒣᕝⓒྜᏊ *3ࠉఀబᆅ㝯 *4ࠉ኱௰ຌ୍ *5ࠉᏳᒸ฼୍ *4ࠉ㔠⏣႐Ύ *6ࠉኒᒱⱥṇ *ࠉ㓇㔝┤ᶞ *8ࠉᯇ⏣ᬛஅ *3ࠉᏱబ⨾▱Ꮚ *1ࠉ⸨஭⛶ஓ *1ࠉ㓇ྥಇ἞ *1ࠉ๓ᓥఙ୍㑻 *8ᡯ⸨ᰤ୍ *6ࠉᅵᒇ㝯 *9ࠉ☾༤ᗣ *10ࠉ኱⏣ோྐ *11*1 ᒱ㜧ಖ೺኱Ꮫࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊ࠉࠉ*2 ⸨⏣་⛉኱Ꮫ୐ᰩグᛕ⑓㝔ࠉࠉ*3 Ⲉᇛ┴❧་⒪኱Ꮫ
*4 ⟃Ἴグᛕ⑓㝔ࠉࠉ*5 ᚿᮧ኱ᐑ⑓㝔ࠉࠉ*6 ⸨⏣་⛉኱Ꮫࠉࠉ  Ώ㎶⑓㝔ࠉࠉ*8 㔠ᇛ኱Ꮫ
*9 ㍤ᒣ఍グᛕ⑓㝔ࠉࠉ*10 ኱㜰኱Ꮫ኱Ꮫ㝔ࠉࠉ *11 Ⲉᇛ┴೺ᗣࣉࣛࢨ

せ᪨2018 ᖺ࠿ࡽ௓ㆤಖ㝤ࡢせ௓ㆤᗘࢆୗࡆࡿ㸦͆ᨵၿ͇㸧ࡇ࡜ࡀ࡛ࡁࡓ஦ᴗ⪅࡟ࡣ௓ㆤሗ㓘㸦ຍ⟬㸧ࡀ௜ࡃࡼ࠺࡟࡞ࡗ
ࡓࠋᮏ◊✲ࡣࠊࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ་⒪ࢆཷࡅᅾᏯ⏕ά࡟ධࡗࡓ៏ᛶ⬻༞୰⪅࡟ᑐࡋ࡚ࠊ㏥㝔࠿ࡽ 10 ᖺ㛫ࡢಶࠎࡢせ௓ㆤᗘࡢ᥎⛣࠿ࡽࠊ͆ᨵၿ͇ࡢኚ໬ࢆ᫂ࡽ࠿࡟ࡋࠊࡉࡽ࡟ࠊ3 ࡘࡢホ౯ἲࠊࡍ࡞ࢃࡕࠊSIAS࣭FIM࣭FAI ࡜せ௓ㆤᗘ࡜ࡢ┦㛵ࢆ᳨ウࡋࠊ⬻༞୰⪅ࡢせ௓ㆤᗘࡢ⛬ᗘࢆࡳࡿホ౯ἲ࡜ࡋ࡚ᥦ᱌ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋᑐ㇟ࡣ 36 ேࠋ⤖ᯝࠊ10 ᖺ㛫ࡢせ௓ㆤᗘࡢᨵၿ࣭⥔ᣢ࣭ᝏ໬࣭༞ᴗ㸦㠀ヱᙜ㸧ࡣࠊே࡟ࡼࡾ␗࡞ࡿ᥎⛣ࢆ♧ࡋ࡚࠸ࡿࡇ࡜ࡀࢃ࠿ࡗࡓࠋࡲࡓࠊせ௓ㆤᗘ࡜ SIAS࣭FIM࣭FAI ࡜ࡣࠊྛᖺ᫬࡜ࡶࠊSpearman ࡢ㡰఩࿴┦㛵ಀᩘࡢ᳨ᐃ⤖ᯝ p<0.01 ࡛᭷ព࡛࠶ࡾࠊ┦㛵ಀᩘȚ =0.4 ௨ୖȚ =0.8 ௨ୗ࡜͆࠿࡞ࡾ͇࠾ࡼࡧ͆ᙉ࠸┦㛵͆ࡀ࠶ࡿࡇ࡜ࡀࢃ࠿ࡗࡓࠋせ௓ㆤᗘࡢ⛬ᗘࢆࡳࡿホ౯ἲ࡜ࡋ࡚ࠊࡇࡢ 3 ࡘࡢホ౯ἲࢆᥦ᱌ࡍࡿࠋ௒ᚋ㛗ᮇ㸦20 ᖺ㛫㸧࡟ࢃࡓࡿせ௓ㆤᗘࡢ᥎⛣ࢆศᯒࡋࠊせ௓ㆤᗘ࡜┦㛵ࡢᙉ࠸ホ౯ἲࢆࡉࡽ࡟ᥦ᱌ࡋࡓ࠸ࠋࡲࡓࠊ⬻༞୰௨እࡢཎᅉ࡟ࡼࡿせ௓ㆤ⪅࡟ᑐࡍࡿホ౯࡟ࡘ࠸࡚ࠊᥦ᱌ࡋࡓホ౯ἲࡀ࠺ࡲࡃᙜ࡚ࡣࡲࡿ࠿࡝࠺࠿࡟ࡘ࠸࡚௒ᚋ᳨ウࡍࡿࠋ࣮࣮࢟࣡ࢻ㸸⬻༞୰ࠊ㏣㊧ㄪᰝࠊせ௓ㆤᗘࠊ⬻༞୰ᶵ⬟ࠊADLࠊ♫఍⏕άᶵ⬟ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021㸬ᑐ㇟࡜᪉ἲ

㸬ࡣࡌࡵ࡟

3.1 ᑐ㇟

௓ㆤಖ㝤࡟࠿࠿ࡿ⥲㈝⏝ࡣࠊ㛤ጞ᫬ࡢ2000 ᖺᗘ࡛3.6
඙෇ࠊ2021 ᖺᗘ࡛ 12 ඙ 8 ༓൨෇࡜⣙ 4 ಸ࡟ቑຍࡋ㸦㈈ึⓎ⬻༞୰࡛Ⓨ⑓༙ᖺ௨ෆ࡟Ⲉᇛ┴❧་⒪኱Ꮫ௜

ົ┬ 2021㸧ࠊࡲࡓࠊせ௓ㆤᗘูㄆᐃ⪅ᩘࡢ᥎⛣ࡣࠊᒓ⑓㝔㸦ࣜࣁᑓ㛛⑓㝔㸧࡟ධ㝔㸦1999 ᖺ 9 ᭶㹼 2000 ᖺ

2000 ᖺ ᗘ ࡀ ⥲ ᩘ 218 ୓ேࠊ2021 ᖺᗘ 6 ᭶ᮎ ⌧ ᅾ ࡛

12 ᭶㸧ࡋࠊࣜࣁ་⒪ࢆ⾜ࡗࡓ 212 ே୰ࠊ⬻༞୰⪅㸦᮲௳㸸

686 ୓ே㸦せᨭ᥼ 1 ࡣࠊ ୓ேࠊせᨭ᥼ 2 ࡣࠊ95 ୓ேࠊⓎ⑓࠿ࡽධ㝔ࡲ࡛ࡢᮇ㛫ࡀ 1 ࣧ᭶㹼 3 ࣧ᭶࡛᫂ࡽ࠿࡞

せ௓ㆤ 1 ࡣࠊ114 ୓ேࠊせ௓ㆤ 2 ࡣࠊ ୓ேࠊせ௓∦㯞⑷ࢆ᭷ࡋࠊពᚿࡢ␯㏻ࡀྍ⬟࡛ࠊㄪᰝ࡟༠ຊࡍࡿ

ㆤ 3 ࡣࠊ91 ୓ேࠊせ௓ㆤ 4 ࡣࠊ86 ୓ேࠊせ௓ㆤ 5 ࡣࠊពᚿ⾲♧ࢆࡋࡓ 40 ṓ௨ୖࡢ⪅㸧125 ேࢆᑐ㇟⪅࡜ࡋࠊ58 ୓ே㸧࡜ 3.2 ಸ࡜࡞ࡾࠊࡉࡽ࡟ቑຍഴྥࡀ⥆࠸࡚࠸ࡿホ౯ࡣࠊධ㝔࣭㏥㝔࣭Ⓨ⑓ 1 ᖺ᫬࠿ࡽⓎ⑓ 25 ᖺ᫬ࡲ㸦 ཌ⏕ປാ ┬ 2021㸧ࠋ ไᗘࡢᏑ ⥆ࡢ༴ ᶵࡀ㏕ࡿ୰ࠊ࡛ẖᖺ 1 ᅇࠊཎ๎⮬Ꮿ࡛⾜࠺ࠋᑐ㇟⪅ࡣࠊⓎ⑓ 10 ᖺ ᖺࠊᮍ᮶ᢞ㈨఍㆟ࡣࠕᮍ᮶ᢞ㈨ᡓ␎ ࡛ࠖࠊ௓

᫬࡟ᅾᏯㄪᰝࡀྍ⬟࡛࠶ࡗࡓ 36 ே࡜ࡋࡓࠋⓎ⑓࠿ࡽධㆤಖ㝤ไᗘࢆᣢ⥆ⓗ࡟⥔ᣢࡍࡿࡓࡵ࡟ࠊࠕ ⮬❧ᨭ᥼௓

㝔ࡲ࡛ࡢᮇ㛫㸹80.2 s  ᪥ࠊධ㝔ᮇ㛫㸹95.4 s  ᪥ࠊㆤࠖ㸦ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥࡢ඘ᐇ࡞࡝ࢆ㏻ࡌ࡚ࠊ
ࠕ἞ࡿࠖ௓

㏥㝔࠿ࡽ 10 ᖺ᫬ホ౯ࡲ࡛ࡢᮇ㛫㸹3,459 ᪥s 48 ᪥ ࡛ㆤࠊ࠶ࡿ࠸ࡣせ௓ㆤㄆᐃࢆእࢀࡿ௓ㆤಖ㝤ࡢࠕ༞ᴗࠖ

࠶ࡿࠋ⏨ᛶ ேࠊዪᛶ 9 ேࠊᖺ㱋ࡣ 10 ᖺ᫬ᖹᆒࢆྵࡵࠊせ௓ㆤ≧ែࡢ͆⥔ᣢ࣭ᨵၿ͇ࢆ┠ᣦࡍᅜࡢᨻ⟇64.1s 9.9 ṓ㸦40 ṓ㹼 81 ṓࠊ୰ኸ್ 65 ṓࠊ⏨ᛶ ṓࠊ㸦୕ཎᓅ 2021㸧㸧
ࢆ๓㠃࡟ฟࡋࠊቑ኱ࡍࡿ௓ㆤ⤥௜㈝ࡢ

ዪᛶ 64.8 ṓ㸧ࠋデ᩿ྡேࡣࠊ⬻᱾ሰ 15 ேࠊ⬻ฟ⾑ᢚไࢆᅗࢁ࠺࡜ࡋࡓࠋձḟᮇ௓ㆤሗ㓘ᨵᐃ࡛ຠᯝࡢ࠶

19 ேࠊከⓎᛶ⬻᱾ሰ 1 ேࠊࡃࡶ⭷ୗฟ⾑ 1 ேࠋ㯞⑷ࡿ⮬❧ᨭ᥼ࢆホ౯ࠊղ⮬❧ᨭ᥼ࡢຠᯝࡀ⛉Ꮫⓗ࡟⿬௜ഃࡣࠊྑ∦㯞⑷ 12 ேࠊᕥ∦㯞⑷ 24 ே࡛࠶ࡗࡓࠋ1 ᖺࡅࡽࢀࡓ௓ㆤࡢᐇ⌧࡟ྥࡅࠊᚲせ࡞ࢹ࣮ࢱࢆ཰㞟࣭ศ᫬௓ㆤࢧ࣮ࣅࢫ฼⏝⪅ࡣࠊ12 ே㸦⏨ᛶ 5 ேࠊዪᛶ  ே㸧ࠊᯒࡍࡿࢹ࣮ࢱ࣮࣋ࢫࢆ 2020 ᖺᗘࡲ࡛࡟ᮏ᱁㐠⏝➼࡛࠶

10 ᖺ᫬ࡣࠊ19 ே㸦⏨ᛶ 12 ேࠊዪᛶே㸧࡛࠶ࡗࡓࠋ

ࡿࠋࡑࡋ࡚ࠊ2018 ᖺࠊせ௓ㆤᗘࢆୗࡆࡿࡇ࡜ࡀ࡛ࡁࡓ

3.2ࠉ᪉ἲ

஦ᴗ⪅࡟ࡣ௓ㆤሗ㓘㸦ຍ⟬㸧ࡀ௜ࡃἲᨵṇࡀ࡞ࡉࢀࡓࠋ

ㄪᰝ᫬ᮇ࡜ㄪᰝἲࡣࠊධ㝔࣭㏥㝔࣭Ⓨ⑓ 1 ᖺ᫬㹼 25

ࡑࡇ࡛ࠊせ௓ㆤᗘࡢ͆⥔ᣢ࣭ᨵၿ͇ࢆ࠸࠿࡟ᐇ⌧ࡍࡿࡀ

ᖺ᫬ࡢⓎ⑕᭶ࡢ๓ྥࡁࢥ࣮࣍ࢺ◊✲࡛࠶ࡿࠋྠ୍ㄪᰝ

኱ࡁ࡞ㄢ㢟࡜࡞ࡗࡓࠋࡑࡢࡓࡵ࡟ࠊࡲࡎࠊಶࠎேࡢ㛗ᮇ

ဨࡀ୍㈏ࡋ࡚ㄪᰝ㸦⮫ᗋ᳨ᰝ㸤࢔ࣥࢣ࣮ࢺ㸧ࡋࠊཎ๎ᅾ

࡟ࢃࡓࡿせ௓ㆤᗘࡢኚ໬࠿ࡽせ௓ㆤᗘࡢ͆⥔ᣢ࣭ᨵၿ͇

Ꮿゼၥ࡛⾜࠺ࠋᅜ㝿⏕άᶵ⬟ศ㢮㸦,&),QWHUQDWLRQDOࡢ⌧≧ࢆ᫂ࡽ࠿࡟ࡍࡿᚲせࡀ࠶ࡿࡀࡑࡢࡼ࠺࡞ሗ࿌ࡣぢ&ODVVL¿FDWLRQRI)XQFWLRQLQJࠉ,Disability and Health, ᅜࡽࢀ࡞࠸ࠋࡲࡓࠊせ௓ㆤᗘࡢ⛬ᗘࢆࡳࡿࡢ࡟せ௓ㆤᗘ㝿⏕άᶵ⬟ศ㢮ࢆཧ⪃࡟ࡋࡓホ౯㡯┠ࡣࠊ௨ୗࡢࡼ࠺

࡜┦㛵ࡢᙉ࠸ホ౯ἲ࡟ࡘ࠸࡚ࠊ⌧ᅾᥦ᱌ࡋ࡚࠸ࡿሗ࿌

࡛࠶ࡿࠋࡣࡳࡽࢀ࡞࠸ࠋ

㸦1㸧ᚰ㌟ᶵ⬟㞀ᐖ㸸ձ Stroke Impairment Assessment Set
㸦SIAS㸧
ղ Brunnstrom Recovery Stage㸦BRS㸧㸬┠ⓗճ KOHS BLOCK-DESIGN TEST㸦KOHS ࢸࢫࢺ㸧ࠉᮏ◊✲࡛ࡣࠊࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ་⒪ࢆཷࡅᅾᏯ⏕㸦2㸧άືไ㝈㸸ά࡟ධࡗࡓ៏ᛶ⬻༞୰⪅࡟ᑐࡋ࡚ࠊ㏥㝔࠿ࡽ 10 ᖺ㛫ࡢಶࠎேࡢせ௓ㆤᗘࡢ᥎⛣࠿ࡽࠊ࡝ࡢࡼ࠺࡟͆⥔ᣢ࣭ᨵၿ͇

ձ Functional Independence Measure㸦FIM㸹self careࡀኚ໬ࡋ࡚࠸ࡃࡢ࠿ࢆ᫂ࡽ࠿࡟ࡍࡿࡇ࡜࡛࠶ࡿࠋࡑࡋ࡚ࠊ

➼ 13 㡯┠ࢆ FIM 㐠ືࠊグ᠈➼ 5 㡯┠ࢆ FIM ㄆ▱࡜せ௓ㆤ࡜ࠊㄆᐃㄪᰝ㡯┠࡜㛵ಀࡀ࠶ࡿ࡜ᛮࢃࢀࡿ 3 ࡘ⾲ࡍ㸧ࡢ ホ ౯ ἲࠊSIAS
㸦Stroke Impairment Assessment Set㸹ղ Canadian Occupational Performance Measure⬻ ༞ ୰ ᶵ ⬟ ホ ౯ 㸧࣭FIM
㸦Functional Independence

㸦COPM㸧

Measure㸹ࡋ࡚ ࠸ ࡿ ADL ࡜ ௓ ㆤ 㔞 ࢆ ホ ౯ 㸧࣭FAIճ㞀ᐖ⪁ேࡢ᪥ᖖ⏕ά⮬❧ᗘ㸦J-ABC㸧㸦)UHQFKD\$FWLYLWLHV,QGH[㸹♫఍⏕ά⬟ຊ IADL ࢆホմ⑵࿈ᛶ⪁ேࡢ᪥ᖖ⏕ά⮬❧ᗘุᐃᇶ‽㸦⑵࿈ ABC㸧౯㸧࡜ࡢ┦㛵ࢆ᳨ウࡋࠊせ௓ㆤࡢ⛬ᗘࢆࡳࡿࡢ࡟せ௓

㸦3㸧ཧຍไ⣙㸸ㆤᗘ࡜┦㛵ࡢᙉ࠸ホ౯ἲࢆᥦ᱌ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡍࡿࠋձ ⬻ ⾑⟶ 㞀 ᐖ ⪅ ࡢ ♫ ఍ ⏕ ά ⬟ ຊ ホ ౯㸦Frenchay$FWLYLWLHV,QGH[㸸FAI㸧ղ⪁೺ᘧάື⬟ຊᣦᶆ
㸦4㸧ಶேᅉᏊ㸸ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

㸦2019 ᖺ 3 ᭶ 12 ᪥ࠉe201㸧ࡉࢀࠊᙜ஦⪅࣭ᐙ᪘ࡢྠព

ձ∦㯞⑷ᡭཷᐜᗘ᳨ᰝ㸦∦㯞⑷ᡭࡢᇳ╔࡜ㅉࡵࢆホ౯㸧ࢆᚓ࡚ᐇ᪋ࡋࡓࠋᑦࠊ᪥ᮏᏛ⾡᣺⯆఍ࡀᥦ౪ࡍࡿ◊✲ղ Zung ࡢ Self-rating Depression Scale㸦SDS㸧ࠊࠉࠉࠉࠉࠉࠉࠉ
೔⌮ e࣮ࣛࢽࣥࢢࢥ࣮ࢫࢆಟ஢ࡋࡓ㸦2021 ᖺ 9᭶28᪥㸧ࠋճ᝟⥴ⓗᨭ᥼ࢿࢵࢺ࣮࣡ࢡ
մ HDS-R㸦㛗㇂ᕝᘧ⡆᫆▱⬟᳨ᰝ̺ᨵゞ∧ホ౯ࢫࢣ࣮ࣝ㸧յ QOL ホ ౯ :Self completed Questionnaire for QOL㸬⤖ᯝ

by Iida and Kohasi
㸦QUIK㸧㸨

4.1 ᑐ㇟⪅࡜せ௓ㆤᗘࡢ᥎⛣ն㏥㝔ᚋ♫఍㈨※฼⏝≧ἣㄪᰝᑐ㇟⪅ࡢධ㝔᫬࡜Ⓨ⑓1ᖺ᫬ࡢᇶᮏࢹ࣮ࢱࢆ♧ࡍ㸦⾲

շ㏥㝔ᚋࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ⦎⩦࢔ࣥࢣ࣮ࢺࠉ

1㸧ࠋᛶࠊデ᩿ேࠊ㯞⑷ഃࠊ♫఍ⓗ⫼ᬒࠊᐙ᪘ᵓᡂࠊ

㸦5㸧⎔ቃᅉᏊ㸸௓ㆤಖ㝤ࢧ࣮ࣅࢫࢆྵࡴ♫఍㈨※ㄪᰝᖺ㱋ࠊᑵປࡢ᭷↓ࠊ㌟య㞀ᐖ⪅ᡭᖒࠊせ௓ㆤᗘࠊホ㏥㝔ᚋࡢㄪᰝࡣࠊẖᖺ 1 ᅇⓎ⑓᭶࡟⮬Ꮿࢆゼၥࡋࠊ౯ࡣࠊSIASࠊFIMࠊFIM 㐠ືࠊFIM ㄆ▱ࠊFAI ࡛࠶ࡿࠋ⮫ᗋホ౯ࢆᐇ᪋ࡍࡿࠋㄪᰝ⚊ࡣࠊᥦฟࡋ࡚࠸ࡓࡔࡁࠊ

ホ౯ 1 ᖺ᫬ࡢせ௓ㆤᗘࡣࠊ௓ㆤಖ㝤ไᗘࡀጞࡲࡗࡓ

ෆᐜ࡟ࡘ࠸࡚☜ㄆࡋࠊಟṇ࠾ࡼࡧ㏣グࡍࡿࠋ

2000 ᖺ 4 ᭶௨㝆 2001 ᖺࡲ࡛࡟せ௓ㆤㄆᐃ࡛Ỵࡲࡗࡓศᯒࡣࠊ⾲ 2 ࡢㄆᐃㄪᰝ⚊ࡢ㡯┠࡜㛵ࢃࡾࡀ࠶ࡿ࡜

ࡶࡢ࡛࠶ࡿࠋ㏥㝔ᚋࡣ඲ဨ⮬Ꮿ࡛⏕άࢆࡋࠊ᪋タධᡤᛮࢃࢀࡿ SIASࠊFIMࠊFAI ࡜せ௓ㆤᗘࡢ᥎⛣㸦10 ᖺ㛫㸧⪅ࡣ࠸࡞࠿ࡗࡓࠋᐷࡓࡁࡾ࡟㏆࠸ே࠿ࡽᑵᴗ⏕άࢆ㏦ࡿࡢ┦㛵ࢆศᯒࡍࡿࠋ⤫ィศᯒࡣ SPSS25 ࢆ౑⏝ࡋࠊࢫேࡲ࡛ࠊࡲࡓࠊάື࡜ཧຍࡣከᵝ࡛࠶ࡗࡓࠋⓎ⑓ 1 ᖺࣆ࢔࣐ࣥࡢ㡰఩࿴┦㛵㸦P<0.01㸧ࢆ⏝࠸ࡿࠋ᫬࡛せ௓ㆤㄆᐃࢆཷࡅ࡚࠸ࡓ 12 ேࡣࠊSIASࠊFIMࠊ
FAI ࡜ࡶపᚓⅬ࡛࠶ࡗࡓ㸦⾲ 1㸧ࠋ

3.3 ◊✲೔⌮⾲ 2 ࡣࠊせ௓ㆤᗘࡢ 10 ᖺ㛫ࡢ᥎⛣࡜௓ㆤࢧ࣮ࣅࢫᮏ ◊✲ࡣࠊ Ⲉᇛ┴❧་⒪኱Ꮫ೔⌮ጤဨ఍࡛ᢎㄆ

ࢆཷࡅࡓேᩘࡢ᥎⛣ࢆ♧ࡋࡓࡶࡢ࡛࠶ࡿࠋⓎ⑓ 1 ᖺ᫬⾲ ࠉᑐ㇟⪅ࡢᇶᮏࢹ࣮ࢱ㸦Q ධ㝔᫬࣭Ⓨ⑓  ᖺ᫬㸧ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021௓ㆤಖ㝤ࢆ฼⏝ࡋ࡚࠸ࡿேࡣ 12 ே㸦33%㸧ࠊ10 ᖺ᫬࡛ࡓ⪅ࡣ 1 ே㸦3%㸧࡛࠶ࡗࡓࠋࡑࡋ࡚ࠊせ௓ㆤ⏦ㄳࢆ 1019 ே㸦53%㸧࡜ᖺࠎቑຍࡋ࡚࠸ࡗࡓࠋ ே㸦19%㸧ࡀ᪂࡟ᖺ㛫඲ࡃࡋ࡞࠿ࡗࡓேࡣ 16 ே㸦44%㸧࡛࠶ࡗࡓࠋ

せ௓ㆤㄆᐃࢆཷࡅࠊ௓ㆤࢧ࣮ࣅࢫࢆ฼⏝ࡋࡓࡇ࡜࡟࡞

せ௓ㆤᗘࡢ 10 ᖺ㛫ࡢ᥎⛣ࢆࡳ࡚ࡳࡿ࡜ࠊせ௓ㆤᗘࡢࡿࠋ୍᪉ࠊせ௓ㆤㄆᐃࡀ㠀ヱᙜ㸦͆௓ㆤ༞ᴗ͇㸧࡜࡞ࡗ͆௓ㆤ༞ᴗ͇ࡣ 1 ேࠊ͆⥔ᣢ͇ࡣ 2 ேࠊᖺࠎせ௓ㆤᗘࡀୖࠉࠉ⾲ ࠉせ௓ㆤᗘࡢ  ᖺ㛫ࡢ᥎⛣࡜฼⏝⪅ᩘࡢ᥎⛣ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ࡀࡗࡓ⪅ࡣ  ேࠊୖࡀࡗ࡚࣭ୗࡀࡗ࡚࣭ୖࡀࡗࡓ⪅ࡣ 3 ேࠊୖࡀࡗ࡚࣭ୗࡀࡗࡓ⪅ࡀ 3 ேࠊୖࡀࡗ࡚࣭ୗࡀࡗ࡚࣭ୖࡀࡗ
࡚࣭ୗࡀࡗࡓ⪅ࡀ 1 ேࠊୗࡀࡗ࡚࣭ୖࡀࡗ࡚࣭ୗࡀࡗࡓ⪅ࡀ 2 ே࡛࠶ࡗࡓࠋࡲ࡜ࡵࡿ࡜ࠊ10 ᖺ㛫࡛ࠊせ௓ㆤᗘࡢ͆௓
ㆤ༞ᴗ͇⪅ࡀ 1 ே㸦5%㸧ࠊ͆ ⥔ᣢ͇⪅ࡀ 2 ே㸦11%㸧ࠊせ௓ㆤᗘࡀୗࡀࡗࡓ㸦ᨵၿ࣭௓ㆤ㔞పୗ㸧⪅ࡀ 6ே㸦32%㸧ࠊせ௓ㆤᗘࡀୖࡀࡗࡓ㸦ᝏ໬࣭௓ㆤ㔞ቑຍ㸧⪅ࡀ 10 ே
㸦52%㸧࡛࠶ࡗࡓࠋ
஦౛ࢆ࠶ࡆࡿࠋ
ձ͆⥔ᣢ࣭ᨵၿ͇ࡣࡳࡽࢀࡎᚎࠎ࡟せ௓ㆤᗘࡀୖࡀࡗ࡚
࠸ࡗࡓ஦౛
case1㸹せ௓ㆤᗘ 1 ࠿ࡽẁ㝵ⓗ࡟せ௓ㆤᗘࢆ࠶ࡆ 10ᖺ┠࡟せ௓ㆤᗘ 5 ࡟࡞ࡗࡓே࡛࠶ࡿࠋ㔜ᗘᕥ∦㯞⑷ࢆ
᭷ࡍࡿ↓⫋ࡢ⏨ᛶ㸦Ⓨ⑓ 1 ᖺ᫬  ṓ㸧࡛࠶ࡿࠋ2 㝵ᘓ࡚ࡢᣢࡕᐙ࡛ኵ፬஧ேᬽࡽࡋࠋᗙ఩ಖᣢࡶ㞴ࡋ࠸≧ែ
࠿ࡽࠊ㏥㝔᫬ࠊ▷ୗ⫥⿦ලࢆ௜ࡅࠊ᮫Ṍ⾜ぢᏲࡾ࡛ᅗ ࠉ ஦౛ࡢせ௓ㆤᗘࡢ᥎⛣10m Ṍࡅࡿࡼ࠺࡟࡞ࡗ࡚㏥㝔ࡋࡓࠋ㌟య㞀ᐖ⪅ᡭᖒࡣ 1⣭ࠋせ௓ㆤᗘ 1ࠋSIAS 38 Ⅼ  Ⅼࠊ
FIM 88 Ⅼ /126 Ⅼࠊ
FIM 59 Ⅼ /91 Ⅼࠊ
FIM ㄆ▱ 29 Ⅼ /35 Ⅼࠊ
FAI 0 Ⅼ /45 Ⅼࠋᅗ 1 ࡟ࠊせ௓ㆤᗘࡢኚ໬ࢆᅗ࡛⾲ࡋࡓࠋጔࡣࠊ㏥㝔ᚋࡢ⏕άࡣࠊ⮬Ꮿ࡛༙᭶ࠊࢩ࣮ࣙࢺࢫࢸ࢖㸦㌴᳔Ꮚ౑⏝㸧࡛༙᭶ࡢ⏕άࢆ㑅ࡧࠊ⮬ᕫ㈇ᢸ㢠ࡣ኱ࡁࡃ࡞ࡗࡓࡀࠊጔ
⮬㌟ࡢ௓ㆤ㈇ᢸࢆ࡛ࡁࡿࡔࡅ㍍ῶࡋ㛗ࡃඹ࡟⏕ά࡛ࡁࡿ᪉ἲࢆ㑅ࢇࡔࠋⓎ⑓ 1 ᖺ┠ࡢホ౯࡛ࡣࠊ୰➼ᗘ⬻༞୰ᶵ⬟㞀ᐖࠊ୰➼ᗘ ADL 㞀ᐖࠊࡑࡋ࡚ࠊ0 Ⅼࡢ♫఍⏕άᶵ⬟࡛࠶ࡗࡓࠋࢺ࢖ࣞ࡟ࡣ⊂ࡾ࡛࣋ࢵࢻ࠿ࡽṌ࠸࡚⾜ࡅࡿࡼ࠺࡟࡞ࡿࠋⓎ⑓ 2 ᖺ┠࡟ࢺ࢖࡛ࣞ㌿ಽࡋጔ୍ேࡢຊ
࡛ࡣ㉳ࡁୖࡀࡾ௓ຓࡀᅔ㞴࡜࡞ࡗࡓࡓࡵᩆᛴ㌴ࢆ࿧ࡪࡇ࡜࡟࡞ࡿࠋ௨ᚋࠊ㌿ಽࡢ୙Ᏻ࠿ࡽࠊṌ⾜ࡣぢᏲࡾ࠿ࡽᅗ FDVH㸹ᚎࠎ࡟せ௓ㆤᗘࡀୖࡀࡗ࡚ࡁࡓ஦౛

⭜ࡦࡶࢆࡋࡗ࠿ࡾᣢࡘṌ⾜࡟ኚࢃࡗ࡚࠸ࡗࡓࠋせ௓ㆤࠉࠉ⛣஌௓ㆤࢆጉࡆࡿ㌴࠸ࡍ࡟⫼୰ࢆᢲࡋ௜ࡅࡿ

ᗘࡣ 2 ࡜࡞ࡿࠋⓎ⑓ 3 ᖺ┠ࠊᮏேࡣࠊ㌿ಽᜍᛧࡀቑࡋࠊ
㌟యࡣࡇࢃࡤࡾࡀቑࡋࡓࡓࡵࠊ⛣ືࡣṌ⾜࠿ࡽ㌴᳔Ꮚ࡜࡞ࡿࠋせ௓ㆤᗘࡣ 3 ࡜࡞ࡗࡓࠋጔࡢࠊ㉳ࡁୖࡀࡾ㌴ࠉࠉᗙ఩ጼໃ㸦Ⓨ⑓  ᖺ᫬㸧ࠉղせ௓ㆤᗘࡀ͆⥔ᣢ࣭ᨵၿ͇ࡋࡓ஦౛

᳔Ꮚ࡬ࡢ⛣஌௓ຓ㔞ࡣᖺࠎቑࡋࠊࡘ࠸࡟ 8 ᖺ┠࡟ࡣせcase22㸹せ௓ㆤᗘ 5 ࠿ࡽࠊせ௓ㆤᗘ 2 ࡟ᨵၿࡋࠊ௨

௓ㆤᗘ 4 ࡜࡞ࡗࡓ㸦ᅗ 2㸧ࠋࡑࡋ࡚ࠊ10 ᖺ┠࡟ࡣࠊጔࡢ

ᚋ⥔ᣢࡋ࡚ࡁࡓே࡛࠶ࡿࠋⓎ⑓ 1 ᖺ᫬ 62 ṓࠉዪᛶࠉⓎ௓ㆤࡣ㝈⏺࡟㐩ࡋࡓࡓࡵ᪋タධᡤ࡜࡞ࡾせ௓ㆤᗘࡣ 5⑓๓⫋ᴗ ㎰ᴗࠉ⬻᱾ሰᚋ ྑୖୗ⫥㔜ᗘ∦㯞⑷ࠊᵓㅮ

࡜࡞ࡗࡓࠋ⩣ᖺࠊᩋ⾑⑕ࡢࡓࡵṚཤࡋࡓࠋ㡢㞀ࡀ࠸㸦㸩㸧ࠊSIAS 38 Ⅼ  ⅬࠊFIM 88 Ⅼ /126 Ⅼࠊ
FIM 㐠 ື 59 Ⅼ /91 ⅬࠊFIM ㄆ▱ 28 Ⅼ /35 ⅬࠊFAI 1
Ⅼ /45 Ⅼࠋࡑࡋ࡚ࠊせ௓ㆤᗘ 4 ࡛࠶ࡗࡓࠋ⮬Ꮿ࡛ࡢṌࢹ࢖ࢧ࣮ࣅࢫ㸦㐌 3 ᪥㸧ࢆ౑࠺ࠋ⾜⦎⩦࡞࡝⮬୺ࢺࣞ࡟ຍ࠼ࠊ
⮬Ꮿ࡟㏥㝔ࡋ࡚࠿ࡽࠊࢺ࢖ࣞࡲ࡛ࡢ᮫Ṍ⾜㸦10m㸧ࢆ 1
᪥  ᅇ⾜࠸ࠊᖖ᫬ፉ࡟ࡼࡿぢᏲࡾࡢ 5 Ⅼࣞ࣋ࣝ࠿ࡽಟ
ṇ⮬❧ 6 Ⅼࣞ࣋ࣝ࡟࡞ࡿࠋࢺ࢖ࣞࡲ࡛ࡢṌ⾜⮬❧࡟㏥㝔ᚋ༙ᖺ࠿࠿ࡗࡓࠋᒃ㛫ࡢ᳔Ꮚࡣࠊ᪼㝆ᘧ᳔Ꮚࢆࣞࣥ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ࢱࣝࡋ㸦ᅗ 3 㸫 1㸧ࠊࢹ࢖ࢧ࣮ࣅࢫ࡛ࡣࠊࣜࣁ⦎⩦࡜ࡋ࡚ࡁ✄ࡢฟ᮶ලྜࢆほᐹࡋࡓࡾࡋ࡚ኵ࡟ຓゝࢆࡋࡓࡾࡋ࡚

㒊ᒇࢆ᮫Ṍ⾜࡛ 5 ࿘ࢆ⮬ศ࡟ㄢࡋ࡚ẖᅇᐇ㊶ࡋࡓ㸦ᅗ 3

9 ᖺ㛫ࢆ㐣ࡈࡋࡓࠋⓎ⑓ 10 ᖺ᫬㸦 ṓ㸧ࡶせ௓ㆤᗘ 2㸫 2㸧ࠋࢺ࢖ࣞࡲ࡛ࡢṌ⾜ࡀ 4 Ⅼ᮫ࢆ⏝࠸࡚⮬❧ࡍࡿ࡜ࢆ⥔ᣢࡋࠊSIAS 39 Ⅼ  ⅬࠊFIM 㐠ື 59 Ⅼ /91 Ⅼࠊ㸦ᅗ 3̿3㸧ࠊせ௓ㆤᗘࡣ 2 ࡜࡞ࡿࠋぢᏲࡾࢆࡋ࡚࠸ࡓፉ

FIM ㄆ▱ 31 Ⅼ /35 Ⅼࠊ)$, Ⅼ /45 Ⅼ࡜㏥㝔᫬ࡼࡾࡶᚓ

ࡣࣃ࣮ࢺ໅ົࡀྍ⬟࡜࡞ࡾࠊኵࡶ⏣ࡢୡヰࡀ෇⁥࡟࡛ࡁ

Ⅼࢆఙࡤࡋࡓࠋᵓ㡢㞀ᐖ࡟㞴⫈ࡀຍࢃࡗ࡚ࡁࡓࡀࠊࡲࡗ

ࡿࡼ࠺࡟࡞ࡗࡓࠋ᪥୰ࡣࠊ᪼㝆ᘧࡢ᳔Ꮚ࡟ᗙࡾࠊᚲせࡓࡃẼ࡟ࡋ࡞࠸ࠋ᪋タ࡛ࡢ⾜஦࡜ፉ࡜ࡢ㈙࠸≀ࢆᴦࡋࡳ࡟ᛂࡌ࡚㧗ࡃࡋ࡚ࠊT Ꮠ᮫ࢆ⏝࠸࡚Ṍ࠸࡚ࢺ࢖ࣞ࡟⾜ࡁࠊࡋ࡟⏕άࢆࡍࡿࠋࡑࡢᚋⓎ⑓ 20 ᖺ᫬ࠊ⮬ຊ࡛㣗஦ࡀTV ࢆほࡓࡾࠊእ࡛ࡢ⛣ືࡣ⊂ࡾ࡛㌴࠸ࡍࢆ⏝࠸࡚㏆ᡤ࡛ࡁ࡞ࡃ࡞ࡾ⫶፝ࢆቑタࡋ࡚⒪㣴ᆺ⑓Ჷ࡛ࡢධ㝔⏕άࡢ཭ேᏯࢆᕠᅇࡋࡓࡾࠊኵࡢ㌴࡟஌ࡏ࡚ࡶࡽࡗ࡚⏣࡟⾜࡟ධࡾࠊせ௓ㆤᗘࡣ 4 ࡜࡞ࡗࡓࠋ

ᅗ FDVH㸹せ௓ㆤᗘࡀᨵၿ࣭⥔ᣢࡋࡓ஦౛
ࠉࠉࢺ࢖ࣞࡲ࡛ࡢṌ⾜⮬❧ࢆࢹ࢖ࢧ࣮ࣅࢫ࡛⋓ᚓ㸦Ⓨ⑓  ᖺ᫬㸧ᅗ ࠉ᪼㝆᳔Ꮚࢆ฼⏝ࡋ࡚ࠉࠉࠉ❧ࡕୖࡀࡿᅗ ࢹ࢖ࢧ࣮ࣅࢫ࡛ᅗ ࢺ࢖ࣞࡲ࡛ ᚟Ṍࡃࠉࠉࠉࠉ⮬୺ⓗ࡟ẖᅇ  ࿘Ṍࡃ
15 ᖺࡲ࡛せ௓ㆤ 1 ࢆ⥔ᣢࡋ࡚ࡁࡓࡀࠊ⩣ᖺ⫵ࡀࢇࡢࡓճせ௓ㆤᗘࢆ͆⥔ᣢ͇ࡋࡓ㸦஦㸧౛ࡵṚཤࡋࡓࠋ

case35㸹せ௓ㆤᗘ 1 ࢆ 10 ᖺ㛫⥔ᣢࡋࡓே࡛࠶ࡿࠋⓎ⑓ 1 ᖺ᫬  ṓࠊ⏨ᛶࠊ㔜ᗘᕥ∦㯞⑷ࠊᕥഃ 1/4 ༙┣ࠊࣉࣛࢫࢳࢵࢡAFO
㸦$QNOH)RRW2UWKRWLF ▷ୗ⫥⿦ල㸧⿦╔࣭㹒Ꮠ᮫࡛Ṍ⾜ 500m ྍࠋጔ࡜ፉࡢ 3ேᬽࡽࡋࠋࢺࣛࢵࢡ㐠㌿ᡭࡢ᚟⫋ᅔ㞴࡜ุ᩿ࡋࠊ㏥⫋ࠋᣢࡕᐙࠋ㌟య㞀ᐖ⪅ᡭᖒ 2 ⣭ྲྀᚓࠋⓎ⑓ 1 ᖺ᫬ࠊせ௓ㆤᗘ 1 ࡛࠶ࡗࡓࠋ
࣋ࢵࢻࡢࡳࣞࣥࢱࣝࡋࠊ㌴࠸ࡍࡣ೉ࡾ࡞࠿ࡗࡓࠋSIAS
45 Ⅼ  ⅬࠊFIM 㐠 ື 82 Ⅼ /91 ⅬࠊFAI 6 Ⅼ /45 Ⅼࠋጔࡣᐙィࢆຓࡅࡿࡓࡵ࡟ࣃ࣮ࢺ໅ົࢆጞࡵࡿࠋፉࡣ⤒῭ⓗ᥼ຓࢆࡍࡿࠋࡓࡔࠊ᚟⫋ࡀ࠿࡞ࢃ࡞࠿ࡗࡓࢩࣙࢵ
ࢡࡀ኱ࡁࡃࠊ2 ᖺ㛫ࠊᩓṌ௨እ࡛ࡣᶵ⬟カ⦎࡟ 1 ᅇ / 㐌ฟ࠿ࡅࡿࡔࡅ࡛࠶ࡗࡓࠋ3 ᖺ┠ࠊዟᵝࡢບࡲࡋࡀຌࢆዌ
ࡋࠊࢹ࢖ࢣ࢔ࡢぢᏛ࡟⾜ࡁࠊࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ㒊㛛࡛ᶵ⬟⦎⩦ࡀཷࡅࡽࢀࡿࡇ࡜ࠊ࢝ࣛ࢜ࢣࡀ࠶ࡿࡇ࡜ࠊࡑࡋ࡚ࠊ
እ࡛ࡢᩓṌࡢ௦ࢃࡾ࡟⮬୺⦎⩦࡛ࠊᗯୗࢆ 1km Ṍࡅࡿࡇ࡜ࡀࢃ࠿ࡾࠊ2 ᅇ / 㐌㏻࠸ࡔࡋࡓࠋᐙ࡛ࡣࠊ␃Ᏺ␒࡜
࠾㢼࿅Ὑ࠸ࢆ✚ᴟⓗ࡟ࡍࡿࡼ࠺࡟࡞ࡾࠊࣛࢪ࢜ࠊ᪂⪺ࢆᅗ FDVH㸹せ௓ㆤᗘࢆ  ᖺ㛫⥔ᣢࡋࡓ஦౛

ㄞࡳ⫈ࡃࡼ࠺࡟࡞ࡗࡓ㸦ᅗ 4㸧ࠋⓎ⑓ 10 ᖺ㸦6,$6 Ⅼࠉࠉ⮬Ꮿࡸࢹ࢖ࢣ࢔࡛ࡢṌ⾜➼ࡢ⦎⩦࡛ពḧࢆ

ࠊFIM 㐠ື Ⅼ /91ࠊFAI 6 Ⅼ /45㸧ࢆ㐣ࡂࠊⓎ⑓ࠉࠉ⥔ᣢ㸦Ⓨ⑓  ᖺ᫬㸧ࠉᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

մせ௓ㆤᗘࡀኚ໬ࡋ࡚࠸ࡗࡓ஦౛

㔝┤୍ࡽ 㸧ࠋ

&DVH せ௓ㆤᗘ 3 ࠿ࡽ 1ࠊ2ࠊ1ࠊ2 ࡜ 10 ᖺ㛫࡛ 4 ᅇ

ᅗ 6 ࡣࠊSIAS/FIM/FIM 㐠 ື /FIM ㄆ ▱ /FAI ࡢ ௓ኚ᭦ࢆ⤒㦂ࡋࡓே࡛࠶ࡿࠋⓎ⑓ 1 ᖺ᫬ 59 ṓࠊዪᛶࠋㆤಖ㝤௓ㆤࢧ࣮ࣅࢫ฼⏝⪅࡜㠀฼⏝⪅㸦せ௓ㆤㄆᐃ㠀୺፬ࠋ㔜ᗘࡢᕥ∦㯞⑷ࠊ༙ഃ✵㛫↓ど࠶ࡾࠋ㔠ᒓᨭᰕ⏦ㄳࢆྵࡴ㸧ࡢධ㝔࠿ࡽⓎ⑓ 10 ᖺ᫬ࡲ࡛ࡢᖹᆒ್ࡢ᥎௜ SLB ࡜ T Ꮠ᮫࡛ 200 㹫Ṍ⾜ྍࠋᣢࡕᐙࠊኵ࡜஧ே

⛣ࢆ⾲ࡋ࡚࠸ࡿࠋSIAS ࡛ࡣࠊ௓ㆤࢧ࣮ࣅࢫ฼⏝⪅ࡣࠊᬽࡽࡋࠋせ௓ㆤᗘ 3ࠋSIAS 34 Ⅼ  ⅬࠊFIM 㐠ືᶵ⬟࡜ࡋ࡚ࡣప࠸ 30 Ⅼ๓༙ࢆ⥔ᣢࡋ࡚࠸ࡓࡀࠊᚎࠎ࡟

Ⅼ /91 ⅬࠊFIM ㄆ▱ 34 ⅬࠊFAI 3 Ⅼ /45 Ⅼࠋ2 ᅇ / 㐌ᶵ⬟ࡀୗ㝆ഴྥࢆ♧ࡋࠊ10 ᖺ᫬࡟ࡣࠊⓎ⑓ 1 ᖺ᫬࡜ྠࡢࢹ࢖ࢧ࣮ࣅࢫ࡜1 ᅇ / 㐌ࡢእ᮶ࣜࣁࣅࣜࢸ̿ࢩࣙࣥ㸦⌮ࡌ≧ែ࡜࡞ࡗࡓࠋ୍᪉ࠊ㠀฼⏝⪅ࡣࠊ୰➼ᗘ௨ୖࡢᶵ

Ꮫ⒪ἲࠊసᴗ⒪ἲ㸧ࢆఇࡲࡎ㏻࠺ࠋࡑࡢ⤖ᯝࠊ2 ᖺ᫬⬟ࢆ⥔ᣢࡋࡘࡘᚎࠎ࡟ᨵၿࢆ♧ࡋࠊ⥔ᣢࢆࡋ࡚࠸ࡓࠋ࡟ࡣࠊせ௓ㆤᗘࡀ 1 ࡜࡞ࡿࠋ⭈⮚ࡢ⑓Ẽࢆᝈ࠸ኵࡢ௓
௓ㆤಖ㝤฼⏝⪅㸦n=19㸧ຓ㔞ࡀቑ࠼ࡿ࡜せ௓ㆤᗘ 2 ࡜࡞ࡾࠊࡑࡢᚋࡸࡸᅇ᚟ࡋ
࡚せ௓ㆤᗘ 1 ࡛ 10 ᖺࢆ㏄࠼ࡓ㸦ᅗ 5㸧ࠋࡑࡢᚋࠊ⭈⮚⑓ࡀቑᝏࡋࠊேᕤ㏱ᯒ࡜࡞ࡾධ㏥㝔ࢆ⧞ࡾ㏉ࡋࠊせ௓ㆤᗘ 5 ࡜࡞ࡿࠋ ᖺ┠࡟⭈୙඲ࡢࡓࡵṚཤࠋ


),0૱఼
),0ӣಊ



),0೟எ

6,$6


)$,





௓ㆤಖ㝤㠀฼⏝⪅㸦Q 㸧








ᅗ ࠉFDVH㸹せ௓ㆤᗘࡀኚ໬ࡋࡓ஦౛

),0૱఼
),0ӣಊ
),0೟எ

ࠉࠉࠉࠉࠉࠉ㔠ᒓᨭᰕ௜ 6/%㸦▷ୗ⫥⿦ල㸧ࢆ


6,$6

ࠉࠉࠉࠉࠉࠉ⮬ຊ࡛⿦╔㸦Ⓨ⑓  ᖺ᫬㸧

4.2 SIAS ࡢ᥎⛣

)$,



1992 ᖺࠊ ៞ ᠕ ⩏ሿ ኱Ꮫࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ⛉ࡣࠊ


SIAS
㸦6WURNHLPSDLUPHQWDVVHVVPHQWVHW ⬻༞୰ᶵ⬟㞀ᐖホ౯ࢭࢵࢺ㸧ࢆ㛤ⓎࡋࠊⓎ⾲ࡋࡓࠋࡇࢀࡣࠊ⬻༞୰ࣜࣁࣅࣜࢸ̿ࢩࣙࣥ࡟㛵ࡍࡿ᪥⡿ࡢඹྠ◊✲ࡢᡂᯝ࡛࠶ࡿᅗ ࠉ௓ㆤಖ㝤฼⏝⪅࡜㠀฼⏝⪅ࡢ࡜࠸ࢃࢀ࡚࠸ࡿࠋSIAS࡛ホ౯ࡍࡿ⬻༞୰ࡢᶵ⬟㞀ᐖࡣࠊ

ࠉࠉࠉ6$,6),0㸦),0 㐠ື࣭ㄆ▱㸧)$, ࡢ᥎⛣

㯞⑷ഃ㐠ືᶵ⬟ࠊ➽⥭ᙇࠊឤぬᶵ⬟ࠊ㛵⠇ྍືᇦࠊ⑊③ࠊయᖿᶵ⬟ࠊど✵㛫ㄆ▱ࠊゝㄒᶵ⬟ࠊ㠀㯞⑷ഃ
ᶵ⬟࡛࠶ࡾࠊయᖿᶵ⬟ࡸ㠀㯞⑷ഃᶵ⬟ࢆࡳࡿ࡜ࡇࢁ࡟
≉Ⰽࡀ࠶ࡿࠋホ౯ࡣ㡰ᗎᑻᗘ࡛ྲྀࡾࠊ⥲ᚓⅬࡣ  Ⅼࠋ
ICF ࡛ࡣࠊ
ࠕᚰ㌟ᶵ⬟࣭㌟యᵓ㐀ࠖࢆࡳࡿࡶࡢ࡛࠶ࡿ㸦༓ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

4.3 FIM ࡢ᥎⛣ᅗ 6 ࠿ࡽࠊFIM
㸦18 㡯┠㸧࡛ࡣࠊ10 ᖺ㛫ࠊ㍍௓ຓࣞ࣋ADL ホ ౯ ἲ ࡢ 1 ࡘ ࡛ ࠶ ࡿ FIM
㸦Functional࡛ࣝ⥔ᣢࡉࢀ࡚࠸ࡓࠋFIM 㐠ື㸦13 㡯┠㸧ࡣࠊ୰➼ᗘ,QGHSHQGHQFH0HDVXUH ᶵ⬟ⓗ⮬❧ᗘホ౯ἲ㸧ࡣࠊ1990௓ຓ࡛ࣞ࣋ࣝ⥔ᣢࡉࢀ࡚࠸ࡓࠋFIM ㄆ▱㸦5 㡯┠㸧ࡣࠊᖺ௦ࠊ⡿ᅜࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ་Ꮫ఍➼࡛㛤Ⓨࡉࢀࡓࡶ⮬❧࡛ࣞ࣋ࣝ⥔ᣢࡉࢀ࡚࠸ࡓࠋ

ࡢ࡛ࠊFIM࣭㐠ື㸦ࢭࣝࣇࢣ࢔࣭᤼ἥࢥࣥࢺ࣮࣭ࣟࣝ⛣஌࣭୰➼ᗘ௓ຓ࡛ࣞ࣋ࣝ⥔ᣢࡉࢀ࡚࠸ࡓ FIM 㐠ື࡟ࡘ࠸⛣ື㸧13 㡯┠㸦91 Ⅼ㸧
࡜ FIM࣭ㄆ▱㸦ࢥ࣑ࣗࢽࢣ࣮ࢩࣙࣥࠊ

࡚᥀ࡾୗࡆ࡚ࡳࡿࠋᅗ  ࡣࠊFIM 㐠ືࡢ௓ㆤࢧ࣮ࣅࢫ

♫఍ⓗ஺ὶࠊၥ㢟ゎỴࠊグ᠈㸧5 㡯┠㸦35 Ⅼ㸧ࡢィ 18฼⏝⪅࡜㠀฼⏝⪅ࡢ 13 㡯┠ࡢ 10 ᖺ㛫ࡢ᥎⛣ࢆᖹᆒ್㡯┠㸦126 Ⅼ㸧࡛ᵓᡂࡉࢀࡿࠋ ẁ㝵㸦㡰ᗎᑻᗘ㸧࡛ホ౯࡛⾲ࡋࡓࡶࡢ࡛࠶ࡿࠋ௓ㆤಖ㝤㠀฼⏝⪅ࡣࠊ㏥㝔ᚋࠊࡋࠊ඲௓ຓ࠿ࡽ᏶඲⮬❧ࡲ࡛ホ౯ࡍࡿࡶࡢ࡛࠶ࡿ㸦༓㔝

඲ 13 㡯┠࡛ 6 Ⅼ㸦ಟṇ⮬❧㸧௨ୖ࡜⥔ᣢ࣭ᨵၿࢆࡋ࡚࠸┤୍ࡽ 㸧ࠋ᪥ᮏࡢࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ་⒪ࡢศ㔝࡛ࡿࡇ࡜࡟ᑐࡋࠊ฼⏝⪅ࡣࠊ⛣஌㸦ᾎᵴ㸧ࠊ㝵ẁࠊΎᣔࡣࠊ%DUWKHO,QGH[
㸦BI㸧ࡼࡾከࡃ౑ࢃࢀ࡚࠾ࡾࠊFIM ࡢᬑ

࡛ 3 Ⅼ㸦୰➼ᗘ௓ຓ㸧ࠊ4 Ⅼྎ㸦㍍ᗘ௓ຓ㸧ࠊ⛣ື㸦Ṍཬࡀୡ⏺࡛㐍ࢇ࡛࠸ࡿࠋFIM ࡢ≉ᚩࡣࠊ24 ᫬㛫ᬑ㏻

⾜㸧ࠊ᭦⾰㸦ୖ࣭ୗ㸧ࡢ 5 Ⅼྎ㸦ᣦ♧࣭ぢᏲࡾ㸧࡛⥔ᣢࡋࠊ࡟⾜ࡗ࡚࠸ࡿ ADL ࢆホ౯ࡋࠊ⮬❧㔞࡜࡜ࡶ࡟௓ㆤ㔞ࡀ௓ㆤࢧ࣮ࣅࢫࢆᚲせ࡜ࡋ࡚࠸ࡿࡇ࡜ࡀศ࠿ࡗࡓࠋࡑࡋ࡚ࠊ

ࡳࡽࢀࡿⅬ࡜ࠊ㐠ື࡜ㄆ▱ࡢ୧㠃ࢆࡳࡿࡇ࡜࡛࠶ࡾࠊୡ

ࢺ࢖ࣞ⛣஌࡜ධᾎࡣࠊ୰➼ᗘ௓ຓࣞ࣋ࣝ௨ୗ࡟ୗࡀࡗ

⏺ඹ㏻ࡢホ౯ἲ࡟࡞ࡗࡓࡇ࡜࡛࠶ࡿࠋICF ࡛ࡣࠊࠕάື࡚ࠖࡁ࡚࠸ࡓࠋ

ࢆࡳࡿࡇ࡜ࡀ࡛ࡁࡿホ౯ἲ࡛࠶ࡿࠋ
FIM㐠ື 㸸௓ㆤಖ㝤฼⏝⪅㸦n=19㸧

FIM㐠ື㸸௓ㆤಖ㝤㠀฼⏝⪅㸦Q 㸧ᅗ ࠉ௓ㆤಖ㝤฼⏝⪅࡜㠀฼⏝⪅ࡢ ),0 㐠ືࡢ᥎⛣
4.4 FAI ࡢ᥎⛣ཧຍࢆホ౯ࡍࡿࡶࡢ࡛࠶ࡿࠋFAI㸦)UHQFKD\$FWLYLWLHV,QGH[ ♫఍⏕ά⬟ຊホ౯㸧

ᅗ 6 ࠿ࡽࠊFAI ࡛ࡣࠊ௓ㆤࢧ࣮ࣅࢫ㠀฼⏝⪅ࡣࠊ10ࡣࠊ⬻༞୰⪅ࡢ♫఍⏕ά⬟ຊࢆホ౯ࡍࡿࡓࡵ࡟ࠊ1983ᖺࢆ࠿ࡅ࡚⑓๓ࡢ♫఍⏕άᶵ⬟ࣞ࣋ࣝ࡟ࡶ࡝ࡗ࡚࠸ࡓࠋ

ᖺࠊ⡿ᅜ࡟࠾࠸࡚㛤Ⓨࡉࢀࡓ㸦Holbrook.M.et al1983㸧ࠋࡋ࠿ࡋࠊ฼⏝⪅ࡣࠊ⑓๓ࡢ 1/3 ࣞ࣋ࣝࡢ♫఍⏕άᶵ⬟

1999 ᖺࠊ᪥ᮏ∧ࡣ⏘ᴗ་⛉኱Ꮫࣜࣁࣅࣜࢸ㸫ࢩࣙࣥ་࡛ 10 ᖺ㛫ࢆ᥎⛣ࡋ࡚࠸ࡓࠋ

Ꮫㅮᗙ࡛సࡽࢀࠊ᪥ᮏேࡢᶆ‽್ࡀⓎ⾲ࡉࢀࡓ㸦ⓑᅵ⍞ ✑ ࡽ 1999㸧ࠋFAI ࡣࠊIADL
㸦,QVWUXPHQWDO$'/ ⏕4.5 ௓ㆤㄆᐃᗘ࡜ホ౯ SIAS࣭FIM࣭FAI ࡜ࡢ┦㛵ά㛵㐃άື㸧ホ౯ἲࡢ୍ࡘ࡛ࠊ15 㡯┠㸦㣗஦ࡢ⏝ពࠊせ௓ㆤㄆᐃࡣࠊࢥࣥࣆ࣮ࣗࢱ࣮࡛➨ 1 ḟุᐃ㸦ㄆᐃㄪᚋ∦௜ࡅࠊὙ℆ࠊᤲ㝖ࡸᩚ㡻ࠊຊ௙஦ࠊ㈙࠸≀ࠊእฟࠊᰝ࡜୺἞་ពぢ᭩㸧ࢆࡋࠊ஧ḟุᐃ㸦௓ㆤㄆᐃᑂᰝ఍㸧ᒇእṌ⾜ࠊ㊃࿡ࠊ஺㏻ᡭẁࡢ฼⏝ࠊ᪑⾜ࠊᗞ௙஦ࠊᐙ

࡛ヱᙜ㸦せᨭ᥼࣭せ௓ㆤᗘ㸧࡜㠀ヱᙜࢆỴࡵࡿࠋࡑࡋ࡚ࠊ

ࡸ㌴ࡢᡭධࢀࠊㄞ᭩ࠊ໅ປ㸧45 Ⅼ࡛ホ౯ࡍࡿࠋICF ࡛ࡣࠊㄆᐃᑂᰝࡢ᰾࡜࡞ࡿࡢࡀࢥࣥࣆ࣮ࣗࢱ࣮࡛➨ 1 ḟุᐃ࡟ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021౑ࢃࢀࡿㄆᐃㄪᰝ࡛࠶ࡿࠋࡇࡢㄆᐃㄪᰝࡣࠊ㌟యᶵ⬟࣭

FIM 㐠 ື࣭FIM ㄆ ▱ 㸧࣭FAI ࡢ ┦ 㛵 ࢆࡳ࡚ ࡳ ࡿ࡜ࠊ㉳ᒃືసࠊ⏕άᶵ⬟ࠊㄆ▱ᶵ⬟ࠊ⢭⚄࣭⾜ື␗ᖖࠊSpearman ࡢ㡰఩࿴┦㛵ಀᩘࡢ᳨ᐃ⤖ᯝࠊp<0.05 ࠾ࡼ♫఍⏕ά࡞࡝඲ᅜඹ㏻ࡢ  㡯┠࡜≉グ஦㡯࠿ࡽ࡞ࡿࡧ p<0.01 ࡛᭷ព࡛࠶ࡾࠊ┦㛵ಀᩘȚ =0.4 ௨ୖȚ =0.8

㸦ཌ⏕ປാ┬ 2009㸧ࠋࡇࡢᇶᮏㄪᰝ⚊㸦⾲ 3㸧ࡢ㡯┠ࢆ௨ୗ࡜ࠊ͆࠿࡞ࡾ͇࠾ࡼࡧ͆ᙉ࠸͇┦㛵ࡀ࠶ࡿࡇ࡜ࡀࢃ࠿ࡗ

ぢࡿ࡜ࠊSIAS࣭FIM࣭FAI ࡢࡑࢀࡒࢀ࡟㛵ࡍࡿ㡯┠ࡀከࡓࠋ⾲ 4 ࡣࠊせ௓ㆤᗘ࡜ FIM࣭㹄 IM 㐠ືࡢ┦㛵ಀᩘࡃࡳࡽࢀࡿࠋ ࡑࡇ࡛ࠊ せ௓ ㆤ ᗘ࡜ SIAS࣭FIM
㸦FIM࣭

࡞ࡽࡧ࡟᭷ព☜⋡ࢆ♧ࡍࠋ⾲ ࠉㄆᐃㄪᰝ⚊㸦≉グ஦㡯㸧⾲ ࠉせ௓ㆤᗘ࡜ 6$,6),0)$, ࡜ࡢ┦㛵ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021㸬⪃ᐹ࡜ே࡟ࡼࡾ␗࡞ࡿ᥎⛣ࢆࡋ࡚࠸ࡿࡇ࡜ࡀࢃ࠿ࡗࡓࠋࡲࡓࠊ

௒ᅇࡢㄪᰝࡣࠊ2000 ᖺ௓ㆤಖ㝤㛤ጞ࠿ࡽ 10 ᖺ㛫ࡢせ ௓ ㆤ ᗘ ࡜ SIAS࣭FIM࣭FAI ࡜ ࡣࠊ ྛ ᖺ ᫬ ࡜ ࡶ᥎⛣ࢆࡳࡓࡶࡢ࡛ࠊ2018 ᖺࡢせ௓ㆤᗘࢆୗࡆࡿ࡜ሗ㓘

Spearman ࡢ㡰఩࿴┦㛵ಀᩘࡢ᳨ᐃ⤖ᯝ p<0.01 ࡛᭷ពࡀฟࡿ࡜࠸࠺௓ㆤண㜵ไᗘࡀฟࡿ๓ࡢ᫬ᮇࡢࡶࡢ࡛࠶

࡛࠶ࡾࠊ┦㛵ಀᩘȚ =0.4 ௨ୖȚ =0.8 ௨ୗ࡜͆࠿࡞ࡾ͇
࠾ࡿࠋせ௓ㆤᗘࡢቑῶࢆ⧞ࡾ㏉ࡋ࡚ῶᑡ࡟㌿ࡎࡿேࡶ࠶

ࡼࡧ͆ᙉ࠸┦㛵͆ࡀ࠶ࡿࡇ࡜ࡀࢃ࠿ࡗࡓࠋせ௓ㆤᗘࡢࢀࡤࠊቑຍ࡟㌿ࡎࡿேࡶ࠸ࡓࡋࠊ௓ㆤᗘࡢኚࢃࡽ࡞࠸ே

͆⥔ᣢ࣭ᨵၿ͇࡟⏝࠸ࡿࡇࡢ 3 ࡘࡢホ౯ἲࢆᥦ᱌ࡋࡓࠋ

ࡶ࠸ࡓࠋ௓ㆤ͆༞ᴗ͇ࢆࡋࡓேࡶ࠸ࡓࠋ୍ᵝ࡛ࡣ࡞ࡃከ

௒ᚋࡉࡽ࡟㛗ᮇ㸦20 ᖺ㛫㸧࡟ࢃࡓࡿせ௓ㆤᗘࡢ᥎⛣ࢆศᵝ࡛࠶ࡿࡇ࡜ࡀศ࠿ࡗࡓࠋࡑࡋ࡚ࠊせ௓ㆤᗘࡀୖࡀࡗࡓ

ᯒࡋ࡚ࠊせ௓ㆤᗘࡢ⛬ᗘࢆࡳࡿࡇ࡜ࡀ࡛ࡁࡿせ௓ㆤᗘ࡜ே 10 ேࢆ࠸࠿࡟͆⥔ᣢ࣭ᨵၿ͇ࡢ᪉ྥ࡟ྥ࠿ࢃࡏࡿ࠿ࡀ

┦㛵ࡢᙉ࠸ホ౯ἲࢆᥦ᱌ࡋࡓ࠸ࠋࡲࡓࠊ⬻༞୰௨እࡢ

ㄢ㢟࡜ࡋ࡚ṧࡗࡓࠋཎᅉ࡟ࡼࡿせ௓ㆤ⪅࡟ᑐࡍࡿホ౯࡟ࡘ࠸࡚ࠊᥦ᱌ࡋࡓࡲࡓࠊホ౯࡛⏝࠸ࡓ SIASࠊFIMࠊFAI ࡀせ௓ㆤᗘ࡜ホ౯ἲࡀ࠺ࡲࡃᙜ࡚ࡣࡲࡿ࠿࡝࠺࠿࡟ࡘ࠸࡚௒ᚋ᳨ウࡋ┦㛵ࡀᙉ࠿ࡗࡓࡇ࡜ࡣࠊせ௓ㆤᗘࡢ͆⥔ᣢ࣭ᨵၿ͇ࢆホࡓ࠸ࠋ౯ࡍࡿࡢ࡟ࠊせ௓ㆤᗘ࡜┦㛵ࡢᙉ࠸ホ౯ἲ࡜ࡋ࡚ࠊࡇࡢ
3 ࡘࢆホ౯ἲ࡜ࡋ࡚ᥦ᱌ࡋࡓ࠸ࠋ࡞ࡐ࡞ࡽࡤࠊ௒ᅇ┦㛵㸬฼┈┦཯

ࡀᙉ࠿ࡗࡓ 3 ࡘࡢホ౯ἲ࠿ࡽࠊせ௓ㆤᗘࢆᨵၿࡍࡿࣄ

Ⓨ⾲࡟㛵㐃ࡋࠊ㛤♧ࡍ࡭ࡁ฼┈┦཯ࡣ࡞࠸ࠋ

ࣥࢺࡀ㞃ࡉࢀ࡚࠸ࡿ࠿ࡽ࡛࠶ࡿࠋᮏே࣭ᐙ᪘ࡢྠពࢆᚓ
ࡿࡇ࡜ࡀ๓ᥦ࡛࠶ࡿࡀࠊ┠ᶆࢆ⬻༞୰ᶵ⬟ࡢࡉࡽ࡞ࡿྥ

㸬ㅰ㎡

ୖࠊADL ࡢ௓ຓ㔞ࡢ㍍ῶࠊ♫఍⏕άᶵ⬟ࡢྥୖࠊ⢭⚄࣭㛗ᖺ࡟ࢃࡓࡾㄪᰝ◊✲࡟ࡈ༠ຊ㡬ࡁࡲࡋࡓᙜ஦⪅࠾ࡼ⾜ື㞀ᐖࡢᨵၿ࡟⨨ࡁࠊࢹ࢖ࢣ࢔ࠊࢹ࢖ࢧ࣮ࣅࢫࠊゼၥࡧࡈᐙ᪘࡟῝ࡃឤㅰ⏦ࡋୖࡆࡲࡍࠋ

┳ㆤࠊゼၥ௓ㆤࠊゼၥࣜࣁࣅࣜࢸ࣮ࢩࣙࣥࠊ௓ㆤண㜵஦ᴗ➼㛫࡛ඹ㏻┠ᶆࢆ❧࡚ࠊ↔Ⅼ໬ࡋࡓඹ㏻ࣉࣛࣥࢆ

ᘬ⏝ᩥ⊩❧᱌ࡋࠊྛ஦ᴗᡤ㛫࡛ᙺ๭ศᢸࢆࡋ࡚ᐇ㊶ࢆࡋ࡚࠸ࡃࡇ

Holbrook.Skilbecket
㸦1983㸧$Q$FWLYLWLHV,QGH[)RU8VH

࡜࡛࠶ࡿࠋ࡞ࡐ㐃ᦠࢆࡍࡿࡢ࠿ࠋFIM 㐠ືࡢ 10 ᖺ㛫

ZLWK6WURNH3DWLHQWV$JHDQG$JHLQJ

ࡢ᥎⛣㸦ᅗ 6㸪㸧࠿ࡽࡶࢃ࠿ࡿࡼ࠺࡟ࠊ௓ㆤࢧ࣮ࣅࢫࢆ

ཌ⏕ປാ┬㸦2009㸧㸸せ௓ㆤㄆᐃࠉㄆᐃㄪᰝဨࢸ࢟ࢫࢺ

฼⏝ࡋࠊ⮬୺⦎⩦ࡶ⾜ࡗࡓ⤖ᯝࠊ⮬❧ᗘࡀୗࡀࡗ࡚࠸ࡃ

ᨵゞ∧ 2009.4-165,㸦ᝏ໬㸧ࡢࡀ⌧ᐇ࡛࠶ࡾࠊせ௓ㆤࢆ͆⥔ᣢ࣭ᨵၿ͇࡟ኚ

ht t ps://w w w.m h lw.go.jp/f ile/06 - Seisa k ujou hou5RXNHQN\RNXSGI
㸦2021 ᖺ 12࠼࡚ࡺࡃࡢࡣ࠿࡞ࡾᅔ㞴࡞ㄢ㢟࡛࠶ࡿ࠿ࡽ࡛࠶ࡿࠋ

᭶ 20 ᪥㸧௒ᚋࠊࡉࡽ࡟㛗ᮇ㸦20 ᖺ㛫㸧࡟ࢃࡓࡿせ௓ㆤᗘࡢ᥎⛣࠿ࡽ͆⥔ᣢ࣭ᨵၿ͇ࡢኚ໬ࢆ᫂ࡽ࠿࡟ࡋࠊࡉࡽ࡟せ௓ㆤཌ⏕ປാ┬㸦2021㸧: 㒔㐨ᗓ┴ู せ௓ㆤ㸦せᨭ᥼㸧ㄆᐃᗘࡢ⛬ᗘࢆࡳࡿࡇ࡜ࡀ࡛ࡁࡿホ౯ἲࢆᥦ᱌ࡍࡿࠋࡲࡓࠊ

⪅ᩘ㸫⏨ዪィ㸫௧࿴ 3 ᖺ 6 ᭶⌧ᅾ . ➨ 23 ᅇ♫఍ಖ⬻༞୰௨እࡢཎᅉ࡟ࡼࡿせ௓ㆤ⪅࡟ᑐࡍࡿホ౯࡟ࡘ࠸㞀ᑂ㆟఍௓ㆤ⤥௜㈝ศ⛉఍௓ㆤሗ㓘ᨵᐃ᳨ド࣭◊࡚ࠊᥦ᱌ࡋࡓホ౯ἲࡀ࠺ࡲࡃᙜ࡚ࡣࡲࡿ࠿࡝࠺࠿࡟ࡘ࠸

✲ጤဨ఍ࠉ௓ㆤಖ㝤஦ᴗሗ࿌ ㈨ᩱ .

࡚௒ᚋ᳨ウࡍࡿࠋ

https://www.mhlw.go.jp/stf/newpage_21002.html㸦2021
ᖺ 12 ᭶ 13 ᪥㸧㸬⤖ㄽ୕ཎᓅ㸦2021㸧㸸
ࠕ἞ࡿࠖ௓ㆤࠊ௓ㆤಖ㝤ࡢࠕ༞ᴗࠖࡣྍ
⬟࠿㸫ᨵṇἲ࡟┒ࡾ㎸ࡲࢀࡓࠕ⮬❧ᨭ᥼௓ㆤࠖࢆ⪃࠼ᮏ◊✲ࡣࠊࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ་⒪ࢆཷࡅᅾᏯ⏕άࡿ , ࢽࢵࢭ࢖ᇶ♏◊✲ᡤ ,࡟ධࡗࡓ៏ᛶ⬻༞୰⪅࡟ᑐࡋ࡚ࠊ㏥㝔࠿ࡽ 10 ᖺ㛫ࡢせ௓ㆤᗘࡢ᥎⛣࠿ࡽࠊ࡝ࡢࡼ࠺࡟ኚ໬ࡍࡿ࠿ࢆ᫂ࡽ࠿࡟ࡍ

h t t p s : // w w w. n l i - r e s e a r c h . c o .j p / r e p o r t /d e t a i l /LG "SQR  VLWH QOL
㸦2021 ᖺ 12 ᭶ 15 ᪥㸧ࡿࡇ࡜ࠋࡲࡓࠊㄆᐃㄪᰝ㡯┠࡜㛵ಀࡀ࠶ࡿ࡜ᛮࢃࢀࡿ 3
ࡘࡢホ౯ࠊSIAS㸦 ⬻༞୰ᶵ⬟ホ౯㸧࣭FIM㸦ࡋ࡚࠸ࡿ

ᮍ᮶ᢞ㈨఍㆟㸦㸧㸸ᮍ᮶ᢞ㈨ᡓ␎ 

ADL ࡜௓ㆤ㔞ࢆホ౯㸧࣭FAI㸦♫఍⏕ά⬟ຊ IADL ࢆホ

https://www.kantei.go.jp/jp/singi/keizaisaisei/pdf/
PLUDLWRXVLBWSGI
㸦2021 ᖺ 12 ᭶ 15 ᪥㸧౯㸧ࡢ᥎⛣࡜せ௓ㆤᗘ࡜ࡢ┦㛵ࢆ᳨ウࡋࠊ⬻༞୰⪅ࡢせ௓ㆤᗘࡢ͆⥔ᣢ࣭ᨵၿ͇࡟ࡘ࡞ࡀࡿホ౯ೃ⿵ࢆᥦ᱌ࡍࡿ㈈ົ┬㸦2021㸧: ௓ㆤಖ㝤㈝⏝ࡢ᥎⛣ . ♫఍ಖ㞀➼㸦ཧ⪃㈨ᩱ㸧.ࠉ

ࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋ
ᑐ㇟ࡣ 36 ேࠋ⤖ᯝࠊせ௓ㆤᗘࡣቑῶࠊ⥔ᣢࠊᾘ⁛https://www.mof.go.jp/about_mof/councils/f iscal_ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

system_council/sub-of_fiscal_system/proceedings/
material/zaiseia20210415/02.pdf
㸦2021 ᖺ 12 ᭶ 15 ᪥㸧ⓑᅵ ⍞ ✑࣭బ ఑ ぬ , ⻏ 㡲 ㈡ ◊஧㸦1999㸧㸸᪥ᮏ ㄒ ∧)UHQFKD\$FWLYLWLHV,QGH[ ⮬ᕫホ౯⾲࠾ࡼࡧࡑࡢ⮫ᗋᛂ⏝࡜ᶆ‽್ . ⥲ྜࣜࣁࣅࣜࢸ̿ࢩࣙࣥ
㸦5㸧༓㔝┤୍⦅ࠉ㔛Ᏹ᫂ඖࠊᅬ⏣ⱱࠊ㐨ච࿴ஂ㸦㸧: ⬻༞୰ᝈ⪅ࡢᶵ⬟ホ౯ࠉSIAS ࡜ FIM ࡢᐇ㝿 . ࢩࣗࣉ࣮࣭ࣜࣥ࢞ࣇ࢙࢔࣮ࣛࢡᮾி ,3-96ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Original Articleࠚ

Transition and Analysis of Long-Term Care Insurance and Level of Care Needfor 10 Years after Onset in Chronic Stroke Patients-Comprehensive Follow-Up Study of Chronic Stroke Patients: Proposal of an
Evaluation Method for Evaluating the Level of Care NeedShunji Sawa*1 Shigeru Sonoda*2 Yuriko Yamakawa*3 Takashi Isaji*4 Koichi Onaka*5
Toshikazu Yasuoka*4 Yoshiki Kanada*6 Hidemasa Iki * Naoki Sakano*8 Tomoyuki Matsuda*3 Tomoko Usami*1
Wakaya Fujii*1ࠉShunji Sakamuki*1 Shinichiro Maeshima*8 Eiichi Saito*6
Takashi Tsuchiya*9 Hiroyasu Iso*10 Hitoshi Ota*11

Abstract
From 2018, care service providers that have been able to lower the level of care needed for long-term care insurance㸦͆improvement͇㸧 will receive long-term care fees 㸦additional fees㸧. The purposes of this study were to clarify
the change in improvement in chronic stroke patients who received rehabilitation therapy and lived at home based on the
WUDQVLWLRQRIWKHLQGLYLGXDOOHYHORIWKHQHHGIRUFDUHGXULQJWKH\HDUVDIWHUGLVFKDUJHIURPWKHKRVSLWDOWRH[DPLQHWKH
correlation between the three evaluation methods of the Stroke Impairment Assessment Set 㸦SIAS㸧, Functional
Independence Measure 㸦FIM㸧DQG)UHQFKD\$FWLYLWLHV,QGH[㸦FAI㸧 and the level of the need for care, and to propose
LWDVDQHYDOXDWLRQPHWKRGIRUHYDOXDWLQJWKHOHYHORIWKHQHHGIRUFDUHE\VWURNHSDWLHQWV7KLUW\VL[㸦36㸧 subjects weresurveyed. The results showed that the transition of improvement, maintenance, deterioration, or leaving the care 㸦notapplicable㸧 of the level of the need for care during the 10 years varied from person to person. In addition, the results ofSpearman̓VUDQNVXPFRUUHODWLRQFRH൶FLHQWWHVWVKRZHGWKDWWKHOHYHORIWKHQHHGIRUFDUH6,$6),0DQG)$,ZHUH
VLJQL¿FDQWDWSIRUHDFK\HDUDQGWKHUHZHUHVLJQL¿FDQWDQGVWURQJFRUUHODWLRQVEHWZHHQFRUUHODWLRQFRH൶FLHQWVȚDQGȚ7KHVHWKUHHHYDOXDWLRQPHWKRGVDUHSURSRVHGDVHYDOXDWLRQPHWKRGVIRUHYDOXDWLQJWKHOHYHORIWKHQHHG
for care. We will analyze the long-term 㸦20 years㸧 transition of the need for care and propose further evaluation methods
WKDWDUHKLJKO\FRUUHODWHGZLWKWKHQHHGIRUFDUH)XUWKHUPRUHZHZLOOH[DPLQHZKHWKHUWKHSURSRVHGHYDOXDWLRQPHWKRGV
are well applicable to the evaluation of persons requiring long-term care due to causes other than stroke.
Keywords: stroke, follow-up, level of care need, stroke functioning, ADL, social functioningᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021࠙◊✲ሗ࿌ࠚ

ᑠᏛᰯపᏛᖺࢧࢵ࣮࢝㑅ᡭࡢᇶ♏ᢏ⬟࡟ᙳ㡪ࡍࡿᅉᏊཬࡧᇶ♏ᢏ⬟㛫ࡢ㛵㐃㸦➨୍ሗ㸧㸫㌟య⬟ຊࠊᏛᖺูࡢẚ㍑̿
⏣୰ᬛஅ *1ࠊ㧗ᶫὒ *2ࠉࠊ᭯ᡃዉኸ *1ࠊ㉔⏣⿱ኴ *1ࠊᒣᮏဏ *1*1 ་⒪ἲேᇸ⋢ᡂᜨ఍⑓㝔ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ⛉*2 ᒱ㜧ಖ೺኱Ꮫࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊せ᪨㸦┠ⓗ㸧ᮏ◊✲࡛ࡣࠊపᏛᖺᑠᏛ⏕ࢧࢵ࣮࢝㑅ᡭ࡟࠾ࡅࡿᇶ♏ᢏ⬟࠾ࡼࡧ㌟య⬟ຊ➼ࡢ㛵㐃ᛶ࡟ࡘ࠸᳨࡚ウࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋ㸦ᑐ㇟㸧ᑠᏛ 1 ᖺ㹼 3 ᖺ⏕ࡢࢧࢵ࣮࢝⤒㦂⪅ 40 ྡ࡜ࡋࡓࠋᇶ♏ᢏ⬟ࡣࣜࣇࢸ࢕ࣥࢢࠊࢻࣜࣈࣝ㸦ࢫ࣮࣒ࣛࣟࠊ8 ࡢᏐ㸧ࠊࢲ࢖ࣞࢡࢺ࢟ࢵࢡ࡜ࡋࠊ㌟య⬟ຊࡣࢫࣉࣜࣥࢺࠊ∦⬮❧఩ࣂࣛࣥࢫࠊ཯᚟ᶓ㊴ࡧ࡜ࡋࡓࠋᇶ♏ᢏ⬟㛫ࡢ㛵㐃ᛶ࠾ࡼࡧྛせᅉ࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸࡚ࠊ᭷ពỈ‽ 5% ᮍ‶࡛⤫ィฎ⌮ࢆ⾜ࡗࡓࠋ㸦⤖ᯝ㸧ࣜࣇࢸ࢕ࣥࢢࡣࠊྛᇶ♏ᢏ⬟࡜ࡢ㛫࡛᭷ព࡞┦㛵ࡣㄆࡵࡽࢀ࡞࠿ࡗࡓࠋࢫ࣮࣒ࣛࣟࡣࠊ8 ࡢᏐ࡜ࢲ࢖ࣞࢡࢺ࢟ࢵ
ࢡࠊ཯᚟ᶓ㊴ࡧࡢ㛫࡛┦㛵ࢆㄆࡵࡓࠋ8 ࡢᏐࡣࠊࢲ࢖ࣞࢡࢺ࢟ࢵࢡ࡜ࡢ㛫࡛┦㛵ࢆㄆࡵࡓࠋࢫࣉࣜࣥࢺࡣࠊࣜࣇࢸ࢕ࣥ
ࢢ࡜ࢫ࣮࣒ࣛࣟࠊ8 ࡢᏐ࡜ࡢ㛫࡛┦㛵ࢆㄆࡵࡓࠋ∦⬮❧఩ࣂࣛࣥࢫ࡜ 8 ࡢᏐ࡜ࡢ㛫࡛┦㛵ࢆㄆࡵࡓࠋᇶ♏ᢏ⬟ࡢྥ
ୖ࡟ࡣ㌟యⓗⓎ㐩ࡢࡳ࡞ࡽࡎࠊ⤒㦂ࡸ⦎⩦㔞࡟ࡼࡿᏛ⩦ຠᯝࡸ㌟యࡢ༠ㄪᛶྥୖ࡞࡝ࡀ㛵୚ࡋ࡚࠸ࡿ࡜⪃࠼ࡽࢀࡿࠋ
࣮࣮࢟࣡ࢻ㸸ᑠᏛ⏕ࢧࢵ࣮࢝ࠊᇶ♏ᢏ⬟ࠊ㌟య⬟ຊᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021࠸࡚࡝ࡢࡼ࠺࡞㛵ಀࡀᚓࡽࢀࡿ࠿ࢆ᳨ウ஦㡯࡜ࡋ࡚ᣲࡆ

⥴ゝ

࡚࠸ࡿࠋ

᪥ᮏࢫ࣏࣮ࢶ⌮Ꮫ⒪ἲᏛ఍㸦2019㸧ࡣࠊタ❧㊃᪨ࢆࠕࢫ
࣏࣮ࢶ⌮Ꮫ⒪ἲ࡟㛵ಀࡍࡿᇶ♏◊✲ࠊ⮫ᗋ◊✲ࢆ᥎㐍୰Ꮫ⏕⏨Ꮚࢧࢵ࣮࢝㑅ᡭࢆᑐ ㇟࡜ࡋࡓᚋ⸨ࡽ㸦ᚋࡋࠊໟᣓⓗ᳨ウࢆຍ࠼ࠊࡑࡢຠᯝ࡜᰿ᣐࢆᏛ⾡ⓗ࡟᥈⸨ ,2005㸧ࡣࠊࢻࣜࣈࣝࡢ㏿ࡉࡸ࢖ࣥࢧ࢖ࢻ࢟ࢵࢡࡢṇ☜ồࡋ࡚࠸ࡃࠋࡑࢀ࡟ࡼࡾࠊ⌮Ꮫ⒪ἲ࡜ࢫ࣏࣮ࢶࡢⓎᒎ࡟ᛶࠊ࢖ࣥࢫࢸࢵࣉ࢟ࢵࢡࡢṇ☜ᛶ࡜ࣜࣇࢸ࢕ࣥࢢ⬟ຊ࡜ࡢᐤ୚ࡍࡿࡇ࡜ࢆάືࡢ┠ⓗ࡜ࡍࡿࠖ࡜ࡋ࡚࠸ࡿࠋ୺࡞㡿㛫࡟ࠊ᭷ព࡞┦㛵㛵ಀࡀㄆࡵࡽࢀࠊ୰࡛ࡶࢻࣜࣈࣝࡢ

ᇦࡢ୍ࡘ࡟ࠕࢫ࣏࣮ࢶάື࡟ᵝࠎ࡞┠ⓗ࡛ྲྀࡾ⤌ࡴேࠎ㏿ࡉ࡜࢖ࣥࢫࢸࢵࣉ࡛ࡢࣜࣇࢸ࢕ࣥࢢࡢ㛫࡛᭱ࡶ㧗࠸┦㛵㸦ᖺ㱋ᒙࠊᛶูࠊάືࣞ࣋ࣝࡸ➇ᢏ✀┠ࢆၥࢃࡎ㸧ࢆࢆㄆࡵࡓ࡜ሗ࿌ࡋ࡚࠸ࡿࠋ

ᑐ㇟࡜ࡋ࡚ࠊࡼࡾⰋ࠸㌟య≧ែ࡛ࡢࢫ࣏࣮ࢶᐇ㊶ࠊእയ୰ᒣࡽࡣ㸦୰ᒣ ,2009㸧ࠊU㸦࢔ࣥࢲ࣮㸧-10㸦9 ṓ࡜ 10ࡸ⑌⑓ࡢண㜵ࠊࢫ࣏࣮ࢶ⬟ຊࡢྥୖࢆࡣ࠿ࡿࠖࡀ࠶ࡿࠋṓ 㸧ࠊU-12㸦11 ṓ ࡜ 12 ṓ 㸧ࠊU-14
㸦13 ṓ ࡜ 14 ṓ 㸧ࠊබ┈㈈ᅋἲே᪥ᮏࢧࢵ࣮࢝༠఍㸦௨ୗ JFA㸧
㸦2019㸧࡟

U-16
㸦15 ṓ࡜ 16 ṓ㸧ࢆᑐ㇟࡟ࠊⓎ㐩ẁ㝵ࡀࣃࢫࡢᢏ⬟ࡼࡿ࡜ࠊ᪥ᮏࡢࢧࢵ࣮࢝ࡢⓏ㘓➇ᢏேཱྀࡣࠊ ᖺ࡟࡟୚࠼ࡿᙳ㡪࡟ࡘ࠸࡚ሗ࿌ࡋ࡚࠸ࡿࠋ୰ᒣࡽࡣࠊࣃࢫࡢ

 ே࡛࠶ࡗࡓࡢࡀࠊ ᖺ࡟ࡣ༠఍ࡢⓏ㘓➇ᢏᡂຌ⋡ࡸࣃࢫࡢᖹᆒ㐃⥆ᮏᩘࡀ 4 ⩌㛫ࡢ㛫࡛᭷ព࡞ᕪ

⪅ᩘࡀࠊ915,306 ே࡜࡞ࡾࠊ⣙ 40 ᖺ㛫࡛࠾ࡼࡑ 3.4 ಸࢆㄆࡵࠊከ㔜ẚ㍑ࡢ⤖ᯝࠊU-10 ࡢᡂຌ⋡ࡸᖹᆒ㐃⥆ࡲ࡛ቑຍࡋ࡚࠸ࡿࠋ௚࡟ࡶⓏ㘓➇ᢏ⪅ᩘ࡟ྵࡲࢀ࡞࠸

ᮏᩘࡀࠊU-12ࠊU-14ࠊU-16 ࡼࡾ᭷ព࡟ప࠸ࡇ࡜ࡀㄆࡵ

ᗂඣࡸ㊃࿡࡜ࡋ࡚ࢧࢵ࣮࢝ࢆᐇ㊶ࡋ࡚࠸ࡿேࠎࢆྵࡵࢀ

ࡽࢀࠊU-10 ࡛ࡣࠊU-12 ௨㝆ࡢᖺ௦ࡼࡾࣃࢫࡢࣃࣇ࢛࣮

ࡤࠊ᪥ᮏᅜෆࡔࡅ࡛ࡶ 100 ୓ே㏆ࡃࡢேࠎࡀࣉ࣮ࣞࡋ࡚

࣐ࣥࢫࡀຎࡗ࡚࠸ࡿ࡜⤖ㄽࡋ࡚࠸ࡿࠋࡑࡢ⌮⏤࡜ࡋ࡚ࠊ࠾ࡾࠊ᪥ᮏᅜෆ࡛ࡶᖺ௦ࡸᛶูࢆၥࢃࡎከࡃࡢேࠎࡀ

⤒㦂ᖺᩘࡢ㐪࠸ࡸ࢟ࢵࢡ࠾ࡼࡧ࣮࣎ࣝࢥࣥࢺ࣮ࣟࣝࡢᢏ

ࢧࢵ࣮࢝ࢆᴦࡋࢇ࡛࠸ࡿࠋࡑࡢ୰࡟ࡣࠊࢺࢵࣉࣞ࣋ࣝࢆ

⬟ࡀຎࡗ࡚࠸ࡓ࡜⪃ᐹࡋ࡚࠸ࡿࠋࡲࡓࠊࣃࢫࡢࣃࣇ࢛࣮

┠ᣦࡍࣉ࣮࣮ࣞࣖ࠿ࡽయຊ࡙ࡃࡾࡸ㊃࿡࡜ࡋ࡚⾜࠺ឡዲ࣐ࣥࢫࡣಶேᢏ⬟ࡢࡳ࡞ࡽࡎࢧ࣏࣮ࢺࣉ࣮ࣞࡀ㔜せ࡛࠶⪅ࡲ࡛࠾ࡾࠊࡑࡢ┠ⓗ࡜ࡍࡿ࡜ࡇࢁࡣᖜᗈࡃከᵝ࡛࠶ࡿࠋࡾࠊU-10 ࡣ௚ࡢᖺ㱋ᒙ࡜ẚ࡭ຠᯝⓗ࡞ࢧ࣏࣮ࢺࣉ࣮ࣞ

ࡲࡓࠊࣉ࣮࣮ࣞࣖ࡜ࡋ࡚ࡢ㛵ࢃࡾࡢࡳ࡞ࡽࡎࠊᣦᑟ⪅ࡸࡀ࡛ࡁ࡚࠸࡞࠸ࡇ࡜ࡶ୍ࡘࡢせᅉ࡜ࡋ࡚ᤊ࠼࡚࠸ࡿࠋ

࣓ࢹ࢕࢝ࣝࢧ࣏࣮ࢱ࣮࡜ࡋ࡚㛵ࢃࡿேࠎࡶቑ࠼ࠊᑗ᮶ࡢ

ᐇ㝿࡟ᑠᏛ⏕ࢧࢵ࣮࢝㑅ᡭࡢ⦎⩦ࡸヨྜ࡟࠾ࡅࡿࣉ

⫋ᴗ࡜ࡋ࡚ࠊᣦᑟ⪅ࡸ࢔ࢫࣞࢸ࢕ࢵࢡࢺ࣮ࣞࢼ࣮ࢆᚿࡍ࣮ࣞࢆほᐹࡍࡿ࡜ࠊྠᖺ௦ࡢ୰࡛ࡶࠊࣜࣇࢸ࢕ࣥࢢᢏ⬟ⱝ⪅ࡶቑຍࡋ࡚࠸ࡿࠋ᫖௒ࠊᡃࠎ⌮Ꮫ⒪ἲኈࡣࠊᏛ⏕ࡸࢻࣜࣈࣝᢏ⬟ࠊ࣮࣎ࣝࢥࣥࢺ࣮ࣟࣝࠊࣃࢫࡢ⢭ᗘ࡞࡝ࣞ࣋ࣝ࠿ࡽࢺࢵࣉࢳ࣮࣒ࡲ࡛ከᒱ࡟ࢃࡓࡿศ㔝࡛ࢧࢵಶࠎࡢࣃࣇ࢛࣮࣐ࣥࢫ࡟ᕪࡀぢࡽࢀࡿࠋ 㔠Ꮚࡽ㸦 㔠࣮࢝㑅ᡭࡢࣃࣇ࢛࣮࣐ࣥࢫྥୖࡸ㞀ᐖண㜵࡟ᑐࡋ࡚ࠊ

Ꮚ ,2012㸧࡟ࡼࡿ࡜ࠊJFA ࡣࢧࢵ࣮࢝㑅ᡭࡢᖺ㱋࡟ࡼࡿά㌍ࡢሙࢆᗈࡆ࡚࠸ࡿࠋ

ẁ㝵ⓗᣦᑟ࡟࠾࠸࡚ࡣࠊ㹼 8࣭9 ṓࢆࠕࣉࣞࢦ࣮ࣝࢹࣥ

ࢧࢵ࣮࢝ࡣᅋయ➇ᢏ࡛࠶ࡾࠊヨྜ࡛຾฼ࡍࡿࡓࡵ࡟ࡣ

࢚࢖ࢪࠖࠊ9 㹼 12 ṓࢆࠕࢦ࣮ࣝࢹ࢚ࣥ࢖ࢪࠖ࡜ᐃ⩏ࡋ࡚ࠊࢳ࣮࣒ࣉ࣮ࣞ
㸦⤌⧊ຊ㸧ࡀ㔜せ࡛࠶ࡿࠋ⤌⧊ຊࢆ㧗ࡵࡿࡑࢀࡒࢀࡢ⫱ᡂ᪉㔪ࢆᥦ♧ࡋ࡚࠸ࡿࠋࡇࢀࡽࡢᖺ௦࡛

࡟ࡣࠊಶேᢏࡔࡅ࡛࡞ࡃࠊࣉ࣮ࣞ୰ࡢ✵㛫ㄆ▱ࡸಶࠎࡢẁ㝵ⓗ࡞ᣦᑟ࡛ࡣࠊScamon㸦⸨஭ ,2013㸧ࡢⓎ⫱Ⓨ㐩ࡢඹ㏻ព㆑ࡀḞ࠿ࡏ࡞࠸ࡀࠊಶேᢏ⬟ࡀࢳ࣮࣒ࣉ࣮ࣞ

᭤⥺࡟♧ࡉࢀࡿࡼ࠺࡟ࠊ8 ṓ࠿ࡽ 10 ṓ๓ᚋ࡟⚄⤒⣔ࡀ࡟ᙉࡃᙳ㡪ࡋ࡚࠸ࡿࡇ࡜ࡣ⣮ࢀࡶ࡞࠸ࠋ኱Ꮫ⏕ࢆᑐ㇟࡜➽ຊ࡟ẚ࡭ⴭࡋࡃⓎ㐩ࡍࡿࡇ࡜࠿ࡽࠊᢏ⾡ࡢ⩦ᚓ࡟᭱ࡋࡓ㯄ࡢሗ࿌㸦㯄 ,1981㸧࡛ࡣࠊಶேᢏ࡜ࢳ࣮࣒ࣉ࣮ࣞ

ࡶ㐺ࡋࡓ᫬ᮇ࡜ࡉࢀࠊ୍᪉ࠕࢦ࣮ࣝࢹ࢚ࣥ࢖ࢪࠖ௨㝆࡛ࡢ┦㛵ࡣ࠿࡞ࡾ㧗࠸ࠋࡇࡢࡇ࡜ࡣࠕ࣮࣎ࣝࢥࣥࢺ࣮ࣟࣝ

ࡣ୍⯡ⓗ࡟➽ຊࡸᣢஂຊࡀⴭࡋ࠸Ⓨ㐩ࢆ♧ࡍࡇ࡜࠿ࡽࠊ

ࡀࡋࡗ࠿ࡾ࡛ࡁࡿࠖ࡜࠸ࡗࡓಶேᢏࡢ⬟ຊࡀࢳ࣮࣒ࣉ

ࢧࢵ࣮࢝㑅ᡭ࡟ᚲせ࡜࡞ࡿ≉␗ⓗ࡞ືࡁ࡛ࡢⓎ᥹ࣃ࣮ࣞࢆ⾜࠺ࡓࡵࡢᚲせ᮲௳࡜࡞ࡗ࡚࠸ࡿࡇ࡜ࢆ♧ࡋ࡚࠸࣮࣡ࡸࢫ࢟ࣝࡢྥୖ࡟୺║ࡀ⨨࠿ࢀ࡚࠸ࡿࠋ

ࡿࠋࡲࡓࠊ࣮࣎ࣝࣜࣇࢸ࢕ࣥࢢ࡜ࢻࣜࣈࣝᢏ⬟ࡣ㧗࠸┦㸬◊✲┠ⓗ㛵ࡀㄆࡵࡽࢀࠊࣜࣇࢸ࢕ࣥࢢᢏ⬟࡜ࢻࣜࣈࣝᢏ⬟ࡣఝ࠿ࡼࡗࡓ⬟ຊ࡛࠶ࡿ࡜⪃ᐹࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊ⤒㦂ᖺᩘࡢᗂඣᮇࡢ㐠ືⓎ㐩➼࡟㛵ࡍࡿ◊✲ࡸ୰㧗⏕࣭኱Ꮫ⏕㛗࠸⪅ࡣࠊ㐃⥆ࣉ࣮ࣞ➼ࠊࢳ࣮࣒ࡢ୍ဨ࡜ࡋ࡚ࡢືࡁࢆ

ࢆᑐ㇟࡜ࡋࡓࢧࢵ࣮࢝ࡢᢏ⬟࡟㛵㐃ࡍࡿᩥ⊩➼ࡣከᩘࡼࡃ▱ࡗ࡚࠾ࡾࠊ㐃⥆ࢩ࣮ࣗࢺ࢟ࢵࢡ࡜ࡢ┦㛵ࡀ᭱ࡶ㧗ࡃࠊᩓぢࡉࢀࡿࡀࠊᑠᏛᰯపᏛᖺࢆᑐ㇟࡜ࡋࡓࢧࢵ࣮࢝ࡢ

⤒㦂ᖺᩘࡣಶேᢏࡼࡾࢳ࣮࣒ࣉ࣮ࣞࠊᨷᧁࡼࡾࡶᏲഛ

ᢏ⬟࡟㛵㐃ࡍࡿඛ⾜◊✲ࡣከࡃࡣ࡞࠸ࠋከࡃࡢᏊࡣᑠ

ࡢ᪉࡟㧗࠸┦㛵ࢆ♧ࡋ࡚࠸ࡿ࡜࠸࠺ሗ࿌ࡀ࠶ࡿࠋ㯄ࡣ௒ᏛᰯධᏛᚋ࡟ࢧࢵ࣮࢝ࢆ⩦࠸ጞࡵࠊ᪩࠸Ꮚ࡛ࡶ 5࣭6 ṓᚋࡢㄢ㢟࡜ࡋ࡚⤒㦂ᖺᩘ࡟኱ᕪࡢ࡞࠸ᑠ࣭୰Ꮫ⏕࡟࠾࠿ࡽ⩦࠸ጞࡵ࡚࠾ࡾࠊࢧࢵ࣮࢝ࢆ⩦࠸ጞࡵ࡚᪥ࡀὸ࠸≧ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ἣ࡟ࡶ࠿࠿ࢃࡽࡎࠊ᪤࡟ᢏ⬟㠃࡛ࠊୖᡭ࣭ୗᡭࡀ୺ほᢏ⬟࠾ࡼࡧ㌟య⬟ຊ➼ࡀࠊ࠾஫࠸࡟࡝ࡢࡼ࠺࡟㛵㐃ࡋ࡚ⓗ࡟ឤࡌࡽࢀࡿࠋࡑࡇ࡛ࠊᐇ㝿࡟ࢧࢵ࣮࢝ࡢᇶ♏࡜࡞ࡿ࠸ࡿ࠿ㄪᰝ᳨࣭ウࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋᢏ⬟ࡀᐈほⓗ࡟࡝ࡢࡼ࠺࡞㐪࠸ࡀ࠶ࡿࡢ࠿ࢆㄪᰝࡍࡿࡇ
࡜ࠋࡲࡓࠊ㉮ࡿ㏿ࡉࡸ㉮ࡾ᪉㸦ࣇ࢛࣮࣒㸧࡟ࡶ㐪࠸ࡀ࠶ࡾࠊ

᪉ἲࡇ࠺ࡋࡓ㐠ື⬟ຊࡀࢧࢵ࣮࢝ࡢᢏ⬟࡟࡝ࡢࡼ࠺࡟㛵ಀࡋ

3.1 ᑐ㇟

࡚࠸ࡿࡢ࠿ࢆ᳨ウࡍࡿࡇ࡜ࡀዎᶵ࡛࠶ࡿࠋ

᯾ࢫ࣏࣮ࢶࢡࣛࣈ࡟ᡤᒓࡍࡿᑠᏛ 1 ᖺ⏕࠿ࡽ 3 ᖺ⏕ᮏ◊✲࡛ࡣࠊࢧࢵ࣮࢝ࡢࣉࣞࢦ࣮ࣝࢹ࢚ࣥ࢖ࢪ࡛࠶ࡾ

㸦8 ࠿ࡽ U-9㸧ࡢࢧࢵ࣮࢝⤒㦂⪅ 40 ྡࢆᑐ㇟࡜ࡋࡓࠋ

⤒㦂ᖺᩘࡀẚ㍑ⓗ▷࠸ࠊᑠᏛᰯపᏛᖺࡢࢧࢵ࣮࢝࡟࠾

⏨ዪẚࡣ 40 ྡࡍ࡭࡚ࡀ⏨ඣ࡛࠶ࡗࡓࠋᖹᆒᖺ㱋ࡣ ࡅࡿᇶ♏ᢏ⬟㸦ࣜࣇࢸ࢕ࣥࢢࠊࢻࣜࣈࣝࠊࢲ࢖ࣞࢡࢺ࢟ࢵs  ṓࠊ ᖹ ᆒ ㌟ 㛗 123.96 s FPࠊ ᖹ ᆒ య 㔜ࢡ㸧࡜㌟య⬟ຊ㸦ࢫࣉࣜࣥࢺຊࠊࣂࣛࣥࢫ⬟ຊࠊ▐Ⓨຊ㸧

24.03 s 3.49kg ࡛࠶ࡗࡓࠋᑐ㇟ࡢᴫせࢆ⾲ 1 ࡟♧ࡍࠋ➼ࢆィ ࡋࠊᑠᏛᰯపᏛᖺࢧࢵ࣮࢝㑅ᡭ࡟࠾ࡅࡿᇶ♏
⾲ ࠉᑐ㇟⪅ࡢᴫせ

㸦ྡ㸧
㸦ṓ㸧
㸦cm㸧
㸦kg㸧
㸦᭶㸧
3.2 ィ ᮇ㛫࣭ᐇ᪋ሙᡤ࣭ィ ⪅ࣜࣇࢸ࢕ࣥࢢࡣࠊ㊊ࡢࡳ࡟ࡼࡗ࡚࣮࣎ࣝࢆⴠ࡜ࡉࡎ࡟

ィ ࡣࠊ2019 ᖺ 4 ᭶࠿ࡽ 5 ᭶ࡢ୰࡛ࠊࢡࣛࣈࡢࢺ࣮ࣞ

㐃⥆ࡋ࡚ࡘࡃㄢ㢟࡛࠶ࡿࠋไ㝈᫬㛫ࢆ 2 ศ࡜ࡋࠊ㛤ጞ࠿ࢽࣥࢢ᪥࡛࠶ࡿ᪥᭙᪥ࢆ฼⏝ࡋ࡚ᐇ᪋ࡋࡓࠋᐇ᪋ሙᡤࡣࠊ

ࡽ 1 ศ 50 ⛊⤒㐣ࡋࡓ᫬Ⅼ࠿ࡽ࢝࢘ࣥࢺࢲ࢘ࣥࢆ⾜࠸ࠊ2ᐇ㝿ࡢヨྜࡸ⦎⩦⎔ቃ࡜ྠ᮲௳࡟ࡍࡿࡓࡵࠊᇸ⋢┴ᮾศ㛫࡛⤊஢࡜ࡋࡓࠋᑐ㇟ඣ 1 ྡ࡟ᑐࡋࠊ
᳨⪅ 1 ྡࡀ┘ど࣭ᯇᒣᕷෆࡢࢧࢵ࣮࢝ሙ㸦ᒇእ㸧࡟࡚ᐇ᪋ࡋࡓࠋᐇ᪋᫬ࡢィ ࡋࡓࠋヨᢏࡣᡭ࡛࣮࣎ࣝࢆⴠ࡜ࡋ࡚㛤ጞ࡜ࡋࠊ࢟ࢵ

ኳೃࡣᬕኳ࡛ࠊࢢࣛ࢘ࣥࢻࢥࣥࢹ࢕ࢩࣙࣥࡣⰋዲ࡛࠶ࡗ

ࢡࡢ✀㢮ࡣ࢖ࣥࢧ࢖ࢻ࢟ࢵࢡ࣭࢖ࣥࢫࢸࢵࣉ࢟ࢵࢡ➼ࡢࡓࠋࢧࢵ࣮࣮࢝࣎ࣝࡣ኱ࡁࡃࠊᨷᏲ࠿ධࢀ᭰ࢃࡿࡓࡵ

㝈ᐃࡣࡏࡎࠊ㊊ࡸ㢌࡛࣮࣎ࣝࢆⴠ࡜ࡉࡎ࡟⾜࠼ࡓ㐃⥆௚ࡢ➇ᢏ࡟ẚ࡭ኳೃ࡟ᙳ㡪ࡉࢀ࡟ࡃࡃࠊࡑࡢ᪥ࡢྠࡌኳ

ᅇᩘࢆィ ࡋࡓࠋᑦࠊ㏵୰࡛࣮࣎ࣝࢆⴠ࡜ࡋࡓሙྜࡣࠊ

ೃ᮲௳࡛ ᐃࡋ࡚࠸ࡿࡓࡵẚ㍑ྍ⬟࡜⪃࠼ࡽࢀࡿࠋィࡶ࠺୍ᗘึࡵ࠿ࡽ࢝࢘ࣥࢺࢆ⾜࠸ࠊไ㝈᫬㛫ෆ࡛࠶ࢀࡤ

⪅ࡣࠊ⌮Ꮫ⒪ἲኈ 6 ྡ࡛⾜ࡗࡓࠋఱᗘ⾜ࡗ࡚ࡶᕪࡋᨭ࠼࡞࠸࡜ࡋࠊไ㝈᫬㛫ෆ࡛ⴠ࡜ࡉࡎ
࡟⾜࠼ࡓ᭱㧗㐃⥆ᅇᩘࢆグ㘓࡜ࡋࡓࠋ

3.3 ィ 㡯┠࡜᪉ἲᐃᙜ᪥ࡣࠊࡲࡎ‽ഛ㐠ື࡜ࡋ࡚ࠊࢳ࣮࣒ࡀᬑẁ⾜ࡗ࡚࠸ࡿ‽ഛ㐠ືࢆᐇ᪋ࡋࡓࠋ⥆࠸࡚ࠊྛ✀┠ࡢ ᐃ᪉ἲ࡟ࡘ࠸࡚ࠊ
ཱྀ㢌࡛ࡢㄝ᫂࡜➹⪅ࡽࡀࢹࣔࣥࢫࢺ࣮ࣞࢩࣙ
ࣥࢆ⾜࠸ࠊᡭᮏࢆぢࡏࡓࠋࡑࡢᚋࠊᐇ㝿࡟㑅ᡭࡓࡕ࡟ᮏ␒ྠᵝ࡟ྛ✀┠ࡢ⦎⩦ࢆヨᢏ㛤ጞ๓࡟⾜ࡗࡓࠋࡑࡋ
࡚ᮏ␒ࡢヨᢏ࡟ධࡗࡓࠋࡲࡓࠊᮏ␒ࡢヨᢏ࡛᫂ࡽ࠿࡟
᪉ἲࢆ㛫㐪࠼ࡓ㑅ᡭࡀ࠸ࡓሙྜࡣࡸࡾ┤ࡋࢆ⾜ࡗࡓࠋᑦࠊ ᐃᙜ᪥ࡢ 1 ࣨ᭶๓࡟ணഛ ᐃࡶ⾜ࡗ࡚࠸ࡿࠋᅗ  ࣜࣇࢸ࢕ࣥࢢ
㸦ὀ㸧෗┿ࡣ஦๓⦎⩦᫬ࡢࡶࡢ࡛ࠊᮏ␒ࡣ

3.3.1 ᇶ♏ᢏ⬟ホ౯ࠉࠉࣜࣇࢸ࢕ࣥࢢࢸࢫࢺ㸦㯄ಙ⩏ ,1981ࠊᚋ⸨ᖾᘯ ,2005㸧㸦ᅗ1㸧

┘どࡀ୍ே1ྡࡎࡘࡘ࠸࡚ᐃᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ࢻࣜࣈࣝࢸࢫࢺ

ࢲ࢖ࣞࢡࢺ࢟ࢵࢡࢸࢫࢺ㸦㯄 1981㸧㸦ᅗ 4㸧

3.3.1.1 ࢫ࣮࣒ࣛࣟࢻࣜࣈࣝ㸦ᅗ 2㸧࢟ࢵࢡࣛ࢖ࣥࡼࡾ10m ๓᪉࡟ᖜ FPࠊ㧗ࡉ 50cm ࡢ㯄㸦㯄 ,1981㸧࠾ࡼࡧኴ⏣㸦ኴ⏣ ,1981㸧ࡢඛ⾜◊✲ࢆཧᯟࢆタ⨨ࡋࡓࠋ࣮࣎ࣝࡣ㠀㍈㊊ഃࡼࡾ 55 ᗘࡢゅᗘ࡛⪃࡟ᐇ᪋ࡋࡓࠋ㊥㞳ࡣࢫࢱ࣮ࢺࣛ࢖ࣥࡼࡾ10m ࡢ ᚟࡜

2m ᩳࡵ๓᪉࠿ࡽ㌿ࡀࡋࡓࠋ࣮࣎ࣝࢆⴠୗࡉࡏࡿ᮲௳ࡣࠊ

ࡋࠊ2m 㛫㝸࡛࣮࢝ࣛࢥ࣮ࣥࢆ 5 ᮏタ⨨ࡋࡓࠋࡍ࡭࡚ࡢ

㧗ࡉ 95cmࠊᩳᗘ 30 ᗘࠊ㛗ࡉ 185cm ࡢഴᩳྎ࠿ࡽ᳨⪅࣮࢝ࣛࢥ࣮ࣥࢆ㏻㐣ࡋࠊ෌ࡧࢫࢱ࣮ࢺࣛ࢖ࣥࢆ⬗య࡜࣮࣎ࡀ㌿ࡀࡋࡓࠋ࢟ࢵࢡࡢ᪉ἲࡣࠊ࢖ࣥࢧ࢖ࢻ࢟ࢵࢡ࣭࢖ࣥ

ࣝࡀ㏻㐣ࡍࡿࡲ࡛ࡢࢱ࢖࣒ࢆィ ࡋࡓࠋᑦࠊヨᢏࡢ୰ࢫࢸࢵࣉ࢟ࢵࢡ࡞࡝㝈ᐃࡣࡏࡎࠊᑐ㇟ඣࡣ⮬⏤࡟ຓ㉮㛫࡛ⴭࡋࡃࢥ࣮ࢫࢆ㐓⬺ࡋࡓሙྜࡣ 2 ᅇ┠ࡢヨᢏࢆᐇ᪋ࡋ

㝸ࢆྲྀࡾࠊᯟࢆ≺ࡗ࡚ࣛ࢖ࣥୖࡶࡋࡃࡣࣛ࢖ࣥࡼࡾᡭ๓࠿

ࡓࠋࡽࢲ࢖ࣞࢡࢺ࢟ࢵࢡࢆ⾜ࡗࡓࠋヨᢏࡣ 10 ᅇ࡜ࡋࠊグ㘓ࡣ࣮࣎ࣝࡀᯟෆࢆ㏻㐣ࡋࡓᅇᩘࢆィ ࡋࡓࠋᅗ  ࢫ࣮࣒ࣛࣟࢻࣜࣈࣝᅗ  ࢲ࢖ࣞࢡࢺ࢟ࢵࢡ

3.3.1.2 8 ࡢᏐࢻࣜࣈࣝ㸦ᅗ 3㸧ᚋ⸨ࡽ㸦ᚋ⸨ ,2005㸧࠾ࡼࡧኴ⏣ࡽ㸦ኴ⏣ ,1981㸧ࡢඛ⾜◊✲ࢆཧ⪃࡟ᐇ᪋ࡋࡓࠋ㊥㞳ࢆ 3m ࡜ࡋࠊ୰ᚰⅬ࡜୧

3.3.2 ㌟య⬟ຊホ౯

ഃ 1.5m ࡟࣮࢝ࣛࢥ࣮ࣥࢆタ⨨ࡋࡓࠋ୰ᚰࡢ࣮࢝ࣛࢥ࣮

ࢫࣉࣜࣥࢺࢸࢫࢺ㸦ᅗ 5㸧ࣥࡢྑഃ࠿ࡽࢫࢱ࣮ࢺࡋࠊ8 ࡢᏐࢆᥥࡃࡼ࠺࡟࿘ᅇࡍࡿ

ᫍᕝࡽࠊᡭᓥࡽ㸦ᫍᕝ ,2012ࠊᡭᓥ ,2016㸧ࡢඛ⾜◊✲ㄢ㢟࡛࠶ࡿࠋ3 ࿘ࡋࡓᚋ࡟෌ࡧ࣮࣎ࣝࢆ୰ᚰࡢ࣮࢝ࣛ

ࢆཧ⪃࡟ࠊ㊥㞳ࡢつᐃࡣ 20m ࡜ࡋࡓࠋࢫࢱ࣮ࢺࣛ࢖ࣥ

ࢥ࣮ࣥࡢᶓ࡛㟼Ṇࡉࡏࡿࡲ࡛ࡢࢱ࢖࣒ࢆィ ࡋࡓࠋヨᢏࡼࡾ 20m ᆅⅬࢆ㏻㐣ࡍࡿࡲ࡛ࡢࢱ࢖࣒ࢆィ ࡋࡓࠋࢫࡢ୰࡛ⴭࡋࡃࢥ࣮ࢫࢆ㐓⬺ࡋࡓሙྜࡣ 2 ᅇ┠ࡢヨᢏࢆᐇࢱ࣮ࢺ⫥఩ࡣࢫࢱࣥࢹ࢕ࣥࢢࢫࢱ࣮ࢺ࡛ᕥྑ࡝ࡕࡽ࠿ࡢ㊊᪋ࡋࡓࠋᑦࠊᑐ㇟ඣࡀ㛫㐪࠼࡞࠸ࡼ࠺࿘ᅇࡍࡿ᪉ྥࢆ

ࢆ୍Ṍᚋࢁ࡟ᘬࡁࠊ㟼Ṇࡋࡓ≧ែ࡜ࡋࡓࠋࢱ࢖࣒ࡢィ᳨⪅ࡀᣦࡋ♧ࡋࠊ3 ࿘┠࡟ධࡗࡓ㝿࡟᳨⪅ࡀࠕ3 ࿘┠ࠖ࡜ࠊ᪉ἲࡣࠊ᳨⪅ࡀ࣍࢖ࢵࢫࣝࢆ㬆ࡽࡋࡓ᫬Ⅼࢆࢫࢱ࣮ࢺ࡜

ᑐ㇟ඣ࡟ཱྀ㢌࡛ఏ࠼࡚ᐇ᪋ࡋࡓࠋ

ࡋࠊ⬗యࡀ 20m ᆅⅬࢆ㏻㐣ࡋࡓ᫬Ⅼࡢࢱ࢖࣒࡜ࡋࡓࠋᅗ  ࡢᏐࢻࣜࣈࣝᅗ  ࢫࣉࣜࣥࢺ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021∦⬮❧఩ࣂࣛࣥࢫࢸࢫࢺ㸦㕥ᮌ ,2009ࠊすᏲ ,2003㸪ࡃࡲ཯᚟ᶓ㊴ࡧࢸࢫࢺ㸦ᩥ⛉┬,2019㸪ᆏᕳࠊᇼᕝ,2011㸧ࡶ࡜ඖẼࡃࡽࡪ ,2019㸧
㸦ᅗ 6㸧

㸦ᅗ 㸧

ᑐ㇟ඣࡀᬑẁ⦎⩦ࡸヨྜ࡛౑⏝ࡋ࡚࠸ࡿࢺ࣮ࣞࢽࣥࢢ
ࢩ࣮ࣗࢬࢆ╔⏝ࡋࡓ≧ែ࡛ᐇ᪋ࡋࠊ

ᩥ㒊⛉Ꮫ┬ࡢ᪂యຊࢸࢫࢺᐇ᪋せ㡯㸦6 ṓ㹼 11 ṓ㸧࡟ᐃ⫥఩ࡣ㛢║࡛‽ࡌ࡚ᐇ᪋ࡋࡓࠋ୰ኸ⥺࡜ᕥྑ 1m ࡢ࡜ࡇࢁ࡟ࣛ࢖ࣥࢆ

ᡭࢆ⭜࡟ᙜ࡚ࠊ㠀ᨭᣢ⬮ࢆᨭᣢ⬮࡟⤡ࡲࡏ࡞࠸ጼໃ࡛

3 ᮏᘬࡁࠊࢧ࢖ࢻࢫࢸࢵࣉࢆ⧞ࡾ㏉ࡋࠊไ㝈᫬㛫 20 ⛊⾜ࡗࡓࠋヨᢏࡣᕥྑ 1 ᅇࡎࡘ⾜࠸ࠊ࢝ࢵࢺ࢜ࣇࢆ 2 ศ࡜㛫ࡢ୰࡛ࣛ࢖ࣥࢆ㋃ࡴ࠿ࠊ㉸࠼ࡓᅇᩘࢆィ ࡋࡓࠋィࡋࡓࠋࡓࡔࡋࠊᕥྑࡢ ᐃ್ࡢᕪࡀ 30 ⛊௨ୖ࠶ࡗࡓ

ࡣᑐ㇟ඣ 1 ྡ࡟ࡘࡁࠊ᳨⪅ 2 ྡࡀ⾜ࡗࡓࠋᑦࠊ ᐃ⪅࡟ࡘ࠸࡚ࡣࠊ▷࠸グ㘓ࡢᨭᣢ⬮ࡢࡳ 2 ᅇ┠ࡢ ᐃࢆ᮲௳ࡣࠊᐇ㝿ࡢࣉ࣮ࣞ⎔ቃ࡜ྠ᮲௳࡜ࡍࡿࡓࡵࠊࢢࣛ

⾜ࡗࡓࠋᑐ㇟ඣ 1 ྡ࡟ᑐࡋࠊ᳨⪅ 1 ྡࡀ┘ど࣭ィ ࡋࠊ࢘ࣥࢻ࡟࡚ᐇ᪋ࡋࡓࠋ

㠀ᨭᣢ⬮ࡀᨭᣢ⬮࡟᥋ゐࡋࡓሙྜࡸᨭᣢ⬮ࡀࢫࢸࢵࣉ

ヨᢏࡢ㛤ጞ⫥఩ࡣࠊ୰ኸ⥺ࢆࡲࡓ࠸ࡔ≧ែ࠿ࡽࢫࢱ࣮

ࢆ㋃ࢇࡔሙྜࠊᡭࡀ⭜࠿ࡽ㞳ࢀࡓሙྜࠊ㠀ᨭᣢ⬮ࡀᆅࢺࡋࡓࠋ࢝࢘ࣥࢺࡣᕥྑࡢࣛ࢖ࣥࢆ㋃ࡴ࠿㉸࠼ࡓࡽ 1 ᅇ㠃࡟᥋ゐࡋࡓሙྜࡣࡑࡢ᫬Ⅼ࡛⤊஢࡜ࡋࡓࠋ

࡜ࡋࠊไ㝈᫬㛫ෆ࡛ࡢྜィᅇᩘࢆグ㘓ࡋࡓࠋᑦࠊࣛ࢖
ࣥࢆ㉺࠼࡚࠸࡞࠸ሙྜࡣ࢝࢘ࣥࢺࡋ࡞࠸ࡇ࡜࡜ࡋࡓࠋᅗ  ∦⬮❧఩ࣂࣛࣥࢫᅗ  ཯᚟ᶓ㊴ࡧ

3.4 ⤫ィᏛⓗゎᯒ㸦ᑐ㤿 ,2002ࠊ㏆⸨ ,2012ࠊᮅ಴ ,2015ࠊ㓄⨨ศᩓศᯒ㸦one-way analysis of variance㸧ࢆ⏝࠸࡚㸦⾲ 2㸧
ụ⏣ ,2013ࠊすෆ 2014㸧⤫ィฎ⌮ࢆ⾜࠸ࠊ୍ඖ㓄⨨ศᩓศᯒࡢ⤖ᯝࠊ᭷ពᕪࢆ

ࢧࢵ࣮࢝ࡢᇶ♏ᢏ⬟㛫ࡢ㛵㐃ᛶ࠾ࡼࡧ㌟య⬟ຊ࡜ࡢㄆࡵࡓ㡯┠࡟ࡘ࠸࡚ࡣࠊTukey-Kramer ἲ࡟࡚ከ㔜ẚ㍑

㛵㐃ᛶࠊᏛ㱋࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸࡚ࡣࣆ࢔ࢯࣥࡢ✚⋡┦᳨ᐃࢆ⾜࠸ࠊྛỈ‽㛫ࡢ᭷ពᕪࢆ᳨ᐃࡋࡓࠋᑦࠊ⤫ィ㛵ゎᯒࡣࠊ4steps ࢚ࢡࢭࣝ⤫ィ㸦ᰗ஭,2015㸧ࢆ⏝࠸࡚⾜࠸ࠊಀᩘ㸦Pearson product-moment cor relation

FRH൶FLHQW㸧ࢆ⏝࠸ࠊྛࠎ┦㛵㛵ಀࢆ☜ㄆࡋࡓࠋࡲࡓࠊ

᭷ពỈ‽ࡣࡍ࡭࡚ 5% ࡜ࡋࠊ᭷ពᕪࢆồࡵࡓࠋᏛᖺูᇶ♏ᢏ⬟࡜㌟య⬟ຊ࡜ࡢẚ㍑࡟ࡘ࠸࡚ࡣࠊ୍ඖ⾲ ࠉ⤫ィゎᯒ✀ูᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

3.5 ೔⌮ⓗ㓄៖ࡧಖㆤ⪅ࡢ⮬⏤࡜ࡋࠊ᧔ᅇࡣᑐ㇟ඣࠊಖㆤ⪅࠸ࡎࢀ࠿ᮏ◊✲ࡣ࣊ࣝࢩࣥ࢟ᐉゝ㸦᪥ᮏ་ᖌ఍ࠊ2002㸧ࢆ㑂Ᏺ୍᪉ࡢពᛮ࡛ࡶ⾜࠼ࡿࡇ࡜࡜ࡋࡓࠋ

ࡋࠊᮏ◊✲ࡢෆᐜ࡟ࡘ࠸࡚ࠊ᪂₲ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ኱
Ꮫ೔⌮ᑂᰝጤဨ఍࡬೔⌮⏦ㄳࢆ⾜࠸ࠊᢎㄆ㸦ཷ௜␒ྕ㸬⤖ᯝ145ࠊᖹᡂ 30 ᖺ 11 ᭶ 29 ᪥ᢎㄆ㸧ࡢୖ࡛ᐇ᪋ࡋࡓࠋࡲࡓࠊ

ᑐ㇟ඣࡣࠊ᯾ࢫ࣏࣮ࢶࢡࣛࣈᡤᒓࡢᑠᏛ 1 ᖺ⏕࠿ࡽ 3ᚓࡽࢀࡓ᝟ሗࡣಶேࡀ≉ᐃࡉࢀ࡞࠸ࡼ࠺ࢹ࣮ࢱධຊࡢ

ᖺ⏕㸦8 ࠿ࡽ U-9㸧ࡲ࡛ࡢ 40 ྡ࡛ࠊᖹᆒᖺ㱋  s 㝿ࡣࠊࢥ࣮ࢻ໬ࡋࠊ༏ྡᛶࡢ☜ಖ࡟༑ศ␃ពࡋࡓࠋࡲࡓࠊ

ṓࠊᖹᆒ㌟㛗123.9sFPࠊᖹᆒయ㔜 24.0s3.4kgࠊࢧࢵ◊✲ࢹ࣮ࢱࡣࠊ௒ᅇࡢ◊✲┠ⓗ௨እ࡟ࡣ౑⏝ࡋ࡞࠸ࡇ࣮࢝ࡢᖹᆒ⤒㦂ᖺᩘ 22.3 s 12.5 ࣨ᭶࡛࠶ࡗࡓࠋᑐ㇟

࡜࡜ࡋࡓࠋࡢᴫせࢆ⾲ 1 ࡟♧ࡍࠋࡲࡓࠊ⾲ 3 ࡟Ꮫᖺูᇶ♏ᢏ⬟ࡢᑐ㇟⪅࡬ࡢᮏ◊✲ࡢཧຍ༠ຊࡣࠊࠕ ◊✲ㄝ᫂᭩ࠖ࡜

⤖ᯝࢆࠊ⾲ 4 ࡟Ꮫᖺู㌟య⬟ຊࡢ⤖ᯝࢆ♧ࡍࠋ∦㊊ࣂ

ࠕྠព᭩ࠖࢆ⏝࠸࡚ࠊཱྀ㢌࠾ࡼࡧ᭩㠃࡟࡚◊✲ࡢ┠ⓗࡸࣛࣥࢫࡣྑᨭᣢ࡜ᕥᨭᣢࡢ⛊ᩘࢆᖹᆒࡋࡓᩘ್࡛࠶ࡿࠋ

᪉ἲࠊ೔⌮ⓗ㓄៖ࠊ⥭ᛴ᫬ࡢᑐᛂࠊㅰ♩➼࡟ࡘ࠸࡚ㄝ

ࡑࡢ⤖ᯝ㌟య⬟ຊ࡟ࡘ࠸࡚ࢫࣉࣜࣥࢺࡣ 1 Ꮫᖺ࡜௚ࡢᏛ

᫂ࢆ⾜࠸ࠊᑐ㇟ඣࡀᮍᡂᖺ࡛࠶ࡿࡇ࡜࠿ࡽࠊᑐ㇟ඣᮏ

ᖺ࡜࡛᭷ពࡢᕪࡀㄆࡵࡽࢀࡓࡀࠊ∦⬮❧఩ࣂࣛࣥࢫ࡜

ே࠾ࡼࡧಖㆤ⪅ࡢ⮬⏤ពᚿ࡛୧⪅ࡢྠពࡢୖ࡛⾜ࡗࡓࠋ཯᚟ᶓ㊴ࡧ࡛ࡣᏛᖺ࡟ࡼࡿ᭷ពࡢᕪࡀㄆࡵࡽࢀ࡞࠿ࡗ

ཧຍ༠ຊࡢ᧔ᅇࡶࠕྠព᧔ᅇ᭩ࠖࢆ㓄ᕸࡋࠊᑐ㇟ඣ࠾ࡼ

ࡓࠋ⾲ ࠉᏛᖺูᇶ♏ᢏ⬟⾲ ࠉᏛᖺู㌟య⬟ຊᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

4.1 ᇶ♏ᢏ⬟㛫ࡢ㛵ಀ㸦⾲ 5㸧Ꮠࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࡢ㛫࡛ࡣࠊ᭷ព࡞ᙉ࠸ṇࡢ┦㛵┦㛵ࡢ᭷↓ࡢุ᩿࡜ࡋ࡚ࠊr=0.4 㹼 1 ࡛ୟࡘ p ್ࡀ

㸦r=.85, p<.001㸧ࢆㄆࡵࠊࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢ⢭ᗘࡢ㛫࡛

p<0.05 ࡢሙྜ࡟ࠕ᭷ព࡞┦㛵࠶ࡾࠖ࡜࡞ࡗ࡚࠸ࡿࡓࡵࠊ

ࡶࠊ᭷ព࡞㈇ࡢ┦㛵㸦r=-.50, p<.001㸧ࢆㄆࡵࡓࠋ8 ࡢᏐ࡝ࡕࡽ࠿୍᪉࡛ࡶᇶ‽್ࢆୗᅇࡿሙྜࠊୖᅇࡿሙྜ࡟

ࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢ⢭ᗘ࡜ࡢ㛫࡛ࡣࠊࡣࠕ᭷ព࡞┦㛵ࡀ࠶ࡿࠖ࡜ࡣゝ࠼࡞࠸ࡓࡵࠊࠕ ┦㛵ࡀ࡞

᭷ព࡞ᙅ࠸㈇ࡢ┦㛵㸦r=-.35, p<.001㸧ࢆㄆࡵࡓࠋ

࠸ࠖࡸࠕ┦㛵ࢆㄆࡵ࡞࠿ࡗࡓࠖ࡜ุ᩿ࠊ⾲グࡋ࡚࠸ࡿࠋ

௨ୖࡢ⤖ᯝ࠿ࡽࠊపᏛᖺᑠᏛ⏕ࢧࢵ࣮࢝㑅ᡭ࡛ࡣࠊᇶ♏ᢏ⬟㛫ࡢ㛵ಀࢆ⾲ 5 ࡟♧ࡍࠋࡑࡢ⤖ᯝࣜࣇࢸ࢕ࣥ

ࣜࣇࢸ࢕ࣥࢢࡢᢏ⬟࡜ࢻࣜࣈࣝࡸࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢᢏ⬟ࢢࡢᅇᩘ࡜ࢫ࣮࣒ࣛࣟࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࡢ㛫㸦r=.45,n.

࡜ࡣࠊ᭷ព࡞┦㛵ࡀㄆࡵࡽࢀ࡞࠸ࡇ࡜ࡀ♧၀ࡉࢀࠊࢻ

s.㸧ࠊ8 ࡢᏐࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࡢ㛫㸦r=.43,n.s.㸧ཬࡧࢲ࢖ࣜࣈࣝࡢᢏ⬟࡜ࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢᢏ⬟࡟ࡣࠊ᭷ព࡞┦ࣞࢡࢺ࢟ࢵࢡࡢ⢭ᗘ࡜ࡢ㛫㸦r=.02,p<.001㸧࡛ࡣ᭷ព࡞┦㛵ࡀㄆࡵࡽࢀࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ

㛵ࢆㄆࡵ࡞࠿ࡗࡓࠋࢫ࣮࣒ࣛࣟࢻࣜࣈࣝࡢࢱ࢖࣒࡜ 8 ࡢ
⾲ ࠉᇶ♏ᢏ⬟㛫ࡢ┦㛵

4.2 ᇶ♏ᢏ⬟࡜㌟య⬟ຊ࡜ࡢ㛵ಀ㸦⾲ 6㸧ࢧࢵ࣮࢝ࡢᇶ♏ᢏ⬟࡜㌟య⬟ຊ࡜ࡢ㛵ಀࢆ⾲ 6 ࡟♧ࡍࠋࡑࡢ⤖ᯝࠊࢫࣉࣜࣥࢺࡢࢱ࢖࣒࡜ࣜࣇࢸ࢕ࣥࢢࡢᅇᩘ

p<.001㸧࡛ࡣࠊ᭷ព࡞┦㛵ࢆㄆࡵ࡞࠿ࡗࡓࠋࡋ࠿ࡋ∦⬮❧఩ࣂࣛࣥࢫ࡜ 8 ࡢᏐࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࡢ㛫࡛ࡣࠊ᭷
ព࡞ᙅ࠸㈇ࡢ┦㛵㸦r=-.31, p<.005㸧ࢆㄆࡵࡓࠋ

࡜ࡢ㛫㸦r=-.39, p<.001㸧ࠊࢫ࣮࣒ࣛࣟࢻࣜࣈࣝࡢࢱ࢖࣒࡜཯᚟ ᶓ ㊴ ࡧ ࡢ ᅇ ᩘ࡜ࣜࣇࢸ࢕ࣥࢢࡢ ᅇ ᩘ࡜ࡢ 㛫ࡢ㛫㸦r=.24, p<.001㸧ཬࡧ 8 ࡢᏐࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࡢ㛫㸦r=.38,n.s.㸧8 ࡢᏐࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࡢ㛫㸦r=-.56,n.s.㸧㸦U S㸧࡛ࡣࠊ᭷ព࡞ᙅ࠸┦㛵ࢆㄆࡵࡓࠋࡋ࠿

ཬࡧࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢ⢭ᗘ࡜ࡢ㛫㸦r=.05, p<001㸧࡛ࡣࠊࡋࢫࣉࣜࣥࢺࡢࢱ࢖࣒࡜ࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢ⢭ᗘ࡜ࡢ㛫࡛᭷ព࡞┦㛵ࢆㄆࡵ࡞࠿ࡗࡓࠋࡋ࠿ࡋ཯᚟ᶓ㊴ࡧࡢᅇᩘࡣࠊ᭷ព࡞┦㛵ࢆㄆࡵ࡞࠿ࡗࡓ㸦U S㸧ࠋࠉ࡜ࢫ࣮࣒ࣛࣟࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࡢ㛫࡛ࡣࠊ᭷ព࡞ᙅ࠸

∦⬮❧఩ࣂࣛࣥࢫࡣࠊᕥྑࡢྜィ᫬㛫ࡢᖹᆒ್࡜ྛ㈇ࡢ┦㛵㸦r=-.38,p<.001㸧ࢆㄆࡵࡓࠋ

ᇶ♏ᢏ⬟ࡢ┦㛵࡟ࡘ࠸᳨࡚ウࡋࡓࠋ௨ୖ࠿ࡽࢫࣉࣜࣥࢺࡣࠊࣜࣇࢸ࢕ࣥࢢࡸࢻࣜࣈࣝᢏ⬟࡜ࡑࡢ⤖ᯝ∦⬮❧఩ࣂࣛࣥࢫ࡜ࣜࣇࢸ࢕ࣥࢢࡢᅇᩘ࡜ࡢ㛫┦㛵ࢆㄆࡵࠊ∦⬮❧఩ࣂࣛࣥࢫࡣࠊ8 ࡢᏐࢻࣜࣈࣝࡢᢏ

㸦r=-.03,n.s.㸧ཬࡧࢫ࣮࣒ࣛࣟ࡜ࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࡢ㛫⬟࡜ࠊ཯᚟ᶓ㊴ࡧࡣࢫ࣮࣒ࣛࣟࢻࣜࣈࣝࡢᢏ⬟࡜┦㛵ࢆ

㸦r=-.23,n.s.㸧ཬࡧࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢ⢭ᗘ࡜ࡢ㛫㸦r=-.02,ㄆࡵࡿ⤖ᯝ࡜࡞ࡗࡓࠋ⾲ ࠉᇶ♏ᢏ⬟࡜ࡢ㌟య⬟ຊ࣭ᖺ㱋࡜ࡢ┦㛵ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

4.3 ᖺ㱋࡜ᇶ♏ᢏ⬟࠾ࡼࡧ㌟య⬟ຊ࡜ࡢ㛵ಀ㸦⾲ 6㸧࡜ᑠ⬻ࡢ⣽⬊ࡀḟ➨࡟ ῶᑡࡍࡿ࡜㏙࡭࡚࠸ࡿࠋᚑࡗ࡚

ᖺ㱋࡜ᇶ♏ᢏ⬟࠾ࡼࡧ㌟య⬟ຊ࡜ࡢ㛵ಀࢆ⾲ 6 ࡟♧ࣜࣇࢸ࢕ࣥࢢࡣᨭᣢഃࡢ㊊㛵⠇ࡢᅛᐃᛶࠊ㋾ࡿഃࡢ㊊ࡍࠊᖺ㱋࡜ࣜࣇࢸ࢕ࣥࢢࡢᅇᩘ࡜ࡢ㛫㸦r=.36, p<.005㸧ཬ㛵⠇ࡢไᚚຊࠊᑠ⬻ࡢⓎ㐩➼ࡀ㛵ಀࡋ࡚࠸ࡿࠋ

ࡧࢫ࣮࣒ࣛࣟࢻࣜࣈࣝࡢࢱ࢖࣒࡜ࡢ㛫㸦r=-.39, p<.001㸧ཬపᏛᖺᑠᏛ⏕࡛ࡣࠊࡇࢀࡽࡢⓎ㐩ࡀᮍ⇍࡞ẁ㝵࡛࠶ࡧ∦⬮❧఩ࣂࣛࣥࢫ࡜ࡢ㛫㸦r=.263, p<.005㸧࡛ࡣࠊ᭷ព

ࡾࠊᏳᐃࡋࡓࣇ࢛࣮࣒࡛ࣜࣇࢸ࢕ࣥࢢࡀ⾜࠼࡚࠸࡞࠸ࡇ࡜

࡞ᙅ࠸┦㛵ࢆㄆࡵࡓࠋࡑࡋ࡚ᖺ㱋࡜ 8 ࡢᏐࢻࣜࣈࣝࡢࢱ

ࡶ୍ࡘࡢせᅉ࡜ࡋ࡚⪃࠼ࡽࢀࡿࠋࡲࡓࠊࣜࣇࢸ࢕ࣥࢢᢏ

࢖࣒࡜ࡢ㛫㸦r=-.45, p<.001㸧ࠊࢫࣉࣜࣥࢺࡢࢱ࢖࣒࡜ࡢ㛫⬟ࡣࠊᖺ㱋࡜ࡢ㛫࡛┦㛵㛵ಀࢆㄆࡵࠊศᩓศᯒࡢ⤖ᯝ

㸦U S㸧ཬࡧ཯᚟ᶓ㊴ࡧࡢᅇᩘ࡜ࡢ㛫㸦r=.603,

࠿ࡽࡣࠊᏛ㱋㛫ࡢ᭷ពᕪࢆㄆࡵ࡚࠸ࡿࠋࡇࢀࡽࡢ⤖ᯝ

p<.001㸧࡛ࡣ᭷ព࡞┦㛵ࢆㄆࡵࡓࠋࡋ࠿ࡋᖺ㱋࡜ࢲ࢖ࣞ࠿ࡽࡶࠊᏛ㱋ࡢቑຍ࡟క࠺㌟యⓗⓎ㐩ࡀࣜࣇࢸ࢕ࣥࢢᢏ

ࢡࢺ࢟ࢵࢡࡢ⢭ᗘ࡜ࡢ㛫࡛ࡣࠊ᭷ព࡞┦㛵ࢆㄆࡵ࡞࠿ࡗ

⬟ྥୖ࡬Ḟ࠿ࡍࡇ࡜ࡢ࡛ࡁ࡞࠸せᅉ࡜⪃࠼ࡽࢀࡿࠋ㌟య

ࡓ㸦r=.05, p<.001㸧ࠋⓗⓎ㐩ࢆ࣮࣋ࢫ࡟⤒㦂ࡸ⦎⩦㔞ࡀᏛ⩦ຠᯝࢆࡶࡓࡽࡋࠊ

௨ୖࡢ⤖ᯝ࠿ࡽࠊᖺ㱋ࡣࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢ⢭ᗘࢆ㝖ึࡵ࡚Ᏻᐃࡋࡓࣇ࢛࣮࣒࡛ࣜࣇࢸ࢕ࣥࢢࡀ⾜࠼ࡿࡼ࠺࡟࡞

ࡃᇶ♏ᢏ⬟࡜㌟య⬟ຊࡢ㛫࡛ࠊ᭷ព࡞┦㛵ࢆㄆࡵࡓࠋ

ࡿ࡜᥎ᐹࡋࡓࠋࢫ࣮࣒ࣛࣟࢻࣜࣈࣝ࡜ 8 ࡢᏐࢻࣜࣈࣝࡣࠊ⪃ᐹࣝࢆ㋾ࡿ᪉ྥࡸᙉࡉࠊ㊊ࡢ౑࠸᪉࡜࠸ࡗࡓⅬ࡛ࠊఝ㏻ࡗ

ྠࡌࢻࣜࣈࣝᢏ⬟ࢆホ౯ࡋࡓ㡯┠࡛࠶ࡿࠋࡑࡢࡓࡵࠊ࣮࣎
ࢧࢵ࣮࢝ࡢᇶ♏ᢏ⬟㛫ࡢ㛵ಀ࡟ࡘ࠸࡚ࠊࣜࣇࢸ࢕ࣥࢢ

ࡓࣃࣇ࢛࣮࣐ࣥࢫ࡜࡞ࡗ࡚࠸ࡿࠋࡋࡓࡀࡗ࡚ࠊᇶ♏ᢏ⬟ࡢᢏ⬟ࡣࠊࢻࣜࣈࣝᢏ⬟ࡸࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢᢏ⬟࡟ࡣ㛫ࡢ㛵㐃࡟࠾࠸࡚ࠊ᭱ࡶᙉ࠸┦㛵㛵ಀࢆ♧ࡋࡓ࡜⪃࠼┦㛵ࡀ࡞࠸ࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋࢻࣜࣈࣝᢏ⬟ࡣࠊࢫࡽࢀࡿࠋࡲࡓࠊྛࢻࣜࣈࣝᢏ⬟ࡣࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢ⢭࣮࣒ࣛࣟࢻࣜࣈࣝ࡜ 8 ࡢᏐࢻࣜࣈࣝࡢᢏ⬟㛫࡛ࡣᙉ࠸┦ᗘ࡜ࡶ᭷ព࡞┦㛵㛵ಀࢆㄆࡵࡓࠋ୧ᢏ⬟ࡢ≉ᚩ࡜ࡋ࡚㛵ࢆㄆࡵࡓࠋࡲࡓࠊࢻࣜࣈࣝᢏ⬟ࡣࢫ࣮࣒ࣛࣟࢻࣜࣈࣝࠊ

ࡣࠊ࣮࣎ࣝࢆ㋾ࡿ᪉ྥࡀỈᖹ᪉ྥ࡛࠶ࡿࡇ࡜࡜ࠊ㞀ᐖ≀

8 ࡢᏐࢻࣜࣈࣝ࡜ࡶ࡟ࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢᢏ⬟࡟┦㛵ࡋ࡚ࡸ┠ᶆ≀ࢆど㔝࡟ධࢀ࡞ࡀࡽ⾜࠺ᢏ⬟࡛࠶ࡿࠋ୍᪉࡛ࠊ

࠸ࡓࠋᚋ⸨ࡽ㸦ᚋ⸨ ,2005㸧࡟ࡼࡿ࡜ࠊ୰Ꮫ⏨Ꮚ࡛ࡣࣜࣇ

ࣜࣇࢸ࢕ࣥࢢࡣᆶ┤᪉ྥ࡬࣮࣎ࣝࢆ㋾ࡿᢏ⬟࡛࣮࣎ࣝ࠿

ࢸ࢕ࣥࢢࡢᅇᩘ࡜ࢻࣜࣈࣝࡢ㏿ࡉࠊ࢖ࣥࢧ࢖ࢻ࢟ࢵࢡࡢṇࡽ࡞ࡿ࡭ࡃ┠ࢆ㞳ࡉࡎ࡟⾜࠺ࡇ࡜ࡀồࡵࡽࢀࡿᢏ⬟࡛ࡶ☜ᛶࠊ࢖ࣥࢫࢸࢵࣉ࢟ࢵࢡࡢṇ☜ᛶ࡟ࡣ᭷ព࡞┦㛵㛵ಀ࠶ࡿࠋࡇ࠺ࡋࡓ≉ᚩࡢ㐪࠸࠿ࡽࠊᇶ♏ᢏ⬟㛫ࡢ㛵㐃ᛶࡀㄆࡵࡽࢀࡿ࡜ሗ࿌ࡋ࡚࠸ࡿࠋࡇࡇ࡛ࡣࠊࣜࣇࢸ࢕ࣥࢢ

ࡀᚓࡽࢀࡓ࡜⪃࠼ࡿࠋࡸࢻࣜࣈࣝࡣࠕ⮬ศ࡬ࡢࣃࢫࠖࠊࣃࢫࡣࠕ┦ᡭ࡬ࡢࣃࢫࠖ

㌟య⬟ຊ࡜ᇶ♏ᢏ⬟࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸࡚ࡣࠊࢫࣉࣜࣥ

࡜⪃࠼ࠊྛࠎࡀఝ㏻ࡗࡓᢏ⬟࡛࠶ࡿ࡜ᤊ࠼࡚࠸ࡿࠋࣜࣇ

ࢺࡣࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢᢏ⬟ࢆ㝖ࡃࠊࣜࣇࢸ࢕ࣥࢢ࡜ࢻࣜ

ࢸ࢕ࣥࢢ࡜ࢻࣜࣈࣝࠊࣃࢫࡢᢏ⬟ࡢ㐪࠸࡜ࡋ࡚ࡣࠊ࣮࣎ࣝ

ࣈࣝᢏ⬟࡜᭷ព࡞┦㛵㛵ಀࡀㄆࡵࡽࢀࡓࠋ∦⬮❧఩ࣂࢆ㋾ࡿ᪉ྥ㸦ࣜࣇࢸ࢕ࣥࢢࡣᆶ┤᪉ྥࠊࢻࣜࣈࣝࡸࣃࢫ

ࣛࣥࢫࡣࠊ8 ࡢᏐࢻࣜࣈࣝࡢᢏ⬟ࡢࡳ᭷ព࡞┦㛵㛵ಀࡀࡣỈᖹ᪉ྥ㸧࡜࣮࣎ࣝࢆ㋾ࡿᙉࡉࢆᣲࡆ࡚࠸ࡿࠋᮏ◊✲ㄆࡵࡽࢀࡓࠋࡲࡓࠊ཯᚟ᶓ㊴ࡧࡣࠊࢫ࣮࣒ࣛࣟࢻࣜࣈࣝ

࡛ࡣࠊࣜࣇࢸ࢕ࣥࢢࡣࢻࣜࣈࣝࡸࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢᢏ⬟ࡢᢏ⬟ࡢࡳ᭷ព࡞┦㛵㛵ಀࡀㄆࡵࡽࢀࡓࠋᮏ◊✲࡛࡜᭷ព࡞┦㛵㛵ಀࡀㄆࡵࡽࢀ࡞࠿ࡗࡓࠋࡑࡢཎᅉ࡜ࡋ࡚ࠊ

ᐃࡋࡓࢫࣉࣜࣥࢺࡸ∦⬮❧఩ࣂࣛࣥࢫࠊ཯᚟ᶓ㊴ࡧ࡜ඛ⾜◊✲࡛ࡣࠊࢧࢵ࣮࢝㒊ᡤᒓࡢ⏨Ꮚ୰Ꮫ⏕࡜୍⯡ࡢ

࠸ࡗࡓ㌟య⬟ຊࡣࠊࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢ⢭ᗘ࡜ࡍ࡭࡚ࡢ

⏨Ꮚ୰Ꮫ⏕ࢆྵࡵࡓᑐ㇟࡜ࡋ࡚࠸ࡿⅬ࡜⤒㦂ᖺᩘࡀ1ࢣ㡯┠ࡢ㛫࡛᭷ព࡞┦㛵㛵ಀࡀㄆࡵࡽࢀ࡞࠸ࡇ࡜ࡀ᫂ࡽ

᭶࠿ࡽ 8 ᖺ࡜ᖜࡀᗈ࠸Ⅼࡀ⪃࠼ࡽࢀࡿࠋᮏ◊✲࡛ࡣࠊ࠿࡜࡞ࡗࡓࠋ୍᪉ࠊࢻࣜࣈࣝᢏ⬟㸦ࢫ࣮࣒ࣛࣟࢻࣜࣈࣝ࡜

ᑐ㇟ඣ඲ဨࡀࢡࣛࣈࢳ࣮࣒࡟ᡤᒓࡍࡿࢧࢵ࣮࢝⤒㦂⪅

8 ࡢᏐࢻࣜࣈࣝ㸧ࡣࠊࢫࣉࣜࣥࢺࡸ∦⬮❧఩ࣂࣛࣥࢫࠊ཯

࡛࠶ࡾࠊ⤒㦂ᖺᩘࡶ 2 㐌㛫࠿ࡽ 4 ᖺ࡜ᖜࡀẚ㍑ⓗ⊃࠸᚟ᶓ㊴ࡧࡢࡍ࡭࡚ࡢ㡯┠࡜ఱࡽ࠿ࡢ㛵㐃ᛶࡀ࠶ࡿࡇ࡜ࡀ

ࡇ࡜ࡀ⪃࠼ࡽࢀࡿࠋࡲࡓࠊࣜࣇࢸ࢕ࣥࢢᢏ⬟ࡣࠊ࣮࣎ࣝ

♧၀ࡉࢀࡓࠋࡲࡓࠊࣜࣇࢸ࢕ࣥࢢᢏ⬟࡟ࡘ࠸࡚ࡣࠊࢫࣉ

ࢆࣃ࣮ࢯࢼࣝࢫ࣮࣌ࢫ࡛ࢥࣥࢺ࣮ࣟࣝࡍࡿࡓࡵࠊ࣮࣎ࣝࢆ

ࣜࣥࢺࡢࡳ࡜㛵㐃ᛶࡀ࠶ࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋ

㍍ࡃ㋾ࡿᢚไᛶࡢ⬟ຊࡀồࡵࡽࢀࡿᢏ⬟࡛࠶ࡿࠋᰗ⏣ࢧࢵ࣮࢝࡟࠾ࡅࡿࢫࣉࣜࣥࢺࡸ࢔ࢪࣜࢸ࢕
㸦ᩄᤩᛶ㸧ࡢ

ࡽࡣ㸦ᰗ⏣ ,2011㸧㊊㛵⠇᤬᣸ഃᨭᣢ࡟ࡼࡿࣂࣛࣥࢫ⬟㔜せᛶࡣࠊJFA ࡸከࡃࡢඛ⾜◊✲࡟࠾࠸࡚ሗ࿌ࡉࢀ࡚

ຊࡣపࡃ࡞ࡿ࡜㏙࡭࡚࠸ࡿࠋబ⸨ࡽࡣ㸦బ⸨ ,2021㸧ࣜࣇ࠸ࡿࠋBrocherie ࡽ㸦Brocherie,2005㸧ࡣࠊ20m ࢫࣉࣜࣥࢸ࢕ࣥࢢ⇍⦎⪅ࡣ㊊㛵⠇ไᚚ࡛ࣜࣇࢸ࢕ࣥࢢࢆ⾜࠺ࡀࠊࢺࡣヨྜࡢ຾ᩋ࡟㛵୚ࡍࡿࡓࡵࡢỴᐃⓗ࡞せᅉ࡜࡞ࡿᮍ⇍⦎⪅ࡣ⭸㛵⠇ไᚚ࡛⾜ࡗ࡚࠸ࡿ࡜㏙࡭ࠊᖹ℩ࡽࡣ㔜せ࡞࢔ࢡࢩ࡛ࣙࣥ࠶ࡿ࡜ࡋ࡚࠾ࡾࠊᐇ㝿ࡢヨྜ≧ἣࢆ㸦ᖹ℩ ,2008㸧㧗㱋⪅ࡢ ࣂࣛࣥࢫ⬟ຊࡢపୗ࡟ࡣ㸪⬻ᖿ཯ᫎࡋࡓホ౯ἲ࡛࠶ࡿ࡜⪃࠼ࡽࢀ࡚࠸ࡿࠋࡲࡓࠊᰗ⃝ࡽᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021㸦ᰗἑ 㸧ࡣࠊ኱Ꮫ⏨Ꮚࢧࢵ࣮࢝㑅ᡭࢆᑐ㇟࡜ࡋࡓ

࡚࠸ࡿᢏ⬟ࢆ⣲᪩ࡃⓎ᥹ࡍࡿࡇ࡜ࡀ࡛ࡁ࡞࠸࡜㏙࡭࡚࠸

◊✲࡛ࠊ࢔ࢪࣜࢸ࢕ࡢ᭷ពᕪࡣ࣏ࢪࢩࣙࣥ㛫࡟࠾࠸࡚ㄆ

ࡿࠋࡘࡲࡾࠊU-10 ௨ୗࡢᖺ௦࡟࠾࠸࡚ࡣࠊ㌿ࡀࡗ࡚࠸ࡵࡽࢀ࡞࠿ࡗࡓࠋࢧࢵ࣮࢝ࡢヨྜ࡟࠾࠸࡚ࠊ㑅ᡭࡣ┦ࡿ࣮࣎ࣝࢆࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡋࠊ10m ඛࢆ≺ࡗ࡚ṇ☜࡟

ᡭࢆ㏣㊧ࡋࡓࡾࠊ࠿ࢃࡋࡓࡾࠊ࠶ࡿ࠸ࡣືࡃ࣮࣎ࣝ࡟཯

㋾ࡿ⬟ຊࡣഛࢃࡗ࡚࠸࡞࠸࡜⪃࠼ࡽࢀࡿࠋ

ᛂࡍࡿࡓࡵ࡟ࡋࡤࡋࡤ▐㛫ⓗ࡞᪉ྥ㌿᥮ࢆ⾜࠺ࠋせࡍᮏ◊✲ࡢᑐ㇟⪅ࡢሙྜࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢᢏ⬟ࢆ㝖ࡿ࡟ࠊ࢔ࢪࣜࢸ࢕ࡣᨷᧁ࡜Ᏺഛࡢ୧㠃࡟࠾࠸࡚㔜せ࡞ࡃࠊࣜࣇࢸ࢕ࣥࢢᢏ⬟࡜ࢻࣜࣈࣝᢏ⬟㸦ࢫ࣮࣒ࣛࣟࢻࣜࣈయຊせ⣲࡛࠶ࡾࠊࣇ࢕࣮ࣝࢻࣉ࣮࣮ࣞࣖࡣ࣏ࢪࢩࣙࣥࡢ

ࣝࠊ8 ࡢᏐࢻࣜࣈࣝ㸧࡜ࡢ㛫࡛᭷ព࡞┦㛵㛵ಀࡀㄆࡵࡽ

㐪࠸࡟㛵ࢃࡽࡎࠊ᪥ࡈࢁ࠿ࡽ࢔ࢪࣜࢸ࢕ࡢせ⣲ࢆྲྀࡾධࢀࡓࠋࣜࣇࢸ࢕ࣥࢢཬࡧࢻࣜࣈࣝᢏ⬟ࡣయ඲యࡢࣂࣛࣥ

ࢀࡓࢺ࣮ࣞࢽࣥࢢࢆࡇ࡞ࡋ࡚࠸ࡿࠋࡑࢀࡺ࠼ࠊ࣏ࢪࢩࣙ

ࢫ⬟ຊ࡟ຍ࠼ୗ⫥యᖿࡢᕦ⦓ᛶࡀᚲせ࡜⪃࠼ࡽࢀࠊᡂ

ࣥ㛫࡟࠾࠸࡚࢔ࢪࣜࢸ࢕ࡢ᭷ពᕪࡀㄆࡵࡽࢀ࡞࠿ࡗࡓࡢ

㛗ᮇࡢࡋ࠿ࡶᑠᏛᰯపᏛᖺࡣ 1 Ꮫᖺࡢ㐪࠸࡛Ⓨ㐩࡟ᕪ࠿ࡶࡋࢀ࡞࠸ࠋࡲࡓࠊ࢔ࢪࣜࢸ࢕࡜ࢫࣉࣜࣥࢺࡣᙉ࠸┦ࡀ࠶ࡿࡇ࡜ࡀ⪃࠼ࡽࢀࡿࠋࢲ࢖ࣞࢡࢺ࢟ࢵࢡࡢሙྜࡣᡂ

㛵ࢆ♧ࡋ࡚࠸ࡿ࡜࠸ࡗࡓሗ࿌ࡶከࡃࡳࡽࢀࡿࠋࢫࣉࣜࣥ

ຌ࣭ኻᩋࡢഅⓎᛶࡀ኱ࡁࡃᙳ㡪ࡍࡿࡓࡵᖺ㱋ࡢᙳ㡪ࡀࢺ㉮ࡢࢱ࢖࣒࡟࣏ࢪࢩࣙࣥ㛫ࡢ᭷ពᕪࡀ࡞࠿ࡗࡓࡇ࡜࠿

⾲࡟ฟ࡟ࡃ࠿ࡗࡓ࡜ᛮࢃࢀࡿࠋࡲࡓࠊᖺ㱋࡜㌟య⬟ຊ࡜ࡽࠊ࢔ࢪࣜࢸ࢕⬟ຊࡶྠᵝ࡟࣏ࢪࢩࣙࣥ㛫ࡢ᭷ពᕪࢆ♧ࡢ㛵㐃ᛶ࡟ࡘ࠸࡚ࠊࢫࣉࣜࣥࢺࡣ 1 Ꮫᖺ࡜௚Ꮫᖺ࡜࡛᭷

ࡉ࡞࠿ࡗࡓ࡜⪃࠼ࡽࢀࡿࠋྠᵝ࡟ࠊᫍᕝࡽ㸦ᫍᕝ ,2012㸧ព࡞ᕪࡀㄆࡵࡽࢀࡓࡀࠊ∦⬮❧఩ࣂࣛࣥࢫ࡜཯᚟ᶓ㊴

ࡸᐑ᳃ࡽ㸦ᐑ᳃ , 2008㸧ࡶࠊ20m ࢫࣉࣜࣥࢺࢱ࢖࣒࡟࠾࠸

ࡧ࡛ࡣᏛᖺ࡟ࡼࡿ᭷ព࡞ᕪࡀㄆࡵࡽࢀ࡞࠿ࡗࡓࠋࡑࡢ

࡚ࣇ࢕࣮ࣝࢻࣉ࣮࣮ࣞࣖࡢ࣏ࢪࢩࣙࣥ㛫࡟᭷ពᕪࡀ࡞

⌮⏤࡜ࡋ࡚ࠊࢧࢵ࣮࢝ࡣࢫࣉࣜࣥࢺ⬟ຊࡀᚲせ࡛ࠊࢧࢵ࠿ࡗࡓࡇ࡜ࢆሗ࿌ࡋ࡚࠸ࡿࠋ

࣮࢝⤒㦂᭶ᩘࢆぢࡿ࡜㸦⾲ 1㸧1 ᖺ⏕ࡢᖹᆒ 15 ࣨ᭶࡜ẚ௨ୖࡢࡼ࠺࡟ࠊࢧࢵ࣮࡛࢝ࡣࠊ࣏ࢪࢩࣙࣥ࡟࠿࠿ࢃࡽࡎࠊ

࡭ࡿ࡜ 2㸪3 ᖺ⏕ࡣࡑࢀࡒࢀ 21.8 ࣨ᭶ࠊ ࣨ᭶࡜࡞ࡗ

ࢫࣉࣜࣥࢺࡸ࢔ࢪࣜࢸ࢕ࡣ on the ballࠊR൵WKHEDOO ࠸ࡎ࡚࠾ࡾࠊࡇࢀࡀ 1 ᖺ⏕ࡀ௚ࡢᏛᖺ࡜ᕪࡀฟࡓ⌮⏤࡜⪃ࢀࡢᒁ㠃࡟࠾࠸࡚ࡶࠊ㠀ᖖ࡟㔜せ࡞㌟య⬟ຊ࡛࠶ࡿࠋ

࠼ࡽࢀࡿࠋᮏ◊✲࡛ࡣࠊᑠᏛᰯపᏛᖺࡢࢫࣉࣜࣥࢺࡣࠊࢻࣜࣈࣝ
ࡸࣜࣇࢸ࢕ࣥࢢ࡜࠸ࡗࡓಶேᢏ⬟࡟┤⤖ࡍࡿࣃࣇ࢛࣮࣐ ⤖ㄽࣥࢫ࡜┦㛵㛵ಀࢆ♧ࡋࡓࠋ཯᚟ᶓ㊴ࡧࡣࠊࢫ࣮࣒ࣛࣟࢻ

ᮏ◊✲࡛ࡣࠊᑠᏛᰯపᏛᖺ࡟࠾ࡅࡿࢧࢵ࣮࢝ࡢᇶ♏

ࣜࣈࣝ࡜┦㛵㛵ಀࢆ♧ࡋࡓࠋᨷᏲ࡟ࢃࡓࡾࠊ
࣮࣏࣎ࣝࢮࢵ

ᢏ⬟࡟㛵ಀࡍࡿせᅉ࡟ࡘ࠸࡚ẚ㍑᳨࣭ウࡋࡓࠋᑐ㇟ඣ

ࢩࣙࣥࢆ㧗ࡵࡿୖ࡛ࢫࣉࣜࣥࢺࡸ཯᚟ᶓ㊴ࡧࡀ㠀ᖖ࡟㔜

ࡣᑠᏛ 1 ᖺ⏕࠿ࡽ 3 ᖺ⏕ࡲ࡛ࡢ 40 ྡ࡜ࡋࠊ඲ဨࡀࢧࢵ

せ࡞せ⣲࡟࡞ࡿ࡜⪃࠼ࡿࠋࡲࡓࠊ∦⬮❧఩ࣂࣛࣥࢫࡣ 8࣮࢝⤒㦂⪅ࡢ⏨ඣ࡛࠶ࡿࠋㄪᰝ㡯┠ࡣࠊᇶ♏ᢏ⬟㸦ࣜࡢᏐࢻࣜࣈࣝ࡜┦㛵㛵ಀࢆ♧ࡋࡓࠋ8 ࡢᏐࢻࣜࣈࣝࡣࠊ

ࣇࢸ࢕ࣥࢢࠊࢫ࣮࣒ࣛࣟࢻࣜࣈࣝࠊ8 ࡢᏐࢻࣜࣈࣝࠊࢲ࢖ࣞ

ヨྜࢆ᝿ᐃࡍࡿ࡜ࠊ⊃࠸⠊ᅖ࡛┦ᡭ࡟ᅖࡲࢀࡓᒁ㠃࡛ࢡࢺ࢟ࢵࢡ㸧࡜ࠊ㌟య⬟ຊ㸦ࢫࣉࣜࣥࢺࠊ∦⬮❧఩ࣂ࣮ࣛࣥ࣎ࣝࢆዣࢃࢀࡎ࡟࠿ࢃࡍࡓࡵ࡟ᚲせ࡞ᢏ⬟࡜⪃࠼ࡽࢫࠊ཯᚟ᶓ㊴ࡧ㸧ࠊࢧࢵ࣮࢝ࡢ⤒㦂ᖺᩘࠊ⦎⩦㔞࡞࡝ࢀࡿࠋࡼࡾ⣽࠿࡞࣮࣎ࣝࢱࢵࢳࡀồࡵࡽࢀࡿ 8 ࡢᏐࢻ࡛ࣜ࠶ࡿࠋࣈࣝࡣࠊࢫࣉࣜࣥࢺࡸ཯᚟ᶓ㊴ࡧࡢࡼ࠺࡞┤⥺ⓗ࡞ືࡁᇶ♏ᢏ⬟㛫ࡢ㛵ಀ࡟ࡘ࠸࡚ࡣࠊࢻࣜࣈࣝᢏ⬟㸦ࢫࣛࡼࡾࡶࠊࡼࡾ」㞧࡞ືࡁ࡬ࡢᑐᛂࡀồࡵࡽࢀࡿࡓࡵࠊࣂ

࣮࣒ࣟࢻࣜࣈࣝࠊ8 ࡢᏐࢻࣜࣈࣝ㸧࡜ࢲ࢖ࣞࢡࢺ࢟ࢵࢡᢏ⬟ࣛࣥࢫ⬟ຊࡢ㛵㐃ࡀ♧၀ࡉࢀࡓ࡜⪃࠼ࡽࢀࡿࠋࡋࡓࡀࡗ

ࡢ㛫࡛᭷ព࡞┦㛵㛵ಀࢆㄆࡵࡓࠋ㌟య⬟ຊ࡜ࡢ㛵㐃࡛࡚ࠊヨྜ࡟࠾ࡅࡿᵝࠎ࡞ᒁ㠃ࢆ᝿ᐃࡍࡿ࡞ࡽࡤࠊ▐Ⓨࡣࠊ▐Ⓨຊࡸ࢔ࢪࣜࢸ࢕ࡢせ⣲࡛࠶ࡿࢫࣉࣜࣥࢺࡣࠊࣜ

ຊࡸᩄᤩᛶࡔࡅ࡛ࡣ࡞ࡃࠋࣂࣛࣥࢫ⬟ຊࢆ㧗ࡵࡿࢺ࣮ࣞ

ࣇࢸ࢕ࣥࢢᢏ⬟ࡸࢻࣜࣈࣝᢏ⬟㸦ࢫ࣮࣒ࣛࣟࢻࣜࣈࣝࠊ8ࢽࣥࢢࢆྲྀࡾධࢀࡿࡇ࡜ࡶᚲせ࡛ࡣ࡞࠸࠿࡜⪃࠼ࡿࠋࡢᏐࢻࣜࣈࣝ㸧࡜ࠊ཯᚟ᶓ㊴ࡧࡣࢫ࣮࣒ࣛࣟࢻࣜࣈࣝᢏ⬟ᖺ㱋࡜ᇶ♏ᢏ⬟࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸࡚ࠊࢲ࢖ࣞࢡࢺ࢟ࢵ

࡜᭷ព࡞┦㛵㛵ಀࢆㄆࡵࡓࠋ㟼ⓗࣂࣛࣥࢫ⬟ຊ࡛࠶ࡿࢡࡢᢏ⬟ࡢࡳ┦㛵㛵ಀࡀㄆࡵࡽࢀ࡞࠿ࡗࡓࠋ୰ᒣࡽࡣ

∦⬮❧఩ࣂࣛࣥࢫࡣࠊ8 ࡢᏐࢻࣜࣈࣝᢏ⬟࡜᭷ព࡞┦㛵㸦୰ᒣ ,2009㸧ྛᖺ௦࡟࠾ࡅࡿࣃࢫࡢࣃࣇ࢛࣮࣐ࣥࢫ࡟ࡘ

㛵ಀࢆㄆࡵࡓࠋ

࠸࡚ࠊU-10 ࡢ㑅ᡭࡣࠊU-12ࠊU-14ࠊU-16 ࡢ㑅ᡭ࡟ẚ࡭ࠊᖺ㱋࡜㌟య⬟ຊࡢ㛵ಀ࡟ࡘ࠸࡚ࠊࢫࣉࣜࣥࢺࡣ 1 Ꮫᖺࣃࢫࡢࣃࣇ࢛࣮࣐ࣥࢫࡀຎࡗ࡚࠸ࡿ⌮⏤ࢆ⤒㦂ᖺᩘࡀ࡜௚Ꮫᖺ࡜࡛᭷ព࡞ᕪࡀㄆࡵࡽࢀࡓࡀࠊ∦⬮❧఩ࣂࣛᑡ࡞ࡃࠊ࢟ࢵࢡࡸ࣮࣎ࣝࢥࣥࢺ࣮ࣟࣝࡀ௚ࡢᖺ௦ࡼࡾࡶ

ࣥࢫ࡜཯᚟ᶓ㊴ࡧ࡛ࡣᏛᖺ࡟ࡼࡿ᭷ព࡞ᕪࡀㄆࡵࡽࢀ

ຎࡗ࡚࠸ࡿࡇ࡜ࠋࡲࡓࠊࣉ࣮࢚ࣞࣜ࢔ࡢ኱ࡁࡉ࡟ࡼࡿไ

࡞࠿ࡗࡓࠋᖺ㱋࡜ᇶ♏ᢏ⬟࡜ࡢ㛵ಀࡣࠊࢲ࢖ࣞࢡࢺ࢟ࢵ

ᗘࡢ㐪࠸ࢆᣲࡆ࡚࠾ࡾࠊ10m ௨ୖ㞳ࢀࡓ࢚ࣜ࢔࡛ࡣᣢࡗ

ࢡᢏ⬟ࢆ㝖ࡃࠊࣜࣇࢸ࢕ࣥࢢᢏ⬟࡜ࢻࣜࣈࣝᢏ⬟㸦ࢫࣛᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021࣮࣒ࣟࢻࣜࣈࣝࠊ8 ࡢᏐࢻࣜࣈࣝ㸧࡜ࡢ㛫࡛᭷ព࡞┦㛵㛵ᖹ℩ 㐩ဢࠊ஭ཱྀࠉⱱࠊሷሯࠉ㡰ࠊ௚㸦2008㸧㸸㧗㱋⪅ಀࢆㄆࡵࡓࠋ

࡟࠾ࡅࡿࣂࣛࣥࢫ⬟ຊ࡜ ୗ⫥➽ຊ࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸➨஧ሗ࡛ࡣࢧࢵ࣮࢝ࡢ⤒㦂ᖺᩘࡸ⮬୺⦎⩦㔞࡜ࡢ㛵࡚ ؐᛶᕪ࣭ᖺ㱋࣭⪁◊ᘧάື⬟ຊᣦᶆู࡛ࡢ᳨ウؐࠊಀ࡟ࡘ࠸࡚ሗ࿌ࡍࡿࠋ

⌮Ꮫ⒪ἲ⛉Ꮫ 23
㸦5㸧㸸±㸪ụ⏣㑳⏨㸦2013㸧: ⤫ィ᳨ᐃࢆ⌮ゎࡏࡎ࡟౑ࡗ࡚࠸ࡿே

฼┈┦཯

ࡢࡓࡵ࡟ III. ໬Ꮫ࡜⏕≀ , 51
㸦㸧ࠊ483-495.

ᮏㄽᩥ࡟㛵ࡋ࡚㛤♧ࡍ࡭ࡁ฼┈┦཯ࡣᏑᅾࡋ࡞࠸ࠋ

බ┈♫ᅋἲேࠉ᪥ᮏ⌮Ꮫ⒪ἲኈᏛ఍ࠊࢫ࣏࣮ࢶ⌮Ꮫ⒪ἲᏛ఍ᴫせ㸦2013㸧ࠉㅰ㎡

http://jspt.japanpt.or.jp/jsspt/about/㸦2019-6-10㸧ᮏ◊✲ࡢᐇ᪋࡜ㄽᩥసᡂ࡟࠶ࡓࡾࠊ⿕᳨⪅ࢆᛌࡃᘬබ┈ ㈈ᅋἲேࠉ᪥ᮏࢧࢵ࣮࢝༠఍ , ࢹ࣮ࢱ࣎ࢵࢡࢫ

ࡁཷࡅ࡚࠸ࡓࡔ࠸ࡓᑐ㇟ඣࠊ࡞ࡽࡧ࡟ಖㆤ⪅ࡢⓙᵝࠊ㸦2019㸧

ࡑࡋ࡚ࠊᮏ◊✲ࡢᐇ᪋ሙᡤࡸࢫࢣࢪ࣮ࣗࣝㄪᩚ࡞࡝࡟ࡈ

KWWSVZZZMIDMSDERXWB MIDRUJDQL]DWLRQGDWDER[༠ຊ࠸ࡓࡔ࠸ࡓ NPO ἲேᮾᯇᒣ࡮࣮ࣞࢽ࢔ࢫ࣏࣮ࢶࢡ
ࣛࣈࡢ㛵ಀ⪅࡟῝ࡃᚚ♩⏦ࡋୖࡆࡲࡍࠋ

player.html
㸦2019-6-11㸧
㔠Ꮚ᠇୍ , ⿙⏣ᬛᏊ , ᯽ᮌᝆ , ௚㸦2012㸧㸸ࢧࢵ࣮࢝⫱ᡂ
ᖺ௦ࡢ㌟య⤌ᡂ࡜ୗ⫥ከ㛵⠇ືస࡛Ⓨ᥹ࡉࢀࡿࣃ

ᘬ⏝ᩥ⊩࣮࣡࠾ࡼࡧࢫࣉࣜࣥࢺ⬟ຊࡢⓎ⫱࣭Ⓨ㐩≉ᛶ . యຊ⛉ᮅ಴ࡇ࠺Ꮚ , ℈㷂ಇග㸦2015㸧: 2 ࡘࡢᖹᆒࡢẚ㍑ . DrugᏛ , 61
㸦2㸧,259-266.

Delivery System,30
㸦2㸧ࠊ149-158.

ࡃࡲࡶ࡜ඖẼࡃࡽࡪ㸦2019㸧:᪂ᮏ᝷୍ᮁ , ᒣᓮᫀᘅ㸦2011㸧: ᑠᏛ⏕࡟࠾ࡅࡿୖ༙㌟

ホ౯ࡢᡭᘬࡁ : ⇃ᮏᆅᇦࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᗈᇦᨭ᥼

ࢺ࣮ࣞࢽࣥࢢࡀ㐠ື⬟ຊ࡟ཬࡰࡍຠᯝ . ᪥ᮏ⏕⌮ே㢮Ꮫ఍ㄅ , 16㸦2㸧ࠊ

ᐃ࣐ࢽࣗ࢔ࣝ㹼㐠ືᶵ⬟ࢭࣥࢱ࣮༠ຊ㸦2019,ᖺ 1 ᭶ᨵṇ∧㸧㏆⸨බஂ㸦2012㸧㸸᭷ពᕪ᳨ᐃࡢࡋࡃࡳ࠿ࡽ⪃࠼ࡿ : ᖹᆒ࡜ศᩓ࠿ࡽ෌☜ㄆ㸦ࡸࡉࡋ࠸ゎㄝ㸧. ᪥ᮏ㡢㡪Ꮫ఍

Brocherie F. Morikawa T. Hayakawa N.et al.
㸦2005㸧:ㄅ ,68㸦8㸧ࠊ

Pre-seasonanaerobic performance of elite Japanesesoccer players. In Science and Football V: The㔠ၿ㮚 , ᯇᾆ⩏⾜㸦1988㸧: ᗂඣཬࡧඣ❺࡟࠾ࡅࡿᇶ♏

Proceedings of the Fifth World Congress on Sports㐠ືᢏ⬟ࡢ㔞ⓗኚ໬࡜㉁ⓗኚ໬࡟㛵ࡍࡿ◊✲ : ㉮ ,Science and Football㸦May㸧
㸦p. 145㸧. Routledge.

㊴ , ᢞ㐠ືࢆ୰ᚰ࡟ . య⫱Ꮫ◊✲ , 33
㸦1㸧ࠊ

㯄ಙ⩏㸦1981㸧㸸ࢧࢵ࣮࢝࡟࠾ࡅࡿㅖ⬟ຊࡢ୺ほⓗホ౯ຍ⸨ㅬ୍ , ᐑ୸ถྐ , ᯇඖ๛㸦2001㸧: ඃࢀࡓᑠᏛ⏕ࢫ࡜ࢫ࢟ࣝࢸࢫࢺ࡜ࡢ㛵㐃࡟ࡘ࠸࡚ . ᘯ๓኱Ꮫᩍ⫱Ꮫ㒊ࣉࣜࣥࢱ࣮࡟࠾ࡅࡿ⑌㉮ືసࡢ≉ᚩ . య⫱Ꮫ◊✲ , 46

⣖せ㸬46ࠊ35-41.

㸦2㸧

⸨஭຾⣖㸦2013㸧: Ⓨ⫱Ⓨ㐩࡜ Scammon ࡢⓎ⫱᭤⥺ .

ᩥ㒊⛉Ꮫ┬᪂యຊࢸࢫࢺᐇ᪋せ㡯㸦6 ṓ㹼 11 ṓᑐ㇟㸧ࢫ࣏࣮ࢶ೺ᗣ⛉Ꮫ ◊✲ = Japanese journal of sports

㸦2014㸧

and health science, 3ࠊ1-16.

K W W S V   Z Z Z P H [ W  J R  M S D B P H Q X V S R U W V ᇼᕝ┿㑣 , ⸨ཎ⣲Ꮚ㸦2011㸧: ཯᚟ᶓ࡜ࡧ࡟࠾ࡅࡿ⣲᪩࠸᪉ྥ㌿᥮ືస . ዉⰋዪᏊ኱Ꮫࢫ࣏࣮ࢶ⛉Ꮫ◊✲ ,stamina/05030101/001.pdf
㸦㸧ᐑ᳃㝯⾜ , ྜྷᮧ㞞ᩥ , ⥤㒊ㄔஓ , ௚㸦2008㸧: ኱Ꮫࢧࢵ࣮࢝㑅ᡭࡢ࣏ࢪࢩูࣙࣥయຊ≉ᛶ࡟㛵ࡍࡿ◊✲ . ⌮13ࠊ13-22.
ᚋ⸨ᖾᘯࠊ㧗ᶫ₶ࠊ㛗஭ຌ㸦2005㸧㸸ࢧࢵ࣮࢝ࡢࣜࣇࢸ࢕

Ꮫ⒪ἲ⛉Ꮫ , 23
㸦2㸧ࠊ189-195.

ࣥࢢ⬟ຊ࡜ಶேᢏ⬟ , ࢤ㺎࣒ࣃࣇ࢛㺎࣐ࣥࢫ࡞ࡽࡧ࡟ᴦ

୰ᒣ㞞㞝ࠊὸ஭Ṋ㸦2009㸧㸸ࢧࢵ࣮࢝ࣉ࣮࣮ࣞࣖࡢⓎ㐩ࡋࡉࡢ㛵ಀࠉ୰Ꮫ⏕⏨Ꮚࢆᑐ㇟࡜ࡋ࡚㸬රᗜᩍ⫱኱ẁ㝵࠾ࡼࡧㄢ㢟ࡢไ⣙࡜ࡋ࡚ࡢࣉ࣮࢚ࣞࣜ࢔ࡢ኱ࡁࡉ

Ꮫ◊✲ᴫせ .

ࡀࣃࢫᢏ⬟࡟୚࠼ࡿᙳ㡪 . య⫱Ꮫ◊✲ࠊ54
㸦2㸧ࠊ343-ᚋ⸨ᖾᘯ , ᐑୗ⚞அ , ዟ㔝ᬸ㏻㸦1992㸧: ືⓗࣂࣛࣥࢫ㐠ືᏛ⩦ࡢ㐺᫬ᮇ࡟ࡘ࠸࡚ : ඣ❺ᮇ࡟࠾ࡅࡿ⦎⩦ຠ

353.
すᏲ㝯㸦2003㸧: ࣂࣛࣥࢫࡢホ౯ . 㛵す⌮Ꮫ⒪ἲ , 3ࠊᯝࡢᖺ㱋ᕪ࠿ࡽ . ᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲㈝୍⯡◊✲㸬ᫍᕝెᗈ , 㣤⏣ᮅ⨾ , ྂ᳃ᨻస , ௚㸦2012㸧: ࢧࢵ࣮࢝㑅
すෆၨ㸦2014㸧: ⤫ィᏛࡀ᭱ᙉࡢᏛၥ࡛࠶ࡿ> ᐇ㊶⦅ @ᡭ࡟࠾ࡅࡿ 20m ㉮ࢱ࢖࣒ࡢホ౯⾲ࡢヨ᱌ : ࢪࣗࢽ࢔࠿ࡽࣉࣟࡲ࡛ࡢ᳨ウ . య⫱Ꮫ◊✲ 㸦1㸧ࠊ249-260.

ࢲ࢖ࣖࣔࣥࢻ♫ .
᪥ᮏ་ᖌ఍㸦2002㸧: ࣊ࣝࢩࣥ࢟ᐉゝே㛫ࢆᑐ㇟࡜ࡍࡿ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021་Ꮫ◊✲ࡢ೔⌮ⓗཎ๎ . 2002 ᖺ , 10.
୰ᒣ㈗ᖾ㸦2019㸧: ࢧࢵ࣮࢝㑅ᡭࡢືࡁࡢホ౯࡜ືࡁ࡙
ࡃࡾࡢࡓࡵࡢᣦᑟࡢせⅬ , ⌮Ꮫ⒪ἲ 36㸦10㸧ࠊ886̿
889.
ኴ⏣ⱱ⛅ , ᭹㒊ᜏ᫂㸦1981㸧: ࢧࢵ࣮࢝࡟࠾ࡅࡿࢫ࢟ࣝࢸ
ࢫࢺࡢ᳨ウ --ࢻࣜࣈࣝ . Ⲉᇛ኱Ꮫᩍ㣴㒊⣖せ ,13,153161.
ዟ㔝ᬸ㏻ , ᚋ⸨ᖾᘯ , ㎷㔝᫛㸦1989㸧: ᢞ㐠ືᏛ⩦ࡢ㐺᫬ᮇ࡟㛵ࡍࡿ◊✲ . ࢫ࣏࣮ࢶᩍ⫱Ꮫ◊✲ ,9
㸦1㸧,23-35.
㕥ᮌဴ , ᖹ⏣῟ஓ , ᰩᮌ㩗⨾ , ௚㸦2009㸧: ∦⬮❧఩᫬ࡢయᖿ➽άື࡜㔜ᚰືᦂ࡜ࡢ㛵ಀ . ⌮Ꮫ⒪ἲ⛉Ꮫ, 24㸦1㸧ࠊ
㓇ᕳᩄኵ , ຍ⸨ᘏ㞝 , ⚟ග⬟㔛Ꮚ, ௚㸦㸧: ཯᚟ᶓ࡜ࡧ ᐃ᪉ἲࡢ᳨ウ . యຊ⛉Ꮫ , 23㸦2㸧ࠊ
㸸Ꮚ࡝ࡶࡢⓎ⫱Ⓨ㐩࡜ࢫ࣏࣮ࢶᣦ
㡲⸨᫂἞ , ௚㸦㸧.
ᑟࡢ࠶ࡾ᪉ . య⫱࣭ࢫ࣏࣮ࢶ⛉Ꮫ◊✲ ᡭᓥ㈗⠊ , ⣽⏣୕஧ , ゅ⏣┤ஓ㸦2016㸧: ⏨Ꮚࢧࢵ࣮࢝
㑅ᡭ࡟࠾ࡅࡿ Yo-Yo test ࠿ࡽࡳࡓ㛫Ḟⓗᣢஂᛶ㉮⬟
ຊࡢⓎ㐩 . ᅜኈ⯓኱Ꮫయ⫱◊✲ᡤሗ , 34ࠊ39-42.
ᑐ㤿ᰤ㍤㸦2002㸧: ⌮Ꮫ⒪ἲࡢ◊✲࡟࠾ࡅࡿಙ㢗ᛶಀᩘࡢ㐺⏝࡟ࡘ࠸࡚ . ⌮Ꮫ⒪ἲ⛉Ꮫ 
㸦3㸧181-18.
㧗ᮏᜨ⨾ , ฟ஭㞝஧ , ᑿ⦩㈉㸦2003㸧: ᑠᏛᰯඣ❺࡟࠾ࡅࡿ㉮ , ㊴࠾ࡼࡧᢞືసࡢⓎ㐩 : ඲ Ꮫᖺࢆᑐ㇟࡜ࡋ
࡚ . ࢫ࣏࣮ࢶᩍ⫱Ꮫ◊✲ , 23
㸦1㸧ࠊ1-15.
ᰗ஭ஂỤ㸦2015㸧: 4Steps ࢚ࢡࢭࣝ⤫ィ . ࣮࢚࣒࢚࢜ࢫฟ∧ .
ᰗ⃝ಟ, ⱝᯇ೺ኴ ,᳜ᮌ⦾ᬕ㸦㸧: ኱Ꮫ⏨Ꮚࢧࢵ࣮࢝
㑅ᡭ࡟࠾ࡅࡿ㌟య⤌ᡂ࡜యຊࡢ㛵 㐃ᛶ࡞ࡽࡧ࡟࣏ࢪ
ࢩࣙࣥ≉ᛶ࡟ࡘ࠸࡚ . ᱜ⨾ᯘㄽ⪃ . ⮬↛⛉Ꮫ࣭⥲ྜ⛉Ꮫ◊✲ , 8ࠊ51-60.
ᰗ⏣ 㮚⋤ , ᪩ᆏ ௮ , బ⸨ ㅬḟ , ௚㸦2011㸧㸸㊊㛵⠇᤬᣸ࡀ∦⬮❧఩ࣂࣛࣥࢫ⬟ຊ࡟ཬࡰࡍᙳ㡪㸬➨ 46 ᅇ᪥ᮏ⌮Ꮫ⒪ἲᏛ⾡኱఍ ᢒ㘓㞟 38㸦1㸧2.
Ώ㑔᐀Ꮥ , ᑎぢ᫓ᜨ , 㔠Ꮚ⩼㸦2008㸧:PT࣭OT ࡢࡓࡵࡢ⤫ィᏛධ㛛 . ୕㍯᭩ᗑ , ᮾி .

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Research Reportࠚ

)DFWRUVWKDWD൵HFWWKHEDVLFVNLOOVRIVRFFHUSOD\HUVLQWKHORZHUJUDGHVRI
elementary school and the relationship between basic skills 㸦¿UVWUHSRUW㸧㸫 Comparison by physical ability and grade 㸫Tomoyuki Tanaka*1ࠉHiroshi Takahashi*2ࠉNao Soga*1ࠉYuta Nieda*1ࠉSaki Yamamoto*1* 1 Department of Rehabilitation, Saitama Seikeikai Hospital* 2 Faculty of Rehabilitation, Gifu University of Health Sciences
Abstract:HH[DPLQHGWKHUHODWLRQVKLSEHWZHHQEDVLFVNLOOVDQGSK\VLFDODELOLWLHVRIORZHUJUDGHHOHPHQWDU\VFKRROVRFFHUSOD\HUV
7KHWDUJHWLVVRFFHUSOD\HUVLQWKH¿UVWWRWKLUGJUDGHVRIDFHUWDLQVSRUWVFOXEZKRVHEDVLFVNLOOVDUHOLIWLQJGULEEOLQJ㸦VODORP¿JXUH㸧, and direct kick, and their physical abilities are sprint, one-leg standing balance, and repeated side
MXPS7KHDVVRFLDWLRQEHWZHHQEDVLFVNLOOVDQGWKHDVVRFLDWLRQZLWKHDFKIDFWRUZHUHVWDWLVWLFDOO\SURFHVVHGDWDVLJQL¿FDQFHOHYHORI/LIWLQJZDVQRWVLJQL¿FDQWO\FRUUHODWHGZLWKHDFKVNLOO6ODORPVKRZHGDFRUUHODWLRQEHWZHHQWKH¿JXUHDQG
GLUHFWNLFNVDQGUHSHDWHGVLGHMXPSVDQGWKH¿JXUHFRUUHODWHGZLWKGLUHFWNLFNV6SULQWIRXQGDFRUUHODWLRQEHWZHHQOLIWLQJDQGVODORP¿JXUHHLJKW$FRUUHODWLRQZDVIRXQGEHWZHHQWKHRQHOHJVWDQGLQJEDODQFHDQGWKH¿JXUHHLJKW%DVLFVNLOOV
were correlated with age. These factors are considered to be physical growth, muscle strength improvement, motor learning
H൵HFW HWF ZLWK LQFUHDVLQJ VFKRRO DJH 3K\VLFDO DELOLW\ PDWXUHV UHJDUGOHVV RI VRFFHU H[SHULHQFH EXW LW LV WKRXJKW WKDWLPSURYHPHQWRIEDVLFVNLOOVLQYROYHVQRWRQO\SK\VLFDOGHYHORSPHQWEXWDOVROHDUQLQJH൵HFWVDQGLPSURYHPHQWRISK\VLFDOFRRUGLQDWLRQGXHWRH[SHULHQFHDQGDPRXQWRISUDFWLFH
Keywords: elementary school soccer, basic skills, physical abilityᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021࠙◊✲ሗ࿌ࠚ

༙ഃ✵㛫↓どᝈ⪅ࡢṌ⾜㛤ጞ᫬࡟࠾ࡅࡿ㠀㯞⑷ഃୗ⫥➽άື࡜㌿ಽண㜵ᑐ⟇㧘ᶫၨኴ *1ࠊ㧗ᶫࠉὒ *2
㸨 1 ་⒪ἲேࡳ࡝ࡾ㔝఍ရᕝ⑓㝔ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ⛉㸨 2 ᒱ㜧ಖ೺኱Ꮫࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊せ᪨
USN
㸦Unilateral Spatial Neglect㸧ᝈ⪅ࡢṌ⾜㛤ጞ᫬࡟࠾ࡅࡿ㠀㯞⑷ഃୗ⫥ࡢ➽άືࢆ⾲㠃➽㟁ィࡼࡾ᥇ྲྀࡋࠊ
USN ᳨ᰝἲ࡛࠶ࡿ Behavioral Inattention Test㸦௨ୗ BIT㸧ࡢⅬᩘ࡜ࡢ┦㛵ࢆㄪ࡭ࡓࠋࡑࡋ࡚㐠ືᏛ࡜㧗ḟ⬻ᏛࡢほⅬ࠿ࡽศᯒࡋࠊ࡝ࡢࡼ࠺࡟ࡋ୍࡚Ṍ┠ࢆᐇ⾜ࡋ࡚࠸ࡿࡢ࠿ࢆ᳨ウࡍࡿࡇ࡜࡜ࡋࡓࠋࡑࡋ࡚ᅾᏯ࡛ࡢ㌿ಽண㜵࡟ᚲせ࡞⎔ቃタᐃࡸ⮬୺ࢺ࣮ࣞࢽࣥࢢࡢᥦ᱌࡟⧅ࡆࡿࡓࡵࡢ᭷⏝࡞࢔ࣉ࣮ࣟࢳ᪉ἲࢆ⪃ᐹࡋࡓࠋᑐ㇟⪅ࡣᮾி㒔ࡢ᯾⥲ྜ⑓㝔࡟ධ㝔ࡋ࡚࠸ࡿ⬻⾑⟶㞀ᐖᝈ⪅ࡢ࠺ࡕࠊ㧗ḟ⬻ᶵ⬟㞀ᐖ࡜デ᩿ࡉࢀ USN ࢆ᭷ࡍࡿᝈ⪅࡜ࡋࡓࠋጞࡵ࡟㠀㯞⑷ഃ๓
⬯㦵➽ࠊ⭌⭡➽እഃ㢌ࡼࡾ⾲㠃➽㟁ᅗࢆᑟฟࡋࡓࠋࡑࡢ⤖ᯝࠊ⑕౛ 1 ࡛ࡣ BIT ࡣ 3 ࠿᭶ᚋࡢ㏻ᖖ᳨ᰝࡣపୗࡋࠊ
๓⬯㦵➽ࡢ➽άືࡀቑຍࡋ⭌⭡➽እഃ㢌ࡢ➽άືࡣῶᑡࡋࡓࠋ⑕౛ 2 ࡛ࡣ BIT ࡣึᅇ࡜3 ࠿᭶ᚋࡢⅬᩘࡣኚࢃࡽࡎࠊ
୧➽ࡢ➽άືࡀῶᑡࡋࡓࠋ⑕౛ 3 ࡛ࡣ 3 ࠿᭶ᚋࡢ BIT ࡣ ᐃ࡛ࡁࡎࠊ➽άືࡣ⑕౛ 1 ࡜཯ᑐࡢ⌧㇟ࡀࡳࡽࢀࡓࠋ
⑕౛ 4࡛ࡣ୧➽ࡢ➽άືࡢቑຍࡀࡳࡽࢀࡓࠋUSN ࡢ᭷↓ࡣカ⦎ࣉࣟࢢ࣒ࣛࡢඃඛ㡰఩ࡀኚ໬ࡍࡿࡇ࡜ࡀ♧၀ࡉࢀࡿࠋ
㠀㯞⑷ഃ࡛ࡢጼໃไᚚࢆᨵၿࡉࡏࡿ⑕౛࡜ࠊ᪩ᮇ࠿ࡽ㯞⑷ഃ࡬἞⒪ࡀྍ⬟࡞⑕౛ࡀ࠶ࡿࡓࡵࠊ㐺ษ࡞⌮Ꮫ⒪ἲホ౯ࡀᚲせ࡛࠶ࡿࠋ
࣮࣮࢟࣡ࢻ㸸⬻⾑⟶㞀ᐖࠊ༙ഃ✵㛫↓どࠊṌ⾜㛤ጞࠊ㠀㯞⑷ഃ➽άືᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ࢀࡿṌ⾜᫬ࡸືసኚ᥮᫬࡟㌿ಽࡀከࡃ⏕ࡌ࡚࠸ࡿࠋᅾ㸬ㅖゝ⬻༞୰∦㯞⑷ᝈ⪅ࡢ USN ࡢᅇ᚟࡟㛵ࡋ࡚᫬㛫⤒㐣࡜Ꮿ⬻༞୰ᝈ⪅  ྡ୰ 16 ྡࡀ㌿ಽࡋ㌿ಽ⋡ࡣ 43% ࡛࡜ࡶ࡟୍ᚊ࡟ᅇ᚟ࡍࡿᝈ⪅࡜ࠊᅇ᚟⤒㐣࡟ኚືࡀ࠶ࡿ

࠶ࡗࡓࡇ࡜ࠊࡑࡢ࠺ࡕ 10 ྡࡣ⧞ࡾ㏉ࡋࡢ㌿ಽࡀ࠶ࡗࡓ࡜

ᝈ⪅࠸ࡿ࡜ࡢ㸦Chen,2015㸧ࡢሗ࿌ࡀ࠶ࡿࠋࡲࡓࠊ1 ᖺ࠿ࡢሗ࿌㸦ྜྷᮧ ,2004㸧ࡀ࠶ࡿࠋࡇࡢࡇ࡜࠿ࡽᅾᏯ࡟࠾ࡅࡽ ᩘ ᖺ ࡟ ࢃ ࡓࡾ USN ࡀ ṧ Ꮡ ࡍ ࡿ ⑕ ౛㸦Jehkonenࡿ㌿ಽண㜵ᑐ⟇ࡣᚲせ࡛࠶ࡿࠋ0㸧ࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋࡑࡢࡓࡵࠊUSN ࡀኚືⓗ

USN ࢆᣢࡘ⬻༞୰∦㯞⑷ᝈ⪅ࡢ㠀㯞⑷ഃࡢୗ⫥➽ά࡞ᅇ᚟⤒㐣ࢆࡓ࡝ࡿᝈ⪅ࡸ㛗ᮇṧᏑࡍࡿᝈ⪅ࡀ࠸ࡿࡇືࢆ BIT ࡢࡳ࡛ぢࡿࡢࡣࠊUSN ࡢ⑕≧ࡸ⑓ែࢆ⪃៖ࡋ࡜ࢆ⪃៖ࡋࠊ㛗ᮇⓗ࡞⌮Ꮫ⒪ἲࣉࣟࢢ࣒ࣛࡢ❧᱌ࡀᚲ࡚࠾ࡽࡎࠊᅇ᚟㐣⛬ࡢホ౯ࠊ⎔ቃタᐃࡸ⮬୺ࢺ࣮ࣞࢽ

せ࡛࠶ࡿࠋࡍ࡞ࢃࡕ㏥㝔ᚋ࡛ࡶ㌟యᶵ⬟ࡀᅇ᚟ࡍࡿྍࣥࢢࢆタᐃࡍࡿ࡟ࡣ㐺ࡋ࡚࠸࡞࠸ࡓࡵ ADL ࡢホ౯ࡀᚲ⬟ᛶࡣ༑ศ࡟࠶ࡿࡓࡵࠊ⮬୺ࢺ࣮ࣞࢽࣥࢢࡢ⥅⥆ࡀ୙せ࡛࠶ࡿࠋྍḞ࡛࠶ࡿࠋ⮬୺ࢺ࣮ࣞࢽࣥࢢࡣᏳ඲࠿ࡘຠᯝⓗ࡞カ┠ⓗ⦎ࡀᮃࡲࡋ࠸ࡓࡵࠊ㌟యᶵ⬟࡟ぢྜࡗࡓ⎔ቃタᐃ࡜㌿ᮏ◊✲࡛ࡣࠊUSN ᝈ⪅ࡢṌ⾜㛤ጞ᫬࡟࠾ࡅࡿ㠀㯞ಽᅇ㑊࡟ᚲせ࡞ࣂࣛࣥࢫ⬟ຊࡸṌ⾜⬟ຊࢆ⋓ᚓࡍࡿࡼ⑷ഃୗ⫥ࡢ➽άືࢆ⾲㠃➽㟁ィࡼࡾ᥇ྲྀࡋࠊUSN ࡢᨵ࠺࡞᪉ἲࡀồࡵࡽࢀࡿࠋ
⬻༞୰∦㯞⑷ᝈ⪅ࡢṌ⾜࡟ࡘ࠸࡚㯞⑷ഃ࡟୺║ࢆ⨨ၿ ࢆ ㏣࠺ࡓ ࡵ ࡟ࠊUSN ᳨ ᰝ ἲ ࡛ ࠶ ࡿ Behavioural࠸ࡓ◊✲ࡣከࠎ࠶ࡿࡀࠊ༙ഃ✵㛫↓どᝈ⪅ࡢ㠀㯞⑷ഃ

Inattention Test㸦௨ୗ BIT㸧ࡢⅬᩘ࡜ࡢ┦㛵ࢆㄪ࡭ࡿࠋࡑ

࡟ࡘ࠸࡚ࡢሗ࿌ࡣⴭ⪅ࡀ᥈ࡋࡓ㝈ࡾ࡛ࡣᑡ࡞࠸ࠋṌ⾜ࡋ࡚㐠ືᏛ࡜㧗ḟ⬻ᏛࡢほⅬ࠿ࡽศᯒࡋࠊ࡝ࡢࡼ࠺࡟ࡋ

ࡢᐇ⏝ᛶྥୖࢆ㜼ᐖࡍࡿཎᅉࡢ୍ࡘ࡟ࠊ㠀㯞⑷ഃࡢ㐣୍࡚Ṍ┠ࢆᐇ⾜ࡋ࡚࠸ࡿࡢ࠿ࢆ᳨ウࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡍ๫ດຊࡀ࠶ࡿࡢ࡛ࡣ࡞࠸࠿࡜⮫ᗋୖឤࡌ࡚࠸ࡓࠋࠉጼ

ࡿࠋࡑࡋ࡚ᅾᏯ࡛ࡢ㌿ಽண㜵࡟ᚲせ࡞⎔ቃタᐃࡸ⮬୺ໃࡢ⥔ᣢࡣ๓ᗞࠊどぬࠊయᛶឤぬࡢឤぬࣇ࢕࣮ࢻࣂࢵ

ࢺ࣮ࣞࢽࣥࢢࡢᥦ᱌࡟⧅ࡆࡿࡓࡵࡢ᭷⏝࡞࢔ࣉ࣮ࣟࢳ᪉

ࢡ࡟ࡼࡾᏳᐃ ࡍࡿ㸦 ▼⏣ ,1999㸧ࠋ ࡋ࠿ࡋ Kinsbourneἲࢆ⪃ᐹࡋࡓࠋ

㸦.LQVXERXUQH㸧ࡢㄝ࡟ࡼࡿ࡜㏻ᖖࠊᕥྑࡢ኱⬻༙ᑐ㇟⌫ࡣ⬻ᱱࢆ௓ࡋ࡚ᢚไࢆࡋྜ࠺ࡇ࡜࡛᝟ሗࡢᆒ⾮ࡀಖࡓࢀࡿࡓࡵࠊᕥྑ✵㛫࡟ὀពࢆྥࡅࡿࡇ࡜ࡀ࡛ࡁࡿࡀࠊ

ᑐ㇟⪅ࡣᮾி㒔ෆ᯾⥲ྜ⑓㝔㸦௨ୗᙜ㝔㸧࡟ධ㝔ࡋ࡚ྑ༙⌫ᦆയ࡟ࡼࡾࡑࡢᆒ⾮ࡀᔂࢀࡿࡇ࡜࡛ᕥ༙⌫ࡢά࠸ࡿ⬻⾑⟶㞀ᐖᝈ⪅ࡢ࠺ࡕࠊ㧗ḟ⬻ᶵ⬟㞀ᐖ࡜デ᩿ࡉືࡀᢚไ࡛ࡁ࡞ࡃ࡞ࡿࡓࡵࠊᕥ༙⌫ࡀᨭ㓄ࡋ࡚࠸ࡿྑ✵ࢀ USN ࢆ᭷ࡍࡿᝈ⪅࡜ࡋࠊ௨ୗࡢ᮲௳ࢆ‶ࡓࡍ⪅࡜ࡋ㛫ࡢࡳ࡟ὀពࡀ೫ࡿ࡜ㄝ᫂ࡋ࡚࠸ࡿࡓࡵࠊ㠀㯞⑷ഃ࡟

ࡓࠋձព㆑㞀ᐖࡀ࡞࠸ࡇ࡜ࠊGlasgow Coma Scale㸦௨ࡶ࡞ࢇࡽ࠿ࡢᙳ㡪ࢆཬࡰࡍࡇ࡜ࡀ⪃࠼ࡽࢀࡿࠋ

ୗ GCSϨ-1㸧ࢆᇶ‽࡜ࡍࡿࠋղ᪤ ࡟ᩚᙧእ⛉ᡭ⾡ࡀ

㏥㝔ᚋࡢ⬻༞୰∦㯞⑷ᝈ⪅ࡢ㌿ಽሙᡤࡣ⣙ 90% ࡀᒇෆ࡛Ⓨ⏕ࡋ࡚࠾ࡾࠊࡼࡾ㧗ᗘ࡞❧఩ࣂࣛࣥࢫࡀせồࡉ࡞ࡃኚᙧᛶ㛵⠇⑕ࢆ᭷ࡋ࡞࠸⏨ᛶ 3 ྡࠊዪᛶ 1 ྡ㸦ྑ⿕Ẇฟ⾑㸧࡜ࡋࡓࠋᑐ㇟⪅ࡢᴫせࢆ⾲ 1 ࡟♧ࡍࠋ⾲ 㸬ᑐ㇟⪅ࡢᴫせᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

᪉ἲ

4.2. ᐇ㦂ㄢ㢟㠀㯞⑷ഃ๓⬯㦵➽ࠊ⭌⭡➽እഃ㢌ࡼࡾ⾲㠃➽㟁ᅗ㸦࣡ᑐ㇟⪅࡟ࡣࠕ㊊ࢆ⫪ᖜ࡟ᗈࡆࠊⰋ࠸᪉ࡢᡭ࡟ࡣఱࡶᣢ

࢖ࣖࣞࢫ EMG ࣮ࣟ࢞ϩࠊᆺᘧ $$ࠊ㏣ᆏ㟁Ꮚࡓ࡞࠸࡛❧ࡘࡼ࠺࡟ࠖ࡜ཱྀ㢌࡛ㄝ᫂ࡋࡓࠋ⌮ゎࡀᚓࡽࢀᶵჾࠊᗈᓥ㸧ࢆᑟฟࡋࠊ➽㟁ᅗࡢ ᐃ⤖ᯝࢆẚ㍑ࡍࡿ

࡞࠸ሙྜࡣ◊✲⪅ࡀᶍೌࢆ♧ࡍࠊࡲࡓࡣᚐᡭ࡟࡚㠀㯞ࡓࡵ࡟ᇶ‽್࡜ࡋ࡚㟼Ṇ❧఩࡟࠾ࡅࡿ㠀㯞⑷ഃ࡟඲య

⑷ഃⲴ㔜ࢆㄏᑟࡋࡓࠋ
ḟ࠸࡛ࠊᑐ㇟⪅࡟ࠕᝏ࠸᪉ࡢ㊊ࢆ๓࡟ฟࡋ࡚ࡃࡔࡉ࠸ࠖ

㔜ࢆ࠿ࡅࠊྛ ᐃ್ࡢṇつ໬ࢆ⾜ࡗࡓࠋ௨ୗ࡟➽㟁ᅗ᥇ྲྀᡭ㡰ࠊᐇ㦂ㄢ㢟ࠊศᯒ᪉ἲࢆ♧ࡍࠋ࡜ᣦ♧ࢆฟࡍࠋࡑࡢ㝿ࠊ㠀㯞⑷ഃୖ⫥ࡣᡭࡍࡾ➼ࢆᢕᣢࡏࡎࠊ㐣ᗘ࡞௦ൾ㐠ືࡸ❧఩࢔ࣛ࢖࣓ࣥࢺࡀᔂࢀ࡞࠸

4.1. ⾲㠃➽㟁ᅗࡢ᥇ྲྀᡭ㡰࣭ᅇᩘ࣭ᮇ㛫ࡼ࠺࡟┠ど࡛☜ㄆࡋ࡞ࡀࡽ⾜ࡗࡓࠋ⾲㠃➽㟁ᅗࡢ᥇ྲྀ㒊఩ࡣᒣཱྀ㸦ᒣཱྀ ,2005㸧ࡢሗ࿌࡟୧⬮ᨭᣢࡢ┤❧ጼໃ࠿ࡽ㯞⑷ഃୗ⫥ࢆ୍Ṍ᣺ࡾฟ‽ᣐࡋࠊ๓⬯㦵➽ୖࡢ➽⭡㸦⬯㦵እഃ㢛࠿ࡽ 4 ᶓᣦ㐲ࡋࠊ㯞⑷ഃ❧⬮୰ᮇࡲ࡛ࠊࡍ࡞ࢃࡕ㠀㯞⑷ഃୗ⫥㸦ᨭ఩㸧ࠊ⭌⭡➽እഃ㢌ୖࡢ➽⭡㸦⬯㦵እഃ㢛ࡼࡾ 3 ᶓᣦᣢ⬮㸧ࡢ❧⬮ᚋᮇࡲ࡛ࢆ ᐃࡋࡓࠋࡲࡓᝈ⪅ࡢ㯞⑷ࡢ

㐲఩㸧࡜ࡋࡓࠋ㟁ᴟ㈞௜㒊఩ࡢỴᐃࡣ๓㏙ࡋࡓ఩⨨ࢆ≧ែ࡟ྜࢃࡏࠊ㛗ୗ⫥⿦ල࠶ࡿ࠸ࡣ▷ୗ⫥⿦ලࢆ౑⏝ᇶ‽࡜ࡋ࡚ࠊᝈ⪅࡟ࡼࡗ࡚⏕ࡌࡿಶయᕪࡀ⏕ࡌ࡞࠸ࡼ࠺

ࡋࡓ㸦ᅗ 3㸧ࠋ
BIT
㸦Behavioural inattention test㸧ࡢᐇ᪋ࡣᖖἲ࡟ᚑࡗ

࡟ࠊゐデ࡟ࡼࡿ➽⭡ࡢ☜ㄆ࡜㐠ື᫬࡟ฟ⌧ࡍࡿ➽㟁ᅗἼᙧࢆࣃࢯࢥࣥ⏬㠃࡛☜ㄆࢆ⾜ࡗࡓ㸦ᅗ 1㸧ࠋᐇ㦂ᅇᩘࡣ㠀㯞⑷ഃ࡟Ⲵ㔜ࢆ࠿ࡅࡓ㟼Ṇ❧఩ࢆ 1 ᗘ⾜࠸ࠊࡑࡢᚋࠊᐇ㦂ㄢ㢟ࢆ 3 ᅇ᪋⾜ࡋࡓࠋࡇࡢㄢ㢟ࢆ࡚⾜࠸ࠊᐇ᪋᪥ࡣ࠸ࡎࢀࡶᛴᛶᮇ⑓Ჷ࠿ࡽᅇ᚟ᮇ⑓Ჷ࡟㌿Ჷᚋ 10 ᪥௨ෆ࡟᪋⾜ࡋࡓࠋ᳨ᰝࡣᙜ㝔ゝㄒ⫈ぬኈ࡟౫㢗ࡋࡓࠋ

㝸㐌࡛᪋⾜ࡋྜィ 10 㐌㛫⾜ࡗࡓࠋᐇ㦂ࡢྜィᅇᩘࡣ
5 ᅇ࡜ࡋࡓ㸦ᅗ 2㸧ࠋᅗ 㸬⾲㠃➽㟁ᅗࡢ᥇ྲྀࢹ࢕ࢫ࣏࣮ࢨࣈࣝ⾲㠃㟁ᴟࢆ 2 ੉௨ୖ㞳ࡋ࡚ᅗ ࠉ᣺ࡾฟࡋ᫬ࡢ (0* ᐃ୧⬮ᨭᣢࡢ┤❧ጼໃ࠿ࡽ㯞⑷ഃୗ⫥ࢆ୍Ṍ᣺㈞௜ࡋࡓࠋ ࢔࣮ࢫࡣ⭌㦵㢌࡟㈞௜ࡋࡓࠋ

ࡾฟࡋࠊ 㠀㯞⑷ഃୗ⫥ 㸦ᨭᣢ⬮㸧ࡢ❧⬮ᚋᮇࡲ࡛ࢆᐃࠋ ᝈ⪅ࡢ㯞⑷ࡢ≧ែ࡟ྜࢃࡏࠊ
㛗ୗ⫥⿦ලࢆ౑⏝ࡋࡓࠋศᯒ᪉ἲ
5.1. ➽㟁ᅗࡢศᯒ⿕㦂⪅ࡢ㠀㯞⑷ഃ๓⬯㦵➽ࠊ⭌⭡➽እഃ㢌࡟ࠊ࣡࢖ࣖࣞࢫ EMG ࣮ࣟ࢞㸦ᅗ 3㸧࠿ࡽྲྀࡾ௜ࡅࡓࢹ࢕ࢫ࣏࣮ࢨ
ࣈࣝ⾲㠃㟁ᴟࢆࠊ2cm ௨ୖ㞳ࡋ࡚㈞௜ࡋࡓࠋ㏦ཷಙᶵࡣࣃࢯࢥࣥ࡟᥋⥆ࡋࡓࠋࢹ࣮ࢱྲྀࡾ㎸ࡳ࡟ࡘ࠸࡚ࡣࠊLabVIEW ࢔ࣉࣜࢣ࣮ࢩࣙࣥ 9HU ࢆ㉳ືࡋࠊᚓࡽࢀࡓᅗ 㸬㟼Ṇ᫬ࡢ (0* ᐃሙ㠃㟼Ṇ❧఩ୗ࡛ᚐᡭ࡟࡚㠀㯞⑷ഃⲴ㔜ࢆㄏᑟࠊ
10 ⛊⾜࠸➽㟁ᅗࢆࢹ࣮ࢱࡣ➃ᮎಖᏑࡋࠊྲྀᚓࡋࡓࢹ࣮ࢱࡣ ([FHO㸦csv ᙧ
ᘧ㸧࡟࡚ಖᏑࡋࡓࠋᐃࡋࡓࠋ

EMG ࣡࢖ࣖࣞࢫ࣮ࣟ࢞࡟ಖᏑࡉࢀࡓࢹ࣮ࢱࡣࠊࢸ࢟ࢫ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ࢺࢹ࣮ࢱ࡜ࡋ࡚᭩ࡁฟࡋ ([FHO ࡟࡚௨ୗࡢศᯒࢩ࣮ࢺࢆ
సᡂࡋศᯒࡋࡓࠋึࡵ࡟ᇶ⥺ base line
㸦0mm ࣎ࣝࢺࣞ࣋ࣝ㸧ࢆタᐃࡋࠊᩚὶ࣭⛣ືᖹᆒἲ࡟ࡼࡿᖹ⁥໬ࢆ⾜ࡗࡓᚋࠊᣦᐃࡋࡓ⠊ᅖࡢ✚ศ್ࢆồࡵࡓࠋ✚ศ್ࡣ㟼Ṇ❧఩࡛ࡣ 5 ⛊㛫ࠊㄢ㢟᪋⾜᫬࡛ࡣ 1 ⛊㛫ࡢἼᙧᏳᐃ
༊㛫࡛⟬ฟࡋࡓࠋࡲࡓ௚ࡢࢹ࣮ࢱ࡜ẚ㍑ࡍࡿࡓࡵ௨ୗࡢ
ṇつ໬ࢆ⾜ࡗࡓࠋ 㟼Ṇ❧఩࡟࡚㠀㯞⑷ഃୗ⫥࡬ࡢ
100% Ⲵ 㔜 ᫬ ࡢ ✚ ศ ➽ 㟁 ᅗ㸦integrated EMG, ௨ ୗ
IEMG㸧ࢆ 100% ࡜ࡋ௚ࡢᐃ್࡜ࡢẚ㍑ࢆ⾜ࡗࡓ㸦ᅗ4㸧ࠋᅗ ࠉ⑕౛ ࠉ⭌⭡➽እഃ㢌ࡢᅇᖐ┤⥺ᅗ  ⑕౛ ࠉ๓⬯㦵➽ࡢᅇᖐ┤⥺ᅗ ࠉ⑕౛ ࠉ๓⬯㦵➽ࡢᅇᖐ┤⥺ᅗ ࠉ⑕౛ ࠉ⭌⭡➽እഃ㢌ࡢᅇᖐ┤⥺ᅗ ࠉ⑕౛ ࠉ๓⬯㦵➽ࡢᅇᖐ┤⥺ᅗ ࠉ⑕౛ ࠉ⭌⭡➽እഃ㢌ࡢᅇᖐ┤⥺ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ୖ㸦▼ྜ ,2009㸧࠶ࢀࡤᐇ᪋ྍ⬟࡜ࡋࡓࠋධ㝔᫬ࠊ3 ࠿᭶
᫬ࠊ㏥㝔᫬ࡢ⥲ᚓⅬࡢኚ໬ࢆ㏣ࡗࡓࠋ⑕౛ 1.2 ࡣධ㝔ᚋࠊ
5 ࠿᭶᫬Ⅼ࡛㏥㝔ࡋࡓࡓࡵࠊ2 ᗘ ᐃࢆ⾜ࡗࡓࠋ⑕౛ 3
ࡣຍ⒪୰࡟⬻᱾ሰࢆⓎ⑕ࡋࡓࡓࡵᛴᛶቑᝏ࡜ࡳ࡞ࡋ
BIT

ᐃ࠿ࡽࡣ㝖እࡋࡓࠋ

೔⌮ⓗ㓄៖ᮏ◊✲ࡣ࣊ࣝࢩࣥ࢟ᐉゝ୪ࡧ࡟ࠕேࢆᑐ㇟࡜ࡍࡿ་
Ꮫ⣔◊✲࡟㛵ࡍࡿ೔⌮ᣦ㔪ࠖࢆ㑂Ᏺࡋࠊᮏ◊✲ࡢෆᐜ࡟ࡘ࠸࡚ࠊ᪂₲ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ኱Ꮫ೔⌮ᑂᰝጤဨ఍
࡬೔⌮⏦ㄳࢆ⾜࠸ࠊᢎㄆ㸦ཷ௜␒ྕ 144㸧ࡢୖ࡛ᐇ᪋ࡋࡓࠋ ⤫ィᏛⓗศᯒᅗ 816 ࡢ࡞࠸⑕౛ ๓⬯㦵➽ࡢᅇᖐ┤⥺0LFURVRIW([FHO ࡟࡚ IEMG
㸦%㸧࡜᫬㛫⤒㐣࡜ࡢ ᅇᖐศᯒࢆ⾜ࡗࡓࠋศᩓศᯒ⾲࠿ࡽᚓࡽࢀࡓ⤖ᯝ࠿ࡽ᭷ព
ᕪࢆ᳨ฟࡋࡓࠋ᭷ពỈ‽ࡣ 5% ࡜ࡋࡓࠋ ⤖ᯝ
8.1 Ṍ⾜ࡢ➨୍Ṍ┠࡟࠾ࡅࡿ㠀㯞⑷ഃ➽άື⑕౛ẖ࡟➽㟁ᅗࡢ⤒᫬ⓗኚ໬ࢆ♧ࡋࡓࢢࣛࣇࢆᅗ 4㸬
1 㹼 8 ࡟♧ࡍࠋ10 㐌㛫ࡢ㐠ື⒪ἲᚋ⑕౛ 㸦ᅗ1
4 㸫1㸪2㸧࡛ࡣࠊึᮇ࡜᭱⤊ ᐃࢆẚ㍑ࡍࡿ࡜๓⬯㦵➽ࡢ➽άືࡀቑຍࠊ⭌⭡➽እഃ㢌ࡢ➽άືࡀῶᑡࡋࡓ㸦p<0.05 ࡛᭷ពᕪ࠶ࡾ㸧ࠋ⑕౛ 2 ࡛ࡣ୧➽ࡢ➽άື࡛ῶᑡࢆㄆࡵࡓ
㸦p<0.05 ࡛᭷ពᕪ࠶ࡾ㸧ࠋ⑕౛ 3 ࡛ࡣ⑕౛ 1 ࡜ࡣᑐ↷ⓗ࡟ࠊ๓⬯㦵➽ࡀῶᑡࠊ⭌⭡➽እഃ㢌ࡢቑຍࡀぢࡽࢀࡓ㸦p<0.05 ࡛᭷ពᕪ࠶ࡾ㸧ࠋUSA ⑕≧ࡢ࡞࠸⑕౛ 4 ࡛ࡣ୧➽ࡢ➽άື࡛ቑຍࢆㄆࡵࡓࡀ 10 㐌㛫ᚋࡢ๓ᚋ࡛ᅗ 816 ࡢ࡞࠸⑕౛ ⭌⭡➽እഃ㢌ࡢᅇᖐ┤⥺᭷ពᕪࡣㄆࡵࡽࢀ࡞࠿ࡗࡓ㸧ࠋ
5.2. ࢹ࣮ࢱࡢ⤒㐣ศᯒ᪉ἲ([FHO ࡟࡚௨ୗࡢศᯒࢩ࣮ࢺࢆసᡂࡋࡓࠋ㟼Ṇ❧఩᫬ࠊ

8.1 BIT㸦Behavioural Inattention Test㸧ᚓⅬࡢ᥎⛣ㄢ㢟᪋⾜᫬࠿ࡽᚓࡽࢀࡓ✚ศ್ࢆᖹᆒ໬ࡋࡓࠋ㟼Ṇ❧

BIT ᚓⅬࡢ᥎⛣ࢆ⾲ 2 ࡟♧ࡍࠋ㠀㯞⑷ഃ➽άືࡀ᫬఩᫬ࡢ✚ศ್ࢆ 100% ࡜ࡋࡓ᫬ࡢ್ࢆྛㄢ㢟᪋⾜᫬ࡢ㛫⤒㐣࡜࡜ࡶ࡟ῶᑡࡍࢀࡤ BIT ᚓⅬࡣᚎࠎ࡟ྥୖࡍࡿ

✚ศ್ࢆ⏝࠸࡚⟬ฟࡋࡓࠋࡢ࡛ࡣ࡞࠸࠿࡜௬ㄝࢆ❧࡚ࠊ➽㟁ᅗάື࡜ BIT࡜ࡢ㛵ಀࢆぢࡓࠋࡑࡢ⤖ᯝࠊ⑕౛ 1 ࡛ࡣ᫬㛫ࡢ⤒㐣࡟క࠸๓

5.3.BIT ࡟ࡼࡿศᯒ

⬯㦵➽ࠊ⭌⭡➽እഃ㢌ࡑࢀࡒࢀࡢ➽άື࡟┦㛵ࡣㄆ

BIT ࡣࢃࡀᅜ࡛⏝࠸ᚓࡿᅜ㝿ⓗ᳨ᰝἲ࡜ࡋ࡚᪥ᮏேྥ

ࡵࡿࡀ᭷ពᕪࢆㄆࡵ࡞࠿ࡗࡓࠋ࡞࠾ F ࡣ ([FHO ࡟ࡼࡿࡅ࡟᭱ᑠ㝈ࡢಟṇࢆຍ࠼ᶆ‽໬ࡉࢀࡓ༙ഃ✵㛫↓どࡢฟຊ⤖ᯝ࡛࠶ࡿࠋ㸦 ๓⬯㦵 ➽ r=0.516
㸦p<0.05㸧᭷ព Fࢸࢫࢺࣂࢵࢸ࣮࡛ࣜ࠶ࡿࠋ᪥ᖖ⏕άࡢഃ㠃ࢆ཯ᫎࡉࡏࡓ

ࠉ⭌⭡➽እഃ㢌 U 
㸦p<0.05㸧᭷ព F 0.152㸧

9 㡯┠ࡢࠕ⾜ື᳨ᰝࠖ࡜ࠊ⣬࡜㖄➹࡟ࡼࡿ⡆༢࡞༙ഃ✵⑕౛ 2 ࡛ࡣ๓⬯㦵➽࡟ࡣ┦㛵ࢆㄆࡵࡎࠊ⭌⭡➽እഃ㛫↓ど᳨ᰝ 6 㡯┠ࡢࠕ㏻ᖖ᳨ᰝࠖ࠿ࡽ࡞ࡗ࡚࠸ࡿࠋ೺ᛀ

㢌࡟┦㛵ࡀ࠶ࡗࡓࡀ᭷ពᕪࢆㄆࡵ࡞࠿ࡗࡓࠋ
㸦๓⬯㦵➽ࡀ࠶ࡗ࡚ࡶᐇ᪋ྍ⬟࡞᳨ᰝ࡛࠶ࡿࡓࡵࠊㄆ▱⑕ࡀ࠶ࡿ

r=0.135
㸦p>0.05㸧᭷ព F 0.828ࠉ⭌⭡➽እഃ㢌 r=0.932ሙྜࡢ┠Ᏻ࡜ࡋ࡚㛗㇂ᕝᘧㄆ▱⑕ࢫࢣ࣮ࣝ㸦HDS-R㸧ࡲ㸦p<0.05㸧᭷ព F 0.02㸧

ࡓࡣ 0LQL0HQWDO6WDWH([DPLQDWLRQ㸦MMSE㸧ࡀ 15 Ⅼ௨⑕౛ 3 ࡛ࡣ๓⬯㦵➽ࠊ⭌⭡➽እഃ㢌ࡑࢀࡒࢀࡢ➽άᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

⾲ %,7 ᚓⅬࡢ᥎⛣άືࡋࠊ⭌⭡➽እഃ㢌ࡣ㐲ᚰᛶ཰⦰ࡲࡓࡣᢚไ࡟ാࡁ
COP ࡀᚋ᪉࡬⛣ືࡋࡓࠋࡑࢀ࡟ࡼࡾ㌟య㉁㔞୰ᚰࡀ๓᪉࡟ຍ㏿ࡍࡿࡓࡵࠊ๓᪉ࣂࣛࣥࢫඃ఩ࡢጼໃᡓ␎ࢆྲྀࡗ
࡚࠸ࡿࡇ࡜ࡀ⪃࠼ࡽࢀࡿࠋࡼࡗ࡚Ⓨ⑕ึᮇࡣ⭌⭡➽እഃ㢌ࡀඃ఩࡟άືࡉࡏࡿᚋ᪉ࣂࣛࣥࢫᡓ␎࡛࠶ࡗࡓࡀࠊ
๓⬯㦵➽ࡢ➽άື࡟ኚ໬ࡀ⏕ࡌࡓࡓࡵࠊ๓⬯㦵➽ࢆ౑⏝ࡋࡓ๓᪉ࣂࣛࣥࢫᡓ␎࡜࡞ࡗࡓྍ⬟ᛶࡀ࠶ࡿࠋ
⑕౛ 3 ࡢⓎ⑕ึᮇ࡛ࡣ๓⬯㦵➽ࡀඃ఩࡟άືࡋ࡚࠾

ື࡟┦㛵ࡣㄆࡵࡿࡀ᭷ពᕪࡣ࡞࠿ࡗࡓࠋ㸦 ๓⬯㦵➽

ࡾࠊ⭌⭡➽እഃ㢌࡟㐲ᚰᛶ཰⦰࣭ᢚไࡀാ࠸࡚࠸ࡿ≧U 㸦p>0.05㸧᭷ព F 0.394ࠉ⭌⭡➽እഃ㢌 r=0.386

ែ࡛࠶ࡾࠊCOPࡣᚋ᪉࡬఩⨨ࡋ࡚࠸ࡓ࡜⪃࠼ࡽࢀࡿࠋ
ᚎࠎ

㸦p>0.05㸧᭷ព F 0.52㸧

࡟࢔ࣉ࣮ࣟࢳ࡟ࡼࡗ࡚⭌⭡➽እഃ㢌ࡀඃ఩࡟άືࡋࠊ

⑕౛ 4 ࡛ࡣ๓⬯㦵➽ࠊ⭌⭡➽እഃ㢌ࡑࢀࡒࢀࡢ➽ά

⑕౛ 1 ࡜ࡣ཯ᑐ࡟๓⬯㦵➽ࡢ㐲ᚰᛶ཰⦰ࡲࡓࡣᢚไ࡟

ື࡟┦㛵ࡣㄆࡵࡿࡀ᭷ពᕪࡣ࡞࠿ࡗࡓࠋ㸦 ๓⬯㦵➽

ാࡃࡇ࡜࡟ࡼࡗ࡚ COP ࡀ๓᪉࡬⛣ືࡋࡓࠋ㌟య㉁㔞୰U 
㸦p>0.05㸧 ᭷ ព F 0.14ࠉ ⭌ ⭡ ➽ እ ഃ 㢌 r=0.94

ᚰࡣᚋ᪉࡬ຍ㏿ࡍࡿࡓࡵࠊᚋ᪉ࣂࣛࣥࢫඃ఩ࡢጼໃᡓ

㸦p>0.05㸧᭷ព F 0.014㸧

␎ࢆྲྀࡗ࡚࠸ࡿࡇ࡜ࡀ♧၀ࡉࢀࡿࠋࡼࡗ࡚Ⓨ⑕ึᮇࡣ๓

⑕౛ 1 ࡢ BIT ึᅇ᳨ᰝ࡛ࡣ㏻ᖖ᳨ᰝ ࠊ⾜ື⬯㦵➽ࢆ౑⏝ࡋࡓ๓᪉ࣂࣛࣥࢫᡓ␎࡛࠶ࡗࡓࡀࠊ⭌⭡᳨ᰝ  ࢆ♧ࡋࠊ3 ࠿᭶᫬Ⅼ࡛ࡣ㏻ᖖ᳨ᰝ 123/146ࠊ➽እഃ㢌ࡢ➽άື࡟ኚ໬ࡀ⏕ࡌࡓࡓࡵࠊ⭌⭡➽እഃ㢌⾜ື᳨ᰝ  ࡜࡞ࡾ㏻ᖖ᳨ᰝᚓⅬࡢῶᑡࢆㄆࡵࡓࠋ

ࢆ౑⏝ࡋࡓᚋ᪉ࣂࣛࣥࢫᡓ␎࡜࡞ࡗࡓྍ⬟ᛶࡀ࠶ࡿࠋ

⑕౛ 2 ࡢ BIT ึᅇ᳨ᰝ࡛ࡣ㏻ᖖ᳨ᰝ 140/146ࠊ⾜ື᳨⑕౛ 1 ࡛ࡣⓎ⑕࠿ࡽࡢ᫬㛫⤒㐣࡟క࠸๓⬯㦵➽ࡢ➽ᰝ  ࢆ♧ࡋࠊ3 ࠿᭶᫬Ⅼ࡛ࡣ㏻ᖖ᳨ᰝ 141/146ࠊ⾜άື࡟ቑຍࢆㄆࡵࠊ⭌⭡➽እഃ㢌ࡢάືࡣῶᑡࡋࡓࠋື᳨ᰝ ࡜࡞ࡾࠊ
ྛ᳨ᰝ㡯┠࡛ 1 Ⅼࡢቑຍࢆㄆࡵࡓࠋ

⑕౛ 3 ࡛ࡣ཯ᑐ࡟⬯㦵➽ࡢ➽άືࡀῶᑡࡋࠊ⭌⭡➽እഃ㢌ࡢ➽άືࡀቑຍࡋࡓࠋ
ࡇࢀࡣྛ⑕౛࡟ࡼࡾ❧఩ࣂࣛࣥࢫࡢ᪉␎ࡀ␗࡞ࡗ࡚࠸㸬⪃ᐹᮏ◊✲ࡣ USN ࢆ᭷ࡍࡿᝈ⪅ࡢṌ⾜㛤ጞ᫬࡟࠾ࡅࡿ

ࡿࡀࠊ┦཯⚄⤒ᢚไ㸦㕥 ,2002㸧࡟ࡼࡗ࡚▮≧㠃ୖ࡛ࢥࣥ

㠀㯞⑷ഃୗ⫥➽άືࢆࠊ➽㟁ᅗ࡟࡚ ᐃࡋࠊBIT ᚓⅬࢺ࣮ࣟࣝࡉࢀࠊጼໃไᚚࡀኚ໬ࡋࡓࡇ࡜ࡀ⪃࠼ࡽࢀࡿࠋ

࡜➽㟁ᅗ࡜ࡢ┦㛵ࢆ᫂ࡽ࠿࡟ࡍࡿࡇ࡜࡛ࠊ㏥㝔ᚋࡢ㌿ಽࡇࡢ᫬ࠊ⭌⭡➽እഃ㢌࡜๓⬯㦵➽ࡣ୺ືస➽࡜ᣕᢠண㜵ࡸ⮬୺ࢺ࣮ࣞࢽࣥࢢࡢᥦ᱌ࠊᐙᒇ⎔ቃࡢタᐃࡢ୍➽ࡢ㛵ಀ࡟࠶ࡿࠋ୺ືస➽࡜ᣕᢠ➽ࡢ㛵ࢃࡾࢆ⪃࠼ࡿຓ࡜ࡍࡿࡓࡵ࡟⾜ࡗࡓࠋࡑࡢࡓࡵ༙ഃ✵㛫↓どࡀṌ⾜᫬࡟ᚲせ࡞⚄⤒ᢚไࡣ┦཯⚄⤒ᢚไ࡛࠶ࡿࠋ┦཯⚄⤒㛤ጞືస࡟ᙳ㡪ࢆཬࡰࡍ⌮⏤ࢆ⪃ᐹࡋࠊࡑࡢ୰࡛㠀㯞ᢚไ࡜ࡣ୺ືస➽ࡢồᚰ⥺⥔㸦Ϩ a ⥺⥔㸧ࡀᣕᢠ➽ࡢ⑷ഃୗ⫥ࡣ࡝ࡢࡼ࠺࡞άືࡀồࡵࡽࢀ࡚࠸ࡿࡢ࠿ࢆ⪃ᐹồᚰ⥺⥔ࡢࢩࢼࣉࢫ࡟ࠊࢩࢼࣉࢫ๓ᢚไ࡜ࡋ࡚⤖ྜࡋࡍࡿࠋࡲࡓࠊ⑕౛࡟ᑐࡍࡿ⪃ᐹ࠿ࡽᚓࡽࢀࡓࡇ࡜ࢆ⏝࠸ᣕ ᢠ ➽ ࡢ ⬨ 㧊 ⚄ ⤒ ᶵ ᵓ ࢆ ᢚ ไࡉࡏࡿࡇ࡜࡛࠶ࡿ

࡚ࠊ⮬Ꮿ㏥㝔ᚋࡢ⎔ቃタᐃࡸ⮬୺ࢺ࣮ࣞࢽࣥࢢ࡟ࡘ࠸࡚

㸦㕥 ,2002㸧ࠋࡇࡢࡼ࠺࡟෇⁥࡞➽⥭ᙇࡢࢥࣥࢺ࣮ࣟ
㸦ᚋࡶ⪃ᐹࡋࡓࠋ

⸨ 2010㸧࡜ COP ࡢ๓ᚋᡂศࡀ⛣ື㸦ᒣ ,2010ࠊᒣ ࠊ

௒ᅇࡢ⑕౛ࡣ⌮Ꮫ⒪ἲ௨እ࡟సᴗ⒪ἲࠊゝㄒ⒪ἲ

బ⸨ ,2016㸧ࡍࡿࡇ࡜࡟ࡼࡗ࡚ࠊ๓⬯㦵➽࣭⭌⭡➽እഃࢆ㏻ᖖ㏻ࡾẖ᪥ 9 ༢఩᪋⾜ࡋ࡚࠾ࡾࠊࡑࢀࡽࡢ USN ࡟㢌࡟᫬㛫ⓗኚ໬ࡀぢࡽࢀࡓ࡜᥎ᐹࡍࡿࠋࡲࡓṌ⾜㛤ጞᑐࡍࡿᙳ㡪ࡣ࡞࠸࡜ࡣゝ࠼࡞࠸ࠋࡋ࠿ࡋ௒ᅇࡣ௓ධ᪉᫬ ࡢ ຊ Ꮫ ⓗ ≉ ᚩ ࡜ࡋ࡚ COP ࡢ ᚋ ᪉ ⛣ ື ࡀ ࠶ ࡿἲ࡟ࡼࡿ➽㟁ᅗኚ໬ࢆㄪᰝࡋࡓࡶࡢ࡛ࡣ࡞ࡃࠊ࠶ࡃࡲ࡛

㸦బ ,2016㸧ࠋࡇࢀࡣ㟼Ṇ❧఩᫬࡟ࡣ㌟య㔜ᚰࡢ┿ୗ࡟༙ഃ✵㛫↓どࡢ⤒᫬ⓗኚ໬ࢆㄪᰝࡋࡓࡶࡢ࡛࠶ࡿࠋ

COP ࡀ఩⨨ࡋࠊຊᏛⓗ࡟Ᏻᐃࡋࡓ≧ែ࠿ࡽᗏᒅ࣮࣓ࣔ
ࣥࢺࡀ⦆ࡲࡿࡇ࡜࡛ COP ࡀᚋ᪉࡬⛣ືࡋࠊࡇࢀ࡟ࡼࡗ

9.1. ⑕౛ 1ࠊ⑕౛ 3 ࡢ⤖ᯝ࡟ᑐࡍࡿ⪃ᐹ

࡚㌟య㔜ᚰ࡟ᑐࡋ࡚๓᪉࡬ࡢᅇ㌿࣮࣓ࣔࣥࢺࡀ⏕ࡌࠊ㌟

⑕౛ 1 ࡢⓎ⑕ึᮇ࡛ࡣ⭌⭡➽እഃ㢌ࡣ๓⬯㦵➽࡜ẚయ 㔜 ᚰ ࡀ ๓ ᪉ ࡬ ᢲࡋ ฟࡉࢀ Ṍ ⾜ ࡀ 㛤 ጞࡉࢀ ࡿ㍑ࡋඃ఩࡟άືࡋ࡚࠾ࡾࠊ๓⬯㦵➽࡟㐲ᚰᛶ཰⦰࣭ᢚ

㸦ᒣ ,2010㸧ࠋᨭᣢ⬮࡬㋖Ⲵ㔜ࢆ⾜࠺࡟ࡣࠊ⬯㦵ࢆᚋഴไࡀാ࠸࡚࠸ࡿ≧ែ࡛࠶ࡾࠊᗋ཯ຊస⏝Ⅼ㸦Ύ 㸧ࡉࡏ㊊㛵⠇ᗏᒅ఩ࡢ࣏ࢪࢩࣙࣥ࡬⛣⾜ࡍࡿᚲせࡀ࠶ࡿࠋ㸦௨ୗ Center Of Pressure㸧ࡀ๓᪉࡬఩⨨ࡋ࡚࠸ࡓ࡜⪃࠼ᗏᒅ࣮࣓ࣔࣥࢺࡀ⦆ࡲࡿ࡜ࡁࡣ⭌⭡➽እഃ㢌ࡀࠊ๓᪉ࡽࢀࡿࠋᚎࠎ࡟࢔ࣉ࣮ࣟࢳ࡟ࡼࡗ࡚๓⬯㦵➽ࡀඃ఩࡟࡬యᖿࢆᅇ㌿ࡉࡏࡿ࡜ࡁࡣ๓⬯㦵➽ࡀస⏝ࡋࠊ᣺ฟ࡜࡞

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ࡿࠋྛ⑕౛࡜ࡶ㌟యࡢ཯ᛂ࡟㐪࠸ࡀ࠶ࡿࡀࠊ㔜ᚰ⛣ືࢆྲྀࡗ࡚࠸ࡿྍ⬟ᛶࡀ࠶ࡿࠋࡇࡢࡼ࠺࡞ጼໃ࡛ࡣ㯞⑷ഃ

ࡢ㝿ࡢᡓ␎࡟࠾ࡅࡿ≉␗ᛶ࡜⪃࠼ࡽࢀࡿࢆㄆ㆑ࡉࡏࡿࡇ࡜ࡣᚲ↛ⓗ࡟㞴῰ࡍࡿࠋḟ࡟㠀㯞⑷ഃ࡜ࡢ㛵㐃ᛶࢆ⪃ᐹࡍࡿࠋࡶ࡜ࡼࡾ➽⥭ᙇ

㯞⑷ഃࢆㄆ㆑ࡍࡿࡓࡵ࡟ࡣ㌟యᅗᘧࡀ୙ྍḞ࡛࠶ࡿ࡜ࡣ⚄⤒⏕⌮Ꮫⓗ࡟⚄⤒ᨭ㓄ࡉࢀ࡚࠸ࡿ➽࡟ᣢ⥆ⓗ࡟㸦⏣ ,2009㸧ࠋ㌟యᅗᘧ࡜ࡣ㌟యྛ㒊఩࡜௚ࡢ㒊఩ࡸ⎔⏕ࡌ࡚࠸ࡿ➽ࡢ୍ᐃࡢ⥭ᙇ≧ែࠊࡶࡋࡃࡣከᩘࡢ➽⥺ቃ࡜ࡢ㛵ࢃࡾࢆㄆ㆑ࡍࡿࡇ࡜࡛࠶ࡿ㸦⏣ ,2009㸧ࠋ✵㛫⥔ࡢ཰⦰ࡢຍ㔜㸦㬞 ,2002㸪ෆᅬ ,2001㸧࡜ᐃ⩏ࡉࢀ࡚࠸

࡟࠾ࡅࡿ㌟య఩⨨ࢆ▱ࡿࡓࡵ࡟ࡣࠊ㌟య඲యࡢឤぬჾࡿࠋ➽⥭ᙇࡣ⏕యࡢጼໃಖᣢᶵᵓ࡟㛵୚ࡋ㐠ື࠶ࡿ࠸ᐁ࠿ࡽࡢ᝟ሗࢆ⤌⧊໬ࡋ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋయᛶឤぬࡣጼໃಖᣢࡢ㝿࡟άືࡍࡿ㦵᱁➽ࡢ‽ഛ≧ែ࡟㔜せ࡞㸦ᅛ᭷ཷᐜჾ࣭⓶⭵ཷᐜჾ࣭㛵⠇ཷᐜჾ㸧ࠊどぬࠊ๓ព࿡ࢆᣢࡘ࡜ࡉࢀ࡚࠸ࡿࠋ୍⯡࡟ࠊ୍ḟ㐠ື㔝࡟ጞࡲᗞឤぬ࠿ࡽࡢ᢯ᾘධຊࡀࠊ㔜ຊཬࡧ⎔ቃ࡜ࡢ㛵ಀࡶ⤫ࡿ㗹య㊰㸦⓶㉁⬨㧊㊰㸧ࡢ኱㒊ศࡣᘏ㧊ୗ➃࡛ᕥྑࡀྜࡋ࡚ࠊࡑࢀࡒࢀ≉᭷࡞᝟ሗࢆࣇ࢕࣮ࢻࣂࢵࢡࡋ࡚࠸ࡿ

஺ཫࡋ࡚཯ᑐഃࡢഃ⣴ࢆୗ⾜ࡍࡿ㸦እഃ⓶㉁⬨㧊㊰㸧㸦⏣ ,2009㸧ࠋᨭᣢᇶᗏ㠃ࡢᏳᐃࡶ㌟యᅗᘧ࡜⮬ᕫࢆྲྀࡀࠊ୍㒊ࡢ⥺⥔ࡣᘏ㧊࡛஺ཫࡍࡿࡇ࡜࡞ࡃྠഃࡢ๓⣴ࡾᕳࡃ⎔ቃࡢ⌮ゎࡢୖ࡟ᡂࡾ❧ࡘ㸦ᚋ⸨ 㸧ࠋࢆୗ ⾜ ࡍࡿ㸦 ๓ ⓶㉁ ⬨ 㧊 ㊰ 㸧ࡇ࡜ࡀ ▱ࡽࢀ࡚ ࠸ࡿ௨ୖࡢࡇ࡜࠿ࡽ㯞⑷ഃ࡟ᑐࡋ࡚㐺ษ࡞యᛶឤぬධຊ㸦Martin,1996㸧ࠋࡘࡲࡾᦆയ༙⌫ഃ࠿ࡽྠഃ࡟ୗ⾜ࡍࡀᅗࢀࡿⲴ㔜カ⦎ࡸṌ⾜カ⦎ࢆ⾜࠺ࡇ࡜ࡣࠊ㠀㯞⑷ഃ

ࡿ⚄⤒⥺⥔ࡀᏑᅾࡍࡿ࡜࠸࠺ࡇ࡜ࡣࠊ㠀㯞⑷ഃୖୗ⫥ୗ⫥ࡢ➽άືࢆῶᑡࡉࡏࠊ㯞⑷ഃ࡟ᑐࡍࡿㄆ㆑ࡀᨵၿ

ࡣᦆയ༙⌫ࡢ๓⓶㉁⬨㧊㊰ࡢᨭ㓄ࢆཷࡅ࡚࠸ࡿࡇ࡜࡟

ࡉࡏࡿྍ⬟ᛶࡀ࠶ࡿࡇ࡜ࢆ♧၀ࡋࡓࠋ࡞ࡿࠋࡇࡢ⚄⤒⥺⥔ࡣ㝶ព㐠ືࢆᐇ⾜ࡍࡿእഃ⓶㉁⬨
㧊㊰࡜ࡣ␗࡞ࡾࠊጼໃಖᣢࡸ➽⥭ᙇࡢࢥࣥࢺ࣮ࣟࣝࢆᢸ

9.3. ⮬Ꮿ㏥㝔ᚋࡢ⎔ቃタᐃ࣭⮬୺ࢺ࣮ࣞࢽࣥࢢ⪃᱌࡟ࡘ࠺㸦ᒣ 㸧ࠋࡼࡗ࡚㠀㯞⑷ഃࡣጼໃಖᣢࡸ➽࡟㞀ᐖ࠸࡚ࡢ⪃ᐹࡀ⏕ࡌࡿྍ⬟ᛶࡀ㧗࠸ࡇ࡜ࡀ᥎ᐹࡉࢀࡿࠋ

⑕౛ 1.3 ࡛ࡣ࢔ࣉ࣮ࣟࢳ๓ᚋ࡛๓⬯㦵➽࣭⭌⭡➽እࡇࡢࡇ࡜࠿ࡽ USN ᝈ⪅࡟ᑐࡋ࡚㯞⑷ഃࢆ᣺ฟࡍࡼ࠺

ഃ㢌ࡢ➽άື࡟ቑຍ࣭ῶᑡࡀ㉳ࡇࡾࠊCOP ࡀ⛣ືࡍࡿ࡞ࠊ㠀㯞⑷ഃ࡟ጼໃಖᣢࡸ෇⁥࡞➽⥭ᙇࡢኚ໬ࢆồࡵࡇ࡜࡟ࡼࡗ࡚❧఩࡛ࡢጼໃไᚚࡢ᪉␎࡟ኚ໬ࡀ⏕ࡌࡓࠋࡿࡇ࡜ࡣࠊ⑕౛ 1.3 ࡢࡼ࠺࡟ᕪࡣ࠶ࡿࡀ㠀㯞⑷ഃୗ⫥➽⑕౛ 2 ࡛ࡣ୧➽࡛➽άືࡢῶᑡࡋࡓࡇ࡜࡛ࠊ㯞⑷ഃୗ

άືࡢῶᑡࡶࡋࡃࡣቑຍ࡜࠸ࡗࡓኚ໬ࢆࡶࡓࡽࡍྍ⬟ᛶ⫥࡬Ⲵ㔜ࡀಁ㏻ࡉࢀ㯞⑷ഃࡢㄆ㆑㸦㌟యᅗᘧ㸧ࢆᨵၿࡀ࠶ࡿࠋࡉࡏࡓྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋࡼࡗ࡚ COP ࡢ⛣ືࠊ㯞⑷ഃୗ⫥࡬ࡢⲴ㔜ཬࡧ㌟యᅗᘧࡢᨵၿࡀ㔜せ࡜⪃࠼ࡿࠋ

9.2. ⑕౛ 2 ࡢ⤖ᯝ࡟ᑐࡍࡿ⪃ᐹᅾᏯ࡛ࡢ⎔ቃタᐃ࡛ࡣ㯞⑷ࡢṧᏑࡶ⪃៖ࡋࠊᒇෆࡢ

⑕౛ 2 ࡣ๓⬯㦵➽࣭⭌⭡➽እഃ㢌ࡢ୧➽࡜ࡶ࡟ィ⛣ືࡣ⊂Ṍ࡛ࡣ࡞ࡃఏ࠸Ṍࡁࢆฟ᮶ࡿࡼ࠺࡞⎔ቃࢆ᥎ዡึᮇࡼࡾ᭱⤊ィ ᫬➽άືࡢῶᑡࢆㄆࡵࡓࠋࡇࢀࡣ㠀ࡋࡓ࠸ࠋࡋ࠿ࡋࠊUSN ࢆⓎ⑕ࡋ࡚࠸࡞࠸⬻⾑⟶㞀ᐖᝈ

㯞⑷ഃࡢ➽⥭ᙇࡀᨵၿࡋࠊ㯞⑷ഃ࡬Ⲵ㔜ࡀಁ㏻ࡉࢀࡓ

⪅ࡶఏ࠸Ṍࡁ࡛⏕άࡍࡿࡇ࡜ࡶ࠶ࡿࡓࡵࠊUSN ≉᭷ࡢࡇ࡜ࡀ⪃࠼ࡽࢀࡿࠋ

㌿ಽண㜵ࢆᥦ᱌ࡍࡿࠋ

㠀㯞⑷ഃୗ⫥ཬࡧయᖿࡢ➽⥭ᙇࢆ㧗ࡵࡓ≧ែࠊࡘࡲ

USN ࡣ㌟య㒊఩ࡢ✵㛫ⓗ࡞఩⨨㛵ಀᛶࢆ㐺ṇ࡟ㄆࡾෆ㒊ᅛᐃࢆᙉࡵࡿࣂࣛࣥࢫᡓ␎ࢆ㑅ᢥࡋ࡚࠸ࡿ≧ែ㆑ࡍࡿࡇ࡜ࡀ࡛ࡁࡎࠊ㌟యࡢᆶ┤ᛶ࣭ᑐ⛠ᛶࢆከឤぬ࡛ࡣࠊ㯞⑷ഃᨭᣢ㠃࡬ࡢⲴ㔜ࡣᅔ㞴࡛࠶ࡾ୙㐺ษ࡞ᅛⓗ ࡟ ⤫ ྜ ࡍࡿࡇ࡜ ࡀ ࡛ ࡁ ࡞ ࠸࡜ࡉ ࢀ࡚ ࠸ ࡿ㸦 ᚋ᭷ཷᐜឤぬ࡛࠶ࡿࠋFay㸦Fay2006㸧࡟ࡼࡿ࡜ࣄࢺࡣᏳᐃ⸨ 㸧ࠋጼໃࢆ⥔ᣢࡍࡿࢫࢺࣛࢸࢪ࣮࡜ࡋ࡚どぬⓗࡋࡓᨭᣢ㠃ୖ࡛ࡣయᛶឤぬ ࠊ๓ᗞឤぬ 20%ࠊど࡞ᡭࡀ࠿ࡾࡸࠊ㠀㯞⑷ഃ㌟య࡟ㄗࡗ࡚ධຊࡉࢀࡿయᛶ

ぬ 10% ࡜࠸࠺๭ྜ࡛ࣂࣛࣥࢫࢆಖࡗ࡚࠾ࡾࠊ⎔ቃኚ໬ឤぬ᝟ሗࢆཧ↷ࡋ࡚ࠊ㠀㯞⑷ഃୖୗ⫥ࢆ㐣๫࡟౑⏝ࡍ㸦ᬯ㜌ࠊ୙Ᏻᐃ࡞ሙᡤ࡞࡝㸧࡟ᛂࡌ࡚ࠊࡇࢀࡽࡢ๭ྜࢆ

ࡿሙྜࡀከ࠸࡜ࡶሗ࿌ࡉࢀ࡚࠸ࡿࠋ

ᰂ㌾࡟ኚ໬ࡉࡏ࡚࠸ࡿ࡜ࡋ࡚࠸ࡿࠋࡼࡗ࡚ࠊ㐣ᗘ࡞㠀㯞ᒣ⏣ࡽࡣ⦪ᡭࡍࡾ࡟ࡼࡿ❧఩カ⦎ࡀ㠀㯞⑷ഃୖୗ⫥⑷ഃ࠿ࡽࡢឤぬࣇ࢕࣮ࢻࣂࢵࢡࡣࠊ➽⥭ᙇ᝟ሗࡔࡅ࡛࡞

ࡢ➽άືࢆᢚไ࡛ࡁࡓࡇ࡜ࢆሗ࿌ࡋ࡚࠸ࡿࠋ⦪ᡭࡍࡾ⮬ࡃࠊどぬࡸ๓ᗞぬ࠿ࡽࡢ᝟ሗࡶኚ໬ࡍࡿࠋ

యࡀ㌟యࡢᆶ┤ᣦᶆ࡜࡞ࡿࡇ࡜ࠊ㠀㯞⑷ഃୖ⫥࡛⦪ᡭ

USN ࡛ࡣ㠀㯞⑷ഃ࡬ྥࡅࡓ㢌㢁㒊࡟ࡼࡾࠊ㢌㒊ࡢ఩ࡍࡾ࡟యᖿࢆᘬࡁࡘࡅࡿࡼ࠺࡟⫝㛵⠇ᒅ᭤᪉ྥ࡟ຊࢆධ

⨨ࡀᅛᐃࡉࢀ୕༙つ⟶ࡸ๓ᗞჾᐁࡢാࡁࡀపୗࡋࠊ㔜ࢀࡿࡇ࡜࡛ୖ⫥ࡢఙᒎືసࢆᢚไฟ᮶ࡿࡇ࡜ࠊཬࡧ⦪

ᚰ఩⨨ࡢኚ໬ࡸຍ㏿ᗘࢆ᳨▱㸦ᚋ ,2005㸧ࡍࡿࡇ࡜ࡀᅔ

ᡭࡍࡾࢆᡭ᥃ࡾ࡟㝶ពⓗ࡟❧఩ࢆ࡜ࡿࡇ࡜࡛㠀㯞⑷ഃୗ

㞴࡜࡞ࡿࠋࡑࡢࡓࡵどぬࡸ➽⥭ᙇ࡟౫Ꮡࡋࡓጼໃᡓ␎

⫥࡬ࡢ㔜ᚰ⛣ືࡸⲴ㔜ࡀྍ⬟࡜࡞ࡾṇ୰໬ࡀᅗࡿࡇ࡜

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

⣴ᑐ㇟ࢆ㑅ᢥ࡛ࡁ࡞࠸ࠊࡶࡋࡃࡣ㑅ᢥࡋᛀࢀࡿࠊᾘࡋ

ࡀฟ᮶ࡿ࡜ሗ࿌ࡋ࡚࠸ࡿ㸦ᒣ⏣ ,2010㸧ࠋ⑕౛ 1.3 ࡢ⪃ᐹ࡛ࡣ㠀㯞⑷ഃ๓⬯㦵➽ࠊ⭌⭡➽እഃࡓᩥᏐࢆఱᗘࡶ᢯ᾘࡍࡿ࡜࠸ࡗࡓ⾜ືࡀึᅇ᫬ࡼࡾከࡃ

㢌ࡢ➽άືࡢቑῶࡀࠊ❧఩࡟࠾ࡅࡿጼໃไᚚࡢ᪉␎ࢆ

ぢཷࡅࡽࢀࡓࠋHalligan
㸦Halligan,1989㸧ࡣࠊ᥈⣴ㄢ㢟ኚ໬ࡉࡏࡓࡇ࡜ࠊ⑕౛ 2 ࡢ⪃ᐹ࡛ࡣ㠀㯞⑷ഃୗ⫥ࡢ➽࡟ࡣ඲⯡ᛶὀព㞀ᐖࡢᙳ㡪ࢆཷࡅࡸࡍࡃࠊ᥈⣴ࢆᅔ㞴άືࡀῶᑡࡍࡿࡇ࡜࡛㯞⑷ഃ࡬Ⲵ㔜ࡀಁ㏻ࡉࢀࡓࡇ࡜

࡟ࡍࡿࣀ࢖ࢬࡀከࡃ࡞ࡿࡇ࡜࡛↓ど✵㛫ࡢぢⴠ࡜ࡋࡀከ

ࡀ⪃࠼ࡽࢀࡓࠋඛ⾜◊✲࠿ࡽ⦪ᡭࡍࡾࡢ౑⏝ࡣࠊ㠀㯞ࡃ࡞ࡿ࡜ሗ࿌ࡋ࡚࠾ࡾࠊGassama
㸦Gassama,2011㸧ࡣぬ㓰⑷ഃୗ⫥࡛ࡢ㔜ᚰ⛣ືࡸᆶ┤ᣦᶆ࡜࡞ࡾ㌟యᅗᘧࡢ୍

ྥୖ࡟క࠺඲⯡ᛶὀពᶵ⬟ࡢᨵၿࡀ↓ど⑕≧࡟࠾ࡅࡿຓ࡜࡞ࡿࡇ࡜࠿ࡽࠊᮏ◊✲ࡢ⪃ᐹ࡜ྜ⮴ࡍࡿ㒊ศࡀ࠶ࡿࠋ

ᅇ᚟࡟ᙳ㡪ࡍࡿࡇ࡜ࢆ♧၀ࡋ࡚࠸ࡿࠋࡇࢀࡽࢆ⪃៖ࡍࡿᚑࡗ࡚⮬Ꮿෆ࡛⦪ᡭࡍࡾࢆ⏝࠸࡚❧఩ࢆక࠺ࡼ࠺࡞ືస

࡜ࠊ᳨ᰝ᫬ࡢᝈ⪅ࡢព㆑≧ែࡸ⢭⚄≧ែࡀᙳ㡪ࡋึᅇ㸦ࢻ࢔ࡢ㛤㛢ࡸࢺ࢖ࣞෆ࡛ࡢୗ⾰╔⬺ࠊṌ⾜㛤ጞ᫬㸧ࢆ

᫬ࡼࡾ 3 ࠿᭶᫬ࡢⅬᩘࡀῶᑡࡋࡓྍ⬟ᛶࡀ࠶ࡿࠋࡲࡓ⾜࠺㝿࡟ࡣࠊ㠀㯞⑷ഃୗ⫥࡛ࡢ෇⁥࡞㔜ᚰ⛣ືࡸࠊど

Azouvi㸦Azouvi,2002㸧ࡽࡣ᥈⣴㛤ጞ఩⨨ࡢホ౯ࡢ㔜せぬ࠿ࡽᆶ┤ᛶࢆᥦ♧ࡍࡿࡇ࡜࡛㌟యᅗᘧ⏕ᡂࡢ୍ຓ࡜

ᛶࡶ㏙࡭࡚࠸ࡿࡓࡵࠊⅬᩘࡢࡳ࡞ࡽࡎ㉁ࡢホ౯ࡀ㔜せ࡞ࡾࠊ㌿ಽண㜵࡟㛵୚ࡍࡿྍ⬟ᛶࡀ࠶ࡿࠋ

࡛࠶ࡿࡇ࡜ࡀ⪃࠼ࡽࢀࡿࠋ㔜ࡡ᭩ࡁࡍࡿࡼ࠺࡞⑕≧ࡣྑ⮬୺ࢺ࣮ࣞࢽࣥࢢࡶྠᵝ࡟ࠊ㠀㯞⑷ഃୗ⫥ࡢ COP ⛣✵㛫ࡢ㐣๫࡞ὀព㓄ศࡸὀពࡢᢚไࠊど✵㛫࣮࣡࢟ࣥື࡟ࡼࡿࣂࣛࣥࢫカ⦎ࠊ㯞⑷ഃ࡬Ⲵ㔜ࢆಁ㏻ࡋ㠀㯞⑷ࢢ࣓ࣔࣜࡢ ೵ ⁫ ࡞ ࡝ ࡀ ྜ ే ࡋ࡚ ࠸ ࡿ ࡜ Doricchiഃ࠿ࡽࡢ㐣๫࡞యᛶឤぬ᝟ሗࢆಟṇࡋ࡚࠸ࡃࡇ࡜ࡀ㔜㸦Doricchi,2003㸧ࡽࡣሗ࿌ࡋ࡚࠸ࡿࠋࡇࢀࡽࡢࡇ࡜࠿ࡽ

せࡔ࡜⪃࠼ࡿࠋࣄࢺࡣᏳᐃࡋࡓᨭᣢ㠃ୖ࡛ࡣయᛶឤぬ༢⣧࡞↓ど⑕≧ࡔࡅ࡛࡞ࡃࠊUSN ࡟ࡣ඲⯡ᛶὀពᶵࠊ๓ᗞឤぬ 20%ࠊどぬ 10% ࡜࠸࠺๭ྜ࡛ࣂࣛࣥࢫ

⬟పୗࠊ㐣๫࡞ศ㓄ᛶὀពࠊ࣮࣡࢟ࣥࢢ࣓ࣔࣜపୗ➼ࠊࢆಖࡗ࡚࠸ࡿࡇ࡜㸦Fay2006㸧࠿ࡽࠊ㠀㯞⑷ഃࡢࡳ࡟㢗ࡗ

ከᵝ࡞ྜే⑕≧ࡀ⏕ࡌࡿ㸦ᘪỌ ,2005㸧ࡇ࡜ࡀ᥎ᐹࡉࢀࠊࡓయᛶឤぬ࣭どぬ࣭๓ᗞឤぬ᝟ሗ࡛ࡣࠊ⮬ศࡢ㌟యࢆ

BIT ࡢࡳࡢホ౯࡛ USN ࡢᨵၿᗘࢆ ࡿࡢࡣ㝈⏺ࡀ࠶ࡿ⌮ゎࡍࡿୖ࡛ࡣ୙฼࡞≧ἣ࡜ゝ࠼ࡼ࠺ࠋࡋ࠿ࡋᮏ◊✲ྍ⬟ᛶࡀ࠶ࡿࠋ

࡛ࡣ௓ධෆᐜࢆㄪᰝࡋ࡚࠸࡞࠸ࡓࡵࠊ᫂☜࡞ᥦ♧ࡣฟ

BIT ࡣㄢ㢟ᐇ᪋᫬ࡢぢⴠ࡜ࡋࢆῶⅬἲ࡟࡚᥇Ⅼࡋ࡚᮶࡞࠸ࠋᚓࡽࢀࡓࢹ࣮ࢱ࠿ࡽゝ࠼ࡿࡇ࡜ࡣ㠀㯞⑷ഃࡢ

࠾ࡾࠊ᥈⣴࡟せࡋࡓᡤせ᫬㛫ࡸ㑅ᢥ᪉␎➼ࢆ⪃៖ࡋ࡚

COP ࢆ▮≧㠃ୖ࡛ࢥࣥࢺ࣮࡛ࣟࣝࡁࡿࡇ࡜ࠊ㯞⑷ഃⲴ㔜

࠸࡞࠸ࠋUSN ࡢ⑓ែᇶ┙࡜ࡋ࡚ど✵㛫ᛶὀពࢿࢵࢺ࣮࣡

ࢆ✚ᴟⓗ࡟㐍ࡵࠊከ✀ࡢឤぬࢆ⤫ྜࡍࡿࡇ࡜ࡣࠊUSNࢡࡢ㞀ᐖ࡜ࡉࢀ࡚࠸ࡿࠋ✵㛫ᛶὀព࡟ࡣ⬟ືⓗ࣭ཷືᝈ⪅࡟࡜ࡗ࡚ᚲせ࡞⮬୺ࢺ࣮ࣞࢽࣥࢢ࡛࠶ࡿ࡜⪃࠼ࡽࢀⓗࡢ 2 ࡘࡢὀពࡀᏑᅾࡋ␗࡞ࡿ⚄⤒ᅇ㊰ࢆᣢࡘࠋ⬟ືࡿࠋⓗὀពࡣ BIT ࡀヲ⣽࡟ホ౯ྍ⬟࡛࠶ࡿࡀࠊእⓎⓗ࡞่⃭࡟ᛂ⟅ࡍࡿ➼࡟≉ᚩ࡙ࡅࡽࢀࡿཷືⓗὀពࢆホ౯

9.4.BIT ᚓⅬ࡜➽㟁ᅗࡢ⤒᫬ⓗኚ໬࡟ᑐࡍࡿ⪃ᐹࡍࡿ࡟ࡣ㝈⏺ࡀ࠶ࡿࠋຍ࠼࡚ཷືⓗὀពࡢ೵⁫ࢆ⬟ື

BIT ᚓⅬࡣึᅇ࡜ 3 ࠿᭶ᚋࡢᚓⅬࡢ⤖ᯝ࠿ࡽ USN ࡟ⓗὀព࡟ࡼࡗ࡚ BIT ㄢ㢟ࢆ㐙⾜࡛ࡁࡿ⑕౛ࡣࠊ௦ൾᡓ

࠾ࡅࡿᅇ᚟㐣⛬ࡣࠊ᫬㛫⤒㐣࡜ඹ࡟⦆ᚎ࡛ࡣ࠶ࡿࡀᨵ

␎ࡢࡶ࡜࡛⾜࠺ࡓࡵṇ☜࡞ホ౯࡜ࡣゝ࠸㞴࠸ࠋ༶ࡕ BIT

ၿഴྥࢆࡓ࡝ࡿ౛࡜ࠊᅇ᚟࡟ኚືࡀ࠶ࡿ౛ࡀᏑᅾࡍࡿ

ᚓⅬࢆ㠀㯞⑷ഃୗ⫥➽㟁ᅗࡢ⤒᫬ⓗኚ໬ࢆ┦㛵ࡉࡏࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ

ࡇ࡜⮬యࡀࠊUSN ⑕≧ࢆຍ࿡ࡏࡎ࡟἞⒪⤒㐣ࢆ㏣࠺ࡇ

⑕౛ 2 ࡢ BIT ᚓⅬࡢኚ໬ࡀஈࡋ࠸ࡢࡣࠊึᅇ᫬࠿ࡽ
ᚓⅬࡀ㧗ࡃࠊᨵၿࡍࡿᖜࡀ⊃ᑠࡋ࡚࠸ࡿࡇ࡜ࡀ᰿ᗏ࡟࠶

࡜࡟࡞ࡿࡓࡵ⑓ែᢕᥱࡢⅬ࠿ࡽ㠀ᖖ࡟ࣜࢫࢡࢆక࠺ࡇ࡜
ࡀ᝿ീ࡛ࡁࡿࠋ

ࡿ࡜⪃࠼ࡿࠋࡋ࠿ࡋ Bonato
㸦Bonato,2012㸧ࡣㄢ㢟ࡢᏛ⩦௨ୖ࠿ࡽ USN ࡢᨵၿࢆ᫬㛫⤒㐣࡛ホ౯ࡋ࡚࠸ࡃ࡟

ຠᯝࡸ௦ൾᡓ␎ࡢᙳ㡪࡟ࡼࡾࠊ↓どࡀṧᏑࡋ࡚࠸࡚ࡶ

ࡣࠊBIT ࡔࡅ࡛࡞ࡃືసࡸጼໃ࠿ࡽࡶኚ໬ࢆ㏣࠸⥆ࡅㄢ㢟ᡂ⦼ࡣⰋዲ࡜࡞ࡿࡇ࡜ࡀ࠶ࡿ࡜㏙࡭࡚࠾ࡾࠊ୍ᴫ࡟ࡿᚲせࡀ࠶ࡾࠊⓎ⑕࠿ࡽࡢ᫬ᮇࡸྜే⑕ࢆ⪃៖ࡋ࡚

USN ࡣῶᑡࡋࡓ࡜ࡣゝ࠸㞴࠸ഃ㠃ࡶ࠶ࡿࠋྛ᳨ᰝ㡯┠

ADL ࡀᨵၿࡍࡿࡼ࠺࡟カ⦎ࢆ㐍ࡵ࡞ࡅࢀࡤ࡞ࡽ࡞࠸࡜

ࡣ࠸ࡎࢀࡶ࢝ࢵࢺ࢜ࣇࢆୖᅇࡗ࡚࠸ࡿࡀࠊ᪥ᖖ⏕άሙ㠃⪃࠼ࡿࠋ࡛ࡣ USN ⑕≧ࡀฟ⌧ࡍࡿࡓࡵࠊᮘୖ᳨ᰝ࡛ࡣ࡞ࡃື
సሙ㠃࠿ࡽ USN ࡢᨵၿ⤒㐣ࢆ㏣ࡗ࡚࠸ࡃࡇ࡜ࡀ㔜せ࡛

9.5.USN ࢆ᭷ࡉ࡞࠸㐠ື㯞⑷ᝈ⪅࡟ᑐࡍࡿ⪃ᐹ
⑕౛ 4 ࡣ๓⬯㦵➽࣭⭌⭡➽እഃ㢌ࡢ୧➽࡜ࡶ࡟➽άࡣ࡞࠸࠿࡜⪃࠼ࡿࠋ⑕౛ 1 ࡛ࡣ⾜ື᳨ᰝᚓⅬࡀῶᑡࡋ࡚࠾ࡾࠊ≉࡟ᩥᏐ
᢯ᾘ࡛ῶⅬࢆㄆࡵࡓࠋᐇ㝿ࡢ᳨ᰝሙ㠃࡛ࡣᕥ✵㛫ࡢ᥈ືࡢቑຍࢆㄆࡵࡓࠋࡇࢀࡣ㐠ື㯞⑷ࡢᅇ᚟㐣⛬࡟࠾ࡅࡿ㐃ྜ཯ᛂࡢຓ㛗ࢆ♧၀ࡋ࡚࠸ࡿ࡜⪃࠼ࡿࠋᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

㐃ྜ཯ᛂࡣ㠀㯞⑷ഃୖୗ⫥ࡢ㐣๫ດຊ࡟ࡼࡾࠊ㯞⑷㛵⠇㐠ືࢆ⾜࠺ࡼ࠺࡞ࠊ㠀㯞⑷ഃ࡜㯞⑷ഃࡢศ㞳ࡀᚲഃୖୗ⫥ࡢ②⦰ࡢ⛬ᗘࡀቑ኱ࡋࡓࡶࡢ࡜ࡋ࡚ゎ㔘ࡉࢀ࡚せ࡜⪃࠼ࡿࠋᚑࡗ࡚ᮏ◊✲ࡢㄢ㢟ࡢࡼ࠺࡟㯞⑷ഃୗ⫥࠸ࡿ㸦ᯇᒣ ,2003㸧ࠋࡲࡓጼໃ཯ᑕࡢஹ㐍㸦ゎᨺ⌧㇟㸧࡜ࡢ㝶ពᛶࢆồࡵࡿሙ㠃࡛ࡣࠊ㯞⑷ഃୗ⫥࡟࠾ࡅࡿ㝶ពࡶᤊ࠼ࡽࢀ࡚࠾ࡾࠊ㠀㯞⑷ഃୖୗ⫥ࡢດຊⓗ࡞㐠ືࡢᛶࡢᨵၿࡀஈࡋ࠸⑕౛࡟࡜ࡗ࡚ࠊ㠀㯞⑷ഃୗ⫥ࡢ㐣๫㝿࡟ᐃᆺⓗ࡞⫥఩࣭ࣃࢱ࣮ࣥ࡜࡞ࡗ࡚㯞⑷ഃୖୗ⫥࡟ฟດຊ࡟ࡼࡗ࡚ືసࢆ㐙⾜ࡋ࡞ࡅࢀࡤ࡞ࡽࡎࠊ᫬㛫⤒㐣࡜⌧ࡍࡿ㸦ᯇᒣ ,2003㸧ࠋඹྠ㐠ືࣃࢱ࣮ࣥ࡜ࡢ㐪࠸ࡣࠊ࡜ࡶ࡟➽⥭ᙇࡀቑຍࡋࡓྍ⬟ᛶࡀ࠶ࡿࠋ

ඹྠ㐠ືࡀୖ఩࣭ୗ఩⬨㧊㛫ࡢఙ➽࣭ᒅ➽ࢽ࣮ࣗࣟࣥ

USN ࢆ᭷ࡋ࡚࠸ࡿᝈ⪅ࡢሙྜࠊ㔜ᗘ῝㒊ឤぬ㞀ᐖ࡟ࡢ␗ᖖ࡞ࢩࢼࣉࢫ⤖ྜ㸦బஂ㛫 ,2013㸧࡟ࡼࡗ࡚ᘬࡁ㉳ࡇ

ࡼࡿ㌟యኻㄆࡸ㠀㯞⑷ഃୖୗ⫥࡛ࡢࣉࢵࢩ࣮ࣕ࡟௦⾲ࡉࢀࡿ㐠ື࡜ࡉࢀ࡚࠸ࡿࡢ࡟ᑐࡋࠊ㐃ྜ཯ᛂࡣྠ୍㧊ࡉࢀࡿ␗ᖖ࡞ጼໃ཯ᑕ㞀ᐖࠊ᪉ྥᛶὀពᶵ⬟ࡢ◚⥢࡟⠇࡟࠾ࡅࡿᕥྑᅄ⫥࡬ࡢάື㟁఩ࡀᨺᩓࡉࢀࡿάື

ࡼࡿ㠀㯞⑷ഃࢆྥࡅࡓ㢌㢁㒊࡞࡝ࠊ⑕≧ࡀ㠀㯞⑷ഃ࡬

㸦࣮࢜ࣂ࣮ࣇ࣮ࣟ㸧࡜ࡉࢀ࡚࠸ࡿࠋ㛵ಀࡍࡿ⤒㊰࡜ࡋ࡚ࠊ⾲ฟࡉࢀࡿࡇ࡜ࡀከࡃࠊ㯞⑷ഃ࡟ὀពࢆྥࡅࡿࡇ࡜ࡀᅔ

➽⥭ᙇஹ㐍࡟≉࡟ᙳ㡪ࢆ୚࠼ࡿ࡜ࡉࢀࡿୗ⾜ᛶ㐠ື㊰㞴࡛࠶ࡿࡇ࡜ࡀከ࠸ࠋࡑࡢࡓࡵ㠀㯞⑷ഃୖୗ⫥ࢆ❧఩ࡢ⓶㉁ ⬨ 㧊 ㊰࡜⥙ ᵝ య ⬨ 㧊 ㊰ࡀᣲࡆࡽࢀࡿ㸦 㧗ⲡࡸᗙ఩࡛෇⁥࡟᧯స࡛ࡁࡿ࠿ࠊ᪥ᖖ⏕άືసࡢ୰࡛㯞ᮌ 㸧ࠋ⑷ഃᶵ⬟ࢆ⿵ሸฟ᮶ࡿ࠿ࡀ㔜せ࡜࡞ࡿࠋࡼࡗ࡚㠀㯞⑷ᮏ◊✲ࡢㄢ㢟ࡣࠊࠕ㠀㯞⑷ഃୗ⫥࡛ᨭᣢࡋ㯞⑷ഃୗ⫥ഃ࡛ࡢ❧఩࣭ᗙ఩➼ࡢጼໃಖᣢ⋓ᚓࢆ┠ᶆ࡟カ⦎ࢆ㛤ࢆ᣺ࡾฟࡍࠖࡇ࡜࡛࠶ࡿࠋᚑࡗ࡚㯞⑷ഃୗ⫥࡟ࡣ⫤㛵⠇ጞࡍࡿᚲせࡀ࠶ࡿࡓࡵࠊ㯞⑷ഃ࡬ࡢ┤᥋ⓗ࡞௓ධࡣ㐜ᒅ᭤ࡸ⭸㛵⠇ᒅ᭤ࠊ㊊㛵⠇⫼ᒅ➼ࡢࠊྛ㛵⠇ࡀศ㞳ࡋᘏࡍࡿࡇ࡜ࡀぢ㎸ࡲࢀࡿࠋࡓ㝶ព㐠ື࡜༠ㄪᛶࡀồࡵࡽࢀࡿㄢ㢟࡜࡞ࡗ࡚࠸ࡿࠋ

USN ࢆ᭷ࡉ࡞࠸㐠ື㯞⑷ࡢሙྜࠊ㯞⑷ഃࢆㄆ㆑ࡋ࡚

㯞⑷ഃୗ⫥ࡢ㝶ពᛶࡀపୗࡋ࡚࠸ࡿ⑕౛࡛࠶ࢀࡤࠊࡼ

࠸ࡿሙྜࡀከࡃ㠀㯞⑷ഃୖୗ⫥࡟≉␗ⓗ࡞⑕≧ࡀฟࡿࡾᙉࡃ㠀㯞⑷ഃୗ⫥ࢆఙᒎࡉࡏࠊ㯞⑷ഃ㐟⬮ࡢࡓࡵ࡟༳㇟ࡣཷࡅ࡞࠸ࠋࡑࡢࡓࡵカ⦎ࡣ㯞⑷ഃ࡬ࡢ௓ධࡀྍ

ᗋ㠃࡟ᑐࡍࡿࢡࣜ࢔ࣛࣥࢫࢆ☜ಖࡋࡼ࠺࡜ࡍࡿᚲせࡀ࠶⬟࡜࡞ࡿࡓࡵࠊⓎ⑕ᙜึ࠿ࡽ✚ᴟⓗ࡞ಁ㏻カ⦎ࡀᐇ᪋ࡿࠋ୍ഃୖୗ⫥ࡢ㝶ព㐠ືࡣࠊᑐഃࡢ⬨㧊๓ゅ⣽⬊ࡢฟ᮶ࡿྍ⬟ᛶࡀ࠶ࡿࠋ

⯆ዧᛶࢆቑຍࡉࡏࠊᑐഃ➽⥭ᙇஹ㐍࡟ࡶᙳ㡪ࢆཬࡰࡍࡘࡲࡾ USN ࡢ᭷↓ࡣカ⦎ࣉࣟࢢ࣒ࣛࡢඃඛ㡰఩ࡀኚࡓࡵ㸦ᯇᒣ ,2003㸧ࠊ㯞⑷ഃୗ⫥ࡣᐃᆺⓗ࡞⫥఩ࢆྲྀࡽ໬ࡍࡿࡇ࡜ࡀ♧၀ࡉࢀࡿࠋ㠀㯞⑷ഃ࡛ࡢጼໃไᚚࢆᨵ

ࡊࡿࢆᚓ࡞ࡃ࡞ࡾࠊ㝶ព㐠ືࡢᙧᡂࡀᅔ㞴࡜࡞ࡗࡓ࡜⪃ၿࡉࡏࡿ⑕౛࡜ࠊ᪩ᮇ࠿ࡽ㯞⑷ഃ࡬἞⒪ࡀྍ⬟࡞⑕౛࠼ࡿࠋࡲࡓ㐃ྜ཯ᛂࡣᕥྑᅄ⫥࡬ࡢᨺᩓάືࡢࡓࡵࠊ

ࡀ࠶ࡿࡓࡵࠊ㐺ษ࡞⌮Ꮫ⒪ἲホ౯ࡀᚲせ࡛࠶ࡿࠋ௨ୗ

㠀㯞⑷ഃୗ⫥ࡢ➽⥭ᙇࢆஹ㐍ࡉࡏࡎ࡟㯞⑷ഃୗ⫥ࡢ༢

࡟ USN ࡢ᭷↓࡛࡝ࡢࡼ࠺࡞ᕪࡀฟࡿ࠿ࢆ➹⪅ࡢ⪃࠼࡛
⾲ 3 ࡟ࡲ࡜ࡵࡓࠋ

⾲ 㸬861 ࡢ᭷↓࡟ࡼࡿ⑕≧࡜ඃඛ㡰఩ࡢ㐪࠸㸬฼┈┦཯

Peii Chen, Christine Chen, kinberly et al㸦2015㸧:Kesslerᮏ◊✲ෆᐜ࡟㛵ࡍࡿ฼┈┦཯஦㡯ࡣ࡞࠸ࠋFoundation Neglect Assessment Process uniquely
measures spatial neglect during activities of dailyཧ⪃࣭ᘬ⏝ᩥ⊩living. Arch. Phys.ࠉ0HG5HKDELOL

Azouvi P㸦2002㸧: Sensitivity of clinical and behavioral

Peii Chen, Kimberly, Hreha et al㸦2015㸧:Impact oftests of spatial neglect after right hemisphere stroke. J

Spatial Neglect on Stroke Rehabilitation. Evidence

1HXUDO1HXURVXUJ3V\FKLDFWU\

From the Setting of an Inpatient Rehabilitation Facility.

Bonato M㸦2012㸧 1HJOHFW DQG H[WLQFWLRQ GHSHQG

Archives of Physical Medicine and Rehabilitation ,96

g reatly on task demands. a review. Front Hum

㸦8㸧, 1458-1466.

Neurosci 6,195.

Doricchi㸦2003㸧:The anatomyࠉof neglectࠉwithoutࠉᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

཯ᛂ . 㛵す⌮Ꮫ⒪ἲᏛ 1ࠊ35-41.

hemianopia: Aࠉkey role for par iet alࠉf ront alࠉ
disconnection.ࠉNeuroreport,㸦14㸧,2239-2243.

బஂ㛫㤶㸦2013㸧: ⬻⾑⟶㞀ᐖᝈ⪅࡟࠾ࡅࡿᒅ➽ඹྠ㐠Fa y H o r a k 㸦 2 0 0 6㸧㸸Po s t u r a l o r i e n t a t i o n a n dື࡜ఙ➽ඹྠ㐠ືࡢ㐪࠸㸸㝶ព➽ຊ࡜ࡢ㛵ಀ࡟╔┠ࡋ࡚ . ⌮Ꮫ⒪ἲᏛ Supplimet,Vol40
㸦2㸧.

equilibrium㸸What do we need to know aboutࠉneuralcontrol of balance to prevent fallsࠋAge and Ageing.

⏣୰⦾㸦2009㸧: ࣮ࣔࢱ࣮ࢥࣥࢺ࣮ࣟࣝཎⴭ➨ 3 ∧ .62-

ᚋ⸨῟㸦2010㸧㸸ឤぬධຊ࡟࠾ࡅࡿጼໃኚ໬㸬㛵す⌮Ꮫ⒪ἲᏛ⾡ㄅࠊ10ࠊ5-14.

 ་ṑ⸆ฟ∧ .
㧗ⲡᮌ⸅㸦㸧: ጼໃ➽⥭ᙇ࡜⬨㧊཯ᑕᘪ㸬᪥ᮏ⏕ᚋ⸨῟㸦2005㸧㸸୰ᯡ⚄⤒⣔ࡢᶵ⬟ゎ๗㸬㛵す⌮Ꮫ⒪ἲᏛ⾡ㄅࠊ5ࠊ11-21.

⌮Ꮫ㞧ㄅ㸬
㸦11㸧㸬340.
ෆⷵ⪔஧㸦2001㸧㸸⚄⤒⏕⌮Ꮫ .143. 㔠ⰾᇽ .

ᚋ⸨ᆂ௓ , ௚㸦㸧: 㔜ᗘ Pusher ⌧㇟ࢆ࿊ࡋࡓ⬻᱾ሰ㧗ᯇὈ⾜ , ஂ⣡ᝆᏊ , ᳃㔝㝧㸦2015㸧: ⬻༞୰ᝈ⪅࡟࠾ᝈ⪅࡟ᑐࡍࡿㄆ▱⚄⤒ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ࢔ࣉ࣮ࣟ

ࡅࡿᅇ᚟ᮇࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ⑓Ჷ㏥㝔ᚋࡢ㌿ಽࣜࢫࢳ㸬⌮Ꮫ⒪ἲᏛᮾிࠊ5ࠊ15-24.

ࢡᅉᏊ . ➨ 50 ᅇ ⌮Ꮫ ⒪ἲᏛ ⾡ ኱఍఍ ㄅࠊ42
㸦2㸧ࠊ

Gassama S㸦2011㸧:ࠉDo spine position and deprivationof visual environment inf luence spatial neglect. Jྜྷᮧ᫴ࠉ㸦2004㸧: ᅾᏯ⬻༞୰ᝈ⪅ࡢ㌿ಽ≧ἣ - ㌿ಽ⩌࡜㠀㌿ಽ⩌ࡢ≉ᚩ . ⌮Ꮫ⒪ἲࢪ࣮ࣕࢼࣝࠊ31
㸦2㸧ࠊ

Neural,258,1288-1294.
Halliday SE, Winter DA, Frank JS, et al㸦1998㸧: The
initiation of gait in young elderly and Parkinsons

245-251.
ᒣཱྀ๛ࠉ㸦2005㸧: Ⲵ㔜ኚ໬࡟క࠺㊊㒊࿘ᅖ➽ࡢ➽㟁ᅗ✚ศ್┦ᑐ್ኚ໬㸬㛵す⌮Ꮫ⒪ἲᏛࠊ
㸦5㸧ࠊ103-108.

disease subjects. Gait Posture,8,8-14.
Halligan PW㸦1989㸧:Visuospatial neglect 㸸Underlyingᒣᮏ⃈Ꮚ , ▼஭ៅ୍㑻 , Ụཎ⩏ᘯ㸦2010㸧: ᇶ♏ࣂ࢖࣓࢜࢝஧ࢡࢫ㸬 58-59.109-114, ་ṑ⸆ฟ∧ .

factors and test sensitivity. Lancet 2,908-911.
▼⏣᫂ඔ㸦1999㸧: ❧఩ጼໃࡢㄪ⠇࡟࠾ࡅࡿయᛶឤぬࡢᒣୗᛅ . ▼⏣ᩔኵ . ᰩᰨ୚ᩥ㸦㸧: Ṍ⾜㛤ጞ᫬ࡢືⓗ≉ᛶࡢゎᯒ㸬ࣂ࢖࣓࢜࢝ࢽࢬ࣒ࠊ4ࠊ186-192.

ᙺ๭㸬᪥ᮏ⮫ᗋࣂ࢖࣓࢜࢝ࢽࢡࢫᏛ఍ㄅࠊ20ࠊᒣ⏣῝㸦㸧: ∦㯞⑷ࡢᅇ᚟ࣃࢱ࣮ࣥ࡜ྠഃᛶ㐠ື㊰ࡢ㛵୚㸬Journal of clinical Rehabilitation, 16
㸦10㸧,919-▼ྜ⣧⏨㸦2009㸧: ⾜ືᛶ↓ど᳨ᰝ㸬㧗ḟ⬻ᶵ⬟㞀ᐖࡢホ౯࡜ゎ㔘ࠊVol18
㸦㸧ࠊ628-632.
Kinsubourne㸦㸧: Hemineglect and hemisphere924.
ᒣ⏣೺ே㸦2010㸧: Ⓨ⑕᪩ᮇ࠿ࡽࡢ❧ࡕୖࡀࡾ࣭❧఩カ⦎࡟ࡼࡾ Pusher ⌧㇟ࡢᾘኻࢆㄆࡵࡓ୍⑕౛ 㸸⦪ᡭࡍULYDOU\$GY1HXURO㬞 ୗ ༤㸦2002㸧: ② ⦰ ࡢ ᪂ ࡋ ࠸ ⌮ ゎ . Clinicalrehabilitation
㸦11㸧ࠊ893-899.

ࡾ࡟ࡼࡿ࢔ࣉ࣮ࣟࢳ㸬⌮Ꮫ⒪ἲ࠸ࡤࡽࡁ 14
㸦1㸧ࠊ84.
ᘪỌஂဴ㸦2005㸧: 㠀㯞⑷ഃ⭜⫼➽ࡢ➽⥭ᙇஹ㐍࡟ࡼࡾ

Jehkonen M㸦㸧: Fluctuation in spontaneous

㯞⑷ഃୖ⫥࡟ⴭྡ࡞㐃ྜ཯ᛂࡀㄏⓎࡉࢀࡓ⬻⾑⟶㞀

recovery of left visual neglect: a 1-year follow-up.

ᐖᝈ⪅࡟ᑐࡍࡿ➽㟁ᅗᏛⓗ᳨ウ㸬㛵す⌮Ꮫ⒪ἲᏛ 5ࠊ

European Neurology, 58㸦4㸧,210-214.

83-89.

Martin JH㸦1996㸧:Descending projection systems andthe motor function of the spinal cord .Neuroanatomy㸸
7H[WDQGDWODVQGHG㸸Stanford,pp249-289.
ᯇᒣΎ἞㸦2003㸧: Ṍ⾜㐠ືไᚚࡢ⚄⤒ᶵᵓ㸬⮫ᗋ⬻Ἴ 45ࠊ191-198.
ΎỈ㈗ྐ㸦㸧: Ṍ⾜㛤ጞືస࠿ࡽᐃᖖṌ⾜࡬ࡢ⛣⾜࡟࠾ࡅࡿ᭱ึࡢ 4 ࢫࢸࢵࣉࡢ㐠ືᏛ , ືຊᏛ࡜ୗ⫥➽άື . 㛵す⌮Ꮫ⒪ἲ 
㕥ᮌᜏᙪ㸦2002㸧: ②⦰ไᚚ࡟࠾ࡅࡿ㐠ື⒪ἲ .Clinicalrehabilitation㸦11㸧
బ⸨㈗ᚨ , ᕤ⸨ៅኴ㸦2016㸧: Ṍ⾜㛤ጞ᫬࡟࠾ࡅࡿୗ⭣୕㢌➽ࡢ཰⦰ືែ . ⌮Ꮫ⒪ἲ⛉Ꮫ 31
㸦3㸧
㕥ᮌಇ᫂㸦2001㸧: ⬻⾑⟶㞀ᐖ∦㯞⑷ᝈ⪅ࡢ②⦰࡜㐃ྜᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Research ReportࠚNon-paralyzed lower limb muscle activity and fall prevention measures atthe start of walking in patients with unilateral spatial neglect

Keita Takahashi*1ࠉHiroshi Takahashi*2*1 Department of Rehabilitation, Medical Corporation Midorinokai Shinagawa Hospital*2ࠉFaculty of Rehabilitationࠊ Gifu University of Health Sciences
Abstract
The muscle activity of the non-paralyzed lower limbs at the start of walking of USN patients was collected from a surface
electromyogram. The correlation with the score of the USN test Behavioral Inattention Test 㸦BIT㸧ZDVH[DPLQHG:H
WKHQDQDO\]HGIURPWKHYLHZSRLQWRINLQHPDWLFVDQGKLJKHUEUDLQIXQFWLRQDOVFLHQFHDQGH[DPLQHGKRZWRFDUU\RXWWKH
¿UVWVWHSThen, we considered a useful approach method for setting the environment necessary for fall prevention at home andproposing independent training. The subjects were patients with cerebrovascular accidents who were admitted to a general
hospital in Tokyo and were diagnosed with higher brain dysfunction and USN. First, surface electromyograms were derived
from the non-paralyzed tibialis anterior muscle and the lateral head of the gastrocnemius muscle. As a result, in case 1,%,7GHFUHDVHGDIWHUPRQWKVRQQRUPDOH[DPLQDWLRQPXVFOHDFWLYLW\RIWKHWLELDOLVDQWHULRUPXVFOHLQFUHDVHGDQGPXVFOH
activity of the lateral head of the gastrocnemius muscle decreased. In case 2, the scores of BIT did not change between
WKH¿UVWWLPHDQGPRQWKVODWHUDQGWKHPXVFOHDFWLYLW\RIERWKPXVFOHVGHFUHDVHG,QFDVHWKH%,7DIWHUPRQWKVFRXOGnot be measured, and the muscle activity showed the opposite phenomenon to that in case 1. In case 4, increased muscle
activity of both muscles was observed. The presence or absence of USN suggests the importance of the priority as thetraining program changes. Appropriate physiotherapy evaluation is necessary because there are cases that improve posturalcontrol on the non-paralyzed side and cases that can be treated on the paralyzed side from an early stage.
Keywords:ࠉCerebrovascular accident, unilateral spatial neglect , walking start, non-paralyzed side muscle activityᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021࠙◊✲ሗ࿌ࠚ

㌿ಽண㜵࡟㛵ಀࡍࡿ⫤㛵⠇ᒅ᭤➽ຊ࡟ᙳ㡪ࡍࡿ㊊㛵⠇ᗏᒅゅᗘ࡟ࡘ࠸࡚ⓑ᳧㑳⨾ *1ࠉ㧗ᶫࠉὒ *2
㸨 1 ୍⯡♫ᅋἲேࠉᕧᶞࡢ఍ࠉཎᐟࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ⑓㝔ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ⛉㸨 2 ᒱ㜧ಖ೺኱Ꮫࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊せ᪨㌿ಽࡢせᅉ࡜ࡋ࡚㊊㛵⠇ᗏᒅྍືᇦ࡜⫤㛵⠇ᒅ᭤➽ຊࡢ㛵ಀᛶࢆㄪᰝࡋࠊୗ⫥ࡢ᣺ࡾฟࡋᨵၿ࡟㊊㛵⠇ᗏᒅゅᗘࡀ㛵ಀࡍࡿྍ⬟ᛶࢆ᳨ウࡋࡓࠋᑐ㇟ࡣ᯾⑓㝔ࢫࢱࢵࣇ 50 ྡ㸦⏨ᛶ 31 ྡ㸸24.29 s 3.15 ṓࠊዪᛶ 19 ྡ㸸 s 4.34
ṓ㸧ࠊ୧ୗ⫥ 100 ⬮࡜ࡋࡓࠋィ ჾࡣᮾ኱ᘧࢦࢽ࣓࣮࢜ࢱ࣮ࢆ⏝࠸࡚ゅᗘࡣ 1 ᗘ༢఩࡛ ᐃࡋࡓࠋ୧㊊㛵⠇ᗏᒅྍືᇦࡢ ᐃࡣࠊ᪥ᮏᩚᙧእ⛉Ꮫ఍࡜᪥ᮏࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ་Ꮫ఍ࡀไᐃࡋࡓࠕ㛵⠇ྍືᇦ⾲♧࡞ࡽࡧ࡟ ᐃἲࠖ࡟ᚑ࠸ࠊᇶᮏ㍈ࡣ⭌㦵࡬ࡢᆶ┤⥺ࠊ⛣ື㍈ࡣ➨ 5 ୰㊊㦵࡜ࡋࡓࠋ⫤㛵⠇ᒅ᭤➽ຊࡢ ᐃᶵჾࡣᚐᡭ➽ຊィ㸦㓇஭་⒪♫〇࣮ࣔࣅ࢕ MT-100㸧ࢆ⏝࠸ࡓࠋࡑࡢ⤖ᯝᕥྑࡢ㊊㛵⠇ᗏᒅྍືᇦࡢẚ࡜ᕥྑࡢ⫤㛵⠇ᒅ᭤➽ຊࡢẚࡢ㛫࡟ࡣṇࡢ┦㛵ࡀࡳࡽࢀ㸦U 㸧㸦p<0.01㸧ࠊ㊊㛵⠇ࡢᗏᒅྍືᇦࡀᣑ኱ࡋ࡚࠸ࡿഃࡢ⫤㛵⠇ᒅ᭤➽ຊࡀᙉ࠸ࡇ࡜ࡀ
♧ࡉࢀࡓࠋ࣮࣮࢟࣡ࢻ㸸㊊㛵⠇ᗏᒅゅᗘࠊ⫤㛵⠇ᒅ᭤➽ຊࠊ㌿ಽண㜵ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

㸬⥴ゝస⏝ࡣ㔜せ࡛࠶ࡿࡇ࡜ࡀఛ࠼ࡿࠋ

ᡃࡀᅜࡢ⥲ேཱྀࡣࠊ௧࿴ඖ㸦2019㸧ᖺ 10 ᭶ 1 ᪥⌧ᅾࠊ㌿ಽⓎ⏕せᅉ࡟ࡘ࠸࡚ࡢሗ࿌ࡣከᩘᣲࡆࡽࢀ࡚࠸ࡿࠋ

1 ൨  ୓ே࡜࡞ࡗ࡚࠸ࡿࠋ65 ṓ௨ୖேཱྀࡣࠊ3,589

ࡋ࠿ࡋࠊ ㌿ ಽ࡟㛵 ࡍࡿඛ⾜◊ ✲㸦 ᒣᓮ 2012ࠊ ᯈ㇂୓ே࡜࡞ࡾࠊ⥲ேཱྀ࡟༨ࡵࡿ๭ྜ㸦㧗㱋໬⋡㸧ࡶ 28.4%

2015㸪࡟ࡋࡴࡽ 2003㸧࡛ࡣࠊ㊊㛵⠇⫼ᒅྍືᇦࡸᗏᒅ

࡜࡞ࡗࡓࠋ௧࿴ 18
㸦2036㸧ᖺ࡟ 33.3%࡛ 3ே࡟1ே࡜࡞ࡿࠋ

➽ຊ࡜ࡢ㛵ಀ࡟ࡘ࠸࡚㏙࡭࡚࠸ࡿࡶࡢࡣከ࠸ࡀࠊᗏᒅ

௧࿴ 㸦
2 2042㸧ᖺ௨㝆ࡣ 65 ṓ௨ୖேཱྀࡀῶᑡ࡟㌿ࡌ࡚ࡶྍືᇦ࡟ࡘ࠸࡚㏙࡭ࡽࢀ࡚࠸ࡿࡶࡢࡣᑡ࡞࠸ࠋࡉࡽ࡟⮫㧗㱋໬⋡ࡣୖ᪼ࢆ⥆ࡅࠊ௧࿴ 
㸦2065 ᖺ࡟ࡣ 38.4% ࡟ᗋ⌧ሙ࡟࠾࠸࡚㊊㛵⠇ࡢᗏᒅྍືᇦࡀᨵၿࡍࡿ࡜ࠊୗ

㐩ࡍࡿ 2㸧ࠋࢃࡀᅜࡢᨻ⟇࡜ࡋ࡚་⒪㈝ࡢ๐ῶࡀᥖࡆࡽ

⫥ࡢ᣺ࡾฟࡋࡀⰋዲ࡜࡞ࡿ⤒㦂ࢆࡋࡓࠋࡼࡗ࡚㊊㛵⠇ᗏࢀ࡚࠾ࡾࠊᆅᇦࡢໟᣓⓗ࡞ᨭ᥼࣭ࢧ࣮ࣅࢫᥦ౪యไ㸦ᆅᒅྍືᇦ࡜⫤㛵⠇ᒅ᭤➽ຊࡢ㛵ಀᛶ࡟ࡘ࠸࡚ㄪᰝࡋࠊ

ᇦໟᣓࢣ࢔ࢩࢫࢸ࣒㸧ࡢᵓ⠏ࢆ᥎㐍ࡋ࡚࠸ࡿࠋࡑࢇ࡞୰ࠊ

㊊㛵⠇ᗏᒅྍືᇦࡀṌ⾜㛤ጞ᫬ࡢ᣺ࡾฟࡋᨵၿ࡜㛵ಀ㌿ಽ࡟క࠺་⒪㈝࣭௓ㆤ㈝⏝ࡣᖺ㛫 9000 ൨෇ࢆ㉸࠼ࡿࡀ࠶ࡿ࠿࡝࠺࠿ࢆ᳨ウࡋࡓࠋࡇ࡜ࡀሗ࿌ࡉࢀ࡚࠸ࡿ㸦ᯘ 2009㸧ࠋࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ
࡛ࡶண㜵ࡢศ㔝ࡀὀ┠ࡉࢀ࡚࠾ࡾࠊࡑࡢ୰࡛ࡶ㌿ಽண㜵㸬᪉ἲࡣࠊཌ⏕ປാ┬㸦ཌປ┬ 2021㸧࡟ࡼࡿ࡜௓ㆤࡀᚲせ࡟

2.1 ᑐ㇟㸦⾲ 1㸧࡞ࡗࡓ୺࡞ཎᅉ࡜ࡋ࡚ࠕ㌿ಽ࣭㦵ᢡࠖࡀ 12.2% ࡜࡞ࡗ࡚⫤㛵⠇ᒅ᭤ྍືᇦࡀ 90r௨ୖಖࡓࢀ࡚࠸ࡿ᯾⑓㝔ࢫ࠸ࡿࠋ㧗㱋⪅ࡢ㦵ᢡࡣࠊ㦵ᢡ࡟⮳ࡽ࡞࠸㍍ᚤ࡞㌿ಽ࡛ࢱࢵࣇ 50 ྡ㸦⏨ᛶ 31 ྡ㸸24.29 s 3.15 ṓࠊዪᛶ 19 ྡ㸸࠶ࡗ࡚ࡶᜍᛧᚰࡸ୙Ᏻឤࢆᣢࡕάືᛶࡀపୗࡋ࡚ࡋࡲ࠸

 s 4.34 ṓ 㸧ࠊ ୧ ୗ⫥ 100 ⬮࡜ࡋࡓࠋ ᖹ ᆒ ㌟㛗㸦 ཌ ປ ┬ 2010㸧ࠊQOL ࡢ ప ୗ㸦Murphy1982, ᒸ す

166.1 s 8.9cm
㸦 ⏨ ᛶ  s FPࠊ ዪ ᛶ 156.53 s

2015㸧ࢆᑟࡃࡇ࡜ࡀᣦ᦬ࡉࢀ࡚࠸ࡿࠋࡑࡢࡓࡵ㧗㱋⪅ࡢ

5.03cm㸧ࠊ ᖹ ᆒ య 㔜 59.42 s 12.05kg㸦 ⏨ ᛶ 65.26 s㌿ಽண㜵ࡣ♫఍ⓗ࡞ㄢ㢟࡜࡞ࡗ࡚࠸ࡿࠋ

11.26kgࠊዪᛶ 49.91 s NJ㸧ࠊ฼ࡁ㊊㸦࣮࣎ࣝࢆ㋾ࡿ㌿ಽሙ㠃࡜ࡋ࡚ࠊ㧗㱋⪅ࡢ㌿ಽࡣṌ⾜㛤ጞ᫬࡟ẚ㍑

ഃࡢ⬮㸧ࡣྑ⬮ 42 ྡࠊᕥ⬮ 8 ྡ࡛࠶ࡗࡓࠋ

ⓗ㢖ᗘࡀ㧗࠸㸦᳃⏣ 2012ࠊすᓥ 2005㸧࡜ࡉࢀ࡚࠸ࡿࠋ⾲  ᑐ㇟ࡢᴫせ⬻༞୰ᝈ⪅࡛ࡣࠊᗙ఩࠿ࡽ❧఩࡬ࡢ⛣ືࡢ㛫ࠊࡲࡓࡣ㟼ⓗጼໃ࠿ࡽືⓗ࡞ጼໃไᚚ࡟ษࡾ᭰࠼ࡿᚲせࡢ࠶ࡿṌ⾜㛤ጞືసࡢࡼ࠺࡞ 2 ࡘࡢ㐠ື≧ែࡢ㛫࡛⛣ືࡍࡿሙ㠃࡟࠾࠸࡚᭱ࡶ㌿ ಽ⋡ࡀ㧗࠸࡜ሗ ࿌ࡉࢀ࡚࠸ࡿ
㸦Robinovitch2013㸧ࠋṌ⾜㛤ጞ᫬ࡢୗ⫥ࡢ᣺ࡾฟࡋࡣࠊ
Ṍ⾜࿘ᮇࡢጼໃ࡛♧ࡍ࡜㐟⬮୰ᮇ࡛࠶ࡿࠋ㐟⬮୰ᮇࡢᙺ๭࡜ࡋ࡚ࠊほᐹ⫥ࢆᘬࡁ⥆ࡁ๓࡬㐠ࡪࡇ࡜ࠊほᐹ⫥ࡢ༑ศ࡞ Toe clearance㸦௨ୗࠊTC㸧ࡢ☜ಖ࡜ࡉࢀ࡚࠸ࡿ

2.2

ᐃ㡯┠࡜᪉ἲ

㸦Nyberg1995㸧ࠋṌ⾜᫬ࡢ㌿ಽⓎ⏕≧ἣࡣࡘࡲࡎࡁ࡟

୧㊊㛵⠇ᗏᒅྍືᇦࡢ ᐃࡣࠊ᪥ᮏᩚᙧእ⛉Ꮫ఍࡜ࡼࡿ㸦᭶ᇛ 2005㸧ࡶࡢࡀከࡃࠊChiba ࡽ㸦Chiba2005㸧ࡢࠊ᪥ᮏࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ་Ꮫ఍ࡀไᐃࡋࡓࠕ㛵⠇ྍືᇦ㌿ಽ⤒㦂⪅࡜㠀㌿ಽ⤒㦂⪅ࢆᑐ㇟࡜ࡋࡓ TC ࡢሗ࿌࡛⾲♧࡞ࡽࡧ࡟ ᐃἲࠖ㸦ዉⰋ 2001㸧࡟ᚑ࠸ࠊᇶᮏ㍈ࡣ⭌ࡣࠊ㌿ಽ⤒㦂⩌ࡀ 1.2cmࠊ㠀㌿ಽ⤒㦂⩌ࡀ 15.2cm ࡜㦵࡬ࡢᆶ┤⥺ࠊ⛣ື㍈ࡣ➨ 5 ୰㊊㦵࡜ࡋࡓࠋ ᐃ⫥఩㌿ಽ⩌ࡀ᭷ព࡟పୗࡋ࡚࠸ࡿࡇ࡜ࢆ♧ࡋ࡚࠸ࡿࠋࡼࡗ࡚

ࡣ⫼⮩఩ࠊ⭸㛵⠇ࡣ࣐ࢡࣛ㸦㧗⏣࣋ࢵࢻ〇సᡤ〇ࢩ࣓ࣕṌ⾜㛤ጞ᫬ࡢ TC ࡢ☜ಖࡣࠊ㌿ಽண㜵࡟⧅ࡀࡿ࡜ண᝿ࣥ㸦すୖ 2006㸧ࢆ⭸ୗ࡬౑⏝ࡋ⭸㛵⠇ᒅ᭤ゅᗘ 45r࡛

࡛ࡁࡿࠋ

⤫୍ࡋࡓࠋ
㸦ᅗ 1㸧ィ ჾࡣᮾ኱ᘧࢦࢽ࣓࣮࢜ࢱ࣮ࢆ⏝࠸Ṍ⾜㛤ጞ᫬ࡢୗ⫥ࡢ᣺ࡾฟࡋ࡟࠾࠸࡚ࠊ⫤㛵⠇ᒅ᭤࡚ゅᗘࡣ 1 ᗘ༢఩࡛ ᐃࡋࠊゅᗘ ᐃࡣࠊ௚ື㐠ື࡟ࡢ୺ືస➽ࡣ⭠⭜➽࡛࠶ࡿࠋ⭠⭜➽ࡣ⫤㛵⠇ࡢᒅ᭤㐠᳨࡚⪅㛫ㄗᕪࢆ㑊ࡅࡿࡓࡵⴭ⪅ࡢ୍ேࡀ඲⑕౛࡟ࡘ࠸

ື௨እ࡟ࠊ⫤㛵⠇ࡢ๓᪉୙Ᏻᐃᛶ࡟ᑐࡋ࡚Ᏻᐃ໬ࡉࡏ

࡚ᐇ᪋ࡋࡓ㸦ᅗ 2㸧
㸦ᅗ 3㸧ࠋࡿࡢ࡟㔜せ࡞➽࡛࠶ࡾࠊ⭠⭜➽ࡢάືࡀῶᑡࡍࢀࡤࠊ

ᐃᶵჾࡣᚐᡭ➽ຊィ㸦㓇஭་⒪♫〇࣮ࣔࣅ࢕ MT-⫤㛵⠇ࡢ๓᪉࡬ࡢ୙Ᏻᐃᛶࡀቑ኱ࡍࡿࡔࡅ࡛ࡣ࡞ࡃࠊ

100㸧ࢆ⏝࠸ࡓ㸦ᅗ 4㸧ࠋ୧⫤㛵⠇ᒅ᭤➽ຊࡢ ᐃࡣྠ᪥㛵⠇඲య࡟⏕ࡌࡿ㈇Ⲵࡶቑ኱ࡍࡿ㸦Cumming1994㸧ࠋ࡟⾜࠸ࠊ⿕㦂⪅ࡀ⑂ປࢆឤࡌࡓሙྜࠊ୺ほⓗ࡟ᅇ᚟ࡍࡑࡋ࡚ࠊᩚᙧእ⛉ⓗ⑌ᝈ࡟⧅ࡀࡾࡸࡍ࠸࡜ሗ࿌ࡉࢀ࡚࠸

ࡿࡲ࡛ఇᜥࢆ୚࠼ࡓࠋ ᐃ⫥఩ࡣ⚄㇂ࡽ㸦⚄㇂ 2010㸧ࢆࡿ㸦LEWIS2009,Long1993㸧ࠋࡇࡢࡇ࡜࠿ࡽࡶ⭠⭜➽ࡢཧ⪃࡟ࠊ࣋ࢵࢻୖ➃ᗙ఩࡟࡚㦵┙୰㛫఩ࠊ୧ᡭࡣ⬚ࡢᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021๓࡛⤌ࡳࠊ᳨ᰝഃୗ⫥ࡣ⫤㛵⠇ᒅ᭤ 90rࠊ⭸㛵⠇ᒅ᭤
90r࡜ࡋࡓࠋ㠀᳨ᰝഃࡢୗ⫥ࡣᗋ࠿ࡽᾋ࠿ࡏࡓ≧ែ࡜ࡋࡓ㸦ᅗ 5㸧ࠋᚐᡭ➽ຊィࡢ෌⌧ᛶ࡟㛵ࡍࡿຍ⸨࣭ᒣᓮࡽࡢ ሗ ࿌㸦 す ୖ 2006ࠊ ᖹ ⃝ 004ࠊ ຍ ⸨ 2006ࠊ ຍ ⸨
2005ࠊຍ⸨ 2004㸧ࡼࡾࠊᅛᐃ࣋ࣝࢺࡣ࣋ࢵࢻࡢ㊊࡜ᗋࡢ㛫࡬ᣳࡴࡼ࠺ᅛᐃࡋࡓ㸦ᅗ 5㸧ࠋࣉࢵࢩࣗࢭࣥࢧ࣮ࡢ఩
⨨ࡣࠊ᳨ᰝഃࡢ኱⭣㒊㐲఩ 1/3 ࡟୰ᚰ㒊ࡀ᮶ࡿࡼ࠺࡟
㓄⨨ࡋࠊ➼ᑻᛶ➽ຊ࡟࡚∦⬮ࡎࡘ ᐃࡋࡓࠋᐃୗ⫥ࡢ㡰␒ࡣࣛࣥࢲ࣒࡜ࡋࠊ⿕㦂⪅࡟ࡣ 5 ⛊㛫᭱኱➽ຊࢆᅗ 㸬࣐ࢡࣛ㸦㧗⏣࣋ࢵࢻ〇సᡤ〇ࢩ࣓ࣕࣥ 㸧

Ⓨ᥹ࡉࡏࠊ ᐃᅇᩘࡣ⦎⩦࡜ࡋ࡚ 1 ᅇᐇ᪋ᚋࠊ2 ᅇ ᐃࡋࡓࠋ➽ຊ ᐃ࡟࠾࠸࡚ࡣ 2 ᅇ ᐃࡢᖹᆒ್ࢆ⏝࠸ࡿࡇ࡜࡛ಙ㢗ᛶࡀ㧗ࡲࡿ㸦すᮧ 2003㸧ࡇ࡜ࡶ♧၀ࡉࢀ࡚࠸
ࡿࡇ࡜࠿ࡽࠊ2 ᅇࡢᖹᆒ್ࢆ⏝࠸ࡿࡇ࡜࡜ࡋࡓࠋ௦ൾື
స࡟ࡣ༑ศ࡟㓄៖ࡋࠊどデ࡛ࢃ࠿ࡿ 5 ᗘ⛬ᗘࡢయᖿࡢ
ఙᒎ࠾ࡼࡧഃᒅࡢ௦ൾࡀ⏕ࡌࡓሙྜ࡟ࡣ ᐃࢆ୰Ṇࡋࡓࠋࡲࡓ཯ᑐഃ⭸ࡢᒅ᭤࡟ࡼࡿᅛᐃ㸦ࣁ࣒ࢫࢺࣜࣥࢢࢫࡢస⏝㸧ࡣどデ࠾ࡼࡧྠ➽ࡢゐᐹ࡟ࡼࡾ᤼㝖ࡋࡓࠋᅗ 㸬ᮾ኱ᘧࢦࢽ࣓࣮࢜ࢱ࣮ᅗ  ㊊㛵⠇ᗏᒅྍືᇦᐃ⫥఩ᅗ  ⫤㛵⠇ᒅ᭤➽ຊᐃ⫥఩

2.3 ⤫ィᏛⓗゎᯒ⤫ィゎᯒࡣࠊᕥྑࡢ㊊㛵⠇ᗏᒅྍືᇦࡢ๭ྜ࡜ᕥྑ
ࡢ⫤㛵⠇ᒅ᭤➽ຊࡢ๭ྜࡢ┦㛵ࢆࣆ࢔ࢯࣥࡢ✚⋡┦㛵ಀᩘࢆ౑⏝ࡋࠊ᭷ពỈ‽ࡣ p=0.05 ࡜ࡋࡓࠋᅗ  ᚐᡭ➽ຊィ㸦㓇஭་⒪♫〇࣮ࣔࣅ࢕ 07㸧ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

2.4 ೔⌮ⓗ㓄៖㸬⤖ᯝᮏ◊✲ࡣ࣊ࣝࢩࣥ࢟ᐉゝ୪ࡧ࡟ࠕேࢆᑐ㇟࡜ࡍࡿ་

ᑐ㇟⪅ಶࠎࡢ㊊㛵⠇ᗏᒅゅᗘࡢᕥྑᕪ࡜⫤㛵⠇ᒅ᭤Ꮫ⣔◊✲࡟㛵ࡍࡿ೔⌮ᣦ㔪ࠖࢆ㑂Ᏺࡋࠊᮏ◊✲ࡢෆᐜ➽ຊࡀ┦㛵ࡍࡿ࠿࡝࠺࠿࡟ࡘ࠸࡚ࠊಶࠎேࡢ㊊㛵⠇ᗏᒅ࡟ࡘ࠸࡚ࠊ᪂₲ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥ኱Ꮫ೔⌮ጤဨ఍㸦ᢎ

ゅᗘࡢᕥྑᕪࡣ࡯ࢇࡢࢃࡎ࠿࡛࠶ࡿࡓࡵࠊ┦㛵㛵ಀࢆ

ㄆ␒ྕ 143ࠊᖹᡂ 30 ᖺ 11 ᭶ 29 ᪥ᢎㄆ㸧ࠊཎᐟࣜࣁࣅࣜ

ぢࡿࡇ࡜ࡀᅔ㞴࡛࠶ࡗࡓࠋࡑࡢࡓࡵᑐ㇟⪅඲ဨࡢ㊊㛵ࢸ࣮ࢩࣙࣥ⑓㝔೔⌮ጤဨ఍ࡢᢎㄆࢆཷࡅࠊ⿕㦂⪅࡟◊⠇ᗏᒅゅᗘࡢᖹᆒ࡟ᕥྑᕪࡀ࠶ࢀࡤࠊ⫤㛵⠇ᒅ᭤➽ຊ✲ࡢㄝ᫂ࢆ⾜࠸ࠊ◊✲ཧຍࡢྠពࢆᚓ࡚ᐇ᪋ࡋࡓࠋࡲ

ࡢᖹᆒ࡟ᕥྑᕪࡀฟࡿ࠿ࢆㄪ࡭ࡓࠋ୧ ᐃ್ࢆᕥྑ࡟

ࡓࠊᚓࡽࢀࡓ᝟ሗࡣಶேࡀ≉ᐃࡉࢀ࡞࠸ࡼ࠺ࢹ࣮ࢱධ

ศࡅࡑࡢᖹᆒࢆ⟬ฟࡋࠊ⤫ィฎ⌮ࢆ⾜ࡗࡓࠋࡑࡢ⤖ᯝຊࡢ㝿ࡣࠊࢥ࣮ࢻ໬ࡋࠊ༏ྡᛶࡢ☜ಖ࡟༑ศ␃ពࡋࡓࠋ

㊊㛵⠇ᗏᒅྍືᇦࡢᖹᆒࡣྑ 59.1 s rࠊᕥ 

ࡲࡓࠊ◊✲ࢹ࣮ࢱࡣࠊ௒ᅇࡢ◊✲┠ⓗ௨እ࡟ࡣ౑⏝ࡋs rࠊᕥྑࡢ㊊㛵⠇ᗏᒅྍືᇦࡢᖹᆒࡢẚࡣ 1.01

࡞࠸ࡇ࡜࡜ࡋࡓࠋ

s 0.08% ࡛࠶ࡗࡓࠋ⫤㛵⠇ᒅ᭤➽ຊࡢᖹᆒࡣྑ 5.48 sᑐ㇟⪅࡬ࡢᮏ◊✲࡬ࡢཧຍ༠ຊࡣࠊ
ࠕ◊✲ㄝ᫂᭩ࠖ࡜
ࠕྠព᭩ࠖࢆ⏝࠸࡚ࠊཱྀ㢌࠾ࡼࡧ᭩㠃࡟࡚◊✲ࡢ┠ⓗࡸ

3.22kgࠊᕥ  s 2.99kgࠊᕥྑࡢ⫤㛵⠇ᒅ᭤➽ຊࡢᖹᆒࡢẚࡣ 1.34 s 0.83% ࡛࠶ࡗࡓ㸦⾲ 2㸧᪉ἲࠊ೔⌮ⓗ㓄៖ࠊ⥭ᛴ᫬ࡢᑐᛂࠊㅰ♩➼࡟ࡘ࠸࡚ㄝ

ᕥྑࡢ㊊㛵⠇ᗏᒅྍືᇦࡢ๭ྜ࡜ᕥྑࡢ⫤㛵⠇ᒅ᭤᫂ࢆ⾜࠸ࠊ⮬⏤ពᚿ࡛ྠពࡢୖ࡛⾜ࡗࡓࠋཧຍ༠ຊࡢ➽ຊࡢ ๭ ྜ ࡢ㛫࡟ࡣ ṇࡢ┦㛵ࡀࡳࡽࢀࡓ㸦 ᅗ 6㸧ࠋ᧔ᅇࡶࠕྠព᧔ᅇ᭩ࠖࢆ㓄ᕸࡋࠊ᧔ᅇࡣᑐ㇟⪅ࡢពᛮ

㸦U 㸧㸦p<0.05㸧ࠋ௨ୖ࠿ࡽ㊊㛵⠇ࡢᗏᒅྍື

࡛⾜࠼ࡿࡇ࡜࡜ࡋࡓࠋ

ᇦࡀᣑ኱ࡋ࡚࠸ࡿഃࡢ⫤㛵⠇ᒅ᭤➽ຊࡀᙉ࠸ࡇ࡜ࡀ♧ࡉࢀࡓࠋ⾲ 㸬㊊㛵⠇ᗏᒅྍືᇦᖹᆒ࡜⫤㛵⠇ᒅ᭤➽ຊᖹᆒᅗ  ᕥྑࡢ㊊㛵⠇ᗏᒅྍືᇦࡢ๭ྜ࡜ᕥྑࡢ⫤㛵⠇ᒅ᭤➽ຊࡢ๭ྜࡢ┦㛵ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021㸬⪃ᐹ㸬฼┈┦཯

⫤㛵⠇ᒅ᭤➽ࡢⓎ᥹ࢺࣝࢡࡣࠊᒅ᭤ 10rࠥ 30r࡛ࡣ

ᮏㄽᩥ࡟㛵ࡋ࡚㛤♧ࡍ࡭ࡁ฼┈┦཯ࡣᏑᅾࡋ࡞࠸ࠋ

኱⭣┤➽࡜⭠⭜➽ࡣྠ➼ࡢᒅ᭤ࢺࣝࢡࢆᣢࡘࡀࠊఙᒎ
20rࠥᒅ᭤ 10r࠾ࡼࡧᒅ᭤ 30r௨ୖ࡛⭠⭜➽ࡀ኱⭣┤➽㸬ㅰ㎡ࡼࡾࡶ኱ࡁ࡞ᒅ᭤ࢺࣝࢡࢆᣢࡘ㸦ຍ⸨ 2002㸧ࠊࡲࡓ⭠⭜ᮏ◊✲࡜ᐇ᪋ࠊㄽᩥసᡂ࡟࠶ࡓࡾࠊ⿕㦂⪅࡜ࡋ࡚ ᐃ➽ࡢ୰࡛ࡶ⭠㦵➽ࡣ⫤㛵⠇ᒅ➽ࡢ୰࡛᭱ᙉ࡛ࠊ㐠ືࡢ࡟༠ຊ࠸ࡓࡔ࠸ࡓࢫࢱࢵࣇࡢ᪉ࠎ࡟῝ࡃឤㅰ⏦ࡋୖࡆࡲ㛤ጞ࠿ࡽ⤊ࢃࡾࡲ࡛స⏝ࡍࡿࠋ௚ࡢᒅ➽࡜ࡣ␗࡞ࡾᒅ᭤

ࡍࠋ

ࡀ 90rࢆ㉸࠼࡚ࡶാࡃ㸦ᑠᰰ 2011㸧࡜㏙࡭ࡽࢀ࡚࠸ࡿࠋ
ࡲࡓ⫤㛵⠇ᒅ᭤ゅᗘࡀቑ኱ࡋࡓ⫥఩࡛ࡢ⫤㛵⠇ᒅ᭤㐠ཧ⪃ᩥ⊩ືࡣࠊ⭠⭜➽ࡢάືࡀ኱⭣➽⭷ᙇ➽ࡢάືࡼࡾඃ఩࡞

Cumming RG, Klineberg RJ.㸦1994㸧:Fall frequency and≧ែ࡟࡞ࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗ࡚࠸ࡿ㸦࣍ࢵ࣍ࢩ࣮ࣝࢻ

characteristics and the risk of hip fractures. JAGS

2011㸧ࠋࡼࡗ࡚➽ຊ ᐃ⫥఩ࡀ⫤㛵⠇ᒅ᭤ 90r࡛࠶ࡿࡇ

࡜࠿ࡽࠊ㊊㛵⠇ࡢᗏᒅྍືᇦᣑ኱ࡣ⫤㛵⠇ᒅ᭤ࡢ୺ື

Chiba H, Ebihara S, Tomita N, et al㸦2005㸧'L൵HUHQWLDOస➽࡛࠶ࡿ⭠⭜➽ࡢ➽ຊ࡟㛵ಀࡋ࡚࠸ࡿࡇ࡜ࡀ⪃࠼ࡽࢀ

gait kinematics between fallers and non-fallers inࡿࠋcommunity dwelling elderly people. Geriatrics &Watanabe㸦Watanabe 2011㸧ࡣࠊ➽ࡢᦆയࡸࠊ≀⌮ⓗGerontology International, 㸦
5 2㸧

ࢫࢺࣞࢫ࡟ᑐࡍࡿ➽ࡢ཯ᛂ࡟ࡼࡾ➽ࡢࢱ࢖ࣉࢆጼໃ➽ᯘ Ὀྐ㸦2009㸧. ㌿ ಽࡢ་ ⒪ ⤒ ῭࡟ཬࡰࡍᙳ 㡪 .The

㸦Postural Type㸧࡜┦ື➽㸦Phasic Type㸧࡟ศ㢮ࡋ࡚࠸

Bone,23
㸦2㸧ࠊ181-184.

ࡿࠋࡑࡢ୰࡛⭠⭜➽ࡣጼໃ➽࡛࠶ࡾ▷⦰ഴྥ࡟࠶ࡿࠋ

ᖹ⃝᭷㔛 , 㛗㇂ᕝ㍤⨾ , ᯇୗ࿴ᙪ , ௚㸦2004㸧㸸೺ᖖ⪅ࡼࡗ࡚ࠊ㊊㛵⠇ᗏᒅࡢྍືᇦᣑ኱ࡣࠊ➽➽⭷ࡢ᥋⥆ࡢ➼ᑻᛶ ⭸ఙᒎ➽ຊ .PT ࢪ࣮ࣕࢼࣝ ,38
㸦4㸧ࠊ330-

㸦Page 2013㸧࠿ࡽ▷㊑ఙ➽ࠊ㛗㊑ఙ➽ࠊ๓⬯㦵➽ࠊᚋ

332.

⬯㦵➽ࡀఙ㛗ࡉࢀࠊ⭠⭜➽ࡸ኱⭣ᅄ㢌➽ࡢ▷⦰ᨵၿ࡟+X[OH\$)6LPPRQV50㸦㸧㸸Proposed mechanismࡼࡾࠊ⫤㛵⠇ࡢᒅ᭤➽཰⦰ຊࡢᨵၿࡀ⪃࠼ࡽࢀࡿࠋࡲ

of force generation in striated muscle. Nature 233,533-ࡓ➽ࡢ▷⦰ᨵၿࡀࠊ➽ࡢᶵᲔⓗ཰⦰≉ᛶࡢ୍ࡘ࡛࠶ࡿ

538.

㛗ࡉѸᙇຊ᭤⥺࡟ࡼࡾࠊ➽ࡢⓎ⏕཰⦰ᙇຊ㸦࣐࢖࣮ࣖࢫ

ᯈ㇂ཌ㸦2015㸧㸸ឤぬ࡜ጼໃไᚚࡢࣇ࢕࣮ࢻࣂࢵࢡࢩࢫࢸ

2009ࠊ+X[OH\㸧ࢆ᭱኱࡟ࡋࡓ࡜ࡶ⪃࠼ࡽࢀࡿࠋ

࣒ . ࣂ࢖࣓࢜࢝ࢽࢬ࣒Ꮫ఍ㄅࠊVol.39,No.4.

Ṍ⾜᫬ࡢୗ⫥ࡢ᣺ࡾฟࡋࡣࠊ⫤㛵⠇ఙᒎ࡟ࡼࡿ⭠⭜J Murphy, B Isaacs B
㸦1982㸧㸸The post-fall syndrome: A➽ࡢఙᙇ཯ᑕࢆ౑⏝ࡋࡓ⫤㛵⠇ᒅ᭤࡛࠶ࡿࠋࡋ࠿ࡋࠊ

study of 36elderly patients.Gerontology,28
㸦4㸧,265-ᮏ◊✲ࡢ⫤㛵⠇ᒅ᭤➽ຊࡢᐃ⫥఩ࡣᗙ఩࡛࠶ࡿࡓ

ࡵࠊఙᙇ཯ᑕࢆ౑⏝ࡋ࡞࠸㝶ពⓗ࡞⫤㛵⠇ᒅ᭤➽ຊࡢཌ⏕ປാ┬ࠉᖹᡂ 30 ᖺᗘ∧㧗㱋♫఍ⓑ᭩㸦2019㸧ᐃ࡜࡞ࡿࠋࡼࡗ࡚Ṍ⾜㛤ጞ᫬ࡢ㝶ពⓗ࡞⫤㛵⠇ᒅ᭤

https://www8.cao.go.jp/kourei/whitepaper/w-2018/html/

࡟ࡼࡿୗ⫥ࡢ᣺ࡾฟࡋᨵၿ࡟ࡘ࡞ࡀࡿ࡜⪃࠼ࡓࠋ㸦㸧ཌ⏕ປാ┬ࠉ௧࿴ 2 ᖺ∧㧗㱋♫఍ⓑ᭩㸦2020㸧㸬⤖ㄽ

https://www8.cao.go.jp/kourei/whitepaper/w-2020/html
㸦㸧㌿ಽண㜵࡟ࡣࠊṌ⾜㛤ጞ᫬ࡢ TC ☜ಖࡢࡓࡵ࡟㝶ពⓗ࡞⫤㛵⠇ᒅ᭤ࡀᚲせ࡛࠶ࡿࠋୗ⫥ࡢ᣺ࡾฟࡋᨵၿ࡟

⚄㇂᫭ኸ , ྡ㉺ኸᶞ , ➉஭ோ㸦2010㸧㸸ࣁࣥࢻ࣊ࣝࢻࢲ࢖

ࡣࠊṌ⾜࡟࠾ࡅࡿ⫤㛵⠇ࡢఙᒎࡼࡿ⭠⭜➽ࡢఙᙇ཯ᑕ

ࢼ࣓࣮ࣔࢱ࣮ࢆ౑⏝ࡋࡓయᖿᅛᐃ➽ຊࢆ཯ᫎࡍࡿ⫤㛵

ࡸ㊊㛵⠇ࡢᗏᒅ࡟ࡼࡿ㋾ࡾฟࡋ࡟╔┠ࡍࡿࡇ࡜ࡀከ࠸ࠋ

⠇࿘ᅖ➽ຊࡋ࠿ࡋࠊṌ⾜㛤ጞ᫬࡟ࡣ⫤㛵⠇ࡢఙᙇ཯ᑕࡸ࢔ࣥࢡࣝ

ࣟࢵ࣮࢝ᶵᵓ࡟ࡼࡿ㋾ࡾฟࡋࡼࡾࡶࠊ㝶ពⓗ࡞ୗ⫥ࡢ᣺ᐃࡢಙ㢗ᛶ , ⌮Ꮫ⒪ἲᏛ ,25
㸦2㸧:193-ຍ⸨᐀つ , ᒣᓮ⿱ྖ㸦2002㸧: ࣁࣥࢻ࣊ࣝࢻࢲ࢖ࢼ࣓࣮ࣔ

ࡾฟࡋࠊࡍ࡞ࢃࡕ⫤㛵⠇ᒅ᭤➽ຊࡀᚲせ࡛࠶ࡿࠋ௒ᅇ

ࢱ࣮࡟ࡼࡿ➼ᑻᛶ ⫤ እ ㌿ ➽ຊࡢࡢ⤖ᯝ࠿ࡽ⫤㛵⠇ࡢᒅ᭤➽ຊ࡟㊊㛵⠇ࡢᗏᒅྍືᇦࡀ

Ꮫ ,29,343.

㛵ಀࡋ࡚࠸ࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ

ᐃ . ⌮Ꮫ⒪ἲ

ຍ⸨᐀つ , ᒣᓮ⿱ྖ , ୰ᓥάᘺ , ௚㸦2004㸧: ࣁࣥࢻ࣊ࣝ
ࢻࢲ࢖ࢼ࣓࣮ࣔࢱ࣮࡟ࡼࡿ➼ᑻᛶ⫤ᒅ᭤ . ఙᒎ➽ຊࡢᐃؐᅛᐃ⏝࣋ࣝࢺࡢ౑⏝ࡀ෌⌧ᛶ࡟୚࠼ࡿᙳ㡪ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

ؐ . 㧗▱ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㝔⣖せ 
ຍ⸨᐀つ , ᒣᓮ⿱ྖ㸦2005㸧: ࣁࣥࢻ࣊ࣝࢻࢲ࢖ࢼ࣓࣮ࣔ

ࡿṌ⾜ศᯒ , 13, ་Ꮫ᭩㝔 .
ࢺ࣮࣐ࢫ࣭W࣭࣐࢖࣮ࣖࢫ , ᯈሙⱥ⾜ , ▼஭ៅ୍㑻㸦2009㸧:ࢱ࣮࡟ࡼࡿ➼ᑻᛶ⫤ෆ㌿ , ෆ᪕ , እ᪕➽ຊࡢ ᐃ - ᅛᐃ⏝࣋ࣝࢺࡢ౑⏝ࡀ෌⌧ᛶ࡟୚࠼ࡿᙳ㡪 , 㧗▱ࣜࣁࣅ࢔ࢼࢺ࣑࣮ࢺࣞ࢖ࣥ. 110-111,202-203, ་Ꮫ᭩㝔 ,Watanabe K, Akima H㸦2011㸧(൵HFWRINQHHMRLQWDQJOH

ࣜࢸ࣮ࢩࣙࣥᏛ㝔⣖せ 

on neuromuscular activation of the vastus intermedius

ຍ⸨᐀つ , ᒣᓮ⿱ྖ㸦2006㸧: ࣁࣥࢻ࣊ࣝࢻࢲ࢖ࢼ࣓࣮ࣔ

muscle during isometric contraction. Scandinavianࢱ࣮࡟ࡼࡿ➼ᑻᛶ㊊ᗏᒅ , ⫼ᒅ➽ຊࡢ ᐃؐᅛᐃ⏝journal of medicine &science in sports, 21,412-420.

࡭ࣝࢺࡢ౑⏝ࡀ෌⌧ᛶ࡟୚࠼ࡿᙳ㡪ؐ . ⌮Ꮫ⒪ἲ㐍ᒣᓮᩔ , బ⸨ಇ㍜ , ௚㸦┘ヂ㸧
㸦2012㸧:Oatis CA: ࣮࢜ࢳṌ࡜ᒎᮃ ,20,56-60.

ࢫࡢ࢟ࢿࢩ࢜ࣟࢪ୍࣮㌟య㐠ືࡢຊᏛ࡜⑓ែຊᏛ

ᑠᰰ㐍ஓ , ᘓෆᏹ㔜 , 㧗ᓥៅ࿃ , ௚㸦2011㸧㸸㛵⠇ゅᗘ୍ . ࣛ࢘ࣥࢻࣇࣛࢵࢺ, ᮾி .

ࡢ㐪࠸࡟ࡼࡿ⫤㛵⠇࿘ᅖ➽ࡢⓎ᥹➽ຊࡢኚ໬ , ⌮Ꮫࣘࢵࢱ࣭࣍ࢵ࣍ࢩ࣮ࣝࢻ , ୸ᒣோྖ , ࣂࣥ࣊ࢠ⿱⨾Ꮚ⒪ἲᏛ ,38㸦2㸧

㸦2011㸧㸸࠿ࡽࡔࡢᶵ⬟࡜ᵓ㐀ϩ . ࢞࢖࢔ࣈࢵࢡࢫ ,132.

Lewis CL, Shirley A, et a1
㸦2009㸧: Effect in synergist
muscle force cont r ibut ion on h ip forces when
SHUIRUPLQJ KLS VWUHQJWKHQLQJ H[HUFLVHV &OLQLFDOBiomechanics 24
㸦1㸧,35-42.
Long WT, Dorr LD, et al㸦1993㸧: Functional recovery of
nonde me nt e d t ot a l h ip a r t h ropla st y. Cl i n ica l
RUWKRSHGLFVDQGUHODWHGUHVHDUFK
᳃⏣ᬛ⨾ , ᐑᓮ⣧ᘺ㸦2012㸧㸸❧ࡕୖࡀࡾືసࢆᐜ᫆࡟
⾜࠺ࡓࡵ࡟ᚲせ࡞㊊㛵⠇⫼ᒅྍືᇦࡢ᳨ウ . ⌮Ꮫ⒪ἲ̿⮫ᗋ࣭◊✲࣭ᩍ⫱ ,19,23-26.
すᓥྜྷ඾ , ຍ⸨㐩㞝 , ୰ᕝ ᏹ , ௚㸦2005㸧㸸୰㧗㱋⪅࡟ࡳࡽࢀࡿ ᖹᆅ Ṍ ⾜ ୰ࡢ Ṍ ᐜ ࡞ࡽࡧ ࡟➽ ά ື ≉ᛶ .Walking Research,9,89-94.
Nyberg L, Gustafson Y㸦1995㸧: Patient falls in stroke
rehabilitation. A challenge to rehabilitation strategies.
Stroke,26, 838- 842.
すᮧ㝯㸦2003㸧㸸ࣂࣛࣥࢫࡢホ౯ . 㛵す⌮Ꮫ 
ዉⰋ໏㸦2001㸧㸸ᶆ‽⌮Ꮫ⒪ἲᏛ ᑓ㛛ศ㔝 ⌮Ꮫ⒪ἲホ౯Ꮫ , ་Ꮫ᭩㝔 すୖᬛᙪ , ୰ᑿ⪽ᚿ , ᴮຬே , ௚㸦2006㸧: ࣁࣥࢻ࣊ࣝࢻ
ࢲ࢖ࢼ࣓࣮ࣔࢱ࣮ࢆ⏝࠸ࡓ㊊㛵⠇ᗏᒅ➽ຊࡢ⤒᪥ⓗ෌⌧ᛶؐ➽ຊỈ‽ࡢ㧗࠸ᑐ㇟⪅࡬ࡢᡭἲؐ . 㧗▱┴⌮Ꮫ⒪ἲ ,13,39-42.
ᒸすဴኵ㸦2015㸧㸸㌿ಽண㜵࡟ᚲせ࡞㐠ືᏛ . ࣜࣁࣅࣜࢼ࣮ࢫ 㸦
8 3㸧,214 -220.
Page P, Frank CC, Lardner R
㸦2013㸧: ࣖࣥࢲ࢔ࣉ࣮ࣟࢳ
࣐ࢵࢫࣝ࢖ࣥࣂࣛࣥࢫ࡟ᑐࡍࡿホ౯࡜἞⒪ , ᑠ಴⚽Ꮚ㸦┘ヂ㸧.49-51, ୕㍯᭩ᗑ , ᮾி .
Robinovitch SN, Feldman F, Yang Y, et al.㸦2013㸧:Video capture of the circumstances of falls in elderly
people residing in long- term care: an observational
VWXG\/DQFHW
᭶ᇛ៞୍ , ᒣᮏ⃈Ꮚ , Ụཎ⩏ᘯ , ௚㸦2005㸧: ほᐹ࡟ࡼᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Research Reportࠚ

$QNOHSODQWDUÀH[LRQDQJOHWKDWD൵HFWVKLSÀH[LRQPXVFOH
strength related to fall prevention

Ikumi Sirakaba*1ࠉHiroshi Takahashi*2*1 Rehabilitation Departmentࠊ Harajuku Rehabilitation Hospital*2ࠉFaculty of Rehabilitationࠊ Gifu University of Health Sciences
Abstract:HLQYHVWLJDWHGWKHUHODWLRQVKLSEHWZHHQWKHUDQJHRIPRWLRQRIWKHDQNOHSODQWDUÀH[LRQDQGWKHKLSÀH[LRQPXVFOH
VWUHQJWK DV WKH FDXVH RI WKH IDOO DQG LQYHVWLJDWHG WKH SRVVLELOLW\ WKDW WKH DQNOH SODQWDU ÀH[LRQ DQJOH LV UHODWHG WR WKHLPSURYHPHQWRIWKHVZLQJRIWKHORZHUOLPEV7KHVXEMHFWVZHUHVWD൵PHPEHUVRIDFHUWDLQKRVSLWDO㸦31 males: 24.29
s\HDUVROGIHPDOHVs 4.34 years old㸧 and 100 legs on both lower limbs. The measuring instrument wasa Todai goniometer, and the angle was measured in units of 1 degree. The range of motion of both ankle joints is measured
according to the "range of motion display and measurement method" established by the Japanese Society of Orthopedic
Surgery and the Japanese Society of Rehabilitation Medicine. A manual muscle strength meter 㸦Moby MT-100
manufactured by Sakai Medical Co., Ltd.㸧ZDVXVHGDVDPHDVXULQJGHYLFHIRUKLSÀH[LRQPXVFOHVWUHQJWK$VDUHVXOWDSRVLWLYHFRUUHODWLRQZDVIRXQGEHWZHHQWKHUDWLRRIWKHOHIWDQGULJKWDQNOHSODQWDUÀH[LRQUDQJHRIPRWLRQDQGWKHUDWLRRIWKHOHIWDQGULJKWKLSÀH[LRQPXVFOHVWUHQJWK㸦U 㸧 㸦p <0.05㸧DQG,WZDVVKRZQWKDWWKHKLSÀH[LRQPXVFOHVWUHQJWKRQWKHVLGHZKHUHWKHSODQWDUÀH[LRQUDQJHRIPRWLRQRIWKHDQNOHMRLQWLVH[SDQGHGLVVWURQJ
.H\ZRUGV$QNOHSODQWDUÀH[LRQDQJOH+LSÀH[LRQVWUHQJWK)DOOSUHYHQWLRQᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙ᐇ㊶ሗ࿌ࠚ

᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕ࣔࢽࢱࣜࣥࢢ᳨ᰝ㸦3&5 ᳨ᰝ㸧ࡢྲྀࡾ⤌ࡳᰣᮏ༓㭯 *1ࠉ✄ⴥᨻᚫ *2ࠉᴬཎ㯞Ꮚ *1ࠉᒾ℩㏻Ụ *1ࠉᑠụᏕᗣ *2
ࠉἙ⏣⨾⣖ *1ࠉᐊᩗஅ *3ࠉ
㸨 1 ᒱ㜧ಖ೺኱Ꮫ┳ㆤᏛ㒊
㸨 2 ᒱ㜧ಖ೺኱Ꮫࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊㸨 3 ᒱ㜧ಖ೺኱Ꮫ஦ົᒁせ᪨> ┠ⓗ @ ឤᰁࣜࢫࢡࡢ㧗࠸Ꮫ⏕࡟ෆ㛶ᗓࣔࢽࢱࣜࣥࢢ᳨ᰝ㸦ၚᾮ PCR ᳨ᰝ㸧ࢆᐇ᪋ࡋࠊ᳨ᰝࡢᶵ఍ࢆ฼⏝ࡋࡓᏛ⏕࡬ࡢឤᰁண㜵࡟ᑐࡍࡿၨⵚάືࡢྲྀࡾ⤌ࡳࡀ࡛ࡁࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋ> ᪉ἲ @ ᮏ኱Ꮫࡢయ⫱㤋ࢆᐇ᪋఍ሙ࡜ࡋࠊᐦࢆ㑊ࡅࡿࡓࡵ࡟ 3 ᪥㛫ࡢ᫬㛫ᕪࢆタࡅ࡚ᐇ᪋ࡋࡓࠋᮏேࡢྠពࡢࡶ࡜
ᐇ᪋ࡋࠊ᳨ᰝ⤖ᯝࡢ࿘▱ࡣᮏே࡜஦ົᒁ࡛ཝ㔜࡟⟶⌮ࡍࡿࡇ࡜ࢆఏ࠼ࡓࠋ> ⤖ᯝ࣭⪃ᐹ @ ᮏ኱Ꮫࡣ་⒪ᚑ஦⪅ࢆ⫱ᡂࡍࡿ኱Ꮫ࡛࠶ࡾࠊᏛ⏕ࡣࠊձྛ⮬ࡀࣔࢽࢱࣜࣥࢢ᳨ᰝࢆᐇ᪋ࡍࡿࡇ࡜࡛ࢥ
ࣟࢼឤᰁᣑ኱㜵Ṇ࡟ࡘ࠸࡚ࡢㄆ㆑ࢆ῝ࡵࡿࡇ࡜ࠊղྛ⮬ࡀᝈ⪅ࡸ⒪㣴⪅ࡢ❧ሙࢆయ㦂ࡍࡿࡇ࡜࡛ࠊ་⒪ᚑ஦⪅࡟࡞ࡗࡓሙྜࡢ᳨ᰝࡢㄝ᫂ࠊ᥋ࡋ᪉ࠊឤᰁ㜵Ṇࡢᢏ⾡࡟ࡘ࠸࡚࢖࣓࣮ࢪ࡙ࡃࡾࠊճࡶࡋ㝧ᛶ࡟࡞ࡗࡓࡽ࡜࠸࠺୙Ᏻ࠿ࡽࠊಶ
ே᝟ሗ㑂Ᏺ࡟ࡘ࠸࡚Ꮫࡪࡇ࡜ࡀ࡛ࡁࡓࡢ࡛ࡣ࡞࠸࠿࡜᥎ ࡋࡓࠋࡲࡓᩍဨ࡜஦ົᒁࡢ༠ྠసᴗ࡛ᐇ᪋࡛ࡁࠊ௒ᚋࡢ
኱Ꮫᩍ⫱࡛ࡢᩍဨ࡜஦ົᒁࡢ㐃ᦠ࡟ࡘ࠸࡚ࡶᮇᚅࡉࢀࡓࠋ
࣮࣮࢟࣡ࢻ㸸᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫࠊࣔࢽࢱࣜࣥࢢ᳨ᰝࠊయ㦂ᩍ⫱ࠊ኱Ꮫࠊከ⫋✀㐃ᦠᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ࡣࡌࡵ࡟
ᮏᏛ࡛ࡣࠊ᫖ᖺ᮶᪂ᆺࢥࣟࢼឤᰁ⑕ᑐ⟇࡜ࡋ࡚ࠊࢡࣛࢫࢱ࣮ࡀⓎ⏕ࡋ࡞࠸ࡼ࠺࡟࡛ࡁࡿ㝈ࡾࡢࡇ࡜ࢆࡋ࡚ࡁࡓࠋ
ࡇ࠺ࡋࡓ୰ࠊᒱ㜧┴ࡣෆ㛶ᐁᡣ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ
⑕ᑐ⟇ࠕឤᰁᣑ኱ࡢண඙ࡢ᪩ᮇ᥈▱ࡢࡓࡵࡢࣔࢽࢱࣜ
ࣥࢢ᳨ᰝࠖເ㞟᱌ෆࢆࡋࡓࠋ඲ᅜࣔࢽࢱࣜࣥࢢ᳨ᰝࡢ≧ἣࡣࠊᐇ᪋⣼ィ  ྡࠊ⤖ᯝ㝧ᛶ␲࠸⪅ 0.12%
㸦2᭶ 22 ᪥㹼 9 ᭶ 20 ᪥⌧ᅾ㸧࡛࠶ࡾࠊᖺ௦ู㝧ᛶ⋡ࡣ 10௦ࡀ᭱ࡶ㧗ࡃࠊḟ࠸࡛ 20 ௦࡛ከࡃ࡞ࡗ࡚࠸ࡿ㸦ෆ㛶ᐁᡣ㸪
2021㸧ࠋᮏ኱Ꮫࡣࠊ་⒪⣔ࡢ኱Ꮫ࡛࠶ࡾࠊ኱Ꮫෆ࡛ࡢ
Ꮫࡧࡶㅮ⩏ᙧᘧࡢ௚࡟Ꮫ⏕㛫࡛Ꮫࡧ࠶࠺₇⩦ᙧᘧࠊ᭦࡟⑓㝔࣭᪋タࡸᆅᇦ࡛ࡢᐇ⩦ࡶ᥍࠼࡚࠸ࡿࠋṤ࡝ࡢᏛ෗┿ ࠉ3&5 ㄝ᫂⏕ࡀ࣡ࢡࢳࣥ᥋✀ࢆ 2 ᅇ⤊࠼࡚࠸ࡿࡀࠊ࣡ࢡࢳࣥ᥋✀ᚋࡢຠᯝ࡟ࡘ࠸࡚ࡣ 100% ࡜࠸࠺ࡇ࡜࡛࡞࠸ࠋࡑࡢࡓࡵ
࡟ࠊᮏ኱Ꮫ࡜ࡋ࡚ࡣࠊᏛ⏕࡟౵くࡢ࡞࠸ࡶࡢ࡛࠶ࢀࡤࠊ
࡛ࡁࡿᑐ⟇ࢆᬑẁ࠿ࡽ⥅⥆ࡋ࡚ᐇ᪋ࡋࠊࢡࣛࢫࢱ࣮Ⓨ⏕ண㜵࡟ດࡵ࡚ࡁࡓࠋ௒ᅇࡣࠊឤᰁࣜࢫࢡࡢ㧗࠸Ꮫ⏕࡟ࣔࢽࢱࣜࣥࢢ᳨ᰝࢆᐇ᪋ࡋࠊ᳨ᰝࡢᶵ఍ࢆ฼⏝ࡋࡓᏛ⏕࡬ࡢឤᰁண㜵࡟ᑐࡍࡿၨⵚάືࡢྲྀࡾ⤌ࡳࡀ࡛ࡁࡿ
ࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋ
㸬ᐇ᪋ᴫせ2.1 ᑐ㇟⪅ࠉᮏᏛࡢᏛ⏕࡜ᩍ⫋ဨ㸦௨ୗ᳨⪅࡜࠸࠺㸧࡛఍ሙ࡟᮶
ሙࡋࡓ⪅
2.2 ᐇ᪋᫬ᮇ
ࠉ3 ᪥㛫ࢆタᐃࡋࠊ᭦࡟᫬㛫ᖏࢆタࡅࡓ෗┿ ࠉཷ௜
2.3 ᐇ᪋ሙᡤ
ࠉᒱ㜧ಖ೺኱Ꮫయ⫱㤋ෆᐜ
2.4.1 ‽ഛࠉ㸦෗┿ 1 㹼 5㸧ࠉㅮᇽ࡟㛗ᮘࢆ 10 ྎ‽ഛࡋࠊ2 ิ࡟㓄⨨ࡋࡓࠋิࡢ
㛫࡟ࣃ࣮ࢸ࣮ࢩࣙࣥࢆタࡅࡓࠋ᳔Ꮚࡣᮘࡢ୧⬥࡟๓᪉ࢆྥࡅ࡚㓄⨨ࡋࡓࠋᮘࡢୖ࡟ࡣࠊ
ྛ⮬ࡀぢ࠼ࡿㄝ᫂᭩㸦࣑ࣛࢿ࣮ࢺ㸧3Ⅼࠊྛ⮬ࡀၚᾮࡢ࣮ࣟࢺࢆᤞ࡚ࡿࡼ࠺࡟ࣅࢽ࣮
ࣝ⿄㸦ᑠ㸧2 ᯛ࡜ࡑࡢ௚ࡢࡶࡢࡀᤞ࡚ࡿࣅࢽ࣮ࣝ⿄㸦኱㸧
1 ᯛࠊ࢔ࣝࢥ࣮ࣝධࡾ㝖⳦ࢩ࣮ࢺ 2 ಶࢆ⏝ពࡋࡓࠋ఍ሙ
ෆࡢㄏᑟࠕЍ࡛ࠖ♧ࡋࡓࠋ෗┿ ࠉၚᾮ᥇ྲྀ఍ሙ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

2.5 ೔⌮ⓗ㓄៖೔⌮ⓗ㓄៖࡜ࡋ࡚ࠊᮏᩥෆᐜࡣᐇ᪋ࡋࡓෆᐜࢆṇ☜࡟グ㍕ࡋࠊ఍ሙࡢ෗┿ࡣ༏ྡᛶ࡟㓄៖ࡋࡓࠋࡲࡓᮏᩥ
ෆᐜ࡟ࡘ࠸࡚ࡣࠊᐇ㊶ሗ࿌⪅࡟ࡼࡿࢳ࢙ࢵࢡࢆ౫㢗ࡋࠊࡑࢀࡽࡢṇ☜ᛶࠊཝᐦᛶࢆ☜ಖࡋࡓࠋ㸬⤖ᯝ࣭⪃ᐹ௒ᅇࡢࣔࢽࢱࣜࣥࢢ᳨ᰝࢆᐇ᪋࡟࠾ࡅࡿᏛ⏕࡬ࡢၨⵚάື࡜ࡋ࡚ࠊឤᰁண㜵ᑐ⟇ࠊ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫ࡬ࡢព
㆑࡙ࡅࠊయ㦂ᩍ⫱ࡢ 3 ࡘ࡜࡞ࡗࡓࠋᐇ᪋࡟࠶ࡓࡾࠊ஦
ົᒁ࡜ከ⫋✀ࡢ㐃ᦠࡀ࠶ࡀࡗࡓࠋ
3.1 ឤᰁண㜵ᑐ⟇᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫࡢ≉ᚩࢆ㋃ࡲ࠼࡚ࠊឤᰁண㜵ᑐ⟇ࢆᚭᗏࡋࡓࠋ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫࡢ≉ᚩ࡟ࡘ࠸࡚ࡣࠊձ
㣕ἓឤᰁ࡛ 0.005 ࣑ࣜ௨ୖ㸦5 ȣ㹫㸧ࡢ㣕ἓឤᰁࢆࡍࡿࠋ
ղࢥࣟࢼ࢘࢖ࣝࢫࡣࠊ࢘࢖ࣝࢫࡢ RNA ࡀ࢚࣮ࣥ࣋ࣟࣉ෗┿ ࠉᮘୖࡢ‽ഛ࡟ᅖࡲࢀ࡚࠾ࡾࠊ࢔ࣝࢥ࣮ࣝࡸ▼㮯࡛࢚࣮ࣥ࣋ࣟࣉࢆ㝖ཤ࡛ࡁࡿࠋճ㣕ἓឤᰁࡣ 1 㹼 2m ࡛ⴠୗࡍࡿࠋմ᥋ゐឤᰁ࡛ࡣࠊࣉࣛࢫࢳࢵࢡୖ࡛ࡣࠊ3 ᪥㛫఩࡛ឤᰁຊࡀ࡞
ࡃ࡞ࡿࠋࡀ࠶ࡆࡽࢀ࡚࠾ࡾ㸦ᓠ௚ ,2020㸧ࠊࡑࢀࡒࢀ࡟
ᑐࡍࡿ఍ሙ‽ഛࢆ⾜ࡗࡓࠋᮘࡢ㓄⨨ࡣ 2m 㛤ࡅࠊ᳔Ꮚࡣᮘࡢ୧⬥࡟๓᪉ࢆྥࡅ࡚㓄⨨ࡋࠊ᳨⪅ྠኈࡀᑐ㠃࡟࡞ࡽ࡞࠸ࡼ࠺࡟ᕤኵࡋࡓࠋࡲࡓ఍ሙෆࡢㄏᑟࠕЍ࡛ࠖ♧ࡋࠊᑐ㠃࡟࡞ࡽ࡞࠸ࡼ࠺࡟ࡋࡓࠋㄝ᫂᭩㸦࣑ࣛࢿ࣮ࢺ㸧ࡸᮘࠊ᳔Ꮚࡣ᳨⪅ࡀᗙࡿ๓ᚋ࡟࢔ࣝࢥ࣮ࣝᾘẘࢆࡋࡓࠋၚᾮࡢධࡗࡓ࣮ࣟࢺࡣูࡢ⿄࡟ᤞ࡚ࡉࡏࠊឤᰁ※ࡢᣑ኱㜵Ṇ࡟ດࡵࡓࠋయ⫱㤋ࡣ❆ࢆ㛤ࡅࠊ᥮Ẽࢆ඘ศ࡟ࡋࡓࠋ
᳨⪅࡟ࡣධሙ๓ࡢὀពࢆఏ࠼ࡓࠋ1 ᫬㛫๓࠿ࡽࡢ㣧㣗ࡢ㜵Ṇࠊಶே᝟ሗࡢ⏝⣬ࠊ᳨ᰝⓏ㘓῭ࡳࡢࢫ࣐࣮ࢺ
ࣇ࢛ࣥࡢᣢཧࠊ
ཬࡧឤᰁ⑕ࡢண㜵ᑐ⟇ࠊձ 3 ⻤ࢆ㑊ࡅࡿࠋղ࣐ࢫࢡࢆ╔⏝ࡍࡿࠋճႅࡽ࡞࠸ࠋ࡟ࡘ࠸࡚ఏ࠼ࡓࠋ᭦
࡟ࠊᩍᐊ࠿ࡽࡢ⛣ື࡟ 10 ศࡢ᫬㛫ᕪࢆタࡅࠊ10 ேࡎ෗┿ ࠉ᳔Ꮚࡢᾘẘࡘ 2m ࡢ㛫㝸ࢆ㛤ࡅ࡚఍ሙ࡬⛣ືࢆࡉࡏࡓࠋࡑࡢࡇ࡜
᳨࡛ᰝ఍ሙ๓ࡢᐦࢆ㑊ࡅࡿࡇ࡜࡜ࠊ᳨ᰝ⤊஢ࡢᏛ⏕࡜

2.4.2 ᑐ㇟⪅࡬ࡢ࿘▱᪉ἲ

ࡀ㏵୰࡛஺ᕪࡋ࡞࠸ࡼ࠺࡟ᕤኵࢆࡋࡓࠋ

஦ົᒁࡼࡾ࣏࣮ࢱࣝࢧ࢖ࢺ࡛ᑐ㇟⪅඲ဨ࡟᱌ෆᩥࠊ࢔

᳨⪅ࡣ 10 ேࡎࡘࡢࢢ࣮ࣝࣉ㞟ᅋ࡛ཷ௜ࠊ఍ሙෆࡢ᳔

ࣉࣜ᱌ෆᩥ㈨ᩱ㸦࢔࢝࢘ࣥࢺⓏ㘓ࠊ᳨ᰝ᪥ࡢண⣙㸧ࠊಶᏊ࡟ㄏᑟࡋࡓࠋ᫬㛫ࢆぢ࡚ࠊ඲ဨࡀ⤊ࢃࡗࡓ࡜ࡇࢁ࡛ࠊ

ே᝟ሗࡢ฼⏝┠ⓗ㸦➨୕⪅ᥦ౪㸧ࠊಶே᝟ሗಖㆤ࡟㛵ᮘ࡜᳔Ꮚࡢ࢔ࣝࢥ࣮ࣝᾘẘࢆࡋ࡚ࠊูࡢࢢ࣮ࣝࣉࢆㄏᑟ

ࡍࡿྠព᭩ࡢ 4 Ⅼࢆῧ௜ࡋࡓࠋ

ࡋࡓࠋࢢ࣮ࣝࣉࡢ୰࡛ࠊၚᾮࡢ᥇ྲྀࡀ࡛ࡁ࡞࠸᳨⪅ࡣྛᏛᖺࡢ࢞࢖ࢲࣥࢫ᫬ࠊ⾨⏕ጤဨ఍ࡼࡾࠊձࢥࣟࢼឤ
ᰁ㸦3 ᐦᑐ⟇ࡢᚭᗏ㸧ࠊղࣁࣛࢫ࣓ࣥࢺ㜵Ṇ㸦ឤᰁ⪅࣭఍ሙࡢቨഃ࡟タࡅࡓᮘ࡜᳔Ꮚ࡟⛣ືࢆࡋ࡚ࠊ᥇ྲྀࡀࡁ
ࡿࡼ࠺࡟ᕤኵࢆࡋࡓࠋ⃰ཌ᥋ゐ⪅࡬ࡢᑐᛂࠊಶே᝟ሗಖㆤ㸧ࠊճࣔࢽࢱࣜࣥ

࢘࢖ࣝࢫࡣ 30 ᠈ᖺ࡟ࢃࡓࡾ⏕ࡁ⥆ࡅࠊ20 ୡ⣖ᚋ༙࡟ࢢ᳨ᰝࡢ┠ⓗ࣭ᐇ᪋᪉ἲࠊࡢ 3 Ⅼ࡟ࡘ࠸࡚㈨ᩱࢆ⏝࠸ࡣࠊ⃭ືࡢ⎔ቃࡢ୰࡛⏕ࡁᢤ࠸ࡓ࢘࢖ࣝࢫࡀே㛫࡟⬣ጾ࡚ㄝ᫂ࢆ⾜ࡗࡓࠋ

ࢆ୚࠼ࡿ࡜࠸࠺㸦ᒣෆ㸪2018㸧ࠋ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫࡣࠊ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021௒⚾ࡓࡕࡢ๓࡟ึࡵ࡚࠶ࡽࢃࢀࠊࡇࢀ࠿ࡽࡶ୍㒊ࡣ⏕ᛂኚࡢᙺ๭ࡀ࡛ࡁࠊຠ⋡ࡼࡃࠊᏳ඲࡟᳨ᰝࢆ㐙⾜ࡍࡿࡁᢤࡃࡇ࡜࡟࡞ࡿࠋ

ࡇ࡜ࡀ࡛ࡁࡓࠋࡲࡓࠊ㐃ᦠ࡟ࡼࡾ‽ഛẁ㝵ࡸᐇ᪋୰࡟

ឤᰁண㜵ᑐ⟇ࡣࠊ᫂ࡽ࠿࡟࡞ࡗ࡚࠸ࡿண㜵ᑐ⟇ࢆᚭࡶᨵၿࢆᅗࡾࠊ๰ពᕤኵࡀ࡛ࡁࡓࠋ᳨ᰝ⤖ᯝࡢ≉ᐃ୙ᗏࡋࠊ᳨ᰝࡢሙࡀឤᰁ※࡟࡞ࡿࡇ࡜ࡔࡅࡣ㑊ࡅࡓ࠸࡜ྍ㸦ヱᙜ୙᫂⪅㸧ࡀฟࡓሙྜࡢண ࢆࡋࠊẶྡ࡜ࢥ࣮ࢻ

⪃࠼ࡓࠋ␒ྕࡢ᥍࠼ࢆసᡂࡋࡓࠋᐇ㝿࡟ࡣࠊ3 ᪥᪥ࡢ≉ᐃ୙᫂⪅ࡣ 32 ே࠸ࡓࡀ඲ဨ㝜ᛶ࡛࠶ࡗࡓࠋࢥ࣮ࢻ␒ྕ໬࠿ࡽ
᳨⪅ࢆ≉ᐃࡋࠊ㏻▱ࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋ

3.2 ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫ࡬ࡢព㆑࡙ࡅ
࢞࢖ࢲࣥࢫ᫬࡟ PCR
㸦Polymerase Chain Reaction㸧᳨ၚᾮᐜჾࡢᗫᲠ࡟ࡘ࠸࡚ࡶࠊ᭱ึࡣ኱ᆺ⿄ 1 ࡘ࡟ࡋᰝ࡜ࡣࠊ≉␗ⓗ࡞ DNA ࢆቑᖜࡉࡏࠊࡑࡢ DNA ࡀᏑᅾ࡚࠸ࡓࡀࠊᚋࡢ࢔ࣝࢥ࣮ࣝᾘẘᐇ᪋࡟࠶ࡓࡾࠊ
ၚᾮࡢ࣮ࣟࡋࡓࡇ࡜࡛యෆ࡟࢘࢖ࣝࢫࡀ࠸ࡓ࡜ุᐃ࡛ࡁࡿࡇ࡜ࢆఏ

ࢺࡔࡅࢆศูࡋ࡚ᑠᆺ⿄࡟ኚ᭦ࡋࡓࠋ᳔Ꮚࠊᮘࡢୖࡢ

࠼ࡓࠋ᳨యࡀṇ☜࡟ྲྀࢀࡿࡓࡵ࡟ࠊ᥇ྲྀ๓ࡢὀពࠊ᥇

ᾘẘࡶᕤኵࡋࠊ࡛ࡁࡿᢸᙜᩍဨࡀ⋡ඛࡋ࡚⾜ࡗࡓࠋࡶࡋࠊ

ྲྀ᫬ࡢὶࢀࢆࣃ࣮࣏࣡࢖ࣥࢺ㈨ᩱ࡛ぢࡏࠊ඲యࡢ࢖࣓࣮

㝧ᛶ⪅ࡀ࡛ࡓሙྜ࡛ࡶࠊ௚ࡢ᳨⪅࡟ᙳ㡪ࡢ࡞࠸ࡼ࠺࡟

ࢪࢆᣢࡓࡏࡓࠋࡲࡓࣁࣛࢫ࣓ࣥࢺ㜵Ṇ㸦ឤᰁ⪅࣭⃰ཌ᥋⣽ᚰࡢὀពࢆᡶ࠺ࡇ࡜ࡀ࡛ࡁࡓࠋ

ゐ⪅࡬ࡢᑐᛂࠊಶே᝟ሗಖㆤ㸧࡟ࡘ࠸࡚ࡶ࢞࢖ࢲࣥࢫ᫬
ࡲ࡜ࡵ࡟ヰࡋࠊ㝧ᛶ࡜デ᩿ࡉࢀࡓሙྜࡢ୙Ᏻ㍍ῶࡸࠊᙜ᪥ࡢ

௒ᅇࡢࣔࢽࢱࣜࣥࢢ᳨ᰝࢆᐇ᪋ࡋࠊ௨ୗࡢࡇ࡜ࡀࢃ࠿

᳨ᰝࡣ௵ព࡛࠶ࡿࡇ࡜ࢆఏ࠼࡚ࠊ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫ࡬

ࡓࠋࡢព㆑࡙ࡅࢆᅗࡗࡓࠋ

1㸬Ꮫ⏕࡬ࡢ᪂ᆺࢥࣟࢼឤᰁ⑕ண㜵࡟ᑐࡍࡿၨⵚάື
ࡢྲྀࡾ⤌ࡳࡀ࡛ࡁࡓࠋ

3.3 య㦂ᩍ⫱2㸬་⒪ࢆᏛࡪᏛ⏕࡜ࡋ࡚ࠊၚᾮᦤྲྀࡢయ㦂Ꮫ⩦ࡀ࡛ࡁၚᾮࡣࠊ᪂ᆺࢥࣟࢼឤᰁ⑕⤒㊰࡜࡞ࡾࠊៅ㔜࡟ྲྀࡾᢅ࠺ᚲせࡀ࠶ࡿࠋ᳨⪅ࡣࠊయ㦂࡟ࡼࡾࠊ᥇ྲྀ᪉ἲࠊᐜ

ࡓࠋჾಖᏑࠊ࿘ᅖ࡬ࡢឤᰁᣑ኱ࠊᥦฟࡢ௙᪉ࢆᏛࡪࡇ࡜ࡀ

3㸬᳨ᰝ஦ᴗࢆ㏻ࡋ࡚ࠊ஦ົ⫋ဨ࡜ከ⫋✀ᩍဨࡢ㐃ᦠ࡛ࡁࡓࠋ⡆༢࡞ࡼ࠺࡛ࡶࠊ
᳨⪅ࡓࡕࡣࠊ࢟ࢵࢺࡢྲྀࡾᢅ࠸ࠊࡢ㔜せᛶࡀ᫂ࡽ࠿࡟࡞ࡗࡓࠋ

ၚᾮ᥇ྲྀ㔞ࡢ☜ㄆࠊ࿘ᅖࡢ࢔ࣝࢥ࣮ࣝΎᣔࠊ᥇ྲྀ≀ရ฼┈┦཯

ࡢᤞ࡚᪉➼☜ㄆࡋ࡞ࡀࡽᐇ᪋ࡋ࡚࠸ࡓࠋ

ᮏㄽᩥ࡟㛵ࡋ࡚㛤♧ࡍ࡭ࡁ฼┈┦཯ࡣ࠶ࡾࡲࡏࢇࠋࠉ

ၚᾮ᥇ྲྀ᫬࡟ࡣࠊᱵᖸࡋ➼ࡢどぬࡸ⯉ୗ⭢➼ࡢ่⃭࠿ࡽၚᾮศἪࢆಁࡍ᪉ἲࢆ♧ࡋࡓࠋࡲࡓၚᾮ᥇ྲྀᚋࡢ

ࠉࠉឤᰁ㜵Ṇ࡟ࡘ࠸࡚ࡶ఍ሙ࡛ぢ࡚ᅇࡗࡓࠋၚᾮᦤྲྀࡀࢢ

ㅰ㎡
ᮏᐇ㊶άື࡟࠶ࡓࡾࡈ༠ຊ㡬࠸ࡓᩍ⫋ဨࡢⓙᵝ࡟῝࣮ࣝࣉ᳨⪅࠿ࡽ㐜ࢀࡓ᳨⪅࡟ࡘ࠸࡚ࡣࠊቨഃ࡟⏝ពࡋࡓᖍ࡟⛣ືࡉࡏࠊࡺࡗࡃࡾၚᾮ᥇ྲྀࡀ࡛ࡁࡿࡼ࠺࡟ࡋࡓࠋ

ࡃឤㅰ⏦ࡋୖࡆࡲࡍࠋ

ၚᾮ᥇ྲྀ఍ሙ࡟ࡣࠊಶே㜵ㆤල㸦PPE㸧ࢆ⿦ഛࡋࡓᩍ
ဨࡀ 3 㹼 5 ேᖖ㥔ࡋࠊಶูࡢࢧ࣏࣮ࢺࢆᐇ᪋ࡋࡓࠋࡑ

ᘬ⏝ᩥ⊩

ࡢ⤖ᯝࠊၚᾮ㔞୙㊊➼ุ࡛ᐃ࡛ࡁ࡞࠿ࡗࡓ᳨⪅ࡣ 4 ேෆ㛶ᐁᡣࠉ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁᑐ⟇ HPࡢࡳ࡛࠶ࡗࡓࠋ

https://corona.go.jp/monitoring/㸦2021 ᖺ 9 ᭶ 26 ᪥㜀ぴ㸧ᓠ᐀ኴ㑻࣭ᒣ୰ᾈஅ㸦2020㸧㸬᪂ᆺࢥࣟࢼ࡜࣡ࢡࢳࣥ▱ࡽ࡞࠸࡜୙㒔ྜ࡞┿ᐇ㸪19-40㸪᪥⤒ࣉ࣑ࣞ࢔࣒ࢩ࣮ࣜ

3.4 ஦ົ࡜ከ⫋✀ᩍဨࡢ㐃ᦠࢬ㸪ᮾி㸬ᮏᏛࡣ┳ㆤᏛ㒊ࠊࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊ࠊࡣࡾ࣭ࡁࡹ

ᒣෆ୍ஓ㸦2018㸧㸬࢘࢖ࣝࢫࡢព࿡ㄽࠉ⏕࿨ࡢᐃ⩏ࢆ㉸࠺➼ࡢᑓ㛛Ꮫᰯࡀ࠶ࡾࠊ඲ဨࡢᏛ⏕ࡸᩍ⫋ဨࡀ᳨⪅ࡢ࠼ࡓᏑᅾ㸪205-206㸪ࡳࡍࡎ᭩ᡣ㸪ᮾி㸬ᑐ㇟࡜࡞ࡗࡓࠋࡑࡢࡓࡵ࡟ࠊྛ㒊㛛ᩍဨࡸ஦ົ⫋ဨࡀ㐃ᦠࡋ࡚఍ሙࡢタႠࠊ㐠Ⴀࢆ⾜ࡗࡓࠋᖹᖖ᫬ࡢᤵᴗࡸ
఍ྜ➼ࡀ࠶ࡿ୰࡛ࠊ᳨ᰝᮇ㛫ࡢࢫࢣࢪ࣮ࣗࣝࢆឤᰁ⑕
ᑐ⟇ࡢᚭᗏࢆᅗࡾ࡞ࡀࡽࠊ෇⁥࡟㐍ࡵࡿ࡟ࡣከ⫋✀㛫ࡢ㐃ᦠࡀḞ࠿ࡏ࡞࠸ࠋ஦ົᒁ࣭⾨⏕ጤဨ఍ࢆ୰ᚰ࡟ࡋ࡚ࠊ
ከࡃࡢᩍဨࡢ༠ຊࢆᚓࡓࠋ
㐃ᦠ࡟ࡼࡾࠊ㈐௵ࡢᡤᅾࢆ᫂☜࡟ࡍࡿ࡜࡜ࡶ࡟ࠊ⮫ᶵᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Practice Reportࠚ

An Initiative to Implement Covid-19 Monitoring Tests 㸦PCR Tests㸧
Chizuru Tochimoto*1,ࠉMasanori Inaba*2, Asako Sakakibara*1, Michie Iwase*1,
Takayasu Koike*2, Miki Kawada*1, Keisuke Muro*3
㸨 1Gifu University of Health Sciences Department of Nursing
㸨 2Gifu University of Health Sciences Department of Rehabilitation㸨 *LIX8QLYHUVLW\RI+HDOWK6FLHQFHV$GPLQLVWUDWLYH2൶FH

Abstract
>$LP@7KHDLPRIWKHVWXG\ZDVWRSURYLGHPRQLWRULQJWHVWV㸦saliva PCR tests㸧 to students and to use this initiative asa means to illuminate the present situation.
>0HWKRG@7HVWVZHUHDGPLQLVWHUHGLQXQLYHUVLW\DXGLWRULXPVRYHUVHSDUDWHGD\VLQRUGHUWRDYRLGFORVHFRQWDFWVHWWLQJVConsent was obtained and subjects were told that the results would be kept under strict control and known only by them
DQGWKHDGPLQLVWUDWLYHR൶FH
>5HVXOWVDQG'LVFXVVLRQ@7KLVXQLYHUVLW\HGXFDWHVPHGLFDOVWD൵DQGLWLVDVVXPHGWKDW㸦1㸧 the carrying out of monitoring
WHVWVGHHSHQHGDZDUHQHVVRIKRZWRSUHYHQWWKHVSUHDGRI&RYLG㸦2㸧 that participants could view the situation from
WKHSHUVSHFWLYHRISDWLHQWVDQGGHYHORSDQLPDJHLQWKHLUPLQGVRIKRZKHDOWKSURIHVVLRQDOVVKRXOGH[SODLQDERXWPHGLFDOWHVWVDQGDGRSWWHFKQLTXHVIRUWKHSUHYHQWLRQRILQIHFWLRQDQG㸦3㸧WKDWSDUWLFLSDQWVFRXOGOHDUQDERXWWKHDQ[LHW\WKDW
accompanies testing positive and about the importance of compliance with rules concerning the handling of personal
information. Furthermore, since this project was conducted through the cooperation of faculty members and the
DGPLQLVWUDWLYHR൶FHLWLVKRSHGWKDWOHVVRQVFDQEHOHDUQHGDERXWKRZWKHVHWZRJURXSVFDQDVVLVWHDFKRWKHUWRGHYHORS
university education.
Keywords㸸&RYLGPRQLWRULQJWHVWVH[SHULHQWLDOHGXFDWLRQXQLYHUVLW\PXOWLSURIHVVLRQOLQNLQJᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙ᐇ㊶ሗ࿌ࠚ

᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕⚝࡟࠾ࡅࡿᆅᇦ஺ὶάື࠿ࡽぢ࠼࡚ࡁࡓㄢ㢟ᰣᮏ༓㭯 *1ࠉ⏿ྜྷ⠇ᮍ *1ࠉ᳃⿱ᚿ *1ࠉᏱబ⨾▱Ꮚ *2ࠉ⚽ᒣṇ࿴ *3ࠉỈ㇂┿⌮Ꮚ *2⏣⚄ಙᘯ *4ࠉᯇἼᐇᬛ㄃ *5
㸨 1 ᒱ㜧ಖ೺኱Ꮫ┳ㆤᏛ㒊
㸨 2 ᒱ㜧ಖ೺኱Ꮫࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊㸨 3 ᒱ㜧ಖ೺኱Ꮫ་⒪ᑓ㛛Ꮫᰯ㸨 4 ♫఍⚟♴༠㆟఍㭘ᨭ㒊
㸨 5 ᒱ㜧ᕷ༡ಖ೺ࢭࣥࢱ࣮せ᪨> ┠ⓗ @ ᒱ㜧ᕷ A ᆅ༊ࢆᑐ㇟࡜ࡋࡓᆅᇦ஺ὶ఍ࢆᐇ᪋ࡋࠊ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕⚝࡟࠾࠸࡚ᆅᇦࢥ࣑ࣗࢽࢸ࢕ࡀ
ᢪ࠼ࡿㄢ㢟ࢆ᫂ࡽ࠿࡟ࡍࡿࡁࡗ࠿ࡅ࡙ࡃࡾࢆヨࡳࡓࠋ> ᪉ἲ@ ᒱ㜧ಖ೺኱Ꮫከ⫋✀㐃ᦠᐇ㊶ࢭࣥࢱ࣮࡟࡚஺ὶ఍ࢆ 2 ᅇᐇ᪋ࡋࡓࠋ࠸ࡃࡘ࠿ࡢࢸ࣮࣐࡟ࡘ࠸࡚ࣈ࣮ࣞࣥࢫࢺ࣮
࣑ࣥࢢ᪉ᘧ࡛ྛ⮬ࡢ⪃࠼ࡸᆅᇦࡀᢪ࠼ࡿၥ㢟Ⅼࠊㄢ㢟ࢆヰࡋྜࡗࡓࠋ> ⤖ᯝ @ ከ⫋✀࡜ᆅᇦࡢ௦⾲⪅ࡀಙ㢗㛵ಀࡢ୰࡛✀ࠎࡢゅᗘ࠿ࡽウㄽࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋࡑࡢ୰࡛᫂☜࡜࡞ࡗ࡚ࡁ
ࡓㄢ㢟ࡣࠊࠕᆅᇦఫẸࡀࠊࡑࢀࡒࢀࡢ౯್ほ࡟┦㐪ࡀ࠶ࡿࡇ࡜ࢆㄆ㆑ࡍࡿᚲせࡀ࠶ࡿࡇ࡜ࠖ
ࠕᆅᇦ࡛ࡣ┦஫࡟ಶேⓗ࡞ಙ㢗㛵ಀࢆ⠏ࡁࠊಶேⓗ࡞᝟ሗࢆඹ᭷ࡍࡿࡇ࡜ࡀ㔜せ࡛࠶ࡿࡇ࡜ࠖ
ࠕ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕ࢆࡁࡗ࠿ࡅ࡜ࡋ࡚ࠊ
ᆅᇦఫẸࡢࡩࢀ࠶࠸᫬㛫ࡀⴭࡋࡃῶᑡࡋ࡚࠸ࡿࡇ࡜ࠖ࡞࡝ࡀヰ㢟࡜࡞ࡗࡓࠋ> ⪃ᐹ @᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕⚝࡛ឤᰁ⑕ᑐ⟇ࢆࡋࡓୖ࡛ࡩࢀ࠶࠸᫬㛫ࢆ☜ಖࡋࠊࡇࡇ࡛ᣲࡀࡗ࡚ࡁࡓᆅᇦࡢㄢ
㢟࡟࡝ࡢࡼ࠺࡟ࡘ࡞ࡆ࡚ᆅᇦࡢ஺ὶࢆ῝ࡵࡿࡇ࡜ࡀ࡛ࡁࡿ࠿ࡀ௒ᚋࡢㄢ㢟࡜࡞ࡗࡓࠋ
࣮࣮࢟࣡ࢻ㸸ᆅᇦ஺ὶ఍ࠊ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕ࠊከ⫋✀㐃ᦠᐇ㊶ࢭࣥࢱ࣮ࠊᆅᇦఫẸࡢࡩࢀ࠶࠸

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ࡣࡌࡵ࡟

㸬᪉ἲ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕ࡣࠊ♫఍άື࡟኱ࡁ࡞ᙳ

2.1ࠉᆅᇦ஺ὶ఍ࡢᐇ᪋᫬ᮇ࠾ࡼࡧᐇ᪋ሙᡤ

㡪ࢆཬࡰࡋ࡚ࡁࡓࠋ⏘ᴗ⏺࡛ࡣࠊឤᰁ⑕ᣑ኱㜵Ṇࡢほ

8 ᭶ࠊ9 ᭶࡟ 2 ᅇࠊᒱ㜧ಖ೺኱Ꮫከ⫋✀㐃ᦠᐇ㊶ࢭ

Ⅼ࠿ࡽᅾᏯ໅ົࡀቑຍࡋࡓࡀࠊ୍᪉࡛⫋ሙෆࡢࢥ࣑ࣗ

ࣥࢱ࣮࡛ᐇ᪋ࡋࡓࠋ

ࢽࢣ࣮ࢩࣙࣥࡢపୗ࡟ࡼࡿ࣓ࣥࢱࣝ࣊ࣝࢫࡢၥ㢟ࡀⓎ⏕ࡋࡓ㸦ᒸ⏣ 2021㸧ࠋ௓ㆤ᪋タࡢ⌧ሙ࡛ࡣ㠃఍ࡀ 1 ᖺ௨

2.2ࠉᆅᇦ஺ὶ఍࡬ࡢཧຍ⪅ୖ࡟ࢃࡓࡾไ㝈ࢆཷࡅࠊ฼⏝⪅ࡸᐙ᪘࠿ࡽࡢ㠃఍ᕼᮃ᫖ᖺᗘࡢᮏࢭࣥࢱ࣮ࡢάື㸦ᒱ㜧ಖ೺኱Ꮫ⣖せ➨ 2

ࡢᑐᛂ࡟ヨ⾜㘒ㄗࡀ⾜ࢃࢀࡓ㸦୰⏣ 2021㸧ࠋᅾᏯ⒪㣴ᕳ SS 㹼 85㸧࡬ࡢཧຍ⪅࡟ࡼࡿ࿧ࡧ࠿ࡅ࡟ᛂࡌࡓ Aࢧ࣮ࣅࢫࢆཷࡅ࡚࠸ࡿ⒪㣴⪅Ꮿ࡛ࡣᅾᏯᨭ᥼⪅㸦࣊ࣝᆅ༊ఫẸ࠾ࡼࡧᮏᏛࡢᩍဨ࣭⾜ᨻ⫋ဨࡀཧຍࡋࡓࠋ௦ࢃࡾ࡟ゼၥ┳ㆤࡀᐇ᪋ࡉࢀࡓ㸦ᒣࣃ࣮㸧
ࡢ᧔㏥ࡀ࠶ࡾࠊ

➨ 1 ᅇ㸸ཧຍ⪅  ྡ㸦A ᆅ༊ఫẸ 1 ྡࠊᩍဨ࣭⾜ᨻᓮ 2021㸧ࠋࡲࡓࠊᶓ὾ᕷࡢ B ᆅ༊ࢭࣥࢱ࣮ࢆ฼⏝ࡍࡿ⫋ဨ 6 ྡ㸧㧗㱋⪅࡬ࡢㄪᰝ࠿ࡽࡣࠊᚋᮇ㧗㱋⪅ࡣᆅᇦࡢ஺ὶࡢሙ

➨ 2 ᅇ㸸ཧຍ⪅ 6 ྡ㸦A ᆅ༊ఫẸ 1 ྡࠊᩍဨ࣭⾜ᨻ࡬ཧຍࡍࡿࡇ࡜࡛࿘ࡾࡢࡶࡢ࡟㏞ᝨࢆ࠿ࡅ࡚ࡣ࠸ࡅ࡞࠸

⫋ဨ 5 ྡ㸧࡜࠸࠺㐲៖ࡀࡳࡽࢀࡓࠋࡑࡇ࡛ࠊᚋᮇ㧗㱋⪅ࡀཧຍࡋࡸࡍࡃ࡞ࡿࡼ࠺࡟ࠊ஫ຓࡢព㆑ࢆ㧗ࡵࡿᆅᇦάື࡟ྲྀࡾ

2.3ࠉᆅᇦ஺ὶ఍ࡢᐇ᪋ෆᐜ

⤌ࢇ࡛࠸ࡿࡇ࡜ࡀ᫂ࡽ࠿࡟࡞ࡗࡓ㸦ሯཎ௚ 2021㸧ࠋࡉࡽ஺ὶ఍ཧຍ⪅ࡢಙ㢗㛵ಀసࡾࠊࢥࣟࢼ⚝࡛ࡢ೺ᗣ㣗࡟ࠊゼၥ┳ㆤࢫࢸ࣮ࢩࣙࣥ➼ࡢㄪᰝ࠿ࡽࠊ㏆㞄⪅࡜ࡢࡢព⩏ࠊᆅᇦࡢṔྐ࡜ᆅᇦࢥ࣑ࣗࢽࢸ࢕ࠊࢥࣟࢼ⚝࡟࠾ฟ఍࠸ࡢᶵ఍ࡢ⮬⢔せㄳ࠿ࡽ㧗㱋⪅ࡣᒇእࡢእฟពḧࡅࡿᆅᇦఫẸࡢ⏕άࢆࢸ࣮࣐࡜ࡋ࡚ྲྀࡾୖࡆࠊཧຍ⪅ࡀࡢῶᑡࡀぢࡽࢀࡿ㸦⏿ 2021㸧ࡇ࡜ࡸ㜵ㆤල╔⏝࡟ࡼࡿ㧗ࣈ࣮ࣞࣥࢫࢺ࣮࣑ࣥࢢ᪉ᘧ࡛ヰࡋྜࡗࡓࠋヰࡋྜࡗࡓෆ

㱋⪅ࡢࢣ࢔࡬ࡢᙳ㡪࠿ࡽᆅᇦࡢᨭ᥼యไࠊឤᰁ⑕ᑐ⟇ᐜࢆせ⣙ࡋࠊ᫂ࡽ࠿࡟࡞ࡗࡓ௒ᚋࡢㄢ㢟ࢆᐇ㊶ሗ࿌࡜ࡋࡢぢ┤ࡋࡀᚲせ࡜ࡢᥦ᱌㸦ཎ⏣௚ 2021㸧ࡀ⾜ࢃࢀࡓࠋࡓࠋෆᐜࡢศᯒ࠾ࡼࡧせ⣙࡟ࡘ࠸࡚ࡣࠊཧຍ⪅࡟ࡼࡿ࡜ࡇࢁ࡛ࠊᮏᏛࡢከ⫋✀㐃ᦠᐇ㊶ࢭࣥࢱ࣮ࡣࠊᑓ㛛ࢳ࢙ࢵࢡࢆ౫㢗ࡋࠊࡑࢀࡽࡢṇ☜ᛶࠊཝᐦᛶࢆ☜ಖࡋࡓࠋ⫋ࡀ㐃ᦠࡍࡿࡇ࡜࡛ᆅᇦࡢ᝟ሗࢆ⥲ྜⓗ࡟ᤊ࠼ࠊᆅᇦ
ࡢ೺ᗣㄢ㢟ゎỴ࡟ྥࡅࡓᐇ㊶άືࢆ⾜࠺ࡇ࡜ࢆ┠ⓗ࡜ࡋ

2.4ࠉ೔⌮ⓗ㓄៖࡚ 3 ᖺ๓ࡢᮏᏛࡢタ❧࡜࡜ࡶ࡟タ⨨ࡉࢀࡓࠋࡋ࠿ࡋࠊ

೔⌮ⓗ㓄៖࡜ࡋ࡚ྛ⮬ࡢⓎゝࡣ༏ྡ࡜ࡋࠊ஺ὶ఍ࡢෆ

ࡑࡢᚋࡢᙜࢭࣥࢱ࣮ࡢάືࡶࡲࡓ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᐜࢆ⣖せ࡟බ⾲ࡍࡿࡇ࡜ࢆཧຍ⪅࡟ཱྀ㢌࡛ఏ࠼ࠊྠព

ᰁ⑕࡟ࡼࡗ࡚ከࡃࡢไ⣙ࢆཷࡅ࡚ࡁࡓࠋ

ࢆᚓࡓࠋ௒ᅇࡢᆅᇦ஺ὶ఍ࡣࠊ௒ᚋࡢάື࡟ఱࡀᚲせࡇࡢࡼ࠺࡞⫼ᬒ࡟㚷ࡳࠊᙜࢭࣥࢱ࣮࡛ࡣᒱ㜧ᕷ A ᆅ࠿ࠊάື᪉㔪ࢆ࡝ࡢࡼ࠺࡟ࡍࡿ࠿ࢆ᫂ࡽ࠿࡟ࡍࡿࡓࡵ⮬ᇦఫẸ࡜ከ⫋✀ࡀྜྠࡋ࡚ࢥࣟࢼ⚝ࡢ⌧ᅾࠊᆅᇦ࡛ᢪ⏤ウㄽࢆ୰ᚰ࡜ࡋࡓ஺ὶ఍ࢆ⾜ࡗࡓࡶࡢ࡛࠶ࡿࠋ

࠼࡚࠸ࡿၥ㢟࡟ࡘ࠸࡚ヰࡋྜ࠺ᆅᇦ஺ὶ఍ࢆ⾜ࡗࡓࠋAᆅ༊ࡣᮏᏛࡢ๓㌟࡛࠶ࡿᒱ㜧ಖ೺▷ᮇ኱Ꮫࡢ᫬௦࠿ࡽ

㸬⤖ᯝヰࡋྜ࠸ࡢᶵ఍ࢆᣢࡗ࡚ࡁࡓ኱Ꮫ㏆㞄ࡢᆅ༊࡛࠶ࡿࠋ

௒ᅇࡢ⮬⏤ウ㆟ࢆ୰ᚰ࡜ࡋࡓᆅᇦ஺ὶάືࡣཧຍ⪅㧗㱋⪅ࡀᴦࡋࡳ࡟ࡋ࡚ࡁࡓ A ᆅ༊ࡢᆅᇦࢧࣟࣥࡣ᪂

㛫ࡢಙ㢗㛵ಀసࡾ࠿ࡽጞࡵࠊձࢥࣟࢼ⚝࡛ࡢ೺ᗣ㣗ࡢᆺࢥࣟࢼឤᰁ⑕⚝࡟ࡼࡗ࡚㛗ᮇ࡟ࢃࡓࡾࠊ㛢㙐ࡉࢀࡓࠋព⩏ࠊղᆅᇦࡢṔྐ࡜ᆅᇦࢥ࣑ࣗࢽࢸ࢕ࠊճࢥࣟࢼ⚝࡟ᆅᇦ஺ὶࡢሙࢆኻࡗࡓ㧗㱋⪅ࡢ⏕άࡣࠊ⌧ᅾࠊ࡝ࡢࡼ

࠾ࡅࡿᆅᇦఫẸࡢ⏕άࡢ 3 Ⅼࢆ୰ᚰ࡟ヰࡋྜࡗࡓࠋ

࠺࡞≧ែ࡟࡞ࡗ࡚࠸ࡿࡢࡔࢁ࠺࠿ࠋ௒ࡲ࡛ࠊᏛᰯࡸ⫋ሙ࡟ฟ࠿ࡅ࡚࠸ࡓᐙ᪘ࡣ࢜ࣥࣛ࢖ࣥᤵᴗࡸࢸ࣮ࣞ࣡ࢡ࡛

3.1ࠉཧຍ⪅㛫ࡢಙ㢗㛵ಀసࡾᅾᏯࡢ᫬㛫ࡀቑ࠼ࡿ୰࡛ࠊᐙ᪘ࡢ఍ヰࡣከࡃ࡞ࡗࡓࡢ࡛

᭱ึ࡟Ẽ㉁ࢳ࢙ࢵࢡ⾲㸦᐀ീD㸧ࢆ౑⏝ࡋࠊྛ⮬࠶ࢁ࠺࠿ࠋ୍᪉࡛ࠊᐙᗞ࡛ࡢᒃఫ✵㛫ࡀ┦ᑐⓗ࡟ᑡ࡞ࡀ┤ឤⓗ࡟ࢳ࢙ࢵࢡ⾲࡟グධࡍࡿࡇ࡜࡟ࡼࡗ࡚⮬ศࡢẼࡃ࡞ࡾࠊᐙ᪘㛫ࡢࢫࢺࣞࢫࡀ㧗ࡲࡗ࡚࠸ࡿࡇ࡜ࡣ࡞࠸࡛㉁ࡢᢕᥱࢆヨࡳࡓࠋࡘ࠸࡛ࠊ
Ẽ㉁࡟ࡣ 3ࡘࡢே᱁Ẽ㉁㸦ᚠ࠶ࢁ࠺࠿ࠋࢥࣟࢼ⚝࡛ࡣண᝿እࡢࢫࢺࣞࢵࢧ࣮ࡀᆅᇦࡢ

⎔࣭⢓╔࣭⮬㛢㸧࡜ 3 ࡘࡢࢫࢺࣞࢫẼ㉁㸦ᇳ╔࣭୙Ᏻ࣭᪂

ఫẸ㝆ࡾ࠿࠿ࡿࡇ࡜ࡶ⪃࠼ࡽࢀࡿࠋ

ወᛶ㸧ࡀ࠶ࡿࡇ࡜ࢆㄝ᫂ࡋࠊྛ⮬ࡢ⤖ᯝ࠿ࡽ⮬ศࡢᛶ᱁௒ᅇࡢᙜࢭࣥࢱ࣮ᆅᇦ஺ὶ఍࡛ࡣࠊ⌧ᅾࡢᒱ㜧ᕷ A

ࡸẼ㉁ࢆ┦஫࡟㏙࡭ྜࡗࡓࠋ඲㒊ࡢẼ㉁࡟ࢳ࢙ࢵࢡࡀ

ᆅ༊࡛㉳ࡁ࡚࠸ࡿၥ㢟ࢆཧຍ⪅ࡀ⮬⏤࡟ㄒࡾࠊࡑࡢ୰

ධࡗࡓ⪅ࠊ⮬㛢ࡔࡅࡢே᱁Ẽ㉁࡟ࢳ࢙ࢵࢡࡀධࡗࡓ⪅ࠊ࠿ࡽᆅᇦఫẸࡢㄢ㢟ࢆ᫂ࡽ࠿࡟࡟ࡍࡿࡇ࡜ࢆ௻⏬ࡋࡓࠋᮏ᮶࡞ࡽ㠃ಽぢࡢ࠸࠸ぶศ⫙ࡢ⢓╔Ẽ㉁࡟ࢳ࢙ࢵࢡࡀ

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021ධࡿࡣࡎ࡞ࡢ࡟ࠊᐇ㝿ࡣࢳ࢙ࢵࢡࡉࢀ࡞࠿ࡗࡓ⪅࡞࡝ࡢ࡜ࢆᆅ༊࠿ࡽࡢཧຍ⪅ࡣᚰ㓄ࡋ࡚࠸ࡓࠋ௒ᚋࡢ⅏ᐖ࡟⤖ᯝࡀ࠶ࡾࠊࡑࢀࢆ஺ὶ఍࡛┦஫࡟㏙࡭ྜࡗࡓࠋ

ഛ࠼ࡿࡓࡵ࡟ࡶ⮬἞఍ࡢάືࢆ⥔ᣢࡍࡿࡇ࡜ࡣ㔜せ࡜ᛮࢃࢀࡿࠋ⮬἞఍άືࢆᨭ࠼ࡿせᅉ࡛ࡶ࠶ࡿ A ᆅ༊ࡢ 4ࡘࡢᆅᇦࢧࣟࣥࡣ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕ண㜵ᑐ⟇࡜

3.2ࠉࢥࣟࢼ⚝࡛ࡢ೺ᗣ㣗ࡢព⩏ᖹᖖ᫬࠿ࡽ೺ᗣ㣗࡟Ẽࢆ௜ࡅࡿࡇ࡜ࡣࠊ⏕ά⩦័⑓ࡋ࡚ఇṆ୰࡛࠶ࡿࠋ⪁ேࢡࣛࣈᩘࡶῶࡗ࡚ࡁࡓࠋᩘᖺ๓

ࡢண㜵࡟Ḟ࠿ࡏ࡞࠸ࡇ࡜ࡣㄡࡶࡀㄆ㆑ࡋ࡚࠸ࡿࡇ࡜࡛࠶

࠿ࡽᆅᇦໟᣓᨭ᥼ࢭࣥࢱ࣮ࢆ୰ᚰ࡟ࠕ࠸࠸⏫ࡘࡃࢁ࠺ቃ

ࡿࡀࠊ௒ᅇࡣࠊࢥࣟࢼ⚝࡛ࡢឤᰁண㜵ࡸ⅏ᐖ᫬ࡢ೺ᗣ

ᕝࠖࡀ࡛ࡁάືࡋ࡚ࡁࡓࡀࠊ⌧ᅾ୰Ṇࡋ࡚࠸ࡿࡇ࡜ࡀࢃ

㣗ࡢព⩏࡟ࡘ࠸࡚ヰࡋྜ࠸ࡀ⾜ࢃࢀࡓࠋࡑࡢ୰࡛ࠊ⋞࠿ࡗࡓࠋከ⫋✀㐃ᦠᐇ㊶ࢭࣥࢱ࣮࡛ࡢᆅᇦ஺ὶ఍࡛ࡣࠊ

⡿㣗ࡢ᭷⏝ᛶࡀ⋞⡿࡜ⓑ⡿ࡢᦤ㣗ᚋࡢ⾑⢾᭤⥺ࡢ┦㐪A ᆅᇦࡢṔྐࢆ⌮ゎࡋࠊࡑࡢୖ࡛ᆅᇦࡢㄢ㢟࡟࡝ࡢࡼ

ࡢ㈨ᩱ࡞࡝࠿ࡽㄝ᫂ࡉࢀࡓࠋཧຍ⪅඲ဨࡀ⋞⡿ࡣ௦⾲࠺࡟࠿࠿ࢃࡗ࡚࠸ࡃ࠿ࢆ㆟ㄽࡋ࡚࠸ࡃࡇ࡜࡟࡞ࡗࡓࠋ

ⓗ࡞೺ᗣ㣗ရ࡛࠶ࡿࡇ࡜ࢆㄆ㆑ࡋ࡚࠸ࡓࡀࠊ⋞⡿ࢆᖖ᫬ᦤ㣗ࡋ࡚࠸ࡿࡢࡣ  ྡ୰ 1 ྡࡔࡅ࡛࠶ࡗࡓࠋᖖ᫬ᦤ

3.4ࠉࢥࣟࢼ⚝࡟࠾ࡅࡿᆅᇦఫẸࡢ⏕ά㣗ࡀ㞴ࡋ࠸⌮⏤࡜ࡋ࡚⋞⡿ࡣࠕ࠿ࡓ࠸ࠖ࡜࠸࠺࢖࣓࣮ࢪࡀ

ࢥࣟࢼឤᰁ⑕࡜ࡢ㛵ಀ࡛⫱ඣ࡟୙Ᏻࢆぬ࠼ࡿẕぶ࠿ᣦ᦬ࡉࢀࡓࠋཧຍ⪅ࡣࠊ඲ဨࡀ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫ࣡ࢡ

ࡽࡢ㟁ヰ┦ㄯࡀ኱ࡁࡃቑຍࡋ࡚࠸ࡿ࡜ࡢሗ࿌ࡸࠊࢥࣟࢼ

ࢳࣥࡢ 2 ᅇࡢ᥋✀ࢆ⤊஢ࡋ࡚࠸ࡓࡀࠊ➨ 6 ὴࡢឤᰁᣑ

⚝࡟ࡼࡗ࡚ே࡜఍ࡗ࡚㐠ືࡍࡿᶵ఍ࡸ఍ヰࡍࡿᶵ఍ࡀ

኱࡟ࡣ୙Ᏻࢆឤࡌ࡚࠸ࡓࠋࡲࡓࠊ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫ࡟

㧗㱋⪅࠿ࡽኻࢃࢀࠊ㧗㱋⪅ࡢᏙ❧ࡀᣦ᦬ࡉࢀࡓࠋ୍᪉ࠊ

ឤᰁࡋࠊ⮬Ꮿ⒪㣴ࡸ࣍ࢸࣝ⒪㣴ࢆ⤒㦂⪅࠿ࡽࡢ᝟ሗ࡜

఍♫➼ࡢ໅ປ⪅࡛࠶ࡿཧຍ⪅࠿ࡽࡣ᪂ᆺࢥࣟࢼ࢘࢖ࣝࡋ࡚ࠊ࿡ぬࡀ⾶࠼ࠊᏯ㓄ࡢ㣗஦ࡀ⬡ࡗࡇࡃ࡚㣗࡭ࡿࡇ࡜ࢫឤᰁ⑕࡟ࡼࡿእฟไ㝈ࡣ࠶ࡗࡓࡀ⫋ሙࡀ࠶ࡾࠊ⏕άࡀ࡛ࡁ࡞࠿ࡗࡓࡇ࡜ࡀ㏙࡭ࡽࢀࡓࠋࡑࢀ࡟ᑐࡋࠊ⋞⡿⎔ቃ➼࡟ࡣఱࡽኚ໬ࡀ࡞࠸࡜ࡢሗ࿌ࡶ࠶ࡗࡓࠋᏛ❺➼㣗ࡣ⭠ෆ⣽⳦ྀࢆάᛶ໬ࡋࠊ⮬↛ච␿ࢆቑᙉࡋࠊࡉࡽ

࡛ࡣࠊᑠᏛ⏕ࡢᏊ࡝ࡶࢆࡶࡘ∗ぶ࠿ࡽࡢᣦ᦬࡜ࡋ࡚ࠊᏛ

࡟ࠊ࣡ࢡࢳࣥ᥋✀࡟ࡼࡿ⋓ᚓච␿ࢆቑᙉࡋ࡚ࠊ᪂ᆺࢥࣟ

ᰯ࡬⾜ࡅ࡞࠸Ꮚ࡝ࡶࡓࡕࡀࢤ࣮࣒➼࡛ክ୰࡟࡞ࡾࠊẕࢼ࢘࢖ࣝࢫࡢឤᰁ㜵Ṇ࡟᭷⏝࡛࠶ࡿ࡜ࡢ᝟ሗᥦ౪ࡀ࠶ࡗ

ぶࡢࢫࢺࣞࢫࡀቑ኱ࡋࡓ࡜ࡢヰࡀ࠶ࡗࡓࠋA ᆅ༊ࡢ♫఍ࡓࠋࡲࡓࠊ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⪅ࡀᏯ㓄ࡢᘚᙜࢆ⚟♴༠㆟఍ᨭ㒊୺஦࠿ࡽࡢ᝟ሗ࡜ࡋ࡚ࠊ᪂ᆺࢥࣟࢼ࢘࢖

㣗࡭ࡽࢀ࡞࠸࡜࠸࠺ᰤ㣴୙Ⰻୗ࡛ࡣච␿ᶵ⬟ࡀపୗࡋࠊ

ࣝࢫឤᰁ⑕ᴗົࡀከᛁ࡛ࠊಖ೺ᖌࡉࢇ࡟᮶࡚ࡶࡽ࠼࡞

ឤᰁ⑕ࡀᝏ໬ࡍࡿ༴㝤ᛶࡀ࠶ࡿࡇ࡜ࡀᣦ᦬ࡉࢀࠊឤᰁ

ࡃ࡞ࡾࠊࡀࡗ࠿ࡾࡍࡿఫẸࡶ࠸ࡓ࡜ࡢᣦ᦬ࡀ࠶ࡗࡓࠋ
ཧຍ⪅࠿ࡽࠊᆅᇦࢧࣟࣥ࡬ཧຍࡋࡓ࠸ࡀᐙࡢ᝟ሗࢆ

⑕࡟࠾ࡅࡿ⋞⡿㣗ࡢ᭷⏝ᛶ࡟ࡘ࠸࡚㛵ᚰࡀᣢࡓࢀࡓࠋA ᆅ༊ࡣࠊ௨๓ࡣ࿘ࡾࡀ⏣⏿࡛㎰సᴗᚑ஦⪅ࡀከࡃࠊ▱ࡽࢀࡓࡃ࡞࠸ேࡀ࠸ࡿࡇ࡜ࡀᣦ᦬ࡉࢀࡓࠋࢧࣟࣥࡢୡ

ࡋࡤࡋࡤὥỈ࡟ぢ⯙ࢃࢀࠊ1959 ᖺ㸦᫛࿴ 34 ᖺ㸧ࡢఀໃヰேࢆࡋ࡚࠸ࡿཧຍ⪅ࡣࠊᆅᇦ࡟ࡣ㐪ࡗࡓ⪃࠼ࡢேࠎࡀ

‴ྎ㢼࡛ࡣ኱ࡁ࡞⿕ᐖࢆཷࡅࡓࠋࡑࡢᚋࠊሐ㜵➼ࡀᩚ࠸ࡿࡓࡵࠊࡳࢇ࡞ࡢពぢࢆ⪺ࡁࠊ༠ຊࡍࡿ᪉㔪ࢆఏ࠼ഛࡉࢀ࡚ࡑࢀ௨ᚋࡢ኱ࡁ࡞⅏ᐖࡣ࡞࠸ࡀࠊ௒ᚋࡢ⅏ᐖ࡚࠸ࡿ࡜ヰࡋࡓࠋ

࡟ഛ࠼࡚ࡢ㣗ᩱ☜ಖ࡟ࡘ࠸࡚ࠊᆅᇦࡢࢥࣥࣅࢽࢫࢺ࢔࡜

ᆅᇦࡢ୰࡛೺ᗣୖᅔࡗ࡚࠸࡚ࡶࠊ≉࡟ࢥࣟࢼ⚝࡟࠾ࡢ㐃ᦠ࡞࡝ࡢ♫఍㈨※ࡢά⏝ࡶど㔝࡟ධࢀ࡚࠸ࡃ➼ࡢ࠸࡚ࠊㄡࡶࡀእฟࡢ⮬⢔ࢆồࡵࡽࢀ࡚࠾ࡾࠊᮏேࡀಶேពぢࡀฟࡉࢀࡓࠋ⋞⡿ࡢ෭෾࠾࡟ࡂࡾࡣࠊᡭ㍍࡟సࢀࠊⓗ࡞᝟ሗࢆඹ᭷࡛ࡁࡿேࡸሙࡀ࡞࠸࡜௚ࡢ⪅ࡀ▱ࡿࡇ࡜ᰤ㣴౯ࡀ㧗ࡃࠊ࠾⭡ᣢࡕࡀࡼ࠸࡜ࡢ᝟ሗᥦ౪ࡀ࠶ࡗࡓࠋ

ࡣ࡛ࡁ࡞࠸࡜࠸࠺ᐇ᝟ࡀヰ㢟࡟࡞ࡗࡓࠋ

3.3ࠉᆅᇦࡢṔྐ࡜ᆅᇦࢥ࣑ࣗࢽࢸ࢕㸬⪃ᐹA ᆅ༊ࡢఫẸࡣ※Ặࡢὶࢀࢆᘬࡃ࡜࠸ࢃࢀࠊ⚄♫ࡀ

Ẽ㉁ࢳ࢙ࢵࢡࡣࡦࡽࡵࡁ࡛ᅇ⟅ࡍࡿࡇ࡜ࡀ኱஦࡛࠶ࡾࠊ

ከࡃࠊ⚄♫࡟ࡣᑿࡢ࡞࠸❳ࡀ⚍ࡽࢀ࡚࠸ࡿࠋ❳ࡀᭀࢀࡲࡓࠊྛ⮬ࡢẼ㉁ࡣࠊ⏕ࡲࢀ࡞ࡀࡽ࡟ࡋ࡚ᣢࡗ࡚࠸ࡿࡶ

ࡔࡋ❳ࡢᑿࡀษࢀࡓ࡜ఏࢃࡗ࡚࠾ࡾࠊ❳ࡀᭀࢀ࡚ᑿࡀษ

ࡢ࡛࠶ࡿ࡜࠸ࢃࢀ࡚࠸ࡿ㸦᐀ീE㸧ࠋẼ㉁ࡣಶேಶ

ࢀࡓ㐣⛬ࡀఏㄝ࡜ࡋ࡚ㄒࡾ⥅ࡀࢀ࡚ࡁࡓࠋࡋ࠿ࡋࠊ௒ࡣ

ே࡛␗࡞ࡾࠊࡑࢀ࡟ࡼࡗ࡚ࡶࡢࡢぢ᪉ࡸ⪃࠼᪉ࡶ␗࡞ࡗ

ࡑࡢㄒࡾ㒊ࡶ࠸࡞ࡃ࡞ࡗࡓࡇ࡜ࡀᣦ᦬ࡉࢀࡓࠋA ᆅ༊ࡢ࡚ࡃࡿࠋ௒ᅇࡢᆅᇦ஺ὶάື࡟࠾ࡅࡿࡼ࠺࡞┦஫ࡢẼ㉁㧗㱋໬⋡ࡣ⣙ 18.0% ࡛࠶ࡿࠋ⌧ᅾࠊA ᆅ༊࡟ࡣᘓ≀ࡀࡢ㐪࠸ࢆ▱ࡿヨࡳࡣྛ⮬ࡢ⪃࠼᪉ࡢ┦㐪ࢆㄆࡵྜ࠺ୖ

ᐦ㞟ࡋࠊᆅ༊እ࠿ࡽ⛣ఫࡋࡓⱝ࠸ᒙࡀቑ࠼ࡿ࡜࡜ࡶ࡟⮬࡛᭷┈࡞ヨࡳ࡛࠶ࡗࡓ࡜ᛮࢃࢀࡓࠋࡲࡓࠊᆅᇦࡢㄢ㢟἞఍ᮍຍධ⪅ࡀቑ࠼ࠊᚑ᮶࠿ࡽࡢ A ᆅ༊ఫேࡢ㧗㱋໬ࢆ᫂ࡽ࠿࡟ࡍࡿࡁࡗ࠿ࡅ࡙ࡃࡾ࡟ࡣᆅᇦఫẸࡸከ⫋✀࡜࡟కࡗ࡚ A ᆅᇦࡢṔྐࢆㄒࡿேࡀ࠸࡞ࡃ࡞ࡗ࡚ࡋࡲ࠺ࡇ

ࡢಙ㢗㛵ಀࡢ୰࡛ࡢヰࡋྜ࠸ࡀᚲせ࡛࠶ࡿࡇ࡜ࡣ⮬᫂ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021࡛࠶ࡾࠊࡇࡢ஺ὶ఍࡛ࡣཧຍ⪅ࡢពぢ࡟⪥ࢆഴࡅࠊ⮬ࢆᣢࡘࡇ࡜ࡣ೺ᗣ⥔ᣢ࡟࡜ࡗ࡚㔜せ࡛࠶ࡾࠊࡑࡢࡼ࠺࡞⏤࡟ពぢࢆฟࡋྜ࠺ࡇ࡜࡛㐍ᒎࡀࡳࡽࢀࡓⅬ࡛᭷┈࡛ሙࡢタᐃ࡟ࡣᆅᇦࡢᣦᑟ⪅ࡢ࣮ࣜࢲ࣮ࢩࢵࣉࡀ㔜せ࡛࠶ࡗࡓࠋࡲࡓࠊ㠀ᖖ᫬࡟ᑐࡍࡿഛ࠼ࢆ⪃࠼ࡓሙྜࠊᆅ

࠶ࡿ࡜⪃࠼ࡽࢀࡓࠋࡇࢀࡣࠊᆅᇦࡢ࣮ࣜࢲ࣮ࡣᆅᇦఫ

ᇦࡢఫẸࡀ┦஫࡟⥭ᐦ࡞㛵ಀࢆ᪥㡭࠿ࡽ⠏ࡃࡇ࡜ࡣ㔜Ẹ࡜࡜ࡶ࡟஭ᡞࡢᆅୗỈࡲ࡛㝆ࡾ࡚⾜ࡁࠊ᰿Ẽࡼࡃάືせ࡛࠶ࡿࠋㄡࡋࡶ௚⪅࡟▱ࡽࢀࡓࡃ࡞࠸ಶேⓗ஦᝟ࡣ࠶ࡍࡿࡇ࡜ࡀ㔜せ࡛࠶ࡿ࡜ࡋࡓἙྜࡽ㸦Ἑྜ 1999a㸧ࡢ୺ᙇࡿࡀࠊ㠀ᖖ᫬࡟ᑐᛂ࡛ࡁࡿయไ࡜ࡋ࡚ಶேⓗ࡞᝟ሗࢆ࡜㌶ࢆ୍࡟ࡍࡿࠋᆅᇦ࡟ࡣ┦ㄯࡀ࡛ࡁࠊ࠾ࡋࡷ࡭ࡾࡀ

ඹ᭷ࡍࡿࡇ࡜ࠊࡑࡢᡭẁࢆ⪃࠼ࡿࡇ࡜ࡣ㔜せ࡛࠶ࡿ࡜⪃࡛ࡁࡿᒃሙᡤࡣ㠀ᖖ᫬࡟ࡶᚲ㡲࡛࠶ࡾࠊᙜࢭࣥࢱ࣮࡟ࡶ

࠼ࡽࢀࡓࠋಶேⓗ࡞஦᝟ࡸ᝟ሗࡢඹ᭷ࢆྍ⬟࡟ࡍࡿࡓࡑࡢࡼ࠺࡞ᶵ⬟ࢆᮇᚅࡍࡿࡇ࡜ࡀ࡛ࡁࡿ࠿ࡶࡋࢀ࡞࠸ࠋ

ࡵ࡟ࡣࠊᬑẁ࠿ࡽࡢ஺ὶ࡜┦஫ࡢಙ㢗㛵ಀࡀ㔜せ࡛࠶㠀ᖖ᫬࡟ഛ࠼࡚ࠊㄡࡶࡀᆅᇦࡢఫẸ࡜ࡢ㛵ಀࢆ᪥㡭ࡿࡀࠊ୍ᐃᆅᇦࡢఫẸ࡛࠶ࡗ࡚ࡶඹ㏻ࡢᡤᒓព㆑ࡸ

࠿ࡽ⠏ࡃࡇ࡜ࡀ࡛ࡁࡿࡼ࠺࡞ᒃሙᡤࡀ࠶ࡿࡇ࡜ࡀ኱஦࡟

ࣇ࢕࣮ࣝࢻ࢔࢖ࢹࣥࢸ࢕ࡀ࠶ࡿࡇ࡜ࡣᮇᚅ࡛ࡁ࡞࠸ࡇ࡜ࡀ

࡞ࡿࠋ࠸ࡘࡶ᮶࡚࠸ࡿேࡀ᮶࡞ࡅࢀࡤࠊ
ࠕඖẼ㸽ࠖ࡜ኌ᥃

᫂ࡽ࠿࡟࡞ࡗࡓࠋ௨๓ࡢ㎰ᴗࡀ୺య࡛࠶ࡗࡓ᫬௦ࡣࠊ

ࡅࡶᮇᚅ࡛ࡁࡿࠋㄡࡶࡀࠊ▱ࡽࢀࡓࡃ࡞࠸ಶே᝟ሗࡣ

ᆅᇦఫẸࡢඹྠసᴗࡸ஫ຓసᴗ࡛⏣⏿ࢆᏲࡾࠊᡤᒓព

࠶ࡿࡀࠊ㠀ᖖ᫬࡟ᑐᛂ࡛ࡁࡿయไ࡜ࡋ࡚ኌ᥃ࡅࡀ࠾஫

㆑ࡸඹ㏻ࡢ౯್ほࡀ㔊ᡂࡉࢀ࡚ࡁࡓࠋࡋ࠿ࡋࠊ⌧ᅾࡣ࠸࡟࡛ࡁࡿ㛵ಀ࡙ࡃࡾࡣᚲせ࡜ᛮࢃࢀࡿࠋA ᆅ༊ࡢ㧗ࡑࡢࡼ࠺࡞ඹ㏻ࡢ౯್ほࡀ㔊ᡂࡉࢀࡿ≧ἣ࡟ࡣ࡞ࡃࠊ

㱋⪅ࡀ㞟ࡲࡿࢧࣟࣥάື࡟ࡣࠊ
ࠕ⮬ຓࠖࠕ஫ຓࠖ࡜ࡋ࡚ࡢ㛵஫ຓព㆑ࡶᙅࡃ࡞ࡿ୍᪉࡛࠶ࡿࠋ౯್ほࡢ┦㐪࠿ࡽࠊಀࡀ㔜せ࡛࠶ࡾࠊ⌧ᅾࠊA ᆅ༊ࡢ໭᪉㠃࡛ࡣࠊ࣮ࣜࢲ࣮

ᆅᇦࡢ஺ὶࡶᑡ࡞ࡃ࡞ࡾࠊᐙᗞࢆࣇ࢕࣮ࣝࢻ㸦Ἑྜ௚ࡀ୙ᅾ࡛ᆅᇦࢧࣟࣥࡀᐇ᪋ࡉࢀ࡚࠸࡞࠸ࡇ࡜࠿ࡽࠊᆅ

1999b㸧࡟ࡍࡿఫẸࡀቑ࠼ࡿࡇ࡜࡛ࠊᆅᇦࡢఫẸࡢ༠ຊᇦఫẸࡢࡩࢀྜ࠸᫬㛫ࡀᑡ࡞ࡃ࡞ࡗ࡚࠸ࡿࡇ࡜ࡀ᫂ࡽ࠿

࡛ᆅᇦࡢၥ㢟ࢆゎỴࡍࡿ࡜࠸࠺ᆅᇦຊࡢపୗࡀࡳࡽࢀ

࡟࡞ࡾࠊࡇࢀ࡟ᑐࡍࡿᑐ⟇ࡀᚲせ࡜ᛮࢃࢀࡓࠋ

ࡿࠋࡑࡢゎỴ⟇ࡢ୍ࡘࡣ┦஫ࡢ౯್ほࡢ┦㐪ࢆㄆࡵྜ࠺㛵ಀ࡙ࡃࡾ࡛ࡣ࡞࠸࠿࡜⪃࠼ࡽࢀࠊᙜࢭࣥࢱ࣮ࡢ௒ᚋ

㸬ࡲ࡜ࡵࡢᙺ๭ࢆ♧၀ࡋ࡚࠸ࡿ࡜ᛮࢃࢀࡓࠋ

᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕⚝࡟࠾࠸࡚ࠊឤᰁ⑕ᑐ⟇೺ᗣ㣗ရ࡜ࡋ࡚ࡢ⋞⡿㣗࡟ࡘ࠸࡚ࡣࠊࢥࣟࢼ⚝࡟࠾ࡅࢆᐇ᪋ࡋ࡞ࡀࡽᑠேᩘࡢᆅᇦ஺ὶ఍ࢆᐇ᪋ࡋࡓࠋࡑࡇ

ࡿ⋞⡿㣗ࡢ᭷⏝ᛶ࡟ࡘ࠸࡚㆟ㄽࡀ⾜ࢃࢀࡓࠋ㧗㱋⪅ࡢ࡛ぢ࠼࡚ࡁࡓᆅᇦࡢㄢ㢟ࡣࠊࠕᆅᇦ࡛ࡣ┦஫࡟ಶேⓗ࡞᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁࡣ㔜⑕໬ࡍࡿሙྜࡀከࡃࠊࡑ

ಙ㢗㛵ಀࢆ⠏ࡁࠊಶேⓗ࡞᝟ሗࢆඹ᭷ࡍࡿࡇ࡜ࠖ
ࠕᆅᇦࡢឤᰁࢆ㜵ࡄࡓࡵ㧗㱋⪅ࡢάືࡣⱝᖺ⪅ࡸ୰ᖺ⪅࡟ẚఫẸࡀࠊࡑࢀࡒࢀࡢ౯್ほ࡟┦㐪ࡀ࠶ࡿࡇ࡜ࢆㄆ㆑ࡍ

࡭࡚ࡼࡾᙉࡃไ㝈ࡉࢀࠊ㐠ື୙㊊ࡸᰤ㣴୙㊊࡟㝗ࡾࡀࡕࡿࡇ࡜ࠖࠕ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕ࢆࡁࡗ࠿ࡅ࡜ࡋ࡚ࠊ

࡛࠶ࡗࡓࠋ㐠ື୙㊊ࡸᰤ㣴୙Ⰻࡣච␿ຊࡢపୗࢆᣍࡁࠊ

ᆅᇦఫẸࡢࡩࢀ࠶࠸᫬㛫ࡀⴭࡋࡃῶᑡࡋ࡚࠾ࡾᑐ⟇ࡀ᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ᫬ࡢ᭦࡞ࡿ㔜⑕໬࡟ࡘ࡞ࡀࡿࠋᚲせ࡛࠶ࡿࡇ࡜࡛ࠖ࠶ࡗࡓࠋ

⋞⡿㣗ࡣ⭠ෆ⣽⳦ࡢ೺඲࡞άືࢆಁࡋࠊయࡢ⪁ᗫ≀ࢆ᤼ฟࡋࠊච␿ຊࡢஹ㐍࡟ࡘ࡞ࡀࡿ࡜ࡉࢀ࡚࠾ࡾ㸦Ᏻಖ฼┈┦཯

2005㸧ࠊ㧗㱋⪅࡟࡜ࡗ࡚ࢥࣟࢼ⚝ࡢࡼ࠺࡞᫬ᮇ࡟⋞⡿㣗ᮏㄽᩥ࡟㛵ࡋ࡚㛤♧ࡍ࡭ࡁ฼┈┦཯ࡣ࡞࠸ࠋ

ࢆᦤ㣗ࡍࡿࡇ࡜ࡣ㔜⑕໬ࢆ㍍ῶࡍࡿࡓࡵ࡟᭷⏝࡛࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋࡉࡽ࡟ࠊ㠀ᖖ᫬࡟ᑐࡍࡿ‽ഛ࡜ࡋ࡚ᖹᖖ᫬

㸬ㅰ㎡࠿ࡽ೺ᗣ㣗࡜ࡣఱ࠿ࢆ▱ࡗ࡚࠾ࡃࡇ࡜ࡣ㔜せ࡛࠶ࡿࠋࡑ
ࢀ࡟ࡣࠊᆅᇦࡢ࣮ࣜࢲ࣮ࡀᬑẁ࠿ࡽᆅᇦࡢఫẸ࡜୍⥴

ᮏᐇ㊶άື࡟ࡈពぢࢆ㡬࠸ࡓⓙᵝ࡟῝ࡃឤㅰࢆ⏦ࡋୖࡆࡲࡍࠋ࡟࡞ࡗ࡚೺ᗣ㣗࡟ࡘ࠸࡚ࡢ▱㆑ࢆᚓ࡚࠾ࡃࡇ࡜ࡀᚲせ࡛࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋࡑࢀ࡟ࡼࡗ࡚ࠊ⅏ᐖ᫬࡟࠾ࡅࡿᆅᇦ

ᘬ⏝ᩥ⊩

ఫẸࡢ೺ᗣࡢ⥔ᣢ࡟ຍ࠼࡚ࠊఫẸ㛫ࡢࠕ஫ຓࠖᶵ⬟ࡀᏳಖᚭ㸦2005㸧㸬Ᏻಖᚭࡢ㣗࡭ࡿච␿ຊ㸪25㸪ୡ⏺ᩥ᭷ᶵⓗ࡟ാࡁࠊ⅏ᐖ᫬ࡢఫẸࡢᩆ࿨࡟ࡶࡘ࡞ࡀࡿ࡜ᮇ
ᚅ࡛ࡁࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ

໬♫㸪ᮾி㸬
⏿ྜྷ⠇ᮍ㸦2021㸧㸬᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕ࡢᣑ኱ࡀ

ࢥࣟࢼ⚝࡛ᆅᇦఫẸࡢࡩࢀྜ࠸᫬㛫ࡀⴭࡋࡃῶᑡࡋ

ᅾᏯࢧ࣮ࣅࢫ࡟୚࠼ࡓᙳ㡪㸸ゼၥ┳ㆤ / ௓ㆤࢧ࣮ࣅ

࡚࠸ࡿࡇ࡜࡟ࡘ࠸࡚ࡢ㆟ㄽ࡛ࡣࠊᐙ᪘࡜୍⥴࡟⏕άࡋ࡚ࢫ஦ᴗ⪅࡬ࡢㄪᰝࢆࡶ࡜࡟㸪➨ 26 ᅇ᪥ᮏᅾᏯࢣᏛ఍

࠸ࡿ㧗㱋⪅ࡶእฟࡢᶵ఍ࡀῶࡗ࡚೺ᗣ㞀ᐖࡀᣍ᮶ࡉࢀ

Ꮫ⾡㞟఍ᢒ㘓㞟㸪᪥ᮏᅾᏯࢣ࢔Ꮫ఍㸪90.

࡚࠸ࡿࡇ࡜ࡀᣦ᦬ࡉࢀࡓࠋ㧗㱋⪅࡟࡜ࡗ࡚ࡩࢀ࠶࠸ࡢሙ

ཎ⏣࠿࠾ࡿࠊ㛗⏿ከ௦㸦2021㸧㸬COVID-19 ឤᰁ⑕ᣑᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021኱≧ἣୗ࡛ゼၥ┳ㆤࢫࢸ࣮ࢩࣙࣥ⟶⌮⪅ࡀឤࡌ࡚࠸
ࡿ㧗㱋⪅┳ㆤ࡟࠾ࡅࡿၥ㢟㸪➨ 26 ᅇ᪥ᮏᅾᏯࢣᏛ
఍Ꮫ⾡㞟఍ᢒ㘓㞟㸪᪥ᮏᅾᏯࢣ࢔Ꮫ఍㸪133.
Ἑྜ㞙㞝࣭ᮧୖ᫓ᶞ㸦1999a㸧㸬ᮧୖ᫓ᶞ㸪Ἑྜ㞙㞝࡟఍࠸࡟࠸ࡃ㸪㸪᪂₻ᩥᗜ㸪ᮾி㸬Ἑྜ㞙㞝ࠊᮧୖ᫓ᶞ㸦1999b㸧㸬ྠୖ㸪㸬᐀ീᜏḟ㸦D㸧㸬SAT ࢆᏛࡪ㸪120㸪㔠Ꮚ᭩ᡣ㸪ᮾி㸬᐀ീᜏḟ㸦E㸧㸬ྠୖ ,129-131.
୰⏣㑳㞝㸦2021㸧㸬ࢥࣟࢼ⚝ࡢ⌧ሙ࡛ఱࡀ㉳ࡁ࡚࠸ࡓࡢ
࠿㸽௓ㆤ᪋タ࡛ࡢ⌧≧࡜ࡇࢀ࠿ࡽ㸪➨ 28 ᅇ᪥ᮏ⏘ᴗಖ೺Ꮫ఍ᢒ㘓㞟㸪⏘ᴗಖ೺㸪29㸦ቑหྕ㸧30.
ᒸ⏣ 㑥ኵ㸦2021㸧㸬ࢥࣟࢼ⚝ࡢാࡁ᪉ᨵ㠉࡜೺ᗣ⤒Ⴀ࡟࠾ࡅࡿ࣓ࣥࢱࣝᑐ⟇㸪➨ 28 ᅇ᪥ᮏ⏘ᴗಖ೺Ꮫ఍ᢒ
㘓㞟㸪⏘ᴗಖ೺㸪29㸦ቑหྕ㸧30.
ሯཎࡺ࠿ࡾࠊ⳥ụ᭷⣖㸦2021㸧㸬ࢥࣟࢼ⚝࡟࠾ࡅࡿ㒔ᕷᅾఫࡢ๓ᮇ㧗㱋⪅࡜ᚋᮇ㧗㱋⪅ࡢព㆑ < ➨ 2 ሗ >̿௓ㆤண㜵࣭೺ᗣ࡙ࡃࡾࠊᆅᇦࡢάື࡟↔Ⅼࢆ࠶࡚࡚࣮
➨ 26 ᅇ᪥ᮏᅾᏯࢣ࢔Ꮫ఍Ꮫ⾡㞟఍ᢒ㘓㞟㸪᪥ᮏᅾᏯࢣ࢔Ꮫ఍㸪118.
ᒣᓮ࿴௦㸦2021㸧㸬ICT ά⏝࡜ࡡࡂࡽ࠸࣭ឤㅰ࡛ࢥࣟࢼ
⚝ࢆ஌ࡾษࡿゼၥ┳ㆤࡢ࣓ࣥࢱࣝ࣊ࣝࢫ㸪➨ 28 ᅇ᪥ᮏ⏘ᴗಖ೺Ꮫ఍ᢒ㘓㞟㸪⏘ᴗಖ೺㸪29㸦ቑหྕ㸧30.

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Practical Reportࠚ

,VVXHV,GHQWL¿HGDW&RPPXQLW\([FKDQJH0HHWLQJV+HOG'XULQJWKH
Covid-19 Pandemic
Chizuru Tochimoto*1, Kiyomi Hata*1, Hiroshi Mori*1, Miwako Usami*2,
Masakazu Hideyama*3, Mariko Mizutani*2, Nobuhiro Tagami*4, Michiyo Matunami*5
㸨 1 Gifu University of Health Sciences Department of Nursing
㸨 2 Gifu University of Health Sciences Department of Rehabilitation
㸨 3 Gifu University of Health Sciences Medical Care School
㸨 4 Social Welfare Council, Uzura Branch㸨 5 South Gifu City Health Center

Abstract
>$LP@7KHDLPRIWKHVWXG\ZDVWRRUJDQL]HFRPPXQLW\H[FKDQJHPHHWLQJVLQ'LVWULFW$RI*LIX&LW\DQGWR¿QGZD\VWR
identify the issues facing the local community in the midst of the Covid-19 pandemic.
>0HWKRG@7ZRFRPPXQLW\H[FKDQJHPHHWLQJVZHUHKHOGDWWKH*LIX8QLYHUVLW\RI+HDOWK6FLHQFHV0XOWL3URIHVVLRQ/LQNLQJ
Center. Attendees engaged in the brainstorming of several topics and thereafter discussed their ideas and the problems andissues facing the community.
>5HVXOWV@3HRSOHIURPYDULRXVSURIHVVLRQVDQGORFDOUHSUHVHQWDWLYHVFRXOGGLVFXVVLVVXHVIURPVHYHUDOSHUVSHFWLYHVLQDUHODWLRQVKLSRIWUXVW&OHDUH[DPSOHVRIWKHLVVXHVWKDWDURVHLQFOXGH͆WKHQHFHVVLW\RIEHLQJDZDUHRIGL൵HUHQFHVLQYDOXHV
between community residents͇, ͆the importance of building mutual trust between individual residents and the sharingof personal information͇, and ͆the considerable reduction in the amount of time that community residents spend incontact with each other due to the Covid-19 pandemic͇.
>'LVFXVVLRQ@7KHLVVXHLVKRZDIWHUWDNLQJPHDVXUHVWRSUHYHQWWKHVSUHDGRI&RYLGWLPHFDQEHREWDLQHGIRUORFDO
residents to spend in contact with each other and the aforementioned issues facing the community can be addressed and
FRPPXQLW\H[FKDQJHFDQEHGHHSHQHG

Keywords㸸FRPPXQLW\H[FKDQJHPHHWLQJ&RYLG0XOWL3URIHVVLRQ/LQNLQJ&HQWHUFRPPXQLW\UHVLGHQWVVSHQGLQJ
time with each otherᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙ᐇ㊶ሗ࿌ࠚ

ࢥࣟࢼ⚝࡟࠾ࡅࡿ㏻ᡤ௓ㆤ᪋タ㸦ࢹ࢖ࢧ࣮ࣅࢫ㸧฼⏝⪅ࡢ᪥ᖖ⏕άάື࡜άຊࡢ㛵㐃ᛶ࡟ࡘ࠸࡚
ᑠ⃝ᩄኵ *1ࠉ㕥ᮌၨ௓ *1ࠉ㔠⏣ᡂ஑ *2ࠉ஭ᡞ㞞኱ *2*1 ᒱ㜧ಖ೺኱Ꮫ ࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊ࠉ*2 ࢹ࢖ࢧ࣮ࣅࢫࢭࣥࢱ࣮ Q-net
㸦ᰴᘧ఍♫࣮࢟ࣗࣛ࢖ࣇ㸧せ᪨ᮏ◊✲ࡣࠊࢥࣟࢼ⚝࡟࠾ࡅ࡚኱ࡁ࡞ᙳ㡪ࢆཬࡰࡉࢀࡓ࡜⪃࠼ࡽࢀࡿ㧗㱋⪅࡟↔Ⅼࢆ࠶࡚ࠊࢹ࢖ࢧ࣮ࣅࢫ฼⏝㧗㱋⪅ࡢ᪥ᖖ⏕άάື࡜άຊ࡜ࡢ㛵㐃ᛶࢆ᳨ウࡍࡿࡇ࡜ࢆ┠ⓗ࡟ㄪᰝࢆ⾜ࡗࡓࠋᑐ㇟ࡣࠊࢹ࢖ࢧ࣮ࣅࢫࢆ฼⏝ࡉࢀ࡚࠸ࡿ㧗㱋⪅ 44 ே㸦⏨ᛶ 16 ேࠊዪᛶ 28 ேࠊᖹᆒᖺ㱋  ṓs 8.36㸧࡛࠶ࡾࠊ௓ㆤᗘࡢ୰ኸ್ࡣせ௓ㆤ 2 ࡛࠶ࡗࡓࠋ
άຊࡣᖺ㱋ቑ࡟ࡼࡿࡤࡽࡘࡁࡀഹ࠿࡟ቑ࠼ࡿࡇ࡜ࡀㄆࡵࡽࢀࠊࡲࡓࠊάຊࡣ᪥ᖖ⏕άάື࡜㌟యⓗ㐠ື⬟ຊ࡜ࡢ㛵㐃ᛶࡀ୰⛬ᗘ࠶ࡿࡇ࡜ࡀㄆࡵࡽࢀࡓࠋ
㧗㱋⪅௓ㆤ᪋タ࡛ࡢ೺ᗣ⥔ᣢ࡟ࡣ㌟యⓗ㐠ື⬟ຊ࡜άຊ➼ࡢ⢭⚄ⓗഃ㠃ࡢ୧ഃ㠃࡛ࡢᨭ᥼ࡀ㔜せ࡜࡞ࡿࡇ࡜ࡀ
♧၀ࡉࢀࡓࠋ
࣮࣮࢟࣡ࢻ㸸άຊࠊ᪥ᖖ⏕άάືࠊ㧗㱋⪅ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

㸬⥴ゝ

㸬┠ⓗ

᪂ᆺࢥࣟࢼ࢘࢖ࣝࢫឤᰁ⑕㸦coronavirus disease 2019:ୡ⏺つᶍ࡟ཬࡪឤᰁ⑕⶝ᘏࡣྂࡃ㐣ཤ࠿ࡽᮍ᮶࡬ே

COVID-19㸧ࡢୡ⏺ⓗ࡞⶝ᘏ࡟ࡼࡗ࡚ࠊᅜෆ࡛ࡣᗄᗘ࡜ࡢண ࢆ㐭࠿࡟㉸࠼࡚⧞ࡾ㏉ࡉࢀࡿ࡜⪃࠼ࡽࢀࡿࠋࡑࡢ

࡞ࡃ⥭ᛴ஦ែᐉゝࢆⓎ௧ࡍࡿ஦ែ࡜࡞ࡗࡓࠋ⥭ᛴ஦ែᗘࠊேࡣ᪥ᖖࡢ⏕άࡀኚ໬ࡍࡿࡇ࡜ࢆవ൤࡞ࡃࡉࢀ࡚ࡁ

ᐉゝ୰࡛ࡣࠊእฟ⮬⢔ࡸ௚⪅࡜ࡢ㛵ࢃࡾࢆᴟຊῶࡽࡍࡇ

ࡓࠋ≉࡟⑓ᙅ⪅ࠊ㧗㱋⪅ࡢ⮬❧ᨭ᥼࡟ࡣࠊẖ᪥ࢆඖẼ࡜ࡀᅜẸ࡟ồࡵࡽࢀࠊၟᴗ᪋タࡸፗᴦ᪋タ࡞࡝ከࡃࡢ

࡛ᬽࡽࡑ࠺࡜ࡍࡿໟᣓⓗᨭ᥼࡜ࡋ࡚ࠊ᪥ᖖ⏕άάື࡜ά

᪋タࡀఇᴗࡏࡊࡿ㈇࠼࡞࠸≧ἣ࡜࡞ࡗࡓࠋࡲࡓࠊఇᴗ

ຊࡢ୧㍯ࡢ㌴㍈ࢆᨭ࠼ࡿᚲせࡀ୙ྍḞ࡛࠶ࡿ࡜⪃࠼ࡽࡣබඹ᪋タ࡟࠾࠸࡚ࡶ౛እ࡛ࡣ࡞ࡃࠊ௓ㆤண㜵஦ᴗ➼ࢀࡿࠋࢥࣟࢼ⚝࡟࠾ࡅࡿ୧㍯ࡢ⌧≧ࢆᢕᥱࡋࠊ௒ᚋࡇ

࡞࡝ࡢ㐠Ⴀ⮬⢔࡟ࡼࡾ㧗㱋⪅ࡢእฟࡍࡿᶵ఍ࡀไ㝈ࡉࡢࡼ࠺࡞㠀ᖖ஦ែࡀ⥆࠸ࡓ࡜ࡁࡢ㧗㱋⪅ࡢ೺ᗣᨭ᥼ࡢ

ࢀࠊᒇእάືࡸᩓṌࠊᐙᗞෆ㐠ືࠊᆅᇦࢥ࣑ࣗࢽࢸ࢕࣮

୍ຓ࡜ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋ➼ࡢཧຍ࡞࡝࡬ࡢάື㢖ᗘࠊ♫఍άື࡬ࡢཧຍ㢖ᗘࡢపୗ㸦኱すࠉ2021㸪ᕷᡞ 2021㸧࡟ࡼࡗ࡚㌟యάື㔞ࡢప㸬ᑐ㇟࡜ㄪᰝᮇ㛫ୗࡀᠱᛕࡉࢀ࡚࠸ࡿࠋࡲࡓࠊእฟไ㝈ࡣ㧗㱋⪅ࡢ㌟య

ᑐ㇟ࡣࠊᒱ㜧ᕷෆ࡛㐠Ⴀࡉࢀ࡚࠸ࡿ㏻ᡤ௓ㆤ᪋タ㸦ࢹ㠃ࡔࡅ࡛࡞ࡃ೺ᗣ㛵㐃 QOL ࡟ࡶᙳ㡪ࢆ୚࠼࡚࠾ࡾࠊ

࢖ࢧ࣮ࣅࢫ㸧ࢆ฼⏝ࡉࢀ࡚࠸ࡿ㧗㱋⪅ 44 ே㸦⏨ᛶ 16 ேࠊ

COVID-19 ๓ ᚋ࡛ẚ ㍑ࡋࡓ◊ ✲ ࡛ࡣࠊ60 ṓ ௦ ࡛ࡣዪᛶ 28 ேࠊᖹᆒᖺ㱋  ṓs 8.36㸧ࠊᑐ㇟ࡢヲ⣽ࡣࠊ

SF-36 ࡢࠕ㌟యᶵ⬟࡛ࠖࠊ ṓ௦࡛ࡣࠕ♫఍⏕άᶵ⬟ࠖせ௓ㆤᗘู࡟せᨭ᥼ 1͐3 ேࠉせᨭ᥼ 2͐ ேࠉせ௓ㆤ࡜ࠕᚰࡢ೺ᗣ࡛ࠖ᭷ព࡟ὶ⾜ᚋࡢ᪉ࡀὶ⾜๓ࡼࡾᚓⅬࡀ

1͐5 ேࠉせ௓ㆤ 2͐18 ேࠉせ௓ㆤ 3͐4 ேࠉせ௓ㆤ 4ప࠿ࡗࡓ࡜ሗ࿌ࡋ࡚࠸ࡿ㸦బ⸨ࠉ2020㸧ࠋ͐3 ேࠉせ௓ㆤ 5͐2 ே࡛࠶ࡗࡓࠋ

COVID-19 ࡟ࡼࡿእฟไ㝈ࡼࡗ࡚㌟యⓗഃ㠃ࡢࡳ࡞ࡽࡲࡓࠊᮏㄪᰝࡣ 2021.4 㹼 2021.9 ࡲ࡛ࡢ༙ᖺ㛫࡛ᐇࡎ⢭⚄ⓗഃ㠃࠿ࡽ QOL ࢆపୗࡉࡏ࡚࠸ࡿࡇ࡜ࡀ᥎ᐹ࡛

᪋ࡋࡓࠋ

ࡁࡿࠋ
೺ᗣ࡜ࡣ WHO㸦ୡ⏺ಖ೺ᶵ㛵㸧᠇❶࡛ࡣࠊࠕ೺ᗣ࡜ࡣㄪᰝ㡯┠࠾ࡼࡧㄪᰝ᪉ἲ

᏶඲࡞⫗యⓗࠊ⢭⚄ⓗཬࡧ♫఍ⓗ⚟♴ࡢ≧ែ࡛࠶ࡾࠊ

4.1 ᪥ᖖ⏕άάື㸦ADL㸧༢࡟⑌⑓ཪࡣ⑓ᙅࡢᏑᅾࡋ࡞࠸ࡇ࡜࡛ࡣ࡞࠸ࠋࠖ

᪥ᖖ⏕άάືࡢホ౯ࡣࠊ་⒪ᶵ㛵ࡸ௓ㆤ⌧ሙ࡞࡝࡛"Health is a state of complete physical, mental and⏝࠸ࡽࢀ࡚࠸ࡿホ౯ᑻᗘ࡜ࡋ࡚ %DUWKHO,QGH[
㸦BI㸧ࢆ⏝

social well-being and not merely the absence of disease࠸ࡓࠋࡇࡢホ౯ࡣᑐ㇟⪅ࡀࠊ௨๓ࡼࡾከࡃືࡅࡿᵝ࡟

RULQ¿UPLW\࡜ࡋ࡚࠸ࡿࠋ

࡞ࡗࡓẼࡀࡍࡿࠊᑡࡋᴦ࡟ື࠿ࡏࡿࡼ࠺࡟࡞ࡗࡓ➼ࡢッ

COVID-19 ࡟ࡼࡿ♫఍ⓗάືࡢไ㝈ࡣ௓ㆤಖ㝤ୗࡢ࠼ࢆឤぬ࡛ཷࡅṆࡵࠊࡑࢀࡽኚ໬ࢆṇ☜࡟ᢕᥱࡍࡿࡇ࡜

ࢧ࣮ࣅࢫࢆ฼⏝ࡍࡿ㧗㱋⪅࡟࡜ࡗ࡚ࡶ኱ࡁ࡞ᙳ㡪ࢆ୚࠼ࡣ㞴ࡋ࠿ࡗࡓࠋBI ࡣࠊᑐ㇟⪅ࡢ ADL ࢆ୺ほ࡟㢗ࡿࡇࡿࡇ࡜ࡀᐜ᫆࡟ண ࡉࢀࡿࠋ௓ㆤಖ㝤ୗࡢࢧ࣮ࣅࢫࢆ

࡜࡞ࡃᐃ㔞໬ࡍࡿホ౯᪉ἲࡢࡦ࡜ࡘ࡜ࡋ࡚ከࡃ฼⏝ࡉࢀ฼⏝ࡍࡿ㧗㱋⪅ࠊࡲࡓࡑࡢᐙ᪘࡟࡜ࡗ࡚᪥ᖖ⏕άάື࡚ࡁࡓࠋ㸦௨ୗ ADL㸧ࡢ⥔ᣢྥୖࡍࡿࡇ࡜ࡣࢧ࣮ࣅࢫࢆ฼⏝ࡍࡿ

ࡲࡓࠊBI ࡣ་⒪௓ㆤᑓ㛛⫋௨እࡢே࡛ࡶ⌮ゎࡋࡸࡍ┠ⓗࡢ 1 ࡘ࡛ࡶ࠶ࡾࠊࡑࡢⅭ࡟ࡣ㌟యⓗ⬟ຊ࡜⢭⚄ⓗ࠸ᣦᶆ࡛ࠊ㣗஦ࡸṌ⾜࡞࡝ᇶᮏⓗ࡞᪥ᖖ⏕άືసࡢ඲

ഃ㠃ࡢࢧ࣏࣮ࢺࡀ㔜せ࡜࡞ࡿࠋ

10 㡯┠࡛ᵓᡂࡉࢀ࡚࠾ࡾࠊ0 ࠥ 100 Ⅼ࡛ホ౯ࡉࢀࡿࠋ

௓ㆤಖ㝤ୗࡢࢧ࣮ࣅࢫࢆ฼⏝ࡍࡿ㧗㱋⪅ࡣࠊ㌟యⓗࡑࢀࡒࢀࡢ㡯┠ࢆ⮬❧ࠊ௓ຓ㔞࡟ࡼࡾ15 Ⅼࠊ10 Ⅼࠊ5 Ⅼࠊ㐠ື⬟ຊ࣭⢭⚄ⓗഃ㠃࡜ࡶ࡟⮬❧ࡋࡓᆅᇦᅾఫ㧗㱋⪅

0 Ⅼ࡛ホ౯ࡋࠊࡑࡢྜィホ౯Ⅼࡢ㧗࠸ᑐ㇟⪅ࡣ ADL

ࡼࡾࡶప࠸ࡇ࡜࠿ࡽࠊ㌟యⓗ࣭⢭⚄ⓗ࡬ࡢࢫࢺࣞࢫ㈇Ⲵ

⮬❧ᗘࡀⰋዲ࡜ุ᩿ࡉࢀࡿࠋ

࡬ᑐᢠࡍࡿవຊࡀᑡ࡞ࡃࠊ௓ㆤࢧ࣮ࣅࢫࢆ฼⏝ࡋ࡞࠸㧗㱋⪅ࡼࡾࡶࢥࣟࢼ⚝ࡢ⎔ቃࡢᙳ㡪ࢆཷࡅࡸࡍ࠸ྍ⬟4.2 άຊ

ᛶࡀ࠶ࡿ࡜⪃࠼ࡽࢀࡿ㸦ᐑཎ 㸧ࠋάຊࡢホ౯ࡣࠊ⹫ᙅ㧗㱋⪅ࢆᑐ㇟࡜ࡋ࡚⥲ྜᶵ⬟ホࡑࡇ࡛ᮏ◊✲࡛ࡣࠊࢥࣟࢼ⚝࡟࠾࠸࡚ࢹ࢖ࢧ࣮ࣅࢫ฼

౯ࡢࡦ࡜ࡘ࡜ࡋ࡚㛤Ⓨࡉࢀࡓ YLWDOLW\LQGH[
㸦VI㸧ࢆ⏝࠸⏝㧗㱋⪅ࡢ㌟యⓗ㐠ື⬟ຊࠊάຊࠊADL ࡢ㛵ಀᛶࢆ

ࡓࠋVI ࡜ࡣࠊ㉳ᗋ࣭ពᚿ␯㏻࣭㣗஦࣭᤼ἥ࣭ࣜࣁࣅࣜࢸ᳨࣮ウࡍࡿࡇ࡜ࢆ┠ⓗ࡟ㄪᰝࢆ⾜ࡗࡓࠋࢩࣙࣥࡢ 5 㡯┠ࡢ᪥ᖖ⏕ά࡟㛵ࡍࡿάຊ࡟ࡘ࠸࡚ᐈほⓗᶵ⬟ホ౯ἲ࡛࠶ࡿ . ᚓⅬ⠊ᅖࡣ 0 㹼 10 Ⅼ࡛࠶ࡾࠊᚓⅬࡀ㧗࠸⛬᪥ᖖ⏕άάຊࡀ㧗࠸ࡇ࡜ࢆ♧ࡍ㸦ᅗ -1㸧ࠋᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021⑕ࡢᙳ㡪ࡀᑡ࡞ࡃࠊୗ⫥➽ຊࠊࣂࣛࣥࢫ㸪Ṍ⾜⬟ຊࡀ㧗࠸࡜ホ౯ࡉࢀࡿࠋࡑࡢ௚ࠊ㌟యⓗ㐠ື⬟ຊࡢホ౯ᑻᗘ࡜ࡋ࡚ᥱຊࠊ∦⬮❧఩᫬㛫ࢆィ ࡋࡓࠋ
4.4 ㄪᰝ᪉ἲ
ྛᑐ㇟⪅࡟⌧ᅾࡢάຊ࡜ࡋ࡚ VI ࢆ⪺ࡁྲྀࡾㄪᰝࡋࡓࠋ
ADL ࡜ࡋ࡚ BIࠊ᭦࡟⏕άᶵ⬟࡟㛵㐃ࡉࢀࡿ࡜⪃࠼ࡽࢀ
ࡿ㌟యᶵ⬟࡜ࡋ࡚ TUGࠊ∦⬮❧఩᫬㛫ࠊᕦ⦓ᶵ⬟࡜ࡋ࡚ᥱຊࢆィ ࡋࡓࠋ᭦࡟ಶู᝟ሗ࡜ࡋ࡚ᙜヱ᪋タࡢ฼⏝㢖ᗘ࠾ࡼࡧᐙ᪘
ᵓᡂᩘࠊ᪤ Ṕࢆ⪺ࡁྲྀࡾㄪᰝࡋࡓࠋᅗ ࠉάຊࡢᣦᶆ㸦9LWDOLW\LQGH[㸧㸦ฟ඾ࠉToba K,et al:Gerontol Int 2002㸧

ᅉࡣࠊKendall ࡢ㡰఩┦㛵ಀᩘࢆ⟬ฟࡋ࡚ྛせᅉ࡜ࡢ㛵

4.3 ㌟యᶵ⬟㐃ᛶࢆ᳨ウࡋࡓࠋࡲࡓࠊBI ྜィⅬࢆᚑᒓኚᩘࠊಶูせᚓࡽࢀࡓྛホ౯⤖ᯝࢆࡶ࡜࡟ VIࠊBI ࡜㌟యᶵ⬟ྛせ㌟యᶵ⬟ࡢホ౯ࡣ Timed Up & Go Test
㸦TUG㸧ࢆ⏝࠸ᅉࢆ⊂❧ኚᩘ࡜ࡋࡓࢫࢸࢵࣉ࣡࢖ࢬἲࡢ㔜ᅇᖐศᯒࢆᐇ

ࡓࠋTUG ࡣ㛤║∦⬮㉳❧᫬㛫࡜࡜ࡶ࡟㐠ືჾ୙Ᏻᐃ

᪋ࡋࡓࠋᮏ◊✲ࡢ⤫ィฎ⌮ࡣࠊSPSS Statistics 20.0J

⑕ Musculoskeletal Ambulation Disability Symptom

for Windows
㸦IBM ♫ 〇㸧ࢆ౑⏝ࡋ᭷ពỈ‽ࡣ༴㝤⋡&RPSOH[㸦MADS㸧ࡢᣦᶆ࡜࡞ࡗ࡚࠸ࡿࠋTUG ࡣࠊୗ⫥5% ࡜ࡋࡓࠋ

➽ຊࠊࣂࣛࣥࢫ㸪Ṍ⾜⬟ຊࠊ᫆㌿ಽᛶ࡜࠸ࡗࡓ᪥ᖖ⏕άᶵ⬟࡜ࡢ㛵㐃ᛶࡀ㧗࠸ࡇ࡜ࡀド᫂ࡉࢀ࡚࠾ࡾࠊ㧗㱋㸬⤖ᯝ⪅ࡢ㌟యᶵ⬟ホ౯࡜ࡋ࡚ಙ㢗ᛶࡶ㧗ࡃᗈࡃ⏝࠸ࡽࢀ࡚࠸

5.1 ᖺ㱋ู௓ㆤᗘࡿࠋᖺ㱋ู࡟௓ㆤᗘࢆࡳࡓ࡜ࡇࢁࠊ80 ௦࡟࠾࠸࡚せ௓ㆤᐃ᪉ἲࡣࠊ᳔Ꮚ࡟ࡺࡗࡓࡾ࡜⭜࠿ࡅࡓ≧ែ࠿ࡽ❧

2 ࣞ࣋ࣝࡀ 13 ே࡛࠶ࡾ඲యࡢ⣙ 30% ࡜࡞ࡗ࡚࠸ࡓࠋᮏ

ࡕୖࡀࡾࠊ3m ࢆࡑࢀࡒࢀࡢ᪥ᖖࡢ᪩ࡉ࡛Ṍࡁࠊᢡࡾ㏉ㄪᰝࡀࢹ࢖ࢧ࣮ࣅࢫ࡟࠾ࡅࡿ⮬Ꮿ࠿ࡽࡢ㏻ᡤྍ⬟࡛࠶ࡿࡋ࡚࠿ࡽ෌ࡧ῝ࡃ╔ᗙࡍࡿࡲ࡛ࡢᵝᏊࢆほᐹࡍࡿࡶࡢ࡛

≉ᛶ࠿ࡽࠊᑐ㇟⪅ࡀẚ㍑ⓗ᪥ᖖ⏕άࡢάືᛶࠊ௓ㆤࢆ

࠶ࡿࠋࡇࡢᶵ⬟ࢸࢫࢺࢆᡤせ᫬㛫࡛ホ౯ࡋࡓࡶࡢࡀ

せࡉ࡞࠸⮬❧ᛶࡢ㧗࠸ࡇ࡜ࡀ♧၀ࡉࢀࡓ㸦ᅗ -2㸧ࠋ

TUG Test ࡛࠶ࡿࠋᡤせ᫬㛫ࡀ▷࠸⛬ࠊ㐠ືჾ୙Ᏻᐃᅗ ࠉᖺ㱋ูࡢ௓ㆤᗘ㸦㹬 㸧ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

5.3VI ್࡜ BI ್ࡢ┦㛵㛵ಀ

5.2 άຊ㸦VI㸧ࡢᖺ㱋ู≉ᛶᑐ㇟⪅ࡢ VI ᚓⅬࡣ 65 㹼  ṓࡢ㧗㱋⪅⩌࡛ 9.2 sྛࢹ࣮ࢱ࠿ࡽ㡰఩┦㛵ಀᩘࢆ⟬ฟࡋࡓ⤖ᯝࠊVI ್࡛ࠊ 㹼 84 ṓࡢᚋᮇ㧗㱋⪅࡛ 9.0 s ࠊ85 ṓ௨ࡣ TUG ࡜ r=0.43ࠊBI ࡛ r= 0.56 ࡑࢀࡒࢀ࡟᭷ព࡞ṇୖ࡛ࡣ 9.0 s 1.40 ࡛࠶ࡗࡓ㸦⾲ -1㸧ࠋVI ᖹᆒ್ࡣࠊᖺ

ࡢ┦㛵ࡀㄆࡵࡽࢀࡓ㸦p<0.05㸧ࠋࡲࡓࠊVI ್࡟኱ࡁ࡞ᙳ㡪ࢆཬࡰࡍ࡜⪃࠼ࡽࢀࡓᖺ㱋㱋ู࡟ࡳࡓ࡜ࡇࢁ኱ࡁ࡞ᕪ␗ࡣ࡞࠿ࡗࡓࠋVI ್ࡣࠊᖺ㱋ቑ࡟ࡼࡗ࡚ࡤࡽࡘࡁࡢቑຍഴྥ࡟࠶ࡿࡇ࡜ࡀㄆࡵࡽࢀ

࡛ࡣ r=-0.05ࠊ௓ㆤᗘ࡛ࡣ U  ഹ࠿࡞ࡀࡽ㈇ࡢ┦㛵ࡓࠋࡀㄆࡵࡽࢀࡓࠋᐙ᪘ேᩘ࡛ࡣ r=-0.03ࠊ᪋タ฼⏝㢖ᗘ⾲ ࠉᖺ㱋ู 9, ᚓⅬ㸦㹬 㸧࡛ ࡣ r=-0.09 ࡜࡞ࡾ┦ 㛵 ࡣ ࡯ ࡰ ㄆ ࡵࡽ ࢀ ࡞ ࠿ ࡗࡓ
㸦p<0.05㸧ࠋ
5.4BI ࡟ᙳ㡪ࢆཬࡰࡍㅖせᅉBI ᚓⅬࢆᚑᒓኚᩘ㸪඲⑕౛ࡢ࢝ࢸࢦ࣮ࣜ໬ࡋࡓࣉࣟ
ࣇ࢕࣮ࣝ➼ࢆ⊂❧ኚᩘ࡜ࡍࡿࢫࢸࢵࣉ࣡࢖ࢻἲ࡟ࡼࡿ㔜ᅇᖐศᯒࢆ⾜ࡗࡓ⤖ᯝ㸪⊂❧ኚᩘ࡜ࡋ࡚ VI㸦ș 㸧࡜ᖺ㱋㸦ș 㸧ࡀᢳฟࡉࢀࠊㄝ᫂⋡ R2 ್ࡣ 0.29 ࡛࠶ࡗࡓࠋ⾲ ࠉ9,%, ࡜୺࡞ホ౯㡯┠࡜ࡢ┦㛵ಀᩘ㸦㹬 㸧㸬⪃ᐹ௨ୖࡢ⪅ࡀ ࠊ5 㸫  Ⅼࡢ⪅ࡀ ࠊ2-4 Ⅼࡢ⪅ࡀᮏ◊✲ࡢ⤖ᯝࡼࡾࠊ㏻ᡤ௓ㆤ฼⏝㧗㱋⪅ࡢពḧࡣ㌟

14.3% ࡜ሗ࿌ࡉࢀ࡚࠸ࡿࠋࡲࡓᑎᒸࡽࡣ௓ㆤ⪁ேಖ೺యᶵ⬟࡜ ADL ⬟ຊ࡟㛵ಀࡋ࡚࠾ࡾࠊADL ⬟ຊ࡟ᙳ㡪᪋タᅾఫせ௓ㆤ㧗㱋⪅ 140 ྡࢆᑐ㇟࡜ࡋࡓㄪᰝ㸦ᖹᆒࢆ୚࠼ࡿᅉᏊ࡜ࡋ࡚ពḧ࡜ᖺ㱋ࡀᢳฟࡉࢀࡓࠋ

ᖺ㱋 84.2 s  ṓ㸧࡛ࡣ VI ࡢᖹᆒ್ࡣ  Ⅼ࡛࠶ࡗࡓ㧗㱋⪅ࡢຍ㱋࡟క࠺ᚰ㌟ࡢኚ໬࡜♫఍ⓗࠊ⎔ቃⓗ࡞㸦ᑎᒸࠉ2009㸧ࠋᮏ◊✲ࡢ⿕㦂⪅ 66 㹼 96 ṓࡢせ௓ㆤ

せᅉࡀྜࢃࡉࡿࡇ࡜ࡀせ௓ㆤ≧ែ࡜࡞ࡿせᅉࡢࡦ࡜ࡘ࡜

㧗㱋⪅࡟࠾࠾ࡅࡿ VI ࡢᖹᆒ್ࡣ 9.2 Ⅼ࡛࠶ࡾࠊ8 Ⅼ௨⪃࠼ࡽࢀࡿࠋ᪥ᮏ⪁ᖺ་Ꮫ఍ࡀ 2014 ᖺ࡟ᥦၐࡋࡓᴫᛕ

ୖࡀ඲యࡢ 90% ࢆ༨ࡵ࡚࠸ࡿࡇ࡜࠿ࡽࠊ௚ࡢሗ࿌ࡼࡾ

ࡢࠕFrailty㸦⹫ᙅ㸧ࠖ࡜ࡣࠊ೺ᗣ࡞≧ែ࡜せ௓ㆤ≧ែࡢ୰ࡶពḧࡀ㧗࠸㞟ᅋ࡛࠶ࡿࡇ࡜ࡀ⌮ゎ࡛ࡁࡿࠋࡲࡓࠊᮏ

㛫࡟఩⨨ࡋࠊάື㔞ࡢపୗ࡜♫఍஺ὶᶵ఍ࡢῶᑡࠊ㌟◊✲࡛ࡣពḧ࡜ TUG
㸦ୗ⫥➽ຊࠊࣂࣛࣥࢫ㸪Ṍ⾜⬟ຊࠊయᶵ⬟ࡢపୗ㸦Ṍ⾜ࢫࣆ࣮ࢻࡢపୗ㸧ࠊ➽ຊࡢపୗ➼࡛᫆㌿ಽᛶ࡜࠸ࡗࡓ᪥ᖖ⏕άᶵ⬟㸧ࠊBI ࡟୰➼ᗘࡢ㛵㐃

࠶ࡾ㌟యⓗᶵ⬟ࡸㄆ▱ᶵ⬟ࡢపୗࡀࡳࡽࢀࡿ≧ែࡢࡇࡀㄆࡵࡽࢀࠊ㔜ᅇᖐศᯒࡼࡾADL ᶵ⬟࡟ࡣពḧࡀ㛵࡜ࢆ♧ࡋ࡚࠸ࡿ㸦୍⯡♫ᅋἲே⪁ᖺ་Ꮫ఍ࠉ2014㸧ࠋࡇ㐃ࡍࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋඛ⾜◊✲࡛ࡣពḧࡢపࡢࡼ࠺࡞≧ἣ࡟࠶ࡗ࡚ࡶ㐺ษ࡞἞⒪ࡸண㜵ࢆ⾜࠺ࡇ࡜࡛ୗࡣ㌟య≧ἣࡢᝏ໬ࡸせ௓ㆤᗘࡢ㔜⑕໬ࠊࣜࣁࣅࣜ

せ௓ㆤ≧ែ࡟㐍ࡲࡎ࡟ࡍࡴྍ⬟ᛶࡀ࠶ࡿ࡜ࡉࢀ࡚࠸ࡿࠋ

ࢸ࣮ࢩࣙࣥຠᯝࡢపୗ࡞࡝ࡢ㛵㐃ࡀሗ࿌ࡉࢀ࡚࠸ࡿ㸦㫽ᚰ㌟ᶵ⬟ࡸ ADL ⥔ᣢࡢࡓࡵ࡟ࡣពḧ࡞࡝ࡢ⢭⚄ᶵ⩚ࠉ2002㸧ࠋࡘࡲࡾࠊ㌟యᶵ⬟ࡸ ADL ᶵ⬟ࢆ⥔ᣢࡋ࡚⬟ࡀ㔜せ࡜࡞ࡿࡀࠊᖹᡂ 30 ᖺᗘ௓ㆤሗ㓘ᨵᐃࡢຠᯝ

ࡃࡓࡵ࡟ࡣពḧࢆ㧗ࡃಖࡘᚲせࡀ࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋ᳨ドཬࡧㄪᰝ◊✲㸦ཌ⏕ປാ┬ࠉ2021㸧࡟ಀࡿㄪᰝ࡛

ᮏㄪᰝࡣ⣙༙ᖺ㛫ࡢྛᑐ㇟⪅ࡢᶓ᩿ⓗホ౯࡟ᇶ࡙ࡃ

ࡣࠊ㏻ᡤࢧ࣮ࣅࢫ࡟㏻࠺せ௓ㆤ㧗㱋⪅࡛ࡣ VI ࡀ 8 Ⅼ⤖ᯝࡢሗ࿌࡛࠶ࡾࠊ⦪᩿ⓗኚ໬ࡢヲ⣽࡟ࡘ࠸࡚ࡣ୙᫂

ᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࡞Ⅼࡶከࡃṧࡉࢀ࡚࠸ࡿࠋࡋ࠿ࡋࠊࢥࣟࢼ⚝ࡢ᭱୰ྛ฼⾜ື࡜⏕άࡢᅔࡾࡈ࡜ . ᪥ᮏ┳ㆤ◊✲Ꮫ఍㞧ㄅ ,44⏝⪅࡜ࡶ࡟ᴟ➃࡞άຊపୗࠊ᪥ᖖ⏕άάືࡀ኱ࡁࡃኚ໬

㸦2㸧, 185-192.

ࡋࡓ⪅ࡣᑡ࡞࠿ࡗࡓࠋࡇࢀࡽࡢせᅉ࡜ࡋ࡚ࠊ᪥ᖖ఍ヰ࡟୍⯡♫ᅋἲே⪁ᖺ་Ꮫ఍㸦2014㸧㸸ࣇࣞ࢖ࣝ࡟㛵ࡍࡿ᪥࡯࡜ࢇ࡝ᨭ㞀ࡀ࡞ࡃ௚⪅࡜ࡢ஺ὶࡀ┒ࢇ࡛࠶ࡾᐃᮇⓗᮏ⪁ᖺ་Ꮫ఍࠿ࡽࡢࢫࢸ࣮ࢺ࣓ࣥࢺ㸦2021-9-28㸧㸬᪋タ฼⏝ࡀྍ⬟࡛࠶ࡗࡓࡇ࡜ࠊ᪋タ฼⏝ࡢ୰࡛ᑡ࡞࠿

ht t p s://jp n -ge r iat- s o c.or.jp/i n fo/t o pic s /ࡽࡎᴦࡋࡳࡀ࠶ࡗࡓࠊ㞟ᅋ࡛ࡢᶵ⬟カ⦎࡟ࡣ✚ᴟⓗ࡟

pdf/20140513_01_01.pdf

ཧຍࡍࡿࡇ࡜ࢆᖖ࡜ࡋ࡚࠸ࡓࠊ༢㌟⏕ά⪅ࡣẚ㍑ⓗᑡ࡞኱ す ᶒ ு㸪 ᘅ ℩ ⱥ ⏕㸪 ఀ ᕥ ḟ ᝅࠉ ௚㸦2021㸧㸸ࡃࠊᐤࡾῧࡗ࡚ࡃࢀࡿᐙ᪘㛵ಀࡀⰋዲ࡛࠶ࡗࡓ஦➼ࡀ⪃

COVID-19 ὶ⾜࡟㛵㐃ࡋࡓእฟ⮬⢔࡛㧗㱋⪅ࡣάື࠼ࡽࢀࡿࠋబ⸨௚㸦2021㸧ࡣࠊఱࡽ࠿ࡢせᅉ࡛⏕ά⠊ᅖ㢖ᗘపୗࢆឤࡌ࡚࠸ࡿ࠿㸽 ᪥ᮏࣉࣛ࢖࣐࣭ࣜࢣ࢔㐃ྜࡀ⦰ᑠࡋ࡚⮬Ꮿ࡟㛢ࡌࡇࡶࡿࡇ࡜ࡀከࡃ࡞ࡿࡇ࡜ࡀᗫ⏝Ꮫ఍ㄅ , 44㸦2㸧㸪㸬ᛶࡢࡉࡽ࡞ࡿᶵ⬟పୗࢆᣍࡃ࡜࠸࠺ᝏᚠ⎔ࢆ⏕ࡌࡸࡍཌ⏕ປാ┬㸦2021㸧㸸ᖹᡂ 30 ᖺᗘ௓ㆤሗ㓘ᨵᐃࡢຠᯝ

࠸ࠊ࡜ሗ࿌ࡋ࡚࠸ࡿࠋᑐ㇟⪅࡟࡜ࡗ࡚᪋タ฼⏝ࡀࡇࡢ᳨ドཬࡧㄪᰝ◊✲࡟ಀࡿㄪᰝ㸦௧࿴ 2 ᖺᗘㄪᰝ㸧ᝏᚠ⎔ࢆ᩿ࡕษࡿせᅉ࡜࡞ࡗࡓྍ⬟ᛶࡣྰᐃ࡛ࡁ࡞࠸

㸦2021-9-28㸧ࡀࠊ᪋タ฼⏝࡜ࡢ᪥ᖖ⏕άάື࡜άຊ࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸KWWSVZZZPKOZJRMSFRQWHQW࡚ࡣࠊ ௒ᚋࡶ⥅ ⥆ ⓗ࡞◊ ✲ ㄢ 㢟࡜ࡋࡓ࠸㸦 బ ⸨ ௚2021ࠊᏳཎ௚ 2013㸧ࠋ

pdf
బ⸨ὒ୍㑻㸪኱ෆ₶Ꮚ㸪ᯘ⿱Ꮚࠉ௚㸦2020㸧㸸᪂ᆺࢥࣟே㛫࡜ࡣࠊඖࠎࡀ♫఍ⓗື≀࡛࠶ࡿࠋᨾ࡟♫఍࡜஺ࢼ࢘࢖ࣝࢫឤᰁ⑕㸦COVID-19㸧ὶ⾜ึᮇ࡟࠾ࡅࡿᆅ

ࢃࡿࡇ࡜࡛⢭⚄ⓗࠊ⫗యⓗᶵ⬟⥔ᣢࡀ࡛ࡁࡿ࡜⪃࠼ࡽᇦ㧗㱋⪅ࡢ೺ᗣ㛵㐃 QOL. ⌮Ꮫ⒪ἲ⛉Ꮫ , 35
㸦6㸧㸪

ࢀࡿࠋ㏻ᡤ௓ㆤ᪋タ࡛ࡢάືࡀឤᰁ⑕ࡢᣑ኱ࢆ኱ࡁ࡞

813-818.

ࣜࢫࢡ࡜ࡋ࡚ᢪ࠼ࡿ୰࡛ࠊ௓ㆤࢆ᭷ࡍࡿ฼⏝⪅ࡢ೺ᗣ⥔బ⸨ ⚽୍㑻 , ᅵ⏣ ‶㸦2021㸧㸸㏻ᡤᆺࢹ࢖ࢧ࣮ࣅࢫ฼
⏝⪅࡟࠾ࡅࡿ ADL ࡜ QOL ࡢ⌧≧ Tsusho-type dayᣢ࡟ఱࡽ࠿ࡢ㈉⊩ࡀ࠶ࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ

service Current status of ADL and QOL in users㸸℩ᮌᏛᅬ⣖せ㸦18㸧㸬ㅰࠉ㎡ᮏ◊✲࡟࠾࠸࡚㏻ᡤ௓ㆤࢧ࣮ࣅࢫࡢ㈗㔜࡞᫬㛫ࢆ㡬ᑎᒸຍ௦ࠉ᳃㔝ᬛᏊ㸦2009㸧㸸᪋タᅾఫせ௓ㆤ㧗㱋⪅ࡁࡲࡋࡓ฼⏝⪅ᵝࠊࡑࡢᐙ᪘ࡢⓙᵝࠊࡲࡓྛホ౯࡟㝿ࡢពḧ㸦9LWDOLW\LQGH[㸧࡜ཱྀ⭍ᶵ⬟࡜ࡢ㛵㐃ᛶ࡟ࡘ࠸ࡋࡈ༠ຊ㡬ࡁࡲࡋࡓᙜヱ᪋タ⫋ဨࡢⓙᵝ࡟ࡇࡢሙࢆ࠾

࡚㸬⪁ᖺṑᏛ㸪24
㸦1㸧㸪28-36㸬೉ࡾࡋ῝ㅰ⏦ࡋୖࡆࡲࡍࠋ

㫽⩚◊஧㸦2002㸧㸸ᚑ᮶ࡢ QOL ࢫࢣุ࣮࡛ࣝᐃ୙⬟࡞㧗㱋⪅࡟ᑐࡍࡿ᪂ࡋ࠸ᐈほⓗᶵ⬟ホ౯ࡢ㛤Ⓨ࡜ᛂ⏝㸬ᖹᡂ 12-14 ᖺᗘཌ⏕ປാ┬㛗ᑑ⛉Ꮫ⥲ྜ◊✲஦೔⌮ⓗ㓄៖ᴗሗ࿌᭩㸪

೔⌮ⓗ㓄៖࡟ࡘ࠸࡚ࡣࠊᮏ◊✲ࡀேࢆᑐ㇟࡜ࡋ࡚࠸
ࡿⅭᙜヱ᪋タࡢ⟶⌮㐠Ⴀጤဨ఍࡟࡚ㄪᰝ┠ⓗࠊ᪉ἲ࡟ᐑཎὒே㸦㸧㸸ᆅᇦ㧗㱋⪅ࡢせ௓ㆤᗘ࡜➽ຊࡢ㛵㐃㸬⌮Ꮫ⒪ἲࡉࡀ㸪3㸦1㸧೔⌮ⓗၥ㢟ࡀ↓࠸ࡇ࡜ࡢᢎㅙࢆᚓࡓࠋࡲࡓࠊㄪᰝ⤖ᯝࡣᑐ㇟⪅ಶேࡀ᩿ᐃ࡛ࡁ࡞࠸஦ࠊࡑࡢ⤖ᯝ࡟࠾࠸࡚௒Ᏻཎ ೺ኴ , ⚟⏣ 㞞ᩄ , 㧗㡲㈡ ⓒࠎᏊ㸦2013㸧㸸୍⯡ᆺᚋࡢ᪋タ฼⏝࡟୙฼┈ࡀ⏕ࡌࡿࡇ࡜ࡣ࡞࠸஦࡟㓄៖ࡋࢹ࢖ࢧ࣮ࣅࢫ฼⏝⪅ࡢ㌟యᶵ⬟ࡢ⤒ᖺⓗ᥎⛣࡟ࡘ࠸ࡓࠋ࡚ :3 ᖺ㛫ࡢ⦪᩿ㄪᰝ࠿ࡽ . ⌮Ꮫ⒪ἲᏛ Supplement2013㸦0㸧, 0953, 2014.

ᮏㄪᰝ๓࡟ࡍ࡭࡚ࡢᑐ㇟⪅࡞ࡽࡧࡑࡢᐙ᪘࡟ᑐࡋ࡚ㄪᰝᴫせࠊ┠ⓗࢆಶู࡟ㄝ᫂ࡋྠពᚋ⨫ྡࢆ㡬࠸ࡓࠋ฼┈┦཯ᮏ◊✲࡟࠾࠸࡚㛤♧ࡍ࡭ࡁ฼┈┦཯ࡣ࡞࠸ࠋ
ཧ⪃ᩥ⊩ᕷᡞඃே㸪኱ෆ₶Ꮚ㸪ᯘ⿱Ꮚࠉ௚㸦2021㸧㸸໭ᾏ㐨࡟࠾ࡅࡿ COVID-19 ឤᰁᣑ኱㜵Ṇ⟇ࡀ㧗㱋⪅࡟୚࠼ࡓ⏕ά࡬ࡢᙳ㡪㸸እฟ⮬⢔せㄳୗ࡟࠾ࡅࡿ㧗㱋⪅ࡢ೺ᗣᒱ㜧ಖ೺኱Ꮫ⣖せࠉVol.3, 2021

࠙Practical Reportࠚ

The relationship between activities of daily living and vitality among
the elderly using day services during the COVID-19 pandemic.
OZAWA Toshio*1ࠉSUZUKI Keisuke*1ࠉKANEDA Narikyu*2ࠉIDO Masahiro*2*1 Gifu University Of Health Science Faculty of Rehabilitationࠉ
*2 Day service center Q-net
Abstract
7KLVVWXG\IRFXVHVRQWKHHOGHUO\ZKRDUHWKRXJKWWRKDYHEHHQD൵HFWHGE\WKH&29,'SDQGHPLF$VXUYH\ZDVFRQGXFWHGZLWKWKHDLPRIH[DPLQLQJWKHUHODWLRQVKLSEHWZHHQDFWLYLWLHVRIGDLO\OLYLQJDQGYLWDOLW\DPRQJWKHHOGHUO\using day service 㸨 . The subjects were 44 elderly individuals㸦PHQZRPHQDYHUDJHDJH\HDUVs 8.36㸧
using day service, with a median care level 2.
It was observed that vitality has a moderate association between activities of daily living and physical function, witha progressive increase in standard deviation with age. It was suggested that physical and mental support are importantfor maintaining health in elderly care.

㸨Day service: A social service system that provides daytime care and physical therapy to the elderly.

Keywords㸸9LWDO,QGH[㸦VI㸧ࠊ%DUWKHO,QGH[㸦BI㸧ࠊ elderly





⑕౛ࡸ஦౛ࠊㄪᰝ◊✲࡟ࡘ࠸࡚ࠊ᭷⏝࡞⤒㦂ࡸᏛ⾡ⓗ࡞ヰ㢟࡟㛵ࡍࡿࢣ࣮ࢫ࣏࣮ࣞ
ࢺࡸࣇ࢕࣮ࣝࢻ࣏࣮ࣞࢺ࡜ࡍࡿࠋ
㸦㸳㸧ࡑࡢ௚ 2WKHUV ୖグ࡟ヱᙜࡋ࡞࠸ࡶࡢ࡛ጤဨ఍ࡀㄆࡵࡓࡶࡢࠋ
㸦ᇳ➹せ㡿㸧➨㸴᮲ ཎ✏ࡢసᡂ࣭ᇳ➹ࡣู࡟ᐃࡵࡿᒱ㜧ಖ೺኱Ꮫ⣖せཎ✏ᇳ➹せ㡿࡟ᚑ࠺ࡶࡢ࡜ࡍࡿࠋ
㸦೔⌮ⓗ㓄៖㸧➨ 㸵 ᮲  ே య ࡲ ࡓ ࡣ ࣄ ࢺ ⤌ ⧊ ࢆ ᑐ ㇟ ࡜ ࡋ ࡓ ㄽ ᩥ ࡣ ࠕ ࣊ ࣝ ࢩ ࣥ ࢟ ᐉ ゝ 㸦 :RUOG 0HGLFDO$VVRFLDWLRQ㸧ࠖࡢ೔⌮ᇶ‽ࠊ⮫ᗋ◊✲࡟㛵ࡍࡿㄽᩥࡣࠕேࢆᑐ㇟࡜ࡍࡿ⏕࿨⛉Ꮫ࣭་Ꮫ⣔◊✲࡟㛵ࡍࡿ೔⌮ᣦ㔪㸦ཌ⏕ປാ┬࣭ᩥ㒊⛉Ꮫ┬࣭⤒῭⏘ᴗ┬㸧ࠖ࡟ᚑ࠺ࡇ࡜ࠋ
࠸ࡎࢀࡢሙྜࡶᡤᒓᶵ㛵ࡢ೔⌮ጤဨ఍ࡢᢎㄆࢆᚓ࡚ᐇ᪋ࡉࢀࡓࡶࡢ࡟㝈ࡗ࡚ᢞ✏ࢆཷࡅ௜ࡅࡿࠋᙜヱㄽᩥࡀࡇࢀࡽ࡟ᚑࡗ࡚ᐇ᪋ࡉࢀࡓࡇ࡜ࢆᮏᩥ୰㸦ᢎㄆ␒ྕࠊᢎㄆ
᭶᪥㸧࡟᫂グࡍࡿࠋ㸦฼┈┦཯㸧➨㸶᮲ ฼┈┦཯㸦&RQIOLFWRI,QWHUHVW&2,㸧࡟㛵ࡋ࡚ࠊ◊✲ࡢ㐙⾜ࡸㄽᩥࡢసᡂ࡟㛵ࡍࡿຓゝ࡞࡝ࡢࡍ࡭࡚ࡢ㔠㖹ⓗࠊಶேⓗ฼┈㛵ಀ࡟ࡘ࠸࡚᝟ሗ㛤♧ࡍࡿࡇ࡜ࠋ᝟ሗ
㛤♧ࡣࠊㄽᩥࡢ᭱ᚋ࡟ࠕ฼┈┦཯ࠖࡢ㡯┠ࢆసᡂࡋࠊࡍ࡭࡚ࡢⴭ⪅࡟ࡘ࠸࡚฼┈┦཯ࡢෆᐜࢆグ㍕ࡍࡿࡇ࡜ࠋ฼┈┦཯ࡀ࡞࠸ሙྜࡣࠊ
ࠕ㛤♧ࡍ࡭ࡁ฼┈┦཯ࡣ࡞࠸ࠖ࡜
グ㍕ࡍࡿࡇ࡜ࠋ
㸦ཎ✏ࡢᥦฟ㸧➨㸷᮲ ཎ✏ࡣࠊࠕ⣖せᢞ✏ཎ✏ࡢᥦฟู⣬ᵝᘧ➨㸯ྕ㸧ࠖཬࡧࠕඹྠ◊✲⪅ᢎㅙ᭩㸦ู⣬ᵝᘧ➨㸰ྕ㸧ࠖࢆῧ࠼࡚ࠊጤဨ఍࡟ᥦฟࡍࡿࡇ࡜㸦㒑㏦ྍ㸧ࠋ 㸦㸯㸧ཎ✏ࡣ㸱㒊㸦࠺ࡕ㸰㒊ࡣ」෗࡜ࡋࠊⴭ⪅ࠊⴭ⪅ᡤᒓࠊㅰ㎡➼ࢆ๐㝖ࡋࡓࡶࡢ࡜ࡍ
ࡿ㸧ࢆᥦฟࡍࡿࠋ㸦㸰㸧⣖せ࡟ᢞ✏ࡍࡿࡓࡵࡢ᭩㢮୍ᘧࡀጤဨ఍࡟฿╔ࡋࡓ᪥௜ࢆࡶࡗ࡚ཎ✏ࡢཷ⌮᪥࡜ࡋࠊཷ㡿ドࢆⓎ⾜ࡍࡿ㸦ู⣬ᵝᘧ➨㸱ྕ㸧ࠋ㸦㸱㸧ᰝㄞ↷఍஦㡯࡟ᇶ࡙࠸࡚ཎ✏ࡢಟṇࢆ⾜࠺ሙྜࡣࠊᪧཎ✏࡜ᰝㄞᡤぢ࡟ᑐࡍࡿᅇ
⟅᭩ࢆῧ࠼࡚ࠊጤဨ఍ࡢᣦᐃࡍࡿ᪥ࡲ࡛࡟෌ᥦฟࡍࡿࠋᮇ㝈ࡲ࡛࡟෌ᥦฟࡉࢀ࡞
࠸ሙྜࡣཎ✏ࢆྲྀࡾୗࡆࡓࡶࡢ࡜ࡍࡿࠋ
㸦㸲㸧ᢞ✏ㄽᩥࡢ᥇⏝Ỵᐃᚋ࡟ࠊᮏᩥࠊᅗࠊ⾲ࢆಖᏑࡋࡓ㟁Ꮚ፹య࡜ࡑࡢࣉࣜࣥࢺ࢔࢘
ࢺࡋࡓࡶࡢࢆ㸯㒊ᥦฟࡍࡿࡇ࡜ࠋ
㸦㸳㸧ཎ✏ᥦฟඛ
ࠛ ᒱ㜧ᕷᮾ㭘  ୎┠   ᒱ㜧ಖ೺኱Ꮫ⣖せጤဨ఍㸦஦ົᒁෆ㸧㒑㏦ࡍ
ࡿሙྜࡣࠊࠕཎ✏ᅾ୰ࠖ࡜ᮒ᭩ࡁࡍࡿࡇ࡜ࠋ 㸦ཎ✏ࡢ᥇ྰ㸧➨  ᮲ ᢞ✏ཎ✏ࡢ᥇ྰࡣࠊ」ᩘࡢᰝㄞ⪅ࢆ⤒࡚ࠊ⣖せጤဨ఍ࡀỴᐃࡍࡿࠋ
㸦㸯㸧ᢞ✏ཎ✏ࡢෆᐜ࡟ᛂࡌ࡚ᏛෆࡢᩍဨࡲࡓࡣᏛእࡢ㐺௵⪅ࡢ୰࠿ࡽᰝㄞ⪅ࢆ㑅ᐃࡋࠊ⣖せጤဨ఍ࡀᰝㄞࢆ౫㢗ࡍࡿࠋ㸦㸰㸧᮲௳௜ࡁ᥇ᢥ࡜࡞ࡗࡓሙྜ࡟ࡣࠊᰝㄞ⪅ࡢពぢࢆ௜ࡋ࡚ゞṇࢆồࡵࠊ෌ᗘᰝㄞࢆ
⾜ࡗࡓୖ࡛᥇ྰࢆỴᐃࡍࡿࠋ
㸦㸱㸧ᢞ✏ㄽᩥࡢ᥇ᢥࡀỴᐃࡋࡓࡽࠊࡑࡢ᪥௜࡛ࠕᥖ㍕ணᐃ㸦ᖺࠊᕳ࣭ྕ㸧ࠖࡢ㏻▱ࢆ⣖せጤဨ㛗࠿ࡽ஺௜ࡍࡿࠋ㸦ู⣬ᵝᘧ➨㸲ྕ㸧ࠋ㸦ⴭ⪅ᰯṇ㸧➨  ᮲ ⴭ⪅ᰯṇࡣ  ᅇ࡜ࡍࡿࠋᰯṇ᫬ࡢ኱ᖜ࡞㏣ຍࠊಟṇࡣཎ๎࡜ࡋ࡚ㄆࡵ࡞࠸ࠋ
㸦㈝⏝㸧➨  ᮲ ㈝⏝ࡣḟࡢ࡜࠾ࡾ࡜ࡍࡿࠋ
㸦㸯㸧ᥖ㍕ᩱ㸸ཎ๎࡜ࡋ࡚↓ᩱ࡜ࡍࡿࠋ
㸦㸰㸧ูๅᩱ㸸ูๅࡾࢆᕼᮃࡍࡿሙྜࡣࠊⴭ⪅ࡢ⮬ᕫ㈇ᢸ࡜ࡍࡿࠋ
㸦㸱㸧ࡑࡢ௚㸸࣮࢝ࣛࡢᅗ⾲ࡸ෗┿➼ࠊ༳ๅୖࠊ≉ู࡞㈝⏝ࢆᚲせ࡜ࡍࡿሙྜࡣⴭ⪅ࡢ⮬ᕫ㈇ᢸ࡜ࡍࡿࠋ
㸦ᥖ㍕Ỵᐃᚋࡢྲྀࡾᾘࡋ㸧➨  ᮲ ጤဨ఍࡟࠾࠸࡚ᥖ㍕ࡀỴᐃࡋࡓᚋ࡛ࡶࠊࡸࡴࢆᚓ࡞࠸஦᝟࡟ࡼࡾỴᐃࢆྲྀࡾᾘ
ࡍࡇ࡜ࡀ࠶ࡿࠋࡇࡢሙྜࡣࠊጤဨ఍ࡣࡑࡢ⌮⏤ࢆ㏿ࡸ࠿࡟ⴭ⪅࡟㐃⤡ࡍࡿࠋ୍᪉ᥖ
㍕Ỵᐃᚋࠊⴭ⪅ࡢពᚿ࡟ࡼࡾ᧔ᅇࡍࡿሙྜࡣࠊࡑࡢ᪨ࢆጤဨ఍࡟᭩㠃࡛㐃⤡ࡍࡿ࡜࡜ࡶ࡟ࠊⴭ⪅ࡣ᧔ᅇ࡟࠿࠿ࡿ⤒㈝ࢆ㈇ᢸࡍࡿࡶࡢ࡜ࡍࡿࠋ
㸦ⴭసᶒ㸧
➨  ᮲ ⴭసᶒࡣᒱ㜧ಖ೺኱Ꮫ࡟ᒓࡍࡿࠋࡲࡓࡑࡢᶵ㛵࣏ࣜࢪࢺ࣮ࣜ࡟ࡘ࠸࡚ࡶ஢ᢎࡋ
ࡓࡶࡢ࡜ࡍࡿࠋ㸦㞧๎㸧➨  ᮲ ࡇࡢᢞ✏つ⛬ࡢᨵṇࡀᚲせ࡞ሙྜࡣࠊࡑࡢ㒔ᗘࠊጤဨ఍࡟࠾࠸࡚༠㆟ࡋࠊᩍᤵ఍
࡟ሗ࿌ࡍࡿࠋ㝃๎ ࡇࡢつ⛬ࡣࠊ௧࿴ඖᖺ  ᖺ  ᪥࠿ࡽ᪋⾜ࡍࡿࠋࡇࡢつ⛬ࡣࠊ௧࿴  ᖺ  ᖺ  ᪥࠿ࡽ᪋⾜ࡍࡿࠋࡇࡢつ⛬ࡣࠊ௧࿴  ᖺ  ᖺ㸯᪥࠿ࡽ᪋⾜ࡍࡿࠋ





編

集

後

記

2021年は4月にリハビリテーション学部が開設し、本学の大学教育が大きく飛躍する1年でした。しかし、COVID-19感染拡大については、オミクロン株の大流行の影響が未だ衰えず、日々感染防止しながら生活するといった状況が続いています。
さて、昨年度に続き岐阜保健大学紀要第3巻を皆様にお届けすることができました。投稿者および査読者の方々に感謝申し上げます。第3巻は、総説1篇、原著3篇（うち英文1篇）、研究報告3篇、実践報告3篇が掲載され、いずれも時代の趨勢に合った内容が報告されています。次年度もますます活発なご投稿をしていただけますよう
お願い申し上げます。
紀要委員会委員長

岐阜保健大学紀要委員会
委員長

多喜田恵子

副委員長

酒向

俊治

委員

石塚

和重

森

裕志

岩島

隆

朝岡みゆき

岐阜保健大学紀要
発行日

第3巻

2022年3月

編集・発行

岐阜保健大学〒500-8281

岐阜県岐阜市東鶉２丁目92番地

TEL

058-274-5001

FAX



058-274-5260

多喜田恵子